Etude des profils génétiques des gliomes de bas-grade pédiatriques by Bergthold, Guillaume
HAL Id: tel-01374734
https://tel.archives-ouvertes.fr/tel-01374734
Submitted on 5 Jul 2017
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Genomic Profiling of Pediatric Low-Grade Gliomas
Guillaume Bergthold
To cite this version:
Guillaume Bergthold. Genomic Profiling of Pediatric Low-Grade Gliomas. Genetics. Université
Paris Sud - Paris XI; Harvard university. Medical school, 2015. English. ￿NNT : 2015PA11T053￿.
￿tel-01374734￿
  
                          
 
 
 
 
UNIVERSITE PARIS-SACLAY 
 
ÉCOLE DOCTORALE 418 DE CANCEROLOGIE 
Laboratoire de Vectorologie et thérapeutiques anticancéreuses 
& 
Cancer Biology Department Dana-Farber Cancer Institute, Boston, USA 
 
 
 
THÈSE DE DOCTORAT 
 
Soutenue le 30/09/2015 
 
par 
 
Guillaume BERGTHOLD 
 
Genomic Profiling of Pediatric Low-Grade Gliomas 
Etude des profils génétiques des gliomes                         
de bas-grade pédiatriques 
 
 
 
Directeur de thèse :            Jacques GRILL  Praticien des CLCC (Gustave Roussy, Villejuif, France) 
Co-directeurs de thèse :       Mark W KIERAN  Assistant Professor (Harvard Medical School, Boston, USA) 
 Rameen BEROUKHIM        Assistant Professor (Harvard Medical School, Boston, USA) 
 
Composition du jury : 
 
Président du jury :   Pascale VARLET       PU-PH (Service de Pathologie, Hôpital Sainte-Anne, Paris) 
 
Rapporteurs :     Natacha ENTZ-WERLE PU-PH (Onco-Hématologie Pédiatrique, CHU Strasbourg) 
    Daniel GAUTHERET PU (Institut de Génétique&Microbiologie, Paris-Sud Orsay)
  
Examinateurs :              Pascale VARLET  PU-PH (Service de Pathologie, Hôpital Sainte-Anne, Paris)
    Marc SANSON  PU-PH (CRICM, Paris 13)!
!
!
!
! 2 
 
 
 
 
 
 
 
 
 
Genomic Profiling of Pediatric Low-Grade Gliomas 
 
 
Etude des profils génétiques des gliomes de bas-grade pédiatriques 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A tous les enfants et leurs familles affectés par le cancer,  
Vous inspirez chaque jour mon travail. 
 
 
A tous les professionnels qui travaillent au quotidien pour améliorer le confort  
Et la survie des enfants atteints par le cancer. 
 
 
A mon épouse Elsa et nos enfants Sarah, Nathan, Timothée et Victor 
Vous représentez pour moi ce qu’il y a de plus précieux au monde. 
  
! 4 
Abstract 
 
 Low-grade gliomas represent the most frequent brain tumor arising during 
childhood. They are characterized by a broad spectrum of tumor types. For most of the 
patients, the overall survival is good, although the morbidity due to the treatments is 
affecting considerably their quality of life.  
 
In the past, the definition of low-grade gliomas (LGG) has been mainly based on 
morphology. This histological classification of pediatric low-grade gliomas (PLGG), 
recently revised in 2007 suffers from the lack of reproducibility and precision, as a non-
negligible number of PLGG are hard to classify in a specific category defined by the 
WHO classification. The recent progress in molecular biology and genetics has brought 
new insights in the biology of those tumors and allows better understanding of the 
biology of the tumors.  
 
This work provides a comprehensive analysis of two different genetic approaches in 
PLGGs. The first part is based on the description of somatic genetic alterations of the 
DNA. Using a large PLGG cohort, we have been able to dissect the genome of those 
tumors and draw the landscape of the genetic alteration of those tumors. Although 
BRAF and FGFR1 alterations are predominantly altered in those tumors, we have 
discovered a new translocation, MYB-QKI, that is almost exclusively present in a specific 
histological subgroup; angiocentric gliomas.  
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The second part of the thesis describes another angle of the biology of PLGGs by 
analyzing the transcriptome of bulk tumors. This work describes molecular differences 
between PLGGs from distinct histologies and arising from different locations in the brain 
as well as different BRAF mutation status. 
 
As bulk tumor analysis is contaminated by several cell types, we were also able to test 
single cell expression analyses in three pilocytic astrocytomas (PAs) using RNA-
sequencing. In this experimental work we have successfully tested the hypothesis that 
we can isolate single cells from fresh PLGG tumors in order to analyze the trasncriptome 
at a large scale. We observed that single cells expressing A2B5, a glial progenitor 
marker, isolated in pediatric pilocytic astrocytomas are characterized as a distinct 
biological population in comparison with A2B5 negative cells. These results underline 
the importance to improve the precision of the transcriptomic studies to capture the 
molecular signal of tumor cells and further understand the different pattern between 
normal cells and tumor cells.  
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Chapter 1: Introduction 
 
1. Clinical and biological characteristics of Pediatric Low-Grade Gliomas (PLGGs) 
 
1.1. Definition 
 
The World Health Organization (WHO) currently classifies PLGGs according to their 
morphological features1. Defined as grade I or II they represent a heterogeneous group 
of tumors, with more than 20 histological subtypes. PLGGs have been distinguished as 
either astrocytic tumors, oligodendroglial or oligoastrocytic tumors, neuronal, mixed 
neuro-glial or neuroepithelial tumors (Table 1). Tumors that do not meet the typical 
criteria of any single category are commonly labeled LGG-NOS for 'not-otherwise 
specified', which comprise more than a third of all PLGGs2. This sometimes results from 
small biopsy samples that lack sufficient material which to assign a WHO grade, and at 
other times, as a result of pathologic features that do not fit any one category.  
 
Grade I pilocytic astrocytomas (PAs) are classically characterized by the presence of 
Rosenthal fibers, biphasic architecture, vascular proliferation, and eosinophilic granular 
bodies1 (Figure 1a). Eosinophilic granular bodies are often located near cystic areas and 
may be implicated in cyst formation3. Less commonly, PAs contain regions of 
calcification4. Useful positive immunohistochemical markers include oligodendroglial 
markers OLIG2, myelin basic protein (MBP), platelet-derived growth factor (PDGF)5-8 as 
well as the astrocytic marker Glial Fibrillary Acid Protein (GFAP), which is also 
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considered a stem cell marker 9,10. Gangliogliomas (GGs) are also grade I tumors and 
are characterized by perivascular chronic inflammation, granular bodies, binucleated 
neurons, calcification, and cystic degeneration11 (Figure 1b). Dysembryoplastic 
neuroepithelial tumors (DNTs) and Angiocentric gliomas (AGs) are recently described 
subtypes also defined as grade I tumors. DNTs include a specific entity characterized by 
GFAP-negative oligodendroglia-like cells and floating neurons with a mucinous 
eosinophilic background 12,13 (Figure 1c). AGs, initially described by Lellouch-Tubiana et 
al., also named angiocentric neuroepithelial tumors (ANET), encompasses classically 
fusiform and bipolar astrocytic cells which stain positively for GFAP and S-100 arranged 
around blood vessels creating palisade-like structures 14,15 (Figure 1d). 
Microcalcifications are infrequently present. WHO grade II lesions include diffuse 
astrocytomas (DAs), pilomyxoid astrocytoma (PMAs), pleomorphic xanthroastrocyoma 
(PXAs), and oligodendroglial tumors.  DAs are characterized by the presence of nuclear 
atypia, a low mitotic rate, and absence of vascular proliferation or palisading necrosis 
(Figure 1e).  PMAs are characterized by astrocytic pleomorphism, significant cellular 
atypia, and multinucleated giant cells with intracellular lipid accumulation (Figure 1f). 
PXAs consist of pleomorphic and lipidized cells and tend to follow a more aggressive 
course with an increased frequency of leptomeningeal disease16,17 (Figure 1g). 
Oligodendroglial tumors contain monomorphic cells with uniform round nuclei and 
perinuclear halos, microcalcifications and network of capillaries (Figure 1h and 1i). 
PLGGs typically have a low proliferative index, with MIB-1 scores between 0.1-10%18-22.  
This index is often higher in younger children where MIB-1 index higher than 10% can 
be seen in true PLGGs. However, correlation to either overall or progression-free 
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survival in most studies has been variable and it remains unclear as to whether there is 
any prognostic significance18,23-31. 
 
 
Table 1: 
 
Major different subtypes of pediatric low-grade gliomas according to the latest 
WHO classification 
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Figure 1: 
Morphological aspect of the major subtypes of PLGGs defined by the  
WHO classification (H&E staining) 
 
 
                                                                                            c. Dysembryoplastic     
   a. Pilocytic Astrocytoma        b. Ganglioglioma                   Neuro-epithelial tumor                                                                  
   !!!!     
                 x200                                     x100                                        x100 
 
 
 d. Angiocentric Glioma         e. Diffuse Astrocytoma          f. Pilomyxoid Astrocytoma 
       
                  x100                                      x100                                       x100 
 
 
g. Pleiomorphic  
    Xanthoastrocytoma             h. Oligoastrocytoma               i. Oligodendroglioma 
      !
                 x60                                         x60                                         x60 
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1.2. Epidemiology 
 
Brain tumors represent the most common solid tumor of childhood, of which PLGGs 
are the most frequent32. The annual incidence of PLGGs is 2.1 per 100,000 persons in 
the United States33,34, accounting for 1600 new diagnosis each year.  
 
Table 2 summarizes the frequency of the major PLGG subtypes reported in recent 
epidemiologic studies2,35-39. The relative incidence of each LGG histological subtype 
varies with age, with clear differences in distribution between pediatric and adult LGGs 
(Figure 2). PAs most frequently develop during childhood and are extremely rare in 
adults. They represent the most common PLGG, accounting for 15% of all pediatric 
brain tumors2,36,37,40,41 (Figure 3). DAs, oligodendrogliomas and oligoastrocytomas are 
more common in adults but extremely rare in children, representing less than 5% of 
PLGG 10,2,27-29. Similarly, neuronal and mixed glial-neuronal tumors occur more 
commonly in the pediatric population. In addition to the defined groups of tumors, LGG-
NOS tumors represent the second most prevalent diagnosis and have been reported to 
account for at least 17% of all PLGGs 2.  This is despite the fact that in most historical 
studies and governmental databases, this category is not included. This highlights the 
increasing need for integration of histology with molecular data to improve categorization 
of PLGG tumors. Although PLGG tumors can occur anywhere throughout the CNS, 
different subtypes demonstrate predilection for specific sites within the brain or the 
spine42.  
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Pediatric DAs, AGs, PXAs and oligodendrogliomas are most frequently supratentorial 43-
45,46, GGs occur most frequently within the temporal lobes17,18,47 while PAs tend to 
localize to the cerebellum or the brainstem48. 
 
A fair fraction of PLGG can arise in the optical pathway as well as in the 
diencephalic/hypothalamic region; the incidence of those tumors is significantly higher in 
patients with neurofibromatosis type 1 (NF1).  
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Table 2: 
 
Overview of six epidemiological studies including PLGGs performed in various 
countries around the world 
 
 
GRADE 
(WHO) 
WHO 
International 
Classification 
of Diseases 
USA Germany France Denmark Brazil 
Number of total 
CNS tumors  5200 20,709 3268 1017 911 1058 
Type of study  Retrospective 
Retrospective         
CBTRUS 
Statistical 
Report 
Retrospective  
German 
Childhood  
Cancer 
Registry 
Prospective  
French 
Brain 
Tumor 
Database 
Retrospective     
Multi-
institution 
Retrospective    
Single-
institution 
Hospital das 
Clinicas of 
Sao Paulo 
Age at diagnosis  0-19 years 0-19 years 1-15 years 0-19 years 0-15 years 0-21 years Follow-up period  1980-1999 2005-2009 1990-1999 2004-2006 1960-1984 1974-2003 
        Frequency of 
tumors (%)        
Astrocytic 
tumors    16.4    
PA I 14.8 15.5 
NA 
23.1 16.5 18.2 
DA II 1.8 5.2 1 
13 6.2 PXA II 0.4 NA 0.3 
        Oligodendroglial 
tumors        
Oligodendroglioma II 1.4 1.1 1.1 4 1.6 0.9 
        Oligoastrocytic 
tumors        
Oligoastrocytoma II 0.6 0.7 NA 1.1 NA NA 
        Neural and mixed 
neuro-glial 
tumors        
GG I 2.5 
7 
3.2 4.6 2.2 3.6 
Desmoplastic 
infantile 
astrocytoma 
I NA NA 0.1 NA 0.3 
DNT I NA NA 3.1 NA 1.3 
        LGG-NOS tumors I, II 0.1-6 11.3 NA 1.8 0.4 NA 
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Figure 2: 
 
Comparison of the distribution of histological subtypes developing during 
childhood (0-19 years) and adulthood, according to the CBTRUS Statistical 
Report, 2012 
!!!!!!!!!!!!! !
 
Figure 3: 
 
Distribution of PLGGs histological subtypes during the 4 stages of development, 
according to the CBTRUS Statistical Report, 2012 
!!!!!!!!!!!! !
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Five percent of all PLGGs primary tumors are located in the spine and these are most 
frequently PAs49. PLGG can also develop in the cervicomedullary region50 as well as in 
the tectum. 
 
1.3. Genetic predisposition syndromes 
 
Initial insight into the molecular characteristics of PLGGs was derived from the 
subset of non-sporadic tumors associated with genetic syndromes.  Among these, the 
most frequent association is with NF1, also known as von Recklinghausen disease. PAs 
and DAs are the most common subtypes associated with NF151 and most commonly 
involve the optic pathway and hypothalamus52-54. NF1 is characterized by a germline 
mutation of neurofibromin 1 (NF1), located on chromosome 17q, which results in 
activation of the RAS/MAPK signaling pathway. Importantly, only 30% of the tumors 
become symptomatic and require treatment, which suggests a unique biology underlying 
these tumors55,56.  
 
Tuberous Sclerosis (TS) is another neuro-cutaneous disorder with increased predilection 
for LGG, with brain tumors found in 5-14% of patients57.  The most frequent brain tumor 
associated with TS is sub-ependymal giant cell astrocytoma (SEGA)58. TS is caused by 
mutations in two tumor suppressor genes, TSC1 (hamartin, on chromosome 9q34) and 
TSC2 (tuberin, on chromosome 16p13)59.  These genes are part of the Rheb-mTOR 
pathways that function in regulation of cell proliferation.  
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These genetic syndromes contributed to our understanding of the importance of the 
ras/mTOR pathway in the oncogenesis of PLGGs.  Additional findings from recent 
genomic studies have added further insights into the vital role of this pathway in the 
pathogenesis of PLGGs. 
 
1.4. Clinical aspects 
 
The clinical presentation of PLGGs is dictated by their location. Tumors in the 
posterior fossa typically present with acute signs and symptoms of elevated intracranial 
pressure secondary to obstructive hydrocephalus, as well as cerebellar signs60, whereas 
LGGs of the optic pathway impair vision.  PLGGs affecting the cerebral cortex typically 
present with focal neurological manifestations such as seizures or behavioral changes. 
Seizures are particularly associated with temporal, frontal, or parietal localization and 
oligodendrogliomas, GGs, DNTs or AGs subtypes61-65. Tumors involving the 
hypothalamus manifest with endocrinopathies or the diencephalic syndrome66-68. Tectal 
gliomas are often associated to hydrocephalus due to their expansion to the 
periaqueductal space. Compared to sporadic PLGGs, the clinical spectrum of NF1-
related PLGGs diverges. NF1 patients more commonly present with multifocal tumors 
compared to sporadic cases69.   
 
PLGGs are most frequently localized at diagnosis, although they can present with 
disseminated disease.  Leptomeningeal dissemination is reported in approximately 3-5% 
of children at presentation, especially in the setting of spinal cord or 
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diencephalic/hypothalamic lesions70-72, and may be associated with inferior overall 
survival compared to those who present with localized disease73-75.  
 
Radiological features of PLGGs are variable. These neoplasms are usually hypodense 
on CT compared to more malignant neoplasms. Grade I PLGGs are typically well-
circumscribed tumors, with T1-hypointensity and T2-hyperintensity on MRI imaging. 
Following gadolinium administration, grade I astrocytomas usually demonstrate 
homogeneous enhancement.  In contrast, grade II gliomas, especially DAs, are typically 
non-enhancing and may be less circumscribed76-80. PMAs express usually 
heterogeneous enhancement80. PLGGs are not usually associated with peri-tumoral 
edema or restricted diffusion on diffusion-weighted MRI sequences81. Magnetic 
resonance spectrometry (MRS), diffusion-weighted MRI (DWI) and diffusion tensor 
imaging (DTI) serve as useful adjuncts in further characterizing PLGGs.  PET-scan and 
single-photon emission CT (SPECT) may also aid assessment of treatment efficiency 
and tumor recurrence. GGs typically exhibit contrast enhancement on CT scans and can 
have variable gadolinium enhancements on MRI – from absence of contrast 
enhancement to nodular or circumferential. Similar to astrocytomas and oligodendroglial 
tumors, they appear T1-hypointense and T2-hyperintense on MRIs. The contrast 
enhancement for oligodendroglial tumors is variable and is related to the infiltrative 
aspect of the tumors with a higher gadolinium contrast enhancement in solid and non-
invasive tumors. DNTs do not displace brain structures but tend to infiltrate and usually 
have low or no contrast enhancement.  They appear as bright T2-weighted and 
hypointense T1 tumors with typically neither mass effect nor peritumoral edema. Their 
slow growth may be associated with skull deformation when located in the cortex. 
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The natural history of pediatric LGGs is distinct from that of adult LGGs.  On the whole, 
PLGGs exhibit slow rates of growth. Thus, the majority of children are diagnosed at least 
six months after symptom onset82. PLGG have been reported to spontaneously regress, 
especially in patients with NF183-87, who have been reported to have superior outcomes 
compared to sporadic cases88-90. Tumors that can be completely resected often require 
no further therapy highlighting the importance of location on outcome. In a recent 
prospective population-based study of a large cohort of 639 PLGGs, the 5-year PFS 
(progression free survival) was 69.4%91, which is comparable to other studies82,92-97. 
Given the fact that two thirds of NF1 patients never progress, the recurrence rate of 
sporadic PLGGs is near 55%, as reported in the recent COG study98. The most 
significant risk factors for progression identified on multivariate analysis were young age 
at diagnosis (<1 year), subtotal resection, and DA histology99. Due in part to a better 
chance of complete resection, tumors involving the optic nerve or cerebellum have 
better progression-free survival (PFS) compared to those involving the chiasm and 
hypothalamus. Even if progression occurs, children diagnosed with PLGG have an 
excellent overall survival long-term, as described in a recent analysis of the SEER 
(Surveillance Epidemiology and End Results) database showing a 20 year overall 
survival of 87%100. In contrast to adults, PLGGs are characterized by a low incidence of 
malignant transformation101-103.  Importantly, adult survivors of PLGG have low glioma 
related mortality, suggesting a very low propensity for malignant transformation of 
PLGG100. 
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1.5. Therapeutic strategies 
 
Given the excellent overall survival for the majority of PLGG patients, the treatment 
goal is to achieve tumor control while minimizing long-term tumor and treatment-related 
morbidity104.  Most patients require only surveillance after surgery. If progression, 
recurrence and/or symptoms occur, then treatment modalities including surgery, 
chemotherapy (including biologic therapy), or less frequently, radiation therapy are 
indicated. 
 
Surgical resection remains the cornerstone of PLGG management. Patients with gross 
total resection of tumor typically do not need further treatment. However, gross total 
resection is not always achievable without significant neurological impairment for some 
tumor locations, such as the optic pathway, hypothalamus, diencephalon, and 
brainstem.  In these instances, the goal of surgery is to achieve maximal resection 
without risking severe neurologic deficits.  Even in the event of a subtotal resection, the 
overall survival of patients remains excellent 100,105-110. 
 
Chemotherapy is usually initiated for radiological and/or symptomatic progression. Over 
the last few decades, many protocols using either monotherapy or poly-chemotherapy 
have been tried for PLGG.  Platinum-based chemotherapy such as carboplatin111-113, 
cisplatin114, oxaliplatin115, ibroplatine116 alone or in combination with vincristine117-125 or 
etoposide (VP16)126 have been widely utilized and evaluated. The combination of 
vincristine and carboplatin is commonly used as first-line therapy, with 5-year overall and 
progression-free survival rates of 86 to 97% and 39 to 61%. Carboplatin hypersensitivity 
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is the most frequent adverse event127-129, which can be effectively managed with pre-
medication32. Ototoxicity is another issue that is important to monitor during treatment 
with platinum compounds. A combination of thioguanine, procarbazine, lomustine, and 
vincristine (TPCV) is another well-established chemotherapy regimen for progressive 
PLGG125,130-132. A prospective randomized clinical trial comparing outcomes of 
vincristine/carboplatin versus TPCV revealed that treatment with TPCV had a trend 
towards superior 5-year event-free survival (EFS) compared to vincristine/carboplatin 
(52% vs 39%, respectively), although this did not reach statistical significance125.  
However, the potential long-term morbidity associated with alkylating agents such as 
infertility and increased risk of secondary malignancy has led most oncologists to use 
vincristine/carboplatin as a first-line therapy over TPCV. Hematologic dyscrasias are 
other potential complications, especially of alkylating agents.  
Alkylating agents have also been tested in combination with tamoxifen 133 or vinblastine 
134 as well as in polychemotherapy regimens with other agents including procarbazine, 
cyclophosphamide, lomustine, vincristine, VP16 or 5-fluorouracile 135-138. Monotherapy 
using temozolomide 139-142, vinblastine 143-145 or cyclophosphamide 146 have been used 
in progressive PLGGs with variable results in terms of outcome, depending on the ages 
of the children and the tumor locations enrolled in the studies.  
Other protocols including vincristine/VP16 147 or vincristine/carmustine 148 associated 
with intrathecal injection of methotrexate have shown 50-70% tumor control (defined as 
radiologic response or stable disease) in progressive PLGGs. Other chemotherapy 
regimens tested include vincristine alone 149, vincristine in combination with actinomycin 
150, high dose ifosfamide 151, high dose cyclophosphamide 152, bleomycine 153, topotecan 
154, idarubicin 155 or lenalinomide 156. 
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The anti-VEGF agent bevacizumab has recently been evaluated in combination with 
irinotecan for PLGG disease progression157-159. A recent phase II study which included 
35 recurrent PLGGs reported at 2-year PFS of 47.8% using this treatment strategy 159. 
Bevacizumab is generally well tolerated, however, patients need close monitoring for the 
development of hypertension or proteinuria and there are concerns for premature 
ovarian failure.  
 
Radiation therapy was once standard-of-care for PLGG, however its use has decreased 
in PLGGs with increased awareness of its devastating long-term morbidities including 
cognitive deficits, increased risk of secondary high-grade malignancies, vasculopathy, 
endocrinopathy, and effects on growth 160-163. Given the excellent overall survival of 
children with PLGG and the numerous available chemotherapy regimens, the use of 
radiation therapy for PLGG is generally avoided to minimize long-term and irreversible 
morbidity, and is used for those in whom disease control cannot be achieved with either 
surgery or chemotherapy (including targeted therapies). Several protocols using 
conformal external beam radiotherapy at doses between 50-59 Gy have been reported 
in the treatment of non-operable or progressive PLGGs with 5-year PFS ranging from 
74%-88% 120,164-166. Over last decade, through the advances in radiotherapy techniques, 
significant progress has been made in minimizing scatter doses to normal brain.  These 
techniques include stereotactic conformational external radiotherapy 167-169, gamma-
knife stereotactic radiotherapy techniques 170-172 and proton beam radiotherapy 173,174.  
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2. Interrogating tumor genomes 
 
One fundamental aspect of research in oncology is to characterize the structural and 
sequences alterations of the genome in tumor cells and to identify how those genetic 
disruptions might influence tumor growth or deregulate the differentiation state of cells.  
 
 2.1. Distinction of copy-number variations (CNVs) 
 
In the late 19th century, Sutton was one of the first scientists that documented the 
presence of chromosomes in grasshoppers. Later in the 1970’s, early studies of tumor 
cells originating from biopsies provided the first insight into tumor cells that were 
essentially arrested in metaphase or prometaphase, where the DNA is the most 
condensed. Despite a resolution of a few megabases, karyotypes from these cells allow 
identification of certain chromosomal abnormalities such as aneuploidy, trisomy and the 
more subtle disruptions such as deletions or insertions. By providing an overview of the 
tumor genome, this technique is still used in clinical routine and has been extremely 
useful to stratify treatment decisions as specific chromosomal disruptions have been 
related to distinct patient outcome, especially in leukemia175,176.  
 
Later techniques using chip-based methods such as CGH (comparative genomic 
hybridization), array-CGH and SNP array, have dramatically improved the resolution of 
the detection of chromosomal imbalances177. These techniques are based on a 
competitive fluorescence in situ hybridization method. Two different sources of DNA, 
labeled with distinct colors of fluorophores are matched on each chromosome for 
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identification of chromosomal differences between the two sources. Comparing to 
traditional techniques such as giemsa banding or fluorescence in situ hybridization 
(FISH), which are limited by the resolution of the microscope, those techniques provide 
a resolution from 5-10 megabases (CGH) to a locus-by-locus resolution of 100 kilobases 
(array CGH). Although conventional CGH and array CGH have been used abundantly to 
detect chromosomal imbalances, they are not able to detect structural alterations such 
as reciprocal translocations or inversions. SNP arrays, that also genotype common 
single nucleotide variants, have the advantage of being able to detect copy-neutral LOH 
(loss of heterozygosity) that can also be involved in oncogenesis. All those DNA chip-
based techniques have been applied to a variety of adult and pediatric cancer subtypes 
providing a comprehensive description of copy-number profiles in those tumors 178,179 
180. One major obstacle of those methods is the limitation of the resolution due to the 
number of probes or markers designed for the platform. Small alterations in the 
sequence (such as indels or short rearrangements) are not identified, as the size and 
the number of markers used does not span all nucleotides.  
 
 2.2. The development of DNA sequencing techniques and its challenges  
 
 The early DNA sequencing techniques were based on the chain termination 
method, developed by Frederic Sanger in the late 1970’s. This method is based on the 
selective incorporation of dideoxynucleotides radioactively or fluorescently labeled for 
the detection. Although this method has been widely used in the last decades, it often 
provides poor quality of the first 15-40 bases due to the primer binding process. 
Additionally, as cloning of the DNA fragments is often used upfront the sequencing, one 
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can find parts of the cloning vector in the resulting sequence. Pyrosequencing 
represents an alternative technique, based on sequencing by synthesis; it allows the 
sequencing of 100-400 megabases in a few hours. 
 
The recent development of next-generation sequencing (NGS) represents a new avenue 
in the exploration of the structure of the cancer genome181. Through digital sequencing 
of both normal (mostly blood) and tumor genomes (issued from biopsies or surgical 
tumor resection), those techniques offer the possibility to detect, at a high-throughput 
level, somatic genetic alterations at a single base resolution. Whole genome sequencing 
(WGS) represents the most comprehensive genomic exploration182. Alternatively, target 
sequencing (of which whole-exome sequencing is a special case183) has recently been 
developed in order to reduce the costs of sequencing184. All those techniques generate 
millions of digital sequences called reads. In order to rebuild the tumor genome from the 
millions of reads generated several analytical methods have been developed. Multiple 
analytical steps are necessary to transform and normalize the raw reads (stored in a 
.fq.gz format) into a collection of mapped reads and their mapping location (stored in a 
.bam file format185). Digital sequencing results in multiple technical biases and artifacts 
that generate noise (biases due to flow cell, lane, dinucleotide context, machine cycles, 
generation of duplicate reads). The challenge of NGS interpretation is to reduce to noise 
in order to provide the best signal. Reads are sorted, normalized, cleaned and marked 
for duplicates. Most of those steps can be performed using SAMtools and Picard tools 
(URLs :!samtools.sourceforge.net, picard.sourceforge.net). These preprocessing steps 
provide the best quality sequencing data that is crucial for further calling applications. 
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Genome Analysis Toolkit (GATK)186 is a powerful computational kit to call somatic 
mutations. 
 
 
 2.3. Detection of somatic point mutations  
 
Two major approaches have been developed to detect structural variants in an 
individual genome from NGS data; de novo assembly and classical alignment 
strategy187. The algorithms used in de novo assembly are trying to reconstruct the entire 
genome of the individual from overlaps between reads generated188. The assembled 
genome is then matched to the reference genome in order to call somatic variants. This 
computational intensive method requires a long reads in order to improve the assembly 
and provide high quality data. In the second strategy, currently the most commonly 
used, structural differences are found by aligning reads from the individual genome to 
the reference genome. Several bioinformatic tools such as BWA, BFAST, Maq have 
been developed to align the billions of reads generated to a reference genome189-191. 
Those approaches are more straightforward for the user and less labor intensive 
computationally. However, sensitive and specific detection of structural variations 
remains still a challenge due to both technological limitations and biological features of 
single variations. Errors in the production of reads, limited read lengths and insert sizes, 
sampling biases (such as CG- rich regions) are the most frequent limitations that are 
causing technical artifacts in DNA sequencing192. Biologically, the presence of numerous 
repetitive sequences is limiting the confidence of the mapping prediction of the 
algorithms. 
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After the assembly step, further algorithms are used to call point mutations. Noisy reads 
(with a low quality score and multiple mismatches) are ignored. Through statistical 
analyses, sites that are likely to carry somatic mutations with high confidence are 
identified193. These detection methods account for the fraction of discordant nucleotides 
between the sequence and its reference, the coverage (average number of reads 
representing a given nucleotide in the reconstructed sequence) at this site as well as the 
quality of the reads. 
 
 2.4. Detection of somatic indels (short insertions and deletions)  
 
By comparing the tumor and the reference sequences, genomic regions that may 
harbor small insertions or deletions (above a specified threshold and having sufficient 
coverage) are called through statistical tools (GATK). In order to decrease the number of 
false positive single nucleotide variations caused by misaligned reads, particularly at the 
3ʼ end, a joint local-realignment of all samples from a same individual (“co- cleaning”) is 
highly recommended (GATK). All sites potentially harboring small insertions or deletions 
in either the tumor or the matched normal are realigned in all samples. 
 
 2.5. Detection of chromosomal rearrangements 
 
Tracking the exact breakpoints of small rearrangements or indels has become 
particularly feasible with whole genome sequencing (WGS). When performing paired-
end sequencing of the tumors (both ends of a fragment are sequenced), depending on 
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the coverage and the length of the reads it is possible to identify rearrangements by 
detecting the presence of discordant reads (the expected distance between two pairs of 
reads is higher or smaller than predicted from the fragment size, or the reads are 
disoriented) that support the presence of structural variations in the genome. 
Rearrangements are predicted from read pairs mapping to different chromosomes or to 
unexpected positions or orientations on the same chromosome. Further tools fish for 
reads spanning a fusion and maps the exact breakpoint using modified alignment 
algorithms. Each breakpoint is called and assigned with a score reflecting the number of 
tumor reads supporting a breakpoint, the fraction of nearby reads with MAPQ0, the 
prevalence of other nearby discordant pairs and the standard deviation of breakpoint 
starting positions194.  
 
 2.6. Distinction of passenger and driver mutations 
 
Since the development of NGS techniques, the number of tumor samples 
sequenced has exponentially increased195. This represents a huge resource in order to 
provide a comprehensive description of the genome of different tumor types. Indeed, 
one crucial aspect in oncology is to distinguish driver mutations, likely to cause directly 
the cells to transform and generate a tumor, from passenger mutations that occur 
randomly across the genome during the replication. Being able to identify driver 
mutations for each cancer type represents an important challenge in oncology as these 
alterations represent potential therapeutic targets. As passenger mutations tend to occur 
randomly across the genome, it becomes easier to reveal potential driver mutations 
when a same mutation is recurrent across multiple tumors. Several analytical tools have 
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been recently developed in order to identify significant recurrent mutations across a wide 
panel of tumors that have been sequenced196,197. Briefly, the concept is to detect the 
mutations that occur in a set of individuals with a higher prevalence, above a mutation 
rate. One example of a tool developed by the Broad Institute is called Mutsig. The 
algorithm determines first the number of mutations and the number of covered bases for 
each gene. The counts are then broken down by mutation context category: four context 
categories discovered by MutSig, and one for indel and 'null' mutations, which include 
indels, nonsense mutations, splice-site mutations, and non-stop (read-through) 
mutations. For each gene, Mutsig calculates the probability of seeing the observed 
distribution of mutations or a more extreme one, given the background mutation rates 
calculated across the dataset198. These algorithms are continuously improved in order to 
increase the specificity to detect potential driver mutations. Several parameters such as 
the gene footprint length, the replication time, the level of expression of genes and the 
GC content have been identified as influencing the mutation rate and are therefore 
considered as confounders.   
 
 2.7. Detection of CNVs using NGS data 
 
In sequencing files, once reads are normalized it is possible to detect structural 
variations using the copy-number ratio obtained through the coverage. Computational 
tools are combining a local change-point analysis and subsequent merging of adjacent 
chromosomal segments with similar copy number. 
 
 2.8. Analyses of the transcriptome 
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For RNA analysis, various techniques have been developed in the past to explore 
the transcriptome of tumors. The most frequent one was the microarray technology that 
measures the relative expression of target genes based on the hybridization of mRNA to 
probes designed on the chip. This cost-effective methodology has been applied widely 
at a large scale across multiple tumor types. However, an important limitation is related 
to the fact that this technique represents a semi-quantitative detection of the gene 
expression. Indeed, the signal is quantified by the amount of chemiluminescence or 
fluorophore emission activated by the amount of nucleid acid that binds to the target. 
The signal can thus be quickly saturated. Alternatively, an analytical technology, Serial 
analysis of gene expression (SAGE) and all the following derivative versions 
(LongSAGE, RL-SAGE, SuperSAGE) provide more a quantitative measure of the 
concentration of mRNA in a cell. This tag-based method allows also the potential 
discovery of new transcripts, as it is not based on a known target. These more costly 
methods are progressively replaced by RNA-sequencing that provides the most 
comprehensive information of the transcriptome of a cell at a particular time. Based on 
the abundance of cDNA reads sequenced, this method provides not only the 
quantitative gene expression level in an organism but is also able to detect alternative 
splice variants, somatic point mutations and rearrangements. 
 
 2.8.1. Distinguishing known classes 
 
 One of the important aspects of transcriptomic analysis is to identify specific 
patterns across the dataset. Supervised learning is one task that is commonly used in 
gene expression analyses. The task consists of analyzing a training set that produces an 
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inferred function, which serves as a model to test new examples and test whether the 
new input vector is correctly predicted by the model and therefore belongs to the class. 
Several supervised learning algorithms are available such as support vector 
machines199, linear regression200, logistic regression and neuronal networks201.  
 
 2.8.2. Detecting subclasses 
 
 A complementary approach used in gene expression analysis is unsupervised 
classification or clustering. Cluster analysis groups objects in clusters in such a way that 
objects in a cluster are more similar to each other than to those in other groups. Different 
approaches exist. Hierarchical clustering (also called connectivity models) are grouping 
samples based on their distance connectivity202. Centroid models (for example k-mean 
algorithms) defined each group by a single mean vector203. In the distribution models, 
clusters are defined by their statistical distribution204. Density models or subspace 
models are other types of algorithms used in unsupervised clustering205. By providing 
the number of subclasses in a specific dataset, those tools give an insight of the degree 
of heterogeneity in the dataset and encourages to explore further the molecular 
specificity of each subgroups. 
 
 2.8.3. Detecting pathway activation 
 
 Several tools are available to identify genes that are significantly overexpressed 
or underexpressed between specific groups, related to different phenotypes or defined 
by the unsupervised clustering methods. It is also possible to identify gene-sets related 
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to a specific biological task that are enriched in a specific group. One example of such a 
method is called gene-set enrichment analyses (GSEA)206. This statistical tool identifies 
groups of genes (directly uploaded from the NCBI databases such as Biocarta and Gene 
Ontology) that are regulated together in a predefined group of samples.  
 
 2.9. Detecting mutations and rearrangements in RNA-seq data 
 
Several analytical tools are currently developed to explore the architecture of the 
RNA207-209. RNA-seq analyses allow the detection of fusion genes as well as different 
splice variant in an usupervised approach.  
Identification of all splice variants represents an important asset. All RNA-Seq reads 
identified as clusters supporting each splice variant are identified. Reads are then 
aligned to a reference genome containing annotated spliced transcript sequences and 
unspliced gene sequences. It is therefore possible to identify alternative splicing that 
occurs in the RNA sequence.  
RNA-sequencing is also powerful to detect rearrangements as long as transcripts are 
expressed. Numerous bioinformatic packages have recently been developed in order to 
detect chimeric reads supporting rearrangements (FusionSeq, TopHat-Fusion, Fusion-
Finder, FusionHunter,…). Those tools are based on the discovery of reads mapping two 
different genes and the presence of chimeric reads spanning the fusion between two 
genes. 
Similar to DNA-sequencing, using a mapping algorithm, it is possible to identify 
candidate mutations by comparing the reads from the tumor to the reference sequence. 
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The detection of somatic mutations in RNA-seq data is possible if the gene is enough 
expressed so that it is characterized by a reasonable coverage.  
As for DNA sequencing analyses, multiple technical artifacts (transcript size, GC 
content, and sequencing depth) interplay in the analyses of RNA-seq data and need to 
be optimized in order to provide better quality data especially to call translocations or 
somatic mutations with a high sensibility, despite the low quality of samples 210.  
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3. Genomic features in PLGGs 
 
Very few reports in the literature describe karyotypes in PLGGs and those that have 
been characterized have been commonly reported to be normal211.  A striking finding of 
PLGGs is the low number of genetic alterations present in the tumors.  Early cytogenetic 
studies revealed almost normal diploid karyotypes across multiple subtypes of 
PLGGs211-213. The most frequent recurrent chromosomal alteration identified was a gain 
of chromosome 7, especially in PAs 212,214-216. Other chromosomal structural 
abnormalities included gains of chromosome 4, 5, 6, 8, and 11 and deletion of 17p in a 
subset of PAs, inversion in chromosome 8, and loss of chromosome 1q212,214-222.  
In the late 2000’s, the first copy-number profiles in PLGGs have been performed. 
Several studies profiling essentially PAs using array-CGH have been performed and 
described a recurrent gain of chromosome region 7q34, representing the only detectable 
genomic alterations in these tumors223-226. Additional genomic profiling of diffuse PLGG 
subtypes, such as DAs, AGs and GGs revealed recurrent gain of chromosome MYBL1 
and loss of MYB and CDKN2A/B227.  
Recent advances in high-throughput genetic sequencing and gene expression profiling 
have shed important insights into the genomic alterations of PLGGs181,228,229.   
 
One important limitation to these studies is the lack of sufficient tumor tissue from rarer 
subtypes of PLGGs such as tectal gliomas, thalamic and optic pathway tumors. 
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3.1. Neurofibromatosis 1 (NF1) 
 
The increased risk of LGGs in children with NF1 germline mutation was one of the 
first clues that dysregulation of the mitogen-activated protein kinases (MAPK) pathway 
may be important in the pathogenesis of PLGGs. NF1 encodes neurofibromin, which is 
ubiquitously expressed at variable levels in different tissue types during development.  
Structurally, neurofibromin contains a central domain homologous to Ras-GTPase-
activating (Ras-GAP) proteins and acts as a negative regulator of the Ras-Raf-MEK-
ERK pathway230. In neurofibromatosis, NF1 mutations produce a loss of function of 
neurofibromin that leads to the constitutive activation of the Ras pathway and results in 
proliferation of astrocytes32, among other phenotypes. Thus, MAPK pathway activation 
has long been known to contribute to the pathogenesis of LGGs in NF1 patients231. In 
addition, constitutive expression of MEK1 causes an increase in astrocytic proliferation.  
 
3.2. BRAF duplication-fusions 
 
Genetic rearrangements of the oncogene BRAF are the most common genomic 
alterations found in sporadic PLGGs.  Early studies utilizing comparative genomic 
hybridization (CGH) identified a gain of the specific chromosomal region 7q34 containing 
the BRAF locus as the most frequent copy number alteration in PLGGs32, involving 50-
100% of pediatric PAs225,232,233. The BRAF duplication is found more frequently in 
cerebellar and hypothalamic-chiasmatic tumors225.   
The 7q34 gain has been characterized to represent a duplication of BRAF with a tandem 
insertion in the KIAA1549 gene32.  This BRAF duplication results in the activation of the 
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downstream effectors of the MAPK pathway, MEK and ERK223,226. Subsequently, 
variants of the fusion transcript involving BRAF gene have been described, involving not 
only KIAA1549 but also other fusion partners, SRGAP3, FAM131B, MACF1, RNF130, 
CLCN6, MKRN1 and GNAI1234-237 228,229. RAF1, which encodes a protein that leads to 
the stabilization and activation of BRAF, has also been described to harbor gene fusions 
with SRGAP3 and QK1, leading to the constitutive activation of MAPK pathway229,234,236. 
These BRAF rearrangements tend to occur frequently in cerebellar lesions. Strikingly, all 
of the fusion protein variants are characterized by loss of the N-terminal inhibitory 
domains of BRAF, resulting in constitutive activation of the BRAF kinase and 
downstream activation of MAPK and its effectors, MEK and ERK.  
Although the BRAF fusion protein has been shown to result in a tandem duplication of 
the BRAF locus, further studies are necessary to explain the precise mechanism by 
which the fusions contribute to the formation of tumor and the specific role of KIAA1549 
and SRGAP3 segments within the BRAF fusion transcripts. One recent study reported 
that regions flanking the breakpoints of the RAF gene fusion are enriched with 
microhomologous sequences.  This has led to the hypothesis that tandem duplications 
of the RAF gene might be generated by microhomology-mediated break-induced 
replication238. In vitro evaluation of the effect of the BRAF fusion protein has suggested 
that this protein has oncogenic properties and is able to activate the MAPK pathway. 
The short form of KIAA1549-BRAF fusion induces anchorage-independent growth in 
multiple cell lines236,239. Furthermore, pharmacologic inhibition of MEK1/2 in short-term 
cultured PLGG cell lines significantly diminishes cell proliferation223, supporting a role of 
the MAPK pathway in promoting proliferation.  Taken together, BRAF and RAF1 fusion 
transcripts, leading to constitutive activation of MAPK pathway, may play a crucial role in 
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the pathogenesis of sporadic PAs and may also present potential therapeutic targets for 
PLGGs.  
 
3.3. BRAF V600E and other less frequent mutations 
 
Another frequent genomic alteration in PLGGs is the BRAF V600E mutation169, 
which also results in deregulation of the MAPK pathway32. This mutation has been 
described in other cancer subtypes, including melanoma240, colorectal cancer241, 
leukemia242, and high-grade gliomas243. BRAF is one of the most mutated genes in 
cancer195.  The BRAF V600E point mutation occurs most commonly in PXAs, GGs, DAs, 
and PMAs228,229,234,244-248 and is only rarely detected in PAs249. Thus BRAF duplications 
and V600E point mutation are almost always mutually exclusive. The BRAF V600E 
alteration confers constitutive BRAF kinase activation, and transforms NIH3T3 
fibroblasts in vitro236. Other rare forms of small amino-acid insertions in BRAF have been 
identified in PAs228.  The BRAF V600E mutation has been shown to promote 
transformation of human neural stem cells, followed by senescence250. However, it 
remains unclear whether this recurrent alteration is sufficient to drive the development of 
PAs.  
 
3.4. Other mutations and rearrangements involving the MAPK pathway 
 
Recent landmark sequencing projects including large cohorts of PLGGs identified 
recurrent genomic alterations in fibroblast growth factor receptor type 1 (FGFR1) 228,229. 
FGFR1 genomic alterations have also been described in breast cancer, lung cancer, 
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and glioblastomas. FGFR1 point mutations (N546K and K656E) were found in 5% of 
supratentorial PAs. Both mutations have been described to transform cells in vitro. In 2% 
of cases, FGFR1 mutations were associated with the presence of a PTPN11 mutation, 
another downstream effector of FGFR1228. In the same study, one PA possessed a 
tandem duplication of FGFR1. Importantly, gene expression analysis revealed that 
FGF2, a ligand of FGFR1, was significantly over-expressed in PAs compared to other 
astrocytic tumors, suggesting that the FGF/FGFR pathway alteration plays an important 
role in tumorigenesis of PLGGs. Additionally, FGFR1 mutations and duplication of its 
tyrosine kinase domain have also been described in PAs, DAs, and DNTs229.  
Alterations of other MAPK members have also been described in PLGG.  These include 
genomic alterations affecting the kinase domain of neurotrophic tyrosine kinase type 2 
(NTRK2), which have been described in pediatric PAs228. Finally, KRAS activating 
mutations have also been described in 3-5% of sporadic PAs228,229,234,251,252. 
 
3.5. PI3K and RTK Signaling 
 
After the MAPK pathway, the other most frequently altered pathways in PLGGs 
include the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin 
(mTOR) pathway, the epidermal growth factor receptor (EGFR) pathway, sonic 
hedgehog (SHH) signaling, and the vascular endothelial growth factor (VEGF) signaling 
pathway. 
PI3K is an intracellular protein that is recruited to the cell membrane after stimulation of 
a transmembrane growth receptor such as EGFR or platelet derived growth factor 
receptor A (PDGFRA - which also signals along the Ras-Raf-MEK-MAPK pathway), 
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resulting in activation of downstream effectors, such as AKT and mTOR, to induce cell 
proliferation and inhibition of apoptosis. As initially suggested by early studies of 
tuberous sclerosis, activation of mTOR through mutations of its upstream inhibitor result 
in increased predisposition for PLGGs, in particular the SEGA subtype. In a series of 
PLGG, 44% of tumors were demonstrated to have evidence of PI3K/Akt/mTOR pathway 
activation32. Over-expression of the BRAF-fusion transcript in neural stem cells results in 
activation of mTOR pathway, leading to the formation of glioma-like lesions and further 
supports the cross communication between these two pathways253. Additionally, the 
deregulation of Rheb and further mTOR activity in TS patients is another important 
insight for the role of MAPK pathway in PLGGs as mTOR pathway is connected to the 
MAPK pathway. In contrast, MEK1/2 knockdown in mice results in the absence of glial 
cell differentiation and proliferation254. 
Activation of the EGFR pathway has been shown in a small series of PLGGs. 
Comparative genomic hybridization and fluorescent in situ hybridization (FISH) studies 
of six disseminated PLGGs demonstrated EGFR amplification, while none was observed 
in a cohort of localized tumors.  This led to speculation that deregulation of the EGFR 
pathway may play a role in the pathogenesis of disseminated PLGGs255. Additionally, 
rare mutations of PDGFRA have been reported in PAs, GGs, and LGG-NOS tumors248.  
Although the sonic hedgehog pathway is most commonly associated with tumorigenesis 
of medulloblastoma and high-grade gliomas256,257, a recent study suggests that this 
pathway could play a role in a subset of pediatric PAs via the over-activity of PTCH258. In 
this series of 20 pediatric PAs, 45% of tumors demonstrated over-expression of PTCH 
mRNA. Interestingly, a significant inverse correlation between PTCH expression level 
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and patient age suggests that the SHH pathway is more frequently activated in young 
patients.  
Finally, the potential role of angiogenesis is highlighted through studies involving the 
VEGF pathway, one of the major signaling pathways in cancer biology, contributing to 
neovascularization which is essential for tumor growth32. Comparative analysis of vessel 
architecture in 59 pediatric PAs and adult high-grade gliomas showed that vessel 
immaturity and instability are present in both tumor types259. Another study of 17 
pediatric PAs demonstrated immunohistochemical reactivity for activated VEGF 
receptors. However, further validation studies are necessary to confirm altered VEGF 
signaling in pediatric PAs.  
 
3.6. Transcription factors  
 
Genomic alterations affecting key transcription factors have been described in 
PLGGs.  These include MYB amplification in DAs and focal deletions of MYB in AGs260.  
MYB is an oncogene that is mutated or altered in T-ALL261,262, breast cancer, pancreatic 
cancer, and CNS tumors, including primitive neuroectodermal tumors and 
medulloblastoma263,264. In PLGGs, MYB expression has been shown to be upregulated 
in a proportion of diffuse LGGs (60%) and PAs (41%). Its role in the normal development 
of the CNS and tumorigenesis remains unknown.  
More recently, a novel recurrent genetic rearrangement involving another member of the 
MYB transcription factor family, MYBL1, was identified in a cohort of grade II DAs and 
AGs229,227. Importantly, this specific duplication-truncation of MYBL1 has demonstrated 
tumorigenic properties in vitro. 
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3.7. Epigenetic alterations 
 
 Aberrant epigenetic regulation has been increasingly described in human cancers 
and has become a major focus in a number of pediatric cancers 265. Epigenetic 
regulation of the genome can be defined as heritable modifications in gene expression 
that do not directly affect the DNA sequence266. Epigenetic modifications include multiple 
mechanisms affecting the chemical properties of DNA, histones, or other proteins 
involved in DNA packaging267.  The frequency of alterations in epigenetic modifiers in 
cancer has been shown in multiple cancer types including hematologic tumors268,269, 
Wilms’ tumors270, retinoblastoma271, neuroblastoma, thyroid carcinoma, hepatocellular 
carcinoma, sarcoma272, and brain tumors such as medulloblastoma273 and Atypical 
teratoid rhabdoid tumors (ATRTs) with SMARCB1 mutations 274,275.  
The evidence that epigenetics is a major factor in pediatric glioma biology is extremely 
strong. Direct mutations in the chromatin modifier H3F3A have been described in 
pediatric GBMs276 as well as DAs and PAs228,229. This suggests that dysregulation of 
chromatin remodeling effectors are also acting with genomic alterations in the 
tumorigenesis of a small subset of PLGGs. Other genomic alterations include HIPK2 
genomic gains and increased mRNA expression level in a subset of sporadic PAs 
arising from the cerebellum232,277 and BCR gene rearrangement in one PMA278. 
 
3.8. Prognostic implications 
 
Recently attempts have been made to correlate specific genomic alterations to 
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clinical outcome with controversial results. A multivariate analysis of 146 patients 
reported that the presence of the KIAA1549-BRAF fusion protein was the most 
significant favorable prognostic factor in pediatric PAs following subtotal resection279. 
Another study including 106 PLGGs, most of which were sporadic PAs, showed no 
statistical superior progression-free survival rates among tumors with the BRAF 
duplication compared to the wild-type tumors280. The observation that BRAF duplicated 
tumors behave differently than the others remains an open question, especially with the 
recent discovery of new BRAF fusion types that might have biased the previous studies. 
Further larger and controlled or prospective analyses are needed to address this 
question.  It has been hypothesized that improved outcome in PAs conferred by the 
BRAF duplication may be due to oncogene-induced senescence (OIS), which occurs 
through the activation of p16Ink4a pathway281.  OIS is a mechanism of tumor 
suppression that has been implicated in other cancer subtypes282. In contrast, p16 
deletion has been identified as a negative prognosticator in 198 PLGG283. This remains 
to be further validated. Similarly, a recent study performed on GGs has showed that the 
presence of the V600E point mutation was associated with significant lower recurrence-
free survival284. The recent discovery of other genomic alterations such as FGFR1 
mutations will also enlarge the field of exploration between clinical outcome and biology.  
 
3.9. PLGG alterations differ from the adults 
 
Genetic alterations in pediatric LGGs differ from adult LGGs. Concomitant deletion of 
chromosome 1p and 19q is one of the most frequent recurrent genetic alterations in 
adult oligodendrogliomas, aiding in diagnosis as well as serving as a favorable 
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prognostic marker285,286. In contrast, concomitant deletion of chromosome 1p and 19q is 
rare in children with oligodendrogliomas287,288, and does not confer similar 
chemosensitivity when present289. Similarly, mutations in TP53, a tumor suppressor 
gene that codes for a nuclear phosphoprotein and regulates cycle cell arrest, apoptosis, 
and genetic stability, are frequently found in adult but rarely in pediatric LGGs290,248,291-
294. IDH1 and IDH2 mutations are also rarely observed in PLGGs while they are frequent 
in adults. In a recent study examining IDH1 and IDH2 in 445 CNS tumors and 494 non-
CNS tumors, IDH1/2 mutations were described to occur with a frequency of more than 
70% in adult patients across a variety of glial tumors including low-grade astrocytomas, 
anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas and secondary 
glioblastomas derived from the lower-grade gliomas295. In contrast, IDH1/2 mutations 
are rare in children, although when found in adolescent patients they may be a 
harbinger of the adult form of the disease, meriting concordant treatment 
recommendations296,297.  
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4. Goal of the study 
 
Our study was articulated around two major goals. In the first study we performed a 
wide DNA sequencing analysis in order to reveal potential new driver mutations, 
especially in more rare histological subtypes. We wanted to extend the recent effort of 
DNA sequencing in PLGG tumors to increase our power to detect new potential driver 
mutations. Based on the recent sequencing studies, we can reasonably hypothesize that 
BRAF and FGFR1 alterations likely drive a large fraction of PLGGs. However, there is 
still a fraction of tumors that exhibit neither BRAF nor FGFR1 mutations (approximately 
10% of supratententorial tumors). By increasing the number of samples sequenced, we 
increase the probability to detect new potential driver mutation in other PLGG 
subtype195. We also applied algorithms developed at the Broad Institute in order to 
validate independently the previous findings published and extend the genomic 
landscape by adding our local cohort of tumors. 
 
The other study was a large RNA expression profiling study. By a transcriptomic 
approach, we wanted to understand how the clinical heterogeneity of PLGGs was 
reflected at a molecular level and whether we could identify potential transcriptional 
patterns that might inform us about the potential lineage of origin of those tumors. 
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Chapter 2: The Genetic Landscape of PLGGs 
 
1. Introduction 
 
In Chapter 1 we described the various genomic alterations in PLGGs as well as the 
new opportunities brought by the next-generation sequencing technology. One of the 
most important parameters in the detection of driver events from genomic sequencing 
analyses is to obtain enough power to detect potentially new recurrent mutations298. In 
this section we describe a meta-analysis of the genetic alterations in PLGGs which we 
performed by integrating next generation sequencing data from the two major PLGG 
sequencing projects that had been recently published229,299, combined with our local 
cohort which includes samples obtained from the Dana-Farber Cancer Center/Boston 
Children’s Hospital Cancer and Blood Disorder Center (DFCI) and others obtained 
through a collaboration with Children’s Hospital of Philadelphia (CHOP) and Necker 
Hospital in Paris (NEM). By increasing the number of samples, especially the non-PA 
tumors, we have been able to discover new recurrent mutations that might be involved in 
oncogenesis of PLGGs.  
 
2. Methods 
 
2.1. Data downloading and sequencing 
 
Our local cohort of tumors (DFCI and CHOP) was sequenced at the BGI platform 
at CHOP. For WGS, DNA was randomly fragmented and libraries were prepared for 
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paired-end sequencing on an Illumina HiSeq 2000. Exome hybrid capture was 
performed with NimbleGen SeqCap EZ Exome Library SR v2.2, Agilent. The other 
sequencing files were obtained through recently published datasets (one from the 
German Cancer Center – DKFZ in Germany299 and the other one from the Pediatric 
Cancer Genome Project –PCGP, led by St-Jude children’s research Hospital and 
Washington, University of St Louis229).  
 
2.2. WGS/WES analyses pipeline 
 
Raw data from recently published datasets obtained from normalized bam files 
229,299 were generated using the Picard SamToFastq command. The preprocessing 
steps are summarized in Figure 4. Read pairs were aligned to the reference genome 
hg19 (Build 37) using the Burrows-Wheeler Aligner (bwa) with options −q 5 −l 32 −k 2 −o 
1190.  
Figure 5 summarizes the different downstream calling analyses we performed. Copy-
number alterations were evaluated using SegSeq300. We then identified significantly 
recurrent copy-number alterations by adding to segmented copy-number data pseudo-
markers every 10,000 bases and analyzing these by GISTIC 2.0301. Somatic point 
mutations and short indels were called using Mutect and IndelLocator193. In order to 
identify genes that are significantly recurrently mutated above a background mutation 
rate, we used the Mutsig algorithm developed at the Broad Institute197. Rearrangements 
and their exact breakpoints were identified using a combination of dRanger and 
BreakPointer algorithms194. These analyses were performed within the Firehose 
environment302. 
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Figure 4: 
Summary of the WGS/WES preprocessing steps performed for all samples 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SamToFastq (Picard) 
Raw data (Fastq) 
Alignment – sampe (bwa) 
Sort bam by coordinate (samtools)  
Normalization (java) 
CleanSam (Picard) 
FixMates (Picard) 
Uniform Read-Groups (Picard) 
Mark Duplicates (GATK) 
Base Quality Score Recalibration (GATK) 
Indel realignment 
Co-cleaning (GATK) 
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Figure 5: 
 
Summary of all the downstream applications performed on the WGS files with the 
algorithms names used within the Firehose environment  
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2.3. RNA-sequencing analysis pipeline 
 
For RNA-sequencing, total RNA was quantified using the Quant-iT™ RiboGreen® 
RNA Assay Kit and normalized to 5ng/ul. An aliquot of 200ng for each sample was 
transferred into library preparation. This method uses oligo dT beads to select mRNA 
from the total RNA sample followed by heat fragmentation and cDNA synthesis from the 
RNA template.  The resultant cDNA then goes through library preparation using the 
Broad designed indexed adapters substituted in for multiplexing. After enrichment the 
libraries were quantified with qPCR using the KAPA Library Quantification Kit for Illumina 
Sequencing Platforms and then pooled equimolarly. Pooled libraries were normalized to 
2nM and denatured using 0.1 N NaOH prior to sequencing. Flowcell cluster amplification 
and sequencing were performed according to the manufacturer’s protocols using either 
the HiSeq 2000 or HiSeq 2500. Each run was a 76bp paired-end with an eight-base 
index barcode read. Data was analyzed using the Broad Picard pipeline, which includes 
de-multiplexing and data aggregation. The preprocessing steps are summarized in 
Figure 6. The other RNA-sequencing files were downloaded from recently published 
datasets. Downloaded RNA-seq bam files were transformed in fastq files using the 
Picard SamToFastq algorithm. Raw paired-end reads were aligned to the reference 
genome hg19 and preprocessed using the PRADA (Pipeline for RNA-sequencing Data 
Analysis)208. Gene-expression levels, exon expression levels, quality metrics as well as 
detection of fusion transcripts were used from the PRADA software platform within the 
Firehose environment.  
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Figure 6: 
 
Summary of the preprocessing steps and downstream applications performed on 
the RNA-seq files 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
SamToFastq (Picard)!
Raw data (Fastq)!
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Mark Duplicates (PRADA)!
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3. Results 
 
3.1. Description of the cohort 
 
We analyzed the genomes of 169 samples, including 138 that had undergone 
WGS (one of which had also undergone WES) and 53 that had undergone RNA-seq (of 
which 22 samples were also analyzed by WGS).  These included data from 88 tumors 
previously published in a survey of PAs (88 WGS only)299, 57 tumors (25 PAs/57) 
previously published in a survey of various PLGG subtypes (15 by WGS only, 21 by 
RNA-seq only and 21 both by WGS and RNA-seq), 229, and 24 tumors (0 PAs/24) whose 
data have not been published (13 by WGS only, 10 by RNA-seq only and 1 by both).  
Clinical and pathological information of the cohort are summarized in Table 3. 
The largest group of tumors was PAs (112 tumors, or 67%). The other tumor subtypes 
were DAs (24 tumors; 14%), angiocentric gliomas (AGs) (6 tumors; 3.5%), 
oligoastrocytomas (OAs) (5 tumors; 3%), oligodendrogliomas (ODs) (4 tumors; 2.4%), 
pilomyxoid astrocytomas (PMAs) (4 tumors; 2.4%), and gangliogliomas (GGs), 
dysembryoplastic neuroepithelial tumors (DNTs), and pleomorphic xanthroastrocytomas 
(PXAs) (one of each; 0.4% each). Eight tumors (4.9%) were classified as PLGG not 
otherwise specified (NOS) and three tumors (1.6%) were not documented in terms of 
histology. Histological central review was not possible for the samples originated from 
DKFZ or St-Jude. 
The median age in the whole cohort was 6 (range, 0.4-21). 
Overall, the coverage in the three cohorts was comparable with a mean of total 
fraction of callable bases of 89% (range, 75.6-90.6), although the sequencing depth 
used by the centers was different (Figure 7). 
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Table 3: 
Clinical information of the cohort analyzed related to the sequencing type 
Sample ID Age Location Histology 
 
Sequencing 
 
PLGG DFCI/CHOP 1 16.1 IT DA DNA 
PLGG DFCI/CHOP 2 2.1 IT DA DNA 
PLGG DFCI/CHOP 3 5.6 Pons DA, grade II/III DNA 
PLGG DFCI/CHOP 4 10.5 Brainstem DA DNA 
PLGG DFCI/CHOP 5 11.8 CBL DA pilo features DNA 
PLGG DFCI/CHOP 6 14.8 CBL DA pilo features DNA 
PLGG DFCI/CHOP 7 3.3 Temporal Lobe DA DNA 
PLGG DFCI/CHOP 8 1.8 CBL DA DNA 
PLGG DFCI/CHOP 9 21,8 ST DA DNA 
PLGG DFCI/CHOP 10 13 ST NOS DNA 
PLGG DFCI/CHOP 11 ND ST DA DNA 
PLGG DFCI/CHOP 12 ND ST DA DNA 
PLGG DFCI/CHOP 13 ND Parietal Lobe AG DNA 
PLGG DFCI/CHOP 14 3 ST AG DNA/RNA 
PLGG DFCI/CHOP 15 ND CBL DA RNA 
PLGG DFCI/CHOP 16 ND Optic chiasm ND RNA 
PLGG DFCI/CHOP 17 ND Optic chiasm AG RNA 
PLGG DFCI/CHOP 18 ND CBL AG RNA 
PLGG DFCI/CHOP 19 ND 4th ventricle NOS RNA 
PLGG DFCI/CHOP 20 ND CBL NOS RNA 
PLGG DFCI/CHOP 21 ND CBL PMA RNA 
PLGG DFCI/NEM 22 5 4th ventricle NOS RNA 
PLGG DFCI/NEM 23 ND 3rd ventricle ND RNA 
PLGG DFCI/NEM 24 2 CBL NOS RNA 
PLGG DKFZ 1 3 Optic chiasm PA DNA 
PLGG DKFZ 2 1 4th ventricle PA DNA 
PLGG DKFZ 3 4 Optic nerve PA DNA 
PLGG DKFZ 4 7 CBL PA DNA 
PLGG DKFZ 5 15 Hypothalamus PA DNA 
PLGG DKFZ 6 3 CBL PA DNA 
PLGG DKFZ 7 11 CBL PA DNA 
PLGG DKFZ 8 14 CBL PA DNA 
PLGG DKFZ 9 5 CBL PA DNA 
PLGG DKFZ 10 4 CBL PA DNA 
PLGG DKFZ 11 4 Brainstem PA DNA 
PLGG DKFZ 12 2 CBL PA DNA 
PLGG DKFZ 13 3 Brainstem PA DNA 
PLGG DKFZ 14 3 Thalamus PA DNA 
PLGG DKFZ 15 8 3rd ventricle PA DNA 
PLGG DKFZ 16 12 Brainstem PA DNA 
PLGG DKFZ 17 14 CBL PA DNA 
PLGG DKFZ 18 4 CBL PA DNA 
PLGG DKFZ 19 11 CBL PA DNA 
PLGG DKFZ 20 9 Brainstem PA DNA 
PLGG DKFZ 21 9 CBL PA DNA 
PLGG DKFZ 22 15 CBL PA DNA 
PLGG DKFZ 23 3 Brainstem PA DNA 
PLGG DKFZ 24 6 Brainstem PA DNA 
PLGG DKFZ 25 9 Thalamus PA DNA 
PLGG DKFZ 26 3 Thalamus PA DNA 
PLGG DKFZ 27 6 CBL PA DNA 
PLGG DKFZ 28 10 Optic chiasm PA DNA 
PLGG DKFZ 29 5 CBL PA DNA 
PLGG DKFZ 30 9 Thalamus PA DNA 
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PLGG DKFZ 31 13 CBL PA DNA 
PLGG DKFZ 32 5 CBL PA DNA 
PLGG DKFZ 33 4 3rd ventricle PA DNA 
PLGG DKFZ 34 17 Brainstem PA DNA 
PLGG DKFZ 35 4 3rd ventricle PA DNA 
PLGG DKFZ 36 16 CBL PA DNA 
PLGG DKFZ 37 6 CBL PA DNA 
PLGG DKFZ 38 6 CBL PA DNA 
PLGG DKFZ 39 2 CBL PA DNA 
PLGG DKFZ 40 9 Brainstem PA DNA 
PLGG DKFZ 41 14 Brainstem PA DNA 
PLGG DKFZ 42 6 4th ventricle PA DNA 
PLGG DKFZ 43 14 CBL PA DNA 
PLGG DKFZ 44 12 CBL PA DNA 
PLGG DKFZ 45 8 CBL PA DNA 
PLGG DKFZ 46 9 Brainstem PA DNA 
PLGG DKFZ 47 4 CBL PA DNA 
PLGG DKFZ 48 11 CBL PA DNA 
PLGG DKFZ 49 4 CBL PA DNA 
PLGG DKFZ 50 6 CBL PA DNA 
PLGG DKFZ 51 8 3rd ventricle PA DNA 
PLGG DKFZ 52 3 CBL PA DNA 
PLGG DKFZ 53 12 3rd ventricle PA DNA 
PLGG DKFZ 54 21 CBL PA DNA 
PLGG DKFZ 55 4 CBL PA DNA 
PLGG DKFZ 56 7 CBL PA DNA 
PLGG DKFZ 57 15 Parietal Lobe PA DNA 
PLGG DKFZ 58 8 CBL PA DNA 
PLGG DKFZ 59 9 4th ventricle PA DNA 
PLGG DKFZ 60 1 4th ventricle PA DNA 
PLGG DKFZ 61 15 CBL PA DNA 
PLGG DKFZ 62 7 CBL PA DNA 
PLGG DKFZ 63 13 Brainstem PA DNA 
PLGG DKFZ 64 4 CBL PA DNA 
PLGG DKFZ 65 5 CBL PA DNA 
PLGG DKFZ 66 5 CBL PA DNA 
PLGG DKFZ 67 12 3rd ventricle PA DNA 
PLGG DKFZ 68 14 CBL PA DNA 
PLGG DKFZ 69 9 CBL PA DNA 
PLGG DKFZ 70 20 CBL PA DNA 
PLGG DKFZ 71 7 CBL PA DNA 
PLGG DKFZ 72 3 CBL PA DNA 
PLGG DKFZ 73 14 Brainstem PA DNA 
PLGG DKFZ 74 11 Optic chiasm PA DNA 
PLGG DKFZ 75 10 CBL PA DNA 
PLGG DKFZ 76 17 Brainstem PA DNA 
PLGG DKFZ 77 2 Brainstem PA DNA 
PLGG DKFZ 78 7 Hypothalamus PA DNA 
PLGG DKFZ 79 12 IT PA DNA 
PLGG DKFZ 80 1 IT PA DNA 
PLGG DKFZ 81 2 DE PA DNA 
PLGG DKFZ 82 11 DE PA DNA 
PLGG DKFZ 83 5 ST PA DNA 
PLGG DKFZ 84 5 ST PA DNA 
PLGG DKFZ 85 1 DE PA DNA 
PLGG DKFZ 86 7 ST PA DNA 
PLGG DKFZ 87 5 ST PA DNA 
PLGG DKFZ 88 8 IT PA DNA 
PLGG SJUDE 1 4 IT PA DNA/RNA 
PLGG SJUDE 2 6 IT PA DNA/RNA 
PLGG SJUDE 3 1 DE PA DNA/RNA 
PLGG SJUDE 4 0.5 DE PA DNA/RNA 
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PLGG SJUDE 5 5 ST DA DNA/RNA 
PLGG SJUDE 6 1 ST OA DNA/RNA 
PLGG SJUDE 7 1 DE PMA DNA/RNA 
PLGG SJUDE 8 17 IT PA DNA/RNA 
PLGG SJUDE 9 6 DE PA DNA/RNA 
PLGG SJUDE 10 3 IT PA DNA/RNA 
PLGG SJUDE 11 12 IT PA DNA/RNA 
PLGG SJUDE 12 13 ST PA DNA/RNA 
PLGG SJUDE 13 7 ST PA DNA 
PLGG SJUDE 14 NA ST ND DNA 
PLGG SJUDE 15 10 IT PA DNA/RNA 
PLGG SJUDE 16 14 ST PA DNA 
PLGG SJUDE 17 15 ST PA/PMA DNA/RNA 
PLGG SJUDE 18 5 DE PA DNA 
PLGG SJUDE 19 5 IT PA DNA 
PLGG SJUDE 20 4 DE PA DNA 
PLGG SJUDE 21 6 ST PA DNA 
PLGG SJUDE 22 3 Brainstem PA DNA 
PLGG SJUDE 23 5 DE PA DNA/RNA 
PLGG SJUDE 24 0.4 ST NOS DNA 
PLGG SJUDE 25 10 DE PA DNA 
PLGG SJUDE 26 1 Spinal cord PA DNA 
PLGG SJUDE 27 5 ST PA DNA 
PLGG SJUDE 28 3 ST DA DNA/RNA 
PLGG SJUDE 29 11 ST GG DNA 
PLGG SJUDE 30 9 CBL PA DNA 
PLGG SJUDE 31 9 ST DA DNA 
PLGG SJUDE 32 15 ST OD DNA/RNA 
PLGG SJUDE 33 5 ST DA RNA 
PLGG SJUDE 34 3 ST DA DNA/RNA 
PLGG SJUDE 35 2 ST DA DNA/RNA 
PLGG SJUDE 36 13 ST PXA DNA/RNA 
PLGG SJUDE 37 10 ST PA DNA/RNA 
PLGG SJUDE 38 8 ST DA RNA 
PLGG SJUDE 39 9 ST PA/PMA RNA 
PLGG SJUDE 40 6 ST OA RNA 
PLGG SJUDE 41 11 ST DA RNA 
PLGG SJUDE 42 4 ST DA RNA 
PLGG SJUDE 43 11 ST AG RNA 
PLGG SJUDE 44 4 ST OD RNA 
PLGG SJUDE 45 4 ST NOS RNA 
PLGG SJUDE 46 13 ST DNT RNA 
PLGG SJUDE 47 6 ST OD RNA 
PLGG SJUDE 48 5 ST OD RNA 
PLGG SJUDE 49 5 ST NOS RNA 
PLGG SJUDE 50 3 ST AG RNA 
PLGG SJUDE 51 4 ST DA RNA 
PLGG SJUDE 52 4 ST OA RNA 
PLGG SJUDE 53 6 ST DA RNA 
PLGG SJUDE 54 3 ST PA RNA 
PLGG SJUDE 55 13 ST DA RNA 
PLGG SJUDE 56 14 ST OA RNA 
PLGG SJUDE 57 2 ST OA RNA 
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Figure 7: 
Summary of the coverage for the WGS samples in the three cohorts 
(T=tumor, B=blood). 
  
!
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3.2. Structural alterations in PLGGs  
 
High depth sequencing of PLGGs revealed that these tumors harbor very few 
somatic genetic events. Using the copy-number ratio provided by WGS sequencing we 
were able to explore the somatic copy-number alterations (SCNA) of the tumors. As 
previously reported, we observed that PLGGs are very silent in terms of CN alterations. 
Indeed, we observed in our cohort that only 2.4% of the genome was affected by broad 
copy-number alterations (spanning more than half of a chromosome arm) and that 
0.15% of the genome was involved in focal copy-number alterations.  
GISTIC analysis revealed that the most frequent copy-number alterations were 
amplifications in chromosome 5, 6, 7 and 11 and deletions in chromosome 6, 9 and 1p 
(Figure 8A). We observed 6 significant focal copy-number gains and 2 focal deletions 
(Figure 8B). The most significant focal amplification peak was observed in chromosome 
7q34, which corresponds to the BRAF duplications. This event is so recurrent that it can 
be distinguished in the raw copy-number profile. The second most significant focal 
amplification peak encompassed 34 genes on chromosome 5p15 including TERT. In the 
focal deletions peak, we observed at the 9p21.3 region that was significantly deleted, 
CDKN2A and CDKN2B were the 2 genes among only 5 genes reported.  
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Figure 8: Copy-number profiles of the WGS cohort 
A. Raw copy-number heat-map of the WGS cohort!
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B. Focal amplifications (left panel) and deletions (right panel) represented by 
GISTIC 
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3.3. Exploration of the somatic mutations in the cohort 
 
PLGGs exhibit low frequency of somatic mutations. Among the 138 samples 
analyzed by WGS, the median of the mutation rate was 1.02x10-5 mutations/base (range 
4.16x10-6 to 2.91x10-5 mutations/base) (Table 4). In the exonic regions, the most 
frequent mutation category observed was the transitions of C to G or A (Table 5). A 
median of one rearrangement was detected per sample (range 0 – 59).  
 
The overall spectrum of mutations and rearrangements in our cohort is presented in 
Figure 9.  
We observed genetic alterations in 152 of the 169 tumors (90%). 127 tumors described 
rearrangements (75%). We were unable to detect recurrent or known driver alterations 
in 17 of the 169 tumors, all of which were profiled with RNA-sequencing alone, most 
likely resulting from lower sensitivity of detection. 
Mutsig analysis performed in our WGS cohort revealed 5 significant genes mutated in at 
least two samples (Table 6).  
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Table 4:   
Summary of the breakdown of exonic mutations by type in the WGS cohort 
Type of mutation n 
Frame Shift Del 32 
Frame Shift Ins 10 
In Frame Del 12 
In Frame Ins 17 
Missense Mutation 808 
Nonsense Mutation 44 
Nonstop Mutation 2 
Silent 402 
Splice Site 40 
      Translation Start Site       12 
TOTAL 1379 
 
 
Table 5:  
Summary of the breakdown of exonic mutations by category in the WGS cohort 
Category n Rate per Mb 
*CpG->T 200 8.2 e-07 
*Cp(A/C/T)->T 146 7.4 e-08 
C->(G/A) 275 1.2 e-07 
A->mut 199 9.5 e-08 
indel+null 157 3.6 e-08 
Double null 0 0 
Total 977 2.2 e-07 
 
 
Table 6:  
Summary of the significant recurrent mutated genes identified  
by Mustig in the WGS cohort 
GENE DESCRIPTION n p q 
BRAF v-raf murine sarcoma viral oncogene homolog B1 10 0 0 
FGFR1 fibroblast growth factor receptor 1  6 0 0 
H3F3A H3 histone, family 3A 4 0 0 
NF1 neurofibromin 1  5 0 0,003 
TP53 tumor protein p53 3 0 0,007 !
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Figure 9: Landscape of somatic mutations in 169 PLGGs 
 
Co-mut plot representing the driver alterations identified in our cohort by whole genome 
sequencing (DNA) and/or RNA-sequencing (RNA). Each column is representing a 
sample. Histological subtypes include Pilocytic Astrocytoma (PA). Pilomyxoid 
Astrocytoma (PMA), Angiocentric Glioma (AG), Oligodendroglioma (OD), Diffuse 
Astrocytoma (DA), Dysembryoplastic Neuroepithelial Tumor (DNT), Ganglioglioma (GG), 
Pleomorphic Xanthoastrocytoma (PXA), PLGG not otherwise specified (NOS). Tumors 
for which histology is unavailable are designated NA.  
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3.3.1. BRAF is the most frequently altered gene in PLGGs 
The gene most frequently altered was BRAF. Duplications were present in 98 
samples (58%), including 89 PAs (representing 80% of the PAs overall: 66/71 or 93% of 
the IT PAs and 23/41 or 56% of the ST PAs), as well as in 5/24 DAs and in 1/4 PMAs 
(this sample is originated from the St-Jude cohort and the histology was not centrally 
reviewed by our group). Table 7 summarizes the 7 different types of BRAF duplications 
related to their different histological subtypes. We confirmed that the most frequent 
BRAF duplication was BRAF-KIAA1549 (92%), involving different exons of KIAA1549 
and BRAF. All the BRAF fusions, however, were characterized by loss of the 3’ end of 
BRAF containing the regulatory domain, suggesting a gain of function mutation. 
 
Table 7:  Summary table of the 7 different BRAF duplication variants 
 
Details 
 
Number 
 
Histology 
 
KIAA1549-BRAF 90 84 PA, 4 DA, 1 PMA, 1 ND 
RNF130-BRAF 2 PA 
FAM131B-BRAF 2 1 PA, 1 DA 
MKRN1-BRAF 1 PA 
GNAI1-BRAF 1 PA 
BRAF-MACF1 1 GG 
FXR1-BRAF 1 NOS 
 
12 tumors showed 4 different mutations in BRAF. The hotspot V600E point 
mutation245,246 was observed in 7 tumors (4 PAs and 3 DAs, 6/7 located in supratentorial 
regions). Three tumors exhibited a previously observed p.599 599T>TT insertion303 (one 
DA, one NOS tumor and 1 PA), one ST PA described an insertion of the three amino 
acids VLR at position 506 as described299 and one tumor (ST PA) was characterized by 
a new mutation, p.E451D (Figure 10).  
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FGFR1 was the second most frequently altered gene. We observed 12 mutated samples 
in our cohort: 6 missense mutations affecting 5 PAs (Figure 9 and 10), 4 duplications 
within the exonic region of the gene, and 3 duplication-inversions between FGFR1 and 
TACC1 (one identified by WGS and the two other one by RNA-sequencing). This 
spectrum of mutations is affecting the Tyrosine Kinase domains (TK1 and TK2), leading 
to a potential hyper activated FGFR1 protein. We also found one rearrangement 
involving FGFR3 with TACC4 in one ST DA. 
 
NTRK2 rearrangements were present in 4 tumors (3 PAs and one OA). In all 4 tumors, 
the alterations were mutually exclusive to BRAF, FGFR1 or other potential oncogenic 
mutations (Figure 9). Two tumors carried the same rearrangement between the exon 15 
of NTRK2 and the exon 6 of QKI. In the other tumors NTRK2 was fused to the 3’ end of 
NAV1 and NACC2. We also identified a rearrangement involving NTRK3 and NAV6 in 
one PXA tumor analyzed by RNA-sequencing. None of the NTRK2 rearrangements 
were similar to those recently described in pediatric high-grade gliomas. Conversely, 
ETV6-NTRK3 mutation has been described in one pediatric gliobastoma although the 
breakpoint sites among ETV6 and NTRK3 were different. 
 
NF1 was mutated in 5 tumors (one tumor carried two mutations in the same gene) 
(Figure 10). 
 
We observed mutations in genes encoding histones in five PLGGs, 2  PAs/Pilomyxoid 
Astrocytomas (PMAs) and 3 DAs (Figure 9). 4/5 were H3F3A mutation, also described in 
pediatric high-grade gliomas and one HIST1H3B. 1/5 mutation was A115G.  
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Figure 10:  Mutation sites in the most frequently mutated genes of the WGS cohort 
For each gene represented (with the number of amino-acids), the different type of 
mutations are summarized.  !
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3.3.2. MYB-QKI rearrangement is the unique recurrent 
mutation in Angiocentric Gliomas (AGs) 
 
PAs as well as other known histologic subtypes have been characterized so far to 
harbor multiple genomic events. Here we show that among the 4 DFCI/CHOP AG 
tumors analyzed, we identified a recurrent translocation between MYB and QKI genes 
(Figure 9). Additionally, one AG from the PCGP cohort showed the similar MYB-QKI 
translocation. In our 2 tumors analyzed by WGS, we were able to identify discordant 
reads using dRanger (Figure 11A). Using the copy-number ratio we were then able to 
visualize the location of the breakpoints in MYB and QKI (Figure 11B).  
 
Figure 11: MYB-QKI rearrangements identified in two AG tumors by WGS analysis 
A. Rearrangements in PLGG DFCI/CHOP 14 (left panel) and PLGG DFCI/CHOP 13 
(right panel). Circos plots are showing intrachromosomal (green) and interchromosomal 
(purple) rearrangements.  
                          PLGG DFCI/CHOP 14                                PLGG DFCI/CHOP 13 
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B. Copy-number profiles in PLGG DFCI/CHOP 14 and PLGG DFCI/CHOP 13 
Top panels are representing the whole genome for both samples. The two bottom 
panels are focusing the Log-2 copy number ratio (obtained from the WGS data) for the 
samples for MYB and QKI genes. 
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For the first tumor (PLGG DFCI/CHOP14), the breakpoints were located between exon 9 
and 10 of MYB and between exon 4 and 5 of QKI, resulting in a in-frame protein fusion 
between exon 9 of MYB and exon 5 of QKI (Figure 12). For the second tumor (PLGG 
DFCI/CHOP 13), we observed a more complex rearrangement involving EYA4 with MYB 
and QKI (Figure 12), resulting in the loss of the last exon of MYB fused to the exon 5-7 
of QKI. The four first exons of QKI were fused to the 11 first exons of EYA4 (Figure 12). 
We also confirmed the MYB-QKI rearrangement in PLGG DFCI/CHOP 13 using RNA-
sequencing by identifying reads spanning the junction between the 3’ end of MYB to the 
5’ extremity of QKI (Figure 12).  
 
We also performed RNA-sequencing in an additional set of 2 typical AGs (PLGG 
DFCI/CHOP 17 and PLGG DFCI/CHOP 18) and observed the same rearrangement 
occurring between the 5’ end of MYB and the 3’ end of QKI in PLGG DFCI/CHOP 17 
with the exact same breakpoints in the exons of MYB and QKI as in PLGG DFCI/CHOP 
13. In PLGG DFCI/CHOP 18, we were able to identify the recurrent fusion reads 
spanning the QKI-MYB junction (between the 5’ end of exon 4 of QKI fused to the 3’ end 
of MYB) (Figure 13A).  
 
In total, using WGS and RNA-seq, among the 6 AGs, five tumors showed a MYB-QKI 
rearrangement. We identified 4 different types of MYB-QKI rearrangements, all resulting 
into a loss of the 3’ end of MYB and the 5’ part of QKI except for one tumor where we 
were not able to identify the reciprocal fusion transcript. 
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Figure 12: 
Schematic representation of the MYB-QKI alterations identified in our cohort 
For each of the four panels, MYB and QKI breakpoints are represented by the red 
dashed lines. For PLGG DFCI/CHOP 13, EYA4 breakpoint is represented with the red 
dashed line. Exons that were not expressed in the RNA-sequencing data are 
represented by a red cross. For PLGG DFCI/CHOP 18, no MYB-QKI forward reads were 
identified in the RNA-seq data. 
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We further analyzed using RNA-seq the expression of the different exons of MYB and 
QKI, relative to matched normal brain expression (Brainspan dataset). For one AG 
tumor (PLGG DFCI/CHOP 13), we observed a dramatic decrease of expression after 
exon 9 of MYB, relative to normal brain, corresponding to the exact site of the breakpoint 
in that tumor (Figure 13B). For the 7 exons in QKI, we did not notice a significant change 
in the expression of the different exons, relative to normal brain. For the 2 other MYB-
QKI tumors that we analyzed by RNA-seq, we did not observe the same pattern of 
decrease of the expression in the exon of MYB after the breakpoint. The expression of 
the QKI exons was always stable, relative to normal brain. This difference might be due 
to the fact that QKI is expressed at a low level in normal brain tissues, whereas MYB 
might only be expressed in the embryonic stage with no significant level of expression 
during childhood. 
 
Besides MYB-QKI rearrangement, we also identified nine additional tumors with a MYB 
family alteration (Figure 9). One ST DA was characterized by a MYBL1-MMP16 
rearrangement as previously described227 and eight ST tumors (6 DAs, 1 DNT and 1 
AG) showed different rearrangements between MYB and several other partners as 
previously described in the PCGP cohort229. We also observed rearrangements involving 
QKI but not MYB in three PAs. 
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Figure 13: 
 
A. Validation of the exact breakpoint using RNA-sequencing data in PLGG 
DFCI/CHOP 18 
Red arrows represent the site of the breakpoint within the MYB and QKI genes. 
Example of a fusion read (blue for MYB and orange for QKI) is represented.  
 
 
 
 
B. MYB (left panel) and QKI (right panel) expression in PLGG DFCI/CHOP 13 
relative to normal brain expression obtained with the RNA-seq data 
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3.4 . MYB-QKI rearrangement is oncogenic through multiple mechanisms 
(Work preformed exclusively by Pratiti Bandopadhayay, Lori Ramkissoon and Payal Jain) 
MYB-QKI is an oncogenic fusion protein 
To test whether the MYB-QKI fusions were oncogenic, we stably expressed MYB-QKI5, and 
MYB-QKI6 in two heterologous cell model systems: NIH3T3 cells and in murine neural stem 
cells. Overexpression of both MYB-QKI5 fusion and MYB-QKI6, but not full-length MYB, was 
sufficient to induce anchorage independent growth in NIH 3T3 cells (Figure 14).  
Figure 14: MYB-QKI protein fusion leads to anchorage independent growth in vitro 
Expression of MYB, MYB-QKI5 and MYB-QKI6 in NIH3T3 cells
 
 
 
Number of colonies of 
NIH3T3 cells expressing 
MYB, MYB-QKI5, MYB-
QKI6 or a vector control in 
soft agar (Left) and 
representative images 
(right). NIH3T3 cells over-
expressing BRAFV600E are 
shown as a positive control. 
Mean of three replicate 
measurements are shown. 
Error bars represent SEM. !
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Furthermore, upon injection as flank xenograft in mice, MYB-QKI fusion expressing NIH 
3T3 cells lead to robust tumor formation as compared to controls (Figure 15A). Similarly, 
in murine neural stem cells (mNSCs), overexpression of either MYB-QKI5 or MYB-QKI6 
led to significant increases in cell proliferation compared to eGFP across five replicate 
pools (Figure 15B) and was sufficient to induce gliomagenesis on average 98 days post-
injection in an intracranial allograft model. Tumors had histologic features of infiltrating 
gliomas with some evidence of enhanced growth around vessels and a clustered growth 
pattern distinct from models of adult glioblastoma. However the tumors differed from 
human AGs in that they had high-grade features with frequent mitoses and marked 
cytologic atypia. Immunohistochemistry of the induced tumors showed diffuse 
expression of GFAP while OLIG2 was present in a subset of cells (Figure 15C), a 
pattern that is similar to that seen in human AGs.  
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Figure 15: MYB-QKI fusion protein is oncogenic 
A. Tumor growth following flank injections of NIH3T3 cells overexpressing MYB, MYB-
QKI5 (Long), MYB-QKI6 (Long) or a vector control. Mean of five measurements are depicted. 
Error bars represent SEM. 
 
B. In vitro cell proliferation rates of mNSCs over-expressing eGFP, MYB-QKI5 
(Short) or MYB-QKI6 (Short). Mean of five independent pools are depicted. Error bars 
represent SEM. Representative images intracranial mNSC-MYB-QKI6 tumors. 
 
C. Expression of GFAP and Olig2 in murine MYB-QKI gliomas. 
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We performed genome-wide gene expression analyses of three independently-generated pools 
of mNSCs overexpressing MYB-QKI5, MYB-QKI6, MYBtrExon1-9, QKItr, or eGFP. Relative to 
eGFP-expressing cells, cells expressing MYB-QKI5 and MYB-QKI6 exhibited significantly 
different expression of 1621 and 1947 genes, respectively, with 1029 genes overlapping. We 
defined a MYB-QKI gene expression signature comprising the 50 genes whose differential 
expression was most correlated with its expression. These genes include KIT and CDK6, which 
have previously been reported to be associated with MYB activation45. Expression of either 
MYBtrExon1-9 or MYB-QKI was associated with enrichment of signatures of MYB pathway 
activation.  
 
Role of aberrant expression of MYB 
In neural stem cells, overexpression of MYB exons 1-9 increased cell proliferation rates 
compared to eGFP controls and induced tumor formation less than 100 days following 
intracranial implantation (Figure 16).  
 
Figure 16: In vitro cell proliferation of mouse neural stem cells which over-express MYBtr or 
eGFP controls. Mean of five independent pools is depicted. Error bars represent SEM. 
Representative images of intracranial mNSC-MYBtr tumors. 
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Role of loss of expression of QKI 
Reduced Qk expression also resulted in increased proliferation of mNSCs, with the greatest 
increase observed in the context of pre-existing MYB-QKI expression (p=0.0007 for MYB-QKI5, 
p=0.0030 for MYB-QKI6 and p=0.03 for MYBtr; Figure 17). These data suggest overexpression 
of MYB-QKI and suppression of QKI has cooperative functional effects in AGs. 
 
 
Figure 17: MYB-QKI disrupts QKI that appears as a tumor suppressor gene 
Cell proliferation of mouse neural stem cells expressing MYBtr, MYB-QKI5, MYB-QKI6 or eGFP 
control with suppression of wild-type qk. Values represent mean of four independent 
experiments ± SEM. 
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MYB-QKI rearrangement translate QKI enhancer elements within the MYB promoters 
To assess the DNA binding pattern and potential transcriptional targets of MYB-QKI, we 
performed chromatin immunoprecipitation with parallel sequencing (ChIP-seq) in mNSCs 
expressing MYB-QKI and compared these results with H3K27ac ChIP-Seq to define the location 
of enhancer regions in the same cells. MYB-QKI5 bound 3672 sites and H3K27ac bound 9122 
sites across the genome (p threshold 1e-6), with overlap at 1907 sites (52% of MYB binding 
sites, p<0.0001) (Figure 18A). These findings are consistent with recent reports in the context of 
T-cell ALL, where MYB binding was also correlated with regions of H3K27ac defined enhancers 
(89% of super-enhancer regions in Jurkat cells). The MYB-QKI5 binding sites were located 
within a 100kb distance of 88% (22/25) of the upregulated genes in the MYB-QKI signature but 
only 40% (10/25) of the downregulated genes. Each of the MYB-QKI binding sites associated 
with an upregulated gene was associated with an H3K27ac enhancer peak, while only 70% of 
MYB-QKI binding sites at downregulated genes overlap with enhancers (p=0.003).  Two of the 
H3K27ac-binding enhancer regions were within 100kb of the 5’ and 3’ ends of Qk, the mouse 
QKI gene (Figure 18B), and each of these was associated with a MYB-QKI binding peak. This 
suggests a possible auto-regulatory feed-back loop between MYB-QKI and Qk in mouse neural 
stem cells. MYB was also associated with a MYB-QKI binding peak, but there was no associated 
enhancer. 
In normal human cortical brain samples, MYB is not associated with H3K27ac peaks, consistent 
with the finding that MYB is not expressed in normal human brain cortex. In contrast, QKI, which 
is expressed in human cortical brain, is associated with several H3K27ac peaks, including 
sequences at the 3’ end of QKI. The MYB-QKI rearrangement is predicted to bring these 
enhancer elements within 15kb of the MYB promoter (Figure 18C), raising the possibility that 
these may contribute to the observed aberrant expression of MYB.  
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Figure 18: MYB-QKI co-localizes with H3K27ac binding across the genome 
 
 
B. Binding of MYB-QKI and H3K27ac to Qk in mNSC. Binding of MYB-QKI to genes included in 
the MYB-QKI gene expression signature. 
 
C. Predicted H3K27ac enhancer elements in MYB-QKI, with translocation of genomic enhancers 
on 3’QKI within 15kb of 5’MYB. 
 
 
A. Heatmap of H3K27ac and MYB-QKI 
levels at MYB-QKI regions. Each row 
shows +/-5 kb centered on MYB-QKI 
peaks. These regions are rank-ordered 
by MYB-QKI signal.  Scaled intensities 
are in units of rpm/bp !
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4. Discussion  
 
In this section we have described the results of a meta-analysis pooling the largest 
genomic dataset of PLGGs.  
 
We confirmed that the structure of the genome of PLGGs is poorly affected by copy-
number alterations and mutations. The strong amplification peak identified by GISTIC is 
related to the BRAF duplication present in 57% of the tumors analyzed. The fact that the 
genome of those tumors is simple and poorly affected by genetic disruptions can be 
considered on one hand as an advantage to identify potential oncogene, as every 
recurrent event is highly likely to become a driver mutation298.  
 
As previously described we confirmed that BRAF duplications were the most frequent 
genetic alteration in those tumors299. We showed 7 different rearrangement types all 
involving BRAF with different partners, although the mechanism of BRAF rearrangement 
was identical with a loss of the 3’ terminal domain, which result in the activation of the 
BRAF protein and further MAPK signaling activation.  
 
We also confirmed that FGFR1 mutations (point mutation, duplication and 
rearrangements), NF1, NTRK2/NTRK3 as well as histone genes alterations are affecting 
significantly a fraction of PLGGs. FGFR1 point mutations were exclusively found in PAs 
(mostly ST, 4/5 PAs), whereas FGFR1 rearrangements were not restricted to PAs (2 
PAs) with alterations described in one DA and 2 OAs. NTRK2 rearrangements were 
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found in 3/4 of PAs (mostly ST, 2/3) and the NTRK3 rearrangement was found in one 
PXA. Histone family genes (H3F3A and HIST1H3B) have already been described to be 
mutated in higher grade gliomas in the pediatric population276. Further functional studies 
are needed to explore the exact role of those mutations in PLGG tumorigenesis. 
 
This study underlines the importance of increasing the number of samples in order to 
gain in power and enhance the chances to identify rare oncogenic events that are 
occurring as a lower frequency195. By increasing the number of samples, especially the 
non-PAs, we were able to identify a recurrent rearrangement between MYB and QKI 
strongly correlated to AGs. This pattern is unique in brain tumors, as a specific mutation 
appears to be restricted to a specific histological subtype. This pattern has been also 
described in other tumor subtypes such as BCR-ABL translocation in chronic 
myelogenous leukemia 304 or MITF (Microphthalmia-associated transcription factor) 
amplification in melanoma305. AGs are rare PLGGs, recently identified as a distinct 
entity14,306,307. Previous copy-number studies performed on AGs have already identified 
CN loss in 6q corresponding to the MYB-QKI region227,308. This rearrangement between 
MYB and QKI was recently described in the PCGP genomic analyses in one AG 
sample229. MYB (v-myb avian myeloblastosis viral oncogene homolog) codes for a 
transcription factor regulating essentially hematopoiesis309. Recently MYB alterations 
have been described in hematopoietic cancer287 but also several other cancer subtypes, 
such as adenoid cystic carcinomas310 and breast298. Additionally, a recent study on 
grade II PLGGs performed by our group has identified that recurrent loss of the 3’ 
terminal end of MYBL1, a member of the superfamily MYB is present in a subset of 
grade II PLGGs227. In our cohort of AGs we were able to describe that the 
! 85 
rearrangement results in a loss of the 3’ terminal end of MYB that contains the 
regulatory domains and fused to the 3’ extremity of QKI. QKI is an RNA-binding protein 
that regulates multiple important key processes in the cell such as pre-mRNA splicing, 
export of mRNAs from the nucleus, protein translation, and mRNA stability. The 
encoded protein is involved in myelinization and oligodendrocyte differentiation311,312. 
QKI is known to harbor different splice variants that are characterized by different 
downstream applications in the cell313,314. QKI has been identified to be significantly lost 
in a recent pan-cancer analysis195 and has recently been described as a tumor 
suppressor candidate in various cancer subtypes such as gastric cancer315, prostate 
cancer313 as well as glioblastomas316. 
 
Further functional work performed by Pratiti Bandopadhayay and Lori Ramkissoon, 
collaborators in the lab, allowed to explore further the role of the MYB-QKI 
rearrangement in various in vitro and in vivo models. They described that MYB-QKI 
disrupts two cancer-associated genes, and likely contributes to the neoplastic process 
by three distinct mechanisms: 1) creation of an oncogenic fusion protein; 2) aberrant, 
elevated expression of MYB, possibly by bringing QKI-related enhancers into proximity 
with MYB; and 3) hemizygous loss of the tumor suppressor QKI, which has specific 
CNS-contextual roles in glial maturation (Work submitted to Nature Genetics). 
 
In our study we observed a non-negligible number of tumors do not show any potential 
driver mutation or rearrangement (18/169, 10%). The fact that all those samples have 
only been assessed by RNA-sequencing raises the concern that restricted RNA-
sequencing analyses is not sufficient to detect potential genomic alterations due to low 
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quality of the tissue or the poor expression level of a fraction of genes that might play an 
important role in oncogenesis mechanisms. Alternatively, this observation suggests that 
genetic alterations might be located outside the coding regions, as it has been identified 
recently described in melanomas317. Additionally, alterations affecting epigenetic 
regulators such as the methylation, acetylation of histones might contribute to the 
particular biology of those tumors.  
 
Finally, this work raises the concern about the new challenges emerging from the 
computational tools used to explore the genomic sequencing of tumors. Depending on 
the aligner and the various calling methods used for indels, rearrangements and 
mutations, one might find different results that can affect the downstream functional 
studies. It might be interesting to compare and match different algorithm to understand 
how the differences observed are emerging and whether there could be a uniform way 
to approach the genomic analysis in oncology in order to increase the accuracy of the 
results. 
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Chapter 3: Bulk expression profiling of PLGGs  
 
 
 
1. Introduction 
 
High-throughput mRNA expression profiling is a useful approach to characterize 
molecular alterations in tumors. However, such profiling has not been done in large 
numbers for non-PAs in the pediatric population318-320. The small numbers of patients 
with these diseases has resulted in limited amounts of tissue available for 
comprehensive genomic characterization, and in particular very little fresh frozen tissue, 
which is required by many genomic assays. 
 
In this chapter we describe the results of gene expression profiles of 151 paraffin-
embedded PLGGs, from a large variety of histological subtypes, using an innovative 
platform that allows expression profiling in paraffin-embedded samples of 6100 genes 
that are commonly dysregulated in cancer. Using these data, we were able to classify 
the tumors according to phenotypic features and identified differences in molecular 
patterns between different types of tumors, including supratentorial (ST) and 
infratentorial (IT) PAs and BRAF-duplicated, V600E-mutated and BRAF wild-type 
tumors. We also compared expression profiles as function of age.  
We related these differences to publicly available expression profiles from normal 
developing brains to determine whether the differences we observed were reflected in 
normal brains.  
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2. Methods 
 
2.1. Tumor sample collection 
 
All tissues used were paraffin-embedded and obtained from Boston Children's 
Hospital (Boston, USA) through IRB-approved protocols. Diagnoses were made 
according to the WHO classification scheme by consensus of three neuropathologists 
(Jennifer Chan, Keith Ligon and Sandro Santagata). For 137 samples (91%), we 
performed FISH to assess the presence of BRAF-KIAA fusion transcripts321. We 
genotyped for BRAF-V600E mutations in 94 samples (62%) using targeted sequencing 
246. All tumors were clinically annotated with outcomes. 
 
2.2. RNA isolation and microarray analysis  
 
RNA was extracted using TRIzol (Life Technologies) followed by purification using 
the RNeasy MinElute Cleanup Kit (Qiagen). Expression profiles were generated using 
the Illumina DASL platform (San Diego, CA)322 and normalized using cubic spline 
interpolation323,324. This platform used 6100 genes that harbor the largest variation 
across a large sample panel across tissue types, as described 323. Samples were run in 
three batches; we applied batch correction using ComBat325. Z-scores were generated 
for each gene across samples. Self Organizing Maps326, hierarchical clustering202, 
Comparative Marker Selection Analysis327,328, and Gene-set Enrichment Analysis 
(GSEA)206,329 were performed using GenePattern330. Principal Component Analyses 
were generated in Matlab. For clustering, PCA plots, and distance measurements, we 
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used the 250 genes with highest variance. Use of 100, 500, or 1000 genes gave similar 
results but poorer average silhouette values. For Comparative Marker Selection, we only 
report genes with differences in mean z-scores of greater than 0.5. The data have been 
deposited in the Gene Expression Omnibus331 (accession number GSE60898). 
 
2.3. Normal brains 
 
Normalized RNA-sequencing data across brain regions and ages (infancy, childhood 
and adolescence) were uploaded from BRAINSPAN332. To allow comparison between 
BRAINSPAN and DASL data, we selected the 5483 genes assessed by both. Forty-
three BRAINSPAN samples (0/234 embryos, 13/73 infants, 22/101 childhood samples, 
6/59 adolescents, and 2/112 adults; Figure 19) exhibited low expression levels across 
most genes and average levels <10 RPKM, two SDs below the mean, suggesting tissue 
degradation. These were removed. 
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Figure 19: 
Average expression among the 5483 genes we selected across all samples in the 
BRAINSPAN cohort, arranged by age.  
Samples whose average expression levels are below 2 standard deviations below 
the mean (10 RPKM) are indicated with red dots.   
We considered these samples to be low quality and excluded them from further 
analyses. 
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2.4. Immunohistochemistry 
 
HLA-DRA immunohistochemistry (Abcam, 1:250) was performed in an additional 
cohort of 18 PA tumors using the Dual Link Envision+ (Dako) detection system. Citrate 
was used for antigen retrieval and diaminobenzidine (DAB) as the chromogen. We 
assessed DAB surface and intensity staining using Cell Profiler (Broad Institute)333!in 15 
representative tumor sections for each sample.   
 
2.5. Statistical analysis 
 
Fisher's exact and Mann-Whitney tests were used to generate p-values as 
appropriate. False discovery rates (FDRs) were determined to account for multiple 
hypotheses334 and FDR<0.25 was considered significant. Log-rank (Mantel-Cox) tests 
were used to examine differences in event-free survival. 
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3. Results 
 
We analyzed expression of 6100 genes in 151 paraffin-embedded PLGG samples 
spanning six histological subtypes: pilocytic astrocytomas (PAs), gangliogliomas (GGs), 
diffuse astrocytomas (DAs), dysembryoplastic neuroepithelial tumors (DNTs), 
oligodendroglial tumors (ODs) and PLGGs Not Otherwise Specified (NOS) (Figure 20A).  
 
The cohort included tumors from 13 infants (birth to 18 months), 89 children (19 months 
to 11 years) and 49 adolescents (12 to 19 years). Primary tumors constituted 135 
samples; 16 were collected after second surgery for relapse or progression, including 
nine for which we had paired primary and recurrent samples.  
 
NOS tumors were the only histological subtype that occurred with equal frequency in 
both the supratentorium and infratentorium. DAs, GGs, DNTs and ODs occurred most 
commonly in the supratentorium (p<0.0001); PAs were primarily infratentorial (and 
primarily cerebellar; p<0.0001) (Figure 20A). 
 
Consistent with prior reports225,228,229,248, we observed BRAF-KIAA duplications most 
frequently in PAs (p<0.0001); BRAF-V600E mutations were significantly associated with 
GGs (p<0.0002) (Figure 20B). Similar fractions of NOS tumors harbored BRAF-
duplications (38%) and V600E mutations (26%) (Figure 20B). Tumors with BRAF-
duplications were predominantly infratentorial (81%, p<0.0001); those with BRAF-V600E 
mutations were predominantly supratentorial (90%, p<0.0001). 
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Figure 20: Description of the sample set 
 
A. Summary of tumor locations and histologies by age in the pediatric population. 
Red and blue numbers indicate ST and IT tumors, respectively.  
 
 
B. BRAF genomic status by histology. DNT and OD tumors did not described 
BRAF alterations. 
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3.1. PLGGs cluster in three molecular groups according to location, 
histological subtype, and BRAF genomic status 
 
 The 135 newly diagnosed PLGGs segregated into three clusters (“Supratentorial”, 
“BRAF-duplicated”, and “Mixed”; Figure 21A), associated with different histologies 
(Figure 21B) by Euclidean SOM326 (Figure 22A and 22B). 
DAs, were enriched in the Supratentorial cluster (p=0.0014), as were ODs and DNTs (p 
values < 0.001). PAs were enriched in the BRAF-duplicated cluster (p<0.0001), with 
most of the remaining in the Mixed cluster. GGs were primarily distributed between 
clusters 1 and 3 (p=0.160). NOS tumors were distributed almost equally across all three 
clusters, indicating that they are molecularly heterogeneous. NOS tumors with BRAF 
duplications preferentially segregated into the BRAF-duplicated cluster (p=0.05), which 
was otherwise dominated by BRAF-duplicated IT PAs. NOS tumors with V600E point 
mutations mostly segregated in clusters 1 and 3 (p=0.2) with the ST GGs and other ST 
tumors. 
The Supratentorial cluster was significantly enriched with ST PLGGs (p<0.0001), 
whereas IT tumors were significantly enriched in the BRAF-duplicated cluster (p<0.0001; 
Figure 21C).  
The Mixed cluster was not significantly enriched with tumors from either location 
(p=0.591). 
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Figure 21: PLGGs divide into three molecular clusters 
A. Self-organizing map (SOM) clustering heat map including the 135 primary PLGGs. 
 
B-D. Distributions among the three clusters of histology (B), ST and IT tumors (C) and 
BRAF genomic status (D) (* p< 0.001, Fisher's exact test between members of the starred cluster vs 
both other clusters). 
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Figure 22: 
 
 
A. Delta Gini Index obtained in the SOM clustering analysis among the 135 newly 
diagnosed PLGGs.  
Increased numbers suggest improved dispersion between clusters. 
 
B. Silhouette plot analysis using the SOM clustering results of the 135 newly 
diagnosed PLGGs.  
Each horizontal bar represents one sample. Positive silhouette values indicate samples that lie 
well within the cluster. A separate K-nearest neighbors (KNN) analysis classifying tumors 
according to their three nearest neighbors generated identical assignments to those here. 
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Tumors from different age groups segregated almost evenly across the three clusters. 
To determine how adult low-grade gliomas (ALGGs) relate to these clusters, we added 
15 primary ALGGs, all supratentorial (7 ODs, 5 DAs, 2 PAs, 1 NOS tumor), to the 
pediatric cohort and performed SOM clustering on the combined cohort of 150 tumors. 
We again obtained three clusters that substantially aligned with the three clusters in the 
original analysis (Figure 23). Of the 15 ALGGs, 12 (80%) segregated with the 
supratentorial PLGGs in cluster 1. 
BRAF-duplicated tumors were significantly enriched in cluster 2 (58%, p<0.0001), 
whereas BRAF-V600E mutated tumors were enriched in clusters 1 and 3 (p=0.066; 
Figure 20D). This observation reflects the finding that BRAF-duplicated tumors are more 
frequent among infratentorial PAs, whereas ST PLGGs more commonly harbor the 
BRAFV600E point mutation. The BRAF status of the NOS tumors followed the same 
distribution, with a significant enrichment of NOS BRAF-duplicated tumors in cluster 2 
and BRAF-V600E mutated tumors in cluster 1 and 3 (p=0.045). 
 
The three clusters exhibited no differences in event-free survival (Figure 24). 
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Figure 23 : 
Self-organizing map (SOM) clustering heat map including 135 primary PLGGs and 
15 primary ALGGs. 
                                                                                                                                         CLUSTER 
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Figure 24: Event-free survival curves for the three clusters. 
 
 
 
 We compared molecular signatures between the different clusters using GSEA 
and the 1320 gene-sets in the C2 canonical pathway (CP) set.  
The Supratentorial cluster was significantly enriched for 34 gene-sets (q-value<0.25; 
Table 8A). Of these, seven were associated with neurotransmission mechanisms (of 18 
total; p<0.0001), suggesting a neuronal signature. No gene-sets were significantly 
enriched in the BRAF-duplicated cluster. The Mixed cluster was significantly enriched for 
33 gene-sets (Table 8B), including three of 21 gene-sets associated with cell cycle 
control (p=0.0139) and five of 67 gene-sets associated with immune response 
(p=0.0227).  
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Table 8: 
 
A. Gene-sets significantly enriched in cluster 1. 
 
NAME p value FDR 
KEGG NITROGEN METABOLISM 0.00 0.00 
REACTOME AMINO ACID AND OLIGOPEPTIDE SLC TRANSPORTERS 0.00 0.03 
REACTOME TRANSPORT OF INORGANIC CATIONS ANIONS AND AMINO ACIDS 
OLIGOPEPTIDES 0.00 0.09 
REACTOME NEUROTRANSMITTER RELEASE CYCLE 0.00 0.10 
REACTOME ION CHANNEL TRANSPORT 0.00 0.11 
REACTOME NEURONAL SYSTEM 0.00 0.12 
REACTOME TRANSMISSION ACROSS CHEMICAL SYNAPSES 0.00 0.12 
REACTOME GABA RECEPTOR ACTIVATION 0.00 0.13 
KEGG PROXIMAL TUBULE BICARBONATE RECLAMATION 0.00 0.14 
KEGG CALCIUM SIGNALING PATHWAY 0.00 0.16 
KEGG CITRATE CYCLE TCA CYCLE 0.01 0.17 
REACTOME TRANSMEMBRANE TRANSPORT OF SMALL MOLECULES 0.00 0.18 
REACTOME PHOSPHOLIPASE C MEDIATED CASCADE 0.01 0.18 
REACTOME FGFR LIGAND BINDING AND ACTIVATION 0.02 0.19 
REACTOME NEUROTRANSMITTER RECEPTOR BINDING AND DOWNSTREAM 
TRANSMISSION IN THE POSTSYNAPTIC CELL 0.01 0.20 
KEGG PARKINSONS DISEASE 0.02 0.20 
REACTOME ION TRANSPORT BY P TYPE ATPASES 0.02 0.20 
REACTOME NEGATIVE REGULATION OF FGFR SIGNALING 0.02 0.20 
REACTOME INWARDLY RECTIFYING K CHANNELS 0.02 0.20 
REACTOME SIGNALING BY FGFR MUTANTS 0.00 0.20 
REACTOME RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS BY 
CHEMIOSMOTIC COUPLING AND HEAT PRODUCTION BY UNCOUPLING 
PROTEINS  
0.03 0.20 
REACTOME POTASSIUM CHANNELS 0.01 0.21 
KEGG OXIDATIVE PHOSPHORYLATION 0.02 0.21 
REACTOME INHIBITION OF VOLTAGE GATED CA2 CHANNELS VIA GBETA 
GAMMA SUBUNITS 0.03 0.21 
BIOCARTA PGC1A PATHWAY 0.03 0.21 
KEGG CARDIAC MUSCLE CONTRACTION 0.02 0.21 
REACTOME MITOTIC PROMETAPHASE 0.02 0.21 
REACTOME RESPIRATORY ELECTRON TRANSPORT 0.04 0.21 
REACTOME SLC MEDIATED TRANSMEMBRANE TRANSPORT 0.00 0.21 
REACTOME NITRIC OXIDE STIMULATES GUANYLATE CYCLASE 0.04 0.21 
REACTOME DARPP 32 EVENTS 0.02 0.24 
BIOCARTA BIOPEPTIDES PATHWAY 0.03 0.24 
REACTOME GABA B RECEPTOR ACTIVATION 0.00 0.00 
ST WNT CA2 CYCLIC GMP PATHWAY 0.00 0.03 !
 Gene-sets involved in neurotransmission mechanisms  !
! 101 
B. Gene-sets significantly enriched in cluster 3. 
NAME  p value FDR 
REACTOME CDK MEDIATED PHOSPHORYLATION AND REMOVAL OF CDC6 0.00 0.18 
REACTOME DESTABILIZATION OF MRNA BY AUF1 HNRNP D0 0.01 0.18 
REACTOME CDT1 ASSOCIATION WITH THE CDC6 ORC ORIGIN COMPLEX 0.00 0.18 
REACTOME INNATE IMMUNE SYSTEM 0.00 0.19 
REACTOME ER PHAGOSOME PATHWAY 0.00 0.19 
REACTOME VIF MEDIATED DEGRADATION OF APOBEC3G 0.01 0.19 
KEGG VIRAL MYOCARDITIS 0.02 0.19 
REACTOME P53 INDEPENDENT G1 S DNA DAMAGE CHECKPOINT 0.00 0.20 
REACTOME SCF BETA TRCP MEDIATED DEGRADATION OF EMI1 0.01 0.20 
REACTOME SIGNAL TRANSDUCTION BY L1 0.01 0.20 
REACTOME HIV INFECTION 0.00 0.20 
REACTOME METABOLISM OF RNA 0.01 0.21 
BIOCARTA PROTEASOME PATHWAY 0.02 0.21 
REACTOME SCFSKP2 MEDIATED DEGRADATION OF P27 P21 0.01 0.21 
BIOCARTA NKCELLS PATHWAY 0.03 0.21 
REACTOME SIGNALING BY WNT 0.01 0.21 
REACTOME METABOLISM OF MRNA 0.01 0.22 
REACTOME REGULATION OF APOPTOSIS 0.01 0.22 
REACTOME AUTODEGRADATION OF THE E3 UBIQUITIN LIGASE COP1 0.00 0.22 
REACTOME ACTIVATION OF NF KAPPAB IN B CELLS 0.01 0.22 
KEGG SYSTEMIC LUPUS ERYTHEMATOSUS 0.04 0.22 
REACTOME REGULATION OF MRNA STABILITY BY PROTEINS THAT BIND AU 
RICH ELEMENTS 0.00 0.23 
REACTOME TGF BETA RECEPTOR SIGNALING ACTIVATES SMADS 0.01 0.23 
REACTOME NUCLEOTIDE BINDING DOMAIN LEUCINE RICH REPEAT 
CONTAINING RECEPTOR NLR SIGNALING PATHWAYS 0.02 0.23 
REACTOME THE ROLE OF NEF IN HIV1 REPLICATION AND DISEASE 
PATHOGENESIS 0.02 0.23 
PID TGFBRPATHWAY 0.01 0.23 
PID NFKAPPABCANONICALPATHWAY 0.02 0.24 
REACTOME REGULATION OF ORNITHINE DECARBOXYLASE ODC 0.02 0.24 
REACTOME CLASS I MHC MEDIATED ANTIGEN PROCESSING PRESENTATION 0.00 0.24 
REACTOME CROSS PRESENTATION OF SOLUBLE EXOGENOUS ANTIGENS 
ENDOSOMES 0.00 0.24 
REACTOME P53 DEPENDENT G1 DNA DAMAGE RESPONSE 0.00 0.24 
KEGG PROTEASOME 0.01 0.24 
REACTOME HOST INTERACTIONS OF HIV FACTORS 0.00 0.24 !
 
   Gene-sets involved in cell cycle control 
 
Gene-sets involved in inflammatory pathways 
! !
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3.2. Variations in expression patterns across histological subtypes  
 
 We analyzed how expression profiles vary across the four major histologies (PAs, 
DAs, DNTs, and GGs) using Comparative Marker Selection Analysis and GSEA. We 
controlled for location by comparing only the ST tumors. 
 
We found that 205 genes and 90 gene-sets were significantly differentially expressed 
between the ST PAs and the ST DAs (Figure 25A, Table 9A and 9B) and 230 genes and 
120 gene-sets were significantly differentially expressed between the ST PAs and the 12 
ST DNTs (Figure 25B, Table 9C and 9D). In both comparisons, 57 gene-sets were 
enriched among PAs, including three gene-sets from each of two families: inflammatory 
pathways (KEGG complement disease, KEGG antigen processing and presentation, 
and reactome interferon gamma signaling) and extracellular matrix organization (pid 
integrin 3 pathway, reactome extracellular matrix organization, and reactome collagen 
formation). Similarly, 99 genes were significantly differentially expressed in ST PAs 
relative to both ST DAs and ST DNTs; two of the five genes with the largest differences 
in expression, two (SERPING1 and CD74) are in inflammatory pathways. Twenty-eight 
gene-sets were enriched in ST DNTs relative to PAs. Thirteen of these related to a 
neurons or neuronal transmission, including four of the five most significant gene-sets 
(reactome post NMDA receptor activation events, reactome neurotransmitter release 
cycle, and reactome neurotransmitter receptor binding, reactome neurotransmission 
across chemical synapses). The four genes with the greatest expression in ST DNTs 
relative to ST PAs are all related to signal transduction (SCN2A2, STMN2, SNAP25, and 
VSNL1). No gene-sets were significantly upregulated in ST DAs relative to ST PAs; 
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among the five genes that had the greatest expression ST DAs relative to ST PAs, two 
(SL17A7 and ATP1A2) are involved in ion transport. We found no genes or gene-sets 
that were significantly differentially expressed between the ST PAs and the 15 ST GGs 
and either the ST PAs or DAs.  
 
Using the first three components of a PCA analysis, we observed differences between 
the ST PAs and DAs (Figure 25C) and between the ST PAs and DNTs (Figure 25D); the 
ST PAs and GGs appear to be mixed (Figure 25E). However, these global differences 
only trend towards statistical significance (p=0.09, 0.08, 0.13, respectively). We 
compared the Euclidean distances within and between all PAs and DAs, PAs and DNTs, 
and PAs and GGs and determined the significance of these differences by permuting 
class labels. We controlled for the location by permuting separately ST and IT tumors 
within each group of tumors. 
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Figure 25: Variation in gene expression profiles across different histological subtypes  
A-B. Heat maps representing genes found to be differentially expressed between ST PAs and 
DAs (A) and between ST PAs and DNTs (B). C-E. PCA analysis comparing the expression 
pattern of ST PAs and ST DAs (C), ST PAs and ST DNTs (D) and  ST PAs and ST GGs (E). 
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Table 9: 
 
A. List of the genes significantly differentially expressed between ST PAs and DAs  
upregulated Gene p value FDR Difference mean z-score PA-DA 
PA RARRES1 0.00 0.06 2.42 
PA SERPING1 0.00 0.08 1.93 
PA CHI3L1 0.01 0.17 1.92 
PA MGP 0.00 0.14 1.82 
PA PLA2G2A 0.00 0.09 1.81 
PA TM4SF1 0.00 0.08 1.76 
PA SERPINA3 0.00 0.13 1.67 
PA PHLDA1 0.00 0.09 1.56 
PA GPX3 0.00 0.10 1.53 
PA CTGF 0.01 0.18 1.46 
PA CAV1 0.00 0.12 1.45 
PA APOC2 0.01 0.19 1.42 
PA SAT 0.01 0.21 1.39 
PA S100A4 0.00 0.13 1.36 
PA LMOD1 0.00 0.11 1.30 
PA CD74 0.00 0.07 1.29 
PA LYZ 0.00 0.08 1.27 
PA S100A11 0.00 0.09 1.22 
PA ACTN1 0.00 0.07 1.21 
PA AHR 0.00 0.08 1.20 
PA DUSP1 0.01 0.14 1.20 
PA PBEF1 0.00 0.13 1.18 
PA COL1A2 0.01 0.15 1.17 
PA CAV2 0.00 0.13 1.16 
PA MSR1 0.00 0.07 1.14 
PA C1R 0.00 0.12 1.14 
PA FCGR2A 0.00 0.06 1.14 
PA CNN2 0.00 0.06 1.11 
PA PODXL 0.01 0.16 1.10 
PA APOD 0.00 0.13 1.08 
PA BGN 0.00 0.09 1.06 
PA RASSF2 0.01 0.20 1.05 
PA MHC2TA 0.01 0.15 1.04 
PA HLA-DPA1 0.00 0.08 1.04 
PA PRSS23 0.00 0.06 1.04 
PA VGF 0.01 0.19 1.02 
PA A2M 0.00 0.06 0.98 
PA DOC1 0.00 0.09 0.97 
PA IFI16 0.00 0.12 0.97 
PA ACTA2 0.01 0.22 0.96 
PA MAP1B 0.01 0.14 0.96 
PA ABHD2 0.00 0.07 0.93 
PA LAMB1 0.00 0.09 0.93 
PA CALB2 0.01 0.14 0.92 
PA TRPM8 0.00 0.06 0.91 
PA RUNX1 0.01 0.14 0.90 
PA GBP2 0.00 0.09 0.87 
PA COL3A1 0.00 0.14 0.87 
PA CSPG4 0.00 0.13 0.87 
PA GADD45A 0.02 0.22 0.83 
PA PLAU 0.00 0.06 0.83 
PA ALDH1A3 0.01 0.16 0.80 
PA COL4A1 0.00 0.09 0.80 
PA TAGLN 0.01 0.18 0.80 
PA HLA-DPB1 0.00 0.06 0.77 
PA SIX1 0.00 0.06 0.75 
PA HLA-DMA 0.00 0.10 0.74 
PA HLA-DRA 0.00 0.10 0.74 
PA IFI30 0.00 0.08 0.73 
PA FRZB 0.01 0.14 0.73 
PA IF 0.00 0.08 0.72 
PA EMP2 0.00 0.08 0.72 
PA VWF 0.00 0.12 0.71 
PA GAD1 0.00 0.10 0.71 
PA IGJ 0.01 0.18 0.70 
PA ARL7 0.00 0.09 0.70 
PA CTSC 0.00 0.07 0.69 
PA IL1RAP 0.00 0.11 0.69 
PA LMAN2 0.00 0.08 0.69 
PA BTG1 0.00 0.12 0.68 
PA C1S 0.00 0.08 0.68 
PA IQGAP1 0.02 0.23 0.68 
PA COL1A1 0.00 0.08 0.68 
PA EVI2B 0.01 0.18 0.68 
PA SLC26A2 0.00 0.09 0.67 
PA WWTR1 0.00 0.08 0.67 
PA DPEP2 0.01 0.17 0.67 
PA TMSB10 0.01 0.17 0.66 
PA PAM 0.00 0.08 0.65 
PA SARA1 0.00 0.11 0.65 
PA CASP4 0.00 0.08 0.65 
PA TRIM14 0.01 0.16 0.64 
PA TUSC3 0.00 0.12 0.64 
PA HSPA6 0.01 0.17 0.64 
PA DSCR1 0.00 0.13 0.64 
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PA NPC2 0.02 0.23 0.63 
PA CDH11 0.00 0.11 0.63 
PA FYB 0.00 0.07 0.62 
PA S100A10 0.00 0.12 0.62 
PA HMGA1 0.02 0.24 0.62 
PA FOSL2 0.00 0.11 0.62 
PA HCLS1 0.00 0.13 0.62 
PA OSMR 0.00 0.08 0.61 
PA MEST 0.01 0.20 0.61 
PA BTG3 0.01 0.20 0.61 
PA PKM2 0.00 0.12 0.60 
PA GYPC 0.02 0.23 0.59 
PA CTHRC1 0.00 0.06 0.59 
PA AKAP13 0.01 0.22 0.57 
PA TEAD4 0.00 0.13 0.57 
PA HLA-DQA1 0.00 0.06 0.57 
PA MMP17 0.01 0.20 0.56 
PA ECM1 0.00 0.08 0.55 
PA SERPINF1 0.01 0.15 0.55 
PA CD59 0.01 0.15 0.55 
PA ARHGDIB 0.02 0.24 0.55 
PA GNB2L1 0.01 0.17 0.55 
PA QSCN6 0.00 0.09 0.55 
PA BCAT1 0.01 0.15 0.54 
PA CPVL 0.00 0.07 0.54 
PA LIF 0.00 0.13 0.54 
PA LBR 0.00 0.06 0.53 
PA VAMP5 0.00 0.07 0.53 
PA STXBP2 0.01 0.19 0.52 
PA ITGB3 0.02 0.23 0.51 
PA ALOX5AP 0.00 0.12 0.50 
DA ACAA1 0.01 0.21 -0.50 
DA CTH 0.00 0.09 -0.50 
DA HRPT2 0.00 0.13 -0.50 
DA CAMK2G 0.00 0.09 -0.51 
DA CROP 0.01 0.16 -0.51 
DA ADIPOR2 0.01 0.19 -0.52 
DA THRA 0.00 0.12 -0.52 
DA PPP1R12B 0.00 0.08 -0.52 
DA APC 0.02 0.23 -0.52 
DA FDFT1 0.00 0.06 -0.52 
DA BTBD3 0.01 0.14 -0.52 
DA AKT3 0.00 0.13 -0.55 
DA PSIP1 0.00 0.07 -0.55 
DA DAPK1 0.00 0.08 -0.55 
DA COG2 0.00 0.08 -0.56 
DA SEPW1 0.01 0.18 -0.57 
DA PHGDH 0.00 0.08 -0.57 
DA KCNJ3 0.01 0.16 -0.58 
DA TRIM2 0.01 0.18 -0.58 
DA KCNJ10 0.01 0.17 -0.58 
DA DST 0.01 0.17 -0.59 
DA SLC14A1 0.00 0.07 -0.59 
DA TLOC1 0.00 0.06 -0.59 
DA TTYH1 0.00 0.08 -0.60 
DA MAPK8IP2 0.01 0.18 -0.60 
DA RASGRF1 0.01 0.15 -0.60 
DA PLCL1 0.01 0.14 -0.61 
DA SLC7A11 0.00 0.08 -0.61 
DA NPY 0.01 0.16 -0.62 
DA PECI 0.01 0.16 -0.62 
DA ARHGAP5 0.00 0.10 -0.63 
DA WASF3 0.00 0.07 -0.63 
DA GAB1 0.00 0.07 -0.63 
DA SLC1A3 0.01 0.14 -0.63 
DA KIAA0103 0.00 0.07 -0.63 
DA EFHD1 0.01 0.19 -0.64 
DA PTPNS1 0.00 0.09 -0.64 
DA RASA4 0.00 0.08 -0.65 
DA ADRA1A 0.00 0.09 -0.66 
DA WSB1 0.02 0.22 -0.66 
DA DCTN1 0.01 0.19 -0.67 
DA MOBP 0.02 0.23 -0.67 
DA PBP 0.01 0.18 -0.67 
DA CYP2J2 0.00 0.13 -0.68 
DA ITPKB 0.01 0.19 -0.68 
DA DAAM2 0.01 0.15 -0.68 
DA TMEM47 0.00 0.08 -0.70 
DA USP1 0.02 0.23 -0.71 
DA GJA4 0.00 0.07 -0.71 
DA RAB30 0.00 0.12 -0.72 
DA PON2 0.02 0.25 -0.73 
DA GPM6B 0.00 0.07 -0.73 
DA SCHIP1 0.01 0.17 -0.73 
DA RAGE 0.00 0.10 -0.73 
DA PCDH9 0.00 0.10 -0.74 
DA PCDH17 0.01 0.18 -0.74 
DA KCNN2 0.00 0.12 -0.76 
DA MACF1 0.01 0.14 -0.77 
DA ITGA6 0.00 0.11 -0.78 
DA TUBB4 0.02 0.25 -0.78 
DA ACTN2 0.01 0.18 -0.80 
DA CAMK4 0.00 0.07 -0.80 
DA PRODH 0.00 0.10 -0.82 
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DA TJP1 0.00 0.06 -0.82 
DA BMPR1B 0.01 0.15 -0.82 
DA KCNJ4 0.00 0.11 -0.84 
DA CPE 0.01 0.19 -0.85 
DA SC5DL 0.00 0.07 -0.86 
DA PTPRS 0.00 0.08 -0.87 
DA INSIG1 0.00 0.08 -0.88 
DA GJA1 0.01 0.16 -0.91 
DA PSAT1 0.00 0.08 -0.92 
DA VIL2 0.01 0.18 -0.95 
DA ELOVL2 0.01 0.17 -0.96 
DA AQP4 0.01 0.16 -0.98 
DA SOX9 0.00 0.13 -0.99 
DA CTNND2 0.00 0.08 -1.01 
DA DIO2 0.01 0.14 -1.05 
DA GPR37 0.00 0.09 -1.10 
DA NDRG2 0.00 0.13 -1.12 
DA FXYD1 0.01 0.15 -1.16 
DA ATP1A2 0.00 0.11 -1.17 
DA CLEC3B 0.01 0.16 -1.18 
DA SLC6A11 0.01 0.16 -1.23 
DA ADD3 0.00 0.08 -1.29 
DA SLC17A7 0.00 0.09 -1.29 
DA RORB 0.00 0.06 -1.40 
DA AHCYL1 0.00 0.07 -1.40 
DA MLC1 0.00 0.09 -1.44 
 !
B. List of the gene-sets significantly differentially expressed between ST PAs and DAs  
NAME p value FDR 
KEGG AUTOIMMUNE THYROID DISEASE 0.00 0.02 
KEGG COMPLEMENT AND COAGULATION CASCADES 0.00 0.01 
KEGG TYPE I DIABETES MELLITUS 0.00 0.02 
KEGG SYSTEMIC LUPUS ERYTHEMATOSUS 0.00 0.02 
KEGG VIRAL MYOCARDITIS 0.00 0.02 
KEGG ALLOGRAFT REJECTION 0.00 0.01 
KEGG ASTHMA 0.00 0.01 
KEGG LEISHMANIA INFECTION 0.00 0.03 
KEGG GRAFT VERSUS HOST DISEASE 0.01 0.03 
KEGG ANTIGEN PROCESSING AND PRESENTATION 0.00 0.03 
PID SYNDECAN 1 PATHWAY 0.01 0.05 
KEGG INTESTINAL IMMUNE NETWORK FOR IGA PRODUCTION 0.00 0.06 
REACTOME MHC CLASS II ANTIGEN PRESENTATION 0.00 0.06 
REACTOME GROWTH HORMONE RECEPTOR SIGNALING 0.00 0.08 
BIOCARTA PML PATHWAY 0.01 0.08 
PID AMB2 NEUTROPHILS PATHWAY 0.00 0.07 
PID INTEGRIN3 PATHWAY 0.00 0.07 
KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION 0.00 0.07 
REACTOME TCR SIGNALING 0.00 0.07 
REACTOME GENERATION OF SECOND MESSENGER MOLECULES 0.00 0.08 
PID INTEGRIN2 PATHWAY 0.02 0.07 
BIOCARTA ETS PATHWAY 0.01 0.08 
REACTOME IMMUNOREGULATORY INTERACTIONS BETWEEN A LYMPHOID AND A NON LYMPHOID CELL 0.01 0.08 
REACTOME INTERFERON GAMMA SIGNALING 0.01 0.08 
KEGG JAK STAT SIGNALING PATHWAY 0.00 0.08 
REACTOME EXTRACELLULAR MATRIX ORGANIZATION 0.01 0.08 
BIOCARTA INTRINSIC PATHWAY 0.02 0.08 
REACTOME RESPONSE TO ELEVATED PLATELET CYTOSOLIC CA2  0.01 0.08 
REACTOME GLYCOSAMINOGLYCAN METABOLISM 0.01 0.08 
PID IL4 2PATHWAY 0.01 0.08 
REACTOME AMYLOIDS 0.00 0.08 
REACTOME COMPLEMENT CASCADE 0.03 0.09 
PID TCR PATHWAY 0.01 0.09 
REACTOME ASPARAGINE N LINKED GLYCOSYLATION 0.00 0.08 
REACTOME INNATE IMMUNE SYSTEM 0.00 0.08 
REACTOME INTRINSIC PATHWAY 0.01 0.09 
REACTOME DOWNSTREAM TCR SIGNALING 0.02 0.09 
BIOCARTA TH1TH2 PATHWAY 0.01 0.09 
KEGG PATHOGENIC ESCHERICHIA COLI INFECTION 0.03 0.09 
REACTOME FORMATION OF FIBRIN CLOT CLOTTING CASCADE 0.03 0.09 
REACTOME CYTOKINE SIGNALING IN IMMUNE SYSTEM 0.00 0.10 
REACTOME COLLAGEN FORMATION 0.01 0.10 
PID PTP1BPATHWAY 0.01 0.10 
KEGG HEMATOPOIETIC CELL LINEAGE 0.01 0.12 
PID AJDISS 2PATHWAY 0.01 0.11 
PID CXCR4 PATHWAY 0.01 0.14 
REACTOME CHONDROITIN SULFATE DERMATAN SULFATE METABOLISM 0.04 0.14 
PID SYNDECAN 4 PATHWAY 0.02 0.14 
REACTOME INTEGRIN CELL SURFACE INTERACTIONS 0.02 0.14 
KEGG CELL ADHESION MOLECULES CAMS 0.01 0.14 
REACTOME REGULATION OF IFNA SIGNALING 0.04 0.14 
REACTOME SIGNALING BY ILS 0.01 0.14 
PID ATF2 PATHWAY 0.02 0.14 
REACTOME CELL SURFACE INTERACTIONS AT THE VASCULAR WALL 0.02 0.14 
PID INTEGRIN1 PATHWAY 0.04 0.14 
REACTOME PLATELET ACTIVATION SIGNALING AND AGGREGATION 0.00 0.15 
BIOCARTA NFKB PATHWAY 0.03 0.15 
PID AVB3 INTEGRIN PATHWAY 0.03 0.15 
PID CD8TCRPATHWAY 0.01 0.16 
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REACTOME NCAM1 INTERACTIONS 0.04 0.16 
REACTOME SMOOTH MUSCLE CONTRACTION 0.04 0.16 
BIOCARTA LAIR PATHWAY 0.05 0.17 
PID SMAD2 3NUCLEARPATHWAY 0.02 0.17 
PID INTEGRIN A9B1 PATHWAY 0.03 0.17 
REACTOME DEGRADATION OF THE EXTRACELLULAR MATRIX 0.07 0.17 
KEGG LEUKOCYTE TRANSENDOTHELIAL MIGRATION 0.02 0.17 
PID IL12 2PATHWAY 0.02 0.17 
KEGG FOCAL ADHESION 0.02 0.17 
PID IL12 STAT4PATHWAY 0.03 0.17 
REACTOME COSTIMULATION BY THE CD28 FAMILY 0.01 0.17 
REACTOME IL1 SIGNALING 0.04 0.17 
REACTOME INTERFERON SIGNALING 0.02 0.18 
REACTOME HEPARAN SULFATE HEPARIN HS GAG METABOLISM 0.04 0.18 
PID UPA UPAR PATHWAY 0.05 0.17 
REACTOME TOLL RECEPTOR CASCADES 0.01 0.21 
PID FOXM1PATHWAY 0.05 0.21 
PID P53DOWNSTREAMPATHWAY 0.02 0.22 
BIOCARTA CTLA4 PATHWAY 0.06 0.22 
KEGG P53 SIGNALING PATHWAY 0.04 0.22 
PID TNFPATHWAY 0.05 0.23 
KEGG ECM RECEPTOR INTERACTION 0.07 0.23 
BIOCARTA SPPA PATHWAY 0.04 0.23 
REACTOME SEMAPHORIN INTERACTIONS 0.04 0.23 
PID GLYPICAN 1PATHWAY 0.04 0.23 
REACTOME LIPID DIGESTION MOBILIZATION AND TRANSPORT 0.04 0.20 
PID DELTANP63PATHWAY 0.05 0.24 
REACTOME INTERFERON ALPHA BETA SIGNALING 0.08 0.24 
PID IL27PATHWAY 0.08 0.24 
REACTOME PRE NOTCH EXPRESSION AND PROCESSING 0.08 0.24 
BIOCARTA CSK PATHWAY 0.08 0.24 !
C. List of the genes significantly differentially expressed between ST PAs and DNTs !
upregulated Gene p value FDR Difference mean                   z-score PA-DNT 
PA SERPING1 0.00 0.08 1.97 
PA SERPINA3 0.00 0.05 1.79 
PA CD74 0.00 0.03 1.76 
PA RARRES1 0.00 0.04 1.69 
PA HLA-DQB1 0.00 0.09 1.57 
PA GFPT2 0.00 0.10 1.41 
PA CTGF 0.01 0.16 1.40 
PA MHC2TA 0.00 0.04 1.38 
PA LYZ 0.00 0.03 1.34 
PA LMOD1 0.00 0.05 1.34 
PA POSTN 0.00 0.04 1.33 
PA CD44 0.00 0.08 1.31 
PA ANXA1 0.01 0.14 1.26 
PA C1R 0.00 0.07 1.23 
PA DOC1 0.00 0.05 1.21 
PA F13A1 0.00 0.07 1.20 
PA GPX3 0.00 0.07 1.19 
PA PFKFB3 0.00 0.10 1.16 
PA S100A4 0.01 0.16 1.15 
PA MS4A6A 0.00 0.03 1.14 
PA AZGP1 0.01 0.17 1.11 
PA MSR1 0.00 0.08 1.10 
PA KIAA0247 0.01 0.13 1.08 
PA C3 0.00 0.03 1.08 
PA HLA-DRA 0.00 0.03 1.08 
PA ZFP36L2 0.00 0.07 1.08 
PA SRPX 0.01 0.11 1.08 
PA AEBP1 0.01 0.13 1.05 
PA GBP2 0.00 0.03 1.04 
PA LGALS1 0.01 0.17 1.04 
PA PHLDA1 0.01 0.12 1.03 
PA HLA-DMA 0.00 0.03 1.01 
PA IGFBP3 0.00 0.05 1.01 
PA CXCR4 0.01 0.11 0.98 
PA CNN2 0.00 0.09 0.95 
PA HLA-DPA1 0.01 0.12 0.95 
PA TM4SF1 0.03 0.25 0.95 
PA TRIM22 0.01 0.11 0.95 
PA IFI16 0.02 0.18 0.95 
PA ACTN1 0.00 0.08 0.94 
PA CHPF 0.00 0.04 0.94 
PA AHR 0.01 0.11 0.93 
PA EVI2B 0.00 0.10 0.90 
PA C1S 0.00 0.03 0.90 
PA SRPX2 0.00 0.03 0.88 
PA ACTA2 0.02 0.23 0.88 
PA WWTR1 0.00 0.07 0.87 
PA PBEF1 0.03 0.25 0.87 
PA RUNX1 0.01 0.12 0.87 
PA SPARC 0.00 0.03 0.86 
PA FCGR2A 0.01 0.12 0.85 
PA PLTP 0.00 0.04 0.83 
PA AKAP13 0.00 0.07 0.83 
PA TNFRSF12A 0.03 0.24 0.81 
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PA NPC2 0.01 0.11 0.81 
PA LAMB1 0.00 0.08 0.81 
PA ITGB4 0.00 0.07 0.81 
PA TYROBP 0.03 0.25 0.80 
PA TAGLN 0.01 0.13 0.80 
PA LMAN2 0.00 0.03 0.80 
PA PODXL 0.02 0.21 0.79 
PA HEXA 0.00 0.03 0.79 
PA LAMP1 0.00 0.08 0.77 
PA LGALS3BP 0.02 0.22 0.77 
PA LY96 0.02 0.19 0.76 
PA TRPM8 0.00 0.08 0.74 
PA ACTG2 0.02 0.21 0.74 
PA BGN 0.02 0.20 0.74 
PA HLA-DPB1 0.00 0.04 0.74 
PA ECM2 0.02 0.19 0.72 
PA OSMR 0.01 0.11 0.72 
PA HSPA6 0.00 0.07 0.71 
PA SLC4A7 0.01 0.13 0.70 
PA ARHGDIB 0.02 0.19 0.69 
PA HCLS1 0.00 0.11 0.69 
PA IF 0.00 0.07 0.69 
PA PRSS23 0.00 0.07 0.68 
PA IGJ 0.00 0.10 0.68 
PA TMSB10 0.01 0.15 0.67 
PA SP100 0.01 0.15 0.67 
PA RCN1 0.01 0.14 0.67 
PA CHMP2A 0.00 0.07 0.67 
PA ENG 0.01 0.17 0.67 
PA COL1A1 0.01 0.13 0.67 
PA STK17A 0.01 0.17 0.66 
PA CD14 0.02 0.21 0.65 
PA NME4 0.02 0.21 0.64 
PA MAP3K8 0.00 0.09 0.63 
PA P4HB 0.01 0.15 0.63 
PA DPEP2 0.01 0.13 0.63 
PA HMGA1 0.00 0.08 0.62 
PA AIF1 0.01 0.16 0.62 
PA TXNIP 0.01 0.16 0.62 
PA COL6A1 0.01 0.16 0.61 
PA C12orf8 0.01 0.18 0.60 
PA FER1L3 0.00 0.04 0.60 
PA GNB2L1 0.00 0.07 0.60 
PA CTNNB1 0.00 0.05 0.59 
PA COL18A1 0.02 0.20 0.59 
PA RGS2 0.01 0.18 0.58 
PA ITGB1 0.00 0.03 0.57 
PA MMP14 0.00 0.09 0.57 
PA PLAU 0.00 0.09 0.57 
PA COL4A1 0.01 0.17 0.57 
PA CALR 0.01 0.14 0.56 
PA CSDA 0.00 0.04 0.56 
PA CALU 0.02 0.18 0.56 
PA PFKL 0.02 0.19 0.56 
PA TRAM1 0.00 0.10 0.56 
PA TFE3 0.00 0.07 0.56 
PA ITGB2 0.00 0.05 0.56 
PA SIX1 0.01 0.12 0.55 
PA SLC20A1 0.01 0.14 0.55 
PA STXBP2 0.02 0.20 0.55 
PA MFGE8 0.00 0.07 0.55 
PA AKAP12 0.01 0.17 0.54 
PA MCFD2 0.01 0.11 0.54 
PA PCNA 0.01 0.14 0.54 
PA MYH9 0.00 0.10 0.53 
PA FGL2 0.00 0.10 0.53 
PA SERPINB6 0.00 0.07 0.53 
PA RNASE6 0.01 0.12 0.52 
PA VAMP5 0.00 0.08 0.51 
PA ITGA3 0.02 0.19 0.51 
PA S100A10 0.02 0.24 0.50 
PA TGFBI 0.00 0.03 0.50 
PA TAGLN2 0.00 0.10 0.50 
PA FYB 0.01 0.18 0.50 
PA FRZB 0.02 0.20 0.50 
DNT NR1D2 0.02 0.23 -0.50 
DNT KLHDC3 0.01 0.12 -0.51 
DNT EDIL3 0.01 0.11 -0.51 
DNT KIAA0103 0.00 0.07 -0.51 
DNT SLC11A2 0.01 0.16 -0.51 
DNT BRP44 0.03 0.25 -0.53 
DNT OMG 0.00 0.05 -0.53 
DNT RASGRF1 0.00 0.03 -0.54 
DNT GLRB 0.00 0.09 -0.54 
DNT UGT8 0.01 0.14 -0.54 
DNT RAB33A 0.00 0.05 -0.54 
DNT ATP8A2 0.00 0.08 -0.55 
DNT MAPRE2 0.00 0.10 -0.55 
DNT SNCB 0.01 0.13 -0.55 
DNT CTNND2 0.00 0.10 -0.55 
DNT OPCML 0.03 0.25 -0.56 
DNT PPP2CA 0.02 0.22 -0.57 
DNT NFYB 0.02 0.18 -0.57 
DNT ARHGAP5 0.01 0.14 -0.57 
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DNT RAN 0.01 0.12 -0.57 
DNT PIK3R1 0.01 0.12 -0.57 
DNT MYO5A 0.01 0.11 -0.57 
DNT ATP6V0A1 0.00 0.03 -0.58 
DNT KLRC3 0.00 0.07 -0.58 
DNT GSTA4 0.01 0.17 -0.58 
DNT STMN1 0.00 0.04 -0.59 
DNT PLCL1 0.00 0.03 -0.59 
DNT GNG4 0.01 0.13 -0.60 
DNT PDE9A 0.00 0.05 -0.60 
DNT STAU2 0.00 0.04 -0.60 
DNT CDK5R1 0.00 0.07 -0.60 
DNT HES1 0.01 0.13 -0.61 
DNT PRKAR1B 0.01 0.11 -0.61 
DNT COX6C 0.01 0.12 -0.61 
DNT SHC3 0.02 0.22 -0.61 
DNT RPL13 0.00 0.05 -0.61 
DNT MOBP 0.01 0.15 -0.62 
DNT NET1 0.00 0.09 -0.62 
DNT CHGB 0.01 0.15 -0.63 
DNT GPSM2 0.00 0.06 -0.63 
DNT RAB6A 0.01 0.15 -0.64 
DNT RORB 0.02 0.20 -0.64 
DNT HRMT1L2 0.01 0.11 -0.64 
DNT PTPRD 0.00 0.05 -0.64 
DNT IDI1 0.00 0.09 -0.64 
DNT SYN2 0.00 0.03 -0.65 
DNT TJP1 0.00 0.05 -0.66 
DNT GPR17 0.03 0.24 -0.66 
DNT TRIM2 0.00 0.03 -0.68 
DNT GRP 0.00 0.07 -0.68 
DNT PTPRN2 0.01 0.18 -0.69 
DNT RGS5 0.00 0.06 -0.69 
DNT BTBD3 0.00 0.05 -0.70 
DNT AMPH 0.00 0.04 -0.71 
DNT CPSF6 0.00 0.05 -0.71 
DNT C11orf8 0.00 0.05 -0.71 
DNT ABCA5 0.00 0.09 -0.73 
DNT KCNN2 0.00 0.07 -0.73 
DNT NPC1 0.01 0.12 -0.74 
DNT CAMK2N1 0.02 0.23 -0.75 
DNT NPY 0.00 0.03 -0.76 
DNT RNF144 0.00 0.05 -0.76 
DNT CLDN10 0.00 0.06 -0.76 
DNT SEZ6L 0.00 0.07 -0.76 
DNT MAP2K4 0.00 0.04 -0.77 
DNT PRKACB 0.00 0.07 -0.77 
DNT PIP5K2A 0.01 0.13 -0.78 
DNT NRGN 0.01 0.14 -0.81 
DNT SPTBN2 0.03 0.25 -0.82 
DNT PCDH17 0.01 0.11 -0.83 
DNT EDG2 0.02 0.22 -0.83 
DNT R3HDM 0.00 0.10 -0.84 
DNT GRIA2 0.01 0.13 -0.85 
DNT RGS7 0.00 0.05 -0.87 
DNT INA 0.00 0.10 -0.88 
DNT CHGA 0.01 0.18 -0.89 
DNT GPR37 0.00 0.10 -0.91 
DNT ELAVL3 0.01 0.16 -0.91 
DNT CAMK4 0.00 0.04 -0.92 
DNT EIF4A2 0.00 0.08 -0.92 
DNT MAPK8IP2 0.00 0.05 -0.93 
DNT KCNK1 0.00 0.03 -0.93 
DNT CSMD1 0.00 0.03 -0.95 
DNT ACVR2A 0.00 0.06 -0.99 
DNT KCNJ4 0.00 0.08 -1.00 
DNT PRKCB1 0.00 0.05 -1.03 
DNT DLGAP1 0.00 0.08 -1.03 
DNT FGF12 0.00 0.06 -1.04 
DNT ATP1B1 0.00 0.04 -1.04 
DNT CNTN1 0.00 0.04 -1.12 
DNT PCP4 0.01 0.11 -1.20 
DNT CHD5 0.01 0.12 -1.21 
DNT ADD3 0.00 0.08 -1.26 
DNT MT1G 0.00 0.07 -1.36 
DNT SLC17A7 0.00 0.03 -1.44 
DNT PLP1 0.01 0.14 -1.50 
DNT CLEC3B 0.00 0.08 -1.51 
DNT VSNL1 0.00 0.06 -1.56 
DNT SNAP25 0.00 0.03 -1.58 
DNT STMN2 0.00 0.06 -1.63 
DNT SCN2A2 0.00 0.06 -1.67 
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D. List of the gene-sets significantly enriched between ST PAs and ST DNTs  
GENE-SETS ENRICHED IN THE ST PAs p value FDR 
KEGG COMPLEMENT AND COAGULATION CASCADES 0.00 0.00 
PID INTEGRIN2 PATHWAY 0.00 0.00 
REACTOME INTEGRIN CELL SURFACE INTERACTIONS 0.00 0.02 
PID UPA UPAR PATHWAY 0.00 0.02 
KEGG VIRAL MYOCARDITIS 0.00 0.03 
KEGG INTESTINAL IMMUNE NETWORK FOR IGA PRODUCTION 0.00 0.03 
KEGG ASTHMA 0.00 0.03 
KEGG GRAFT VERSUS HOST DISEASE 0.01 0.03 
KEGG ALLOGRAFT REJECTION 0.01 0.03 
KEGG AUTOIMMUNE THYROID DISEASE 0.00 0.03 
KEGG LEISHMANIA INFECTION 0.01 0.03 
REACTOME COMPLEMENT CASCADE 0.00 0.03 
PID INTEGRIN CS PATHWAY 0.00 0.03 
KEGG HEMATOPOIETIC CELL LINEAGE 0.00 0.03 
KEGG ANTIGEN PROCESSING AND PRESENTATION 0.01 0.03 
BIOCARTA INTRINSIC PATHWAY 0.01 0.03 
REACTOME IMMUNOREGULATORY INTERACTIONS BETWEEN  
A LYMPHOID AND A NON LYMPHOID CELL 0.01 0.04 
KEGG SYSTEMIC LUPUS ERYTHEMATOSUS 0.01 0.04 
REACTOME RESPONSE TO ELEVATED PLATELET CYTOSOLIC CA2  0.00 0.04 
PID INTEGRIN1 PATHWAY 0.01 0.04 
BIOCARTA TH1TH2 PATHWAY 0.01 0.04 
PID INTEGRIN3 PATHWAY 0.01 0.06 
KEGG ECM RECEPTOR INTERACTION 0.01 0.07 
REACTOME GLYCOSAMINOGLYCAN METABOLISM 0.01 0.07 
PID SYNDECAN 4 PATHWAY 0.00 0.10 
REACTOME INTERFERON GAMMA SIGNALING 0.02 0.10 
KEGG TYPE I DIABETES MELLITUS 0.03 0.10 
PID AVB3 INTEGRIN PATHWAY 0.01 0.11 
PID PTP1BPATHWAY 0.02 0.11 
PID ARF6 TRAFFICKINGPATHWAY 0.00 0.12 
PID INTEGRIN A9B1 PATHWAY 0.02 0.12 
BIOCARTA AMI PATHWAY 0.02 0.12 
REACTOME FORMATION OF FIBRIN CLOT CLOTTING CASCADE 0.03 0.12 
REACTOME POST TRANSLATIONAL PROTEIN MODIFICATION 0.00 0.12 
PID IL4 2PATHWAY 0.04 0.12 
PID AMB2 NEUTROPHILS PATHWAY 0.02 0.13 
REACTOME GENERATION OF SECOND MESSENGER MOLECULES 0.01 0.13 
KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION 0.01 0.13 
REACTOME EXTENSION OF TELOMERES 0.02 0.13 
KEGG JAK STAT SIGNALING PATHWAY 0.00 0.13 
REACTOME HEPARAN SULFATE HEPARIN HS GAG METABOLISM 0.02 0.13 
KEGG NUCLEOTIDE EXCISION REPAIR 0.01 0.13 
REACTOME LIPOPROTEIN METABOLISM 0.02 0.13 
PID CXCR4 PATHWAY 0.01 0.13 
REACTOME CELL SURFACE INTERACTIONS AT THE VASCULAR WALL 0.02 0.13 
REACTOME CHONDROITIN SULFATE DERMATAN SULFATE METABOLISM 0.02 0.13 
PID HIVNEFPATHWAY 0.01 0.13 
PID AJDISS 2PATHWAY 0.01 0.13 
KEGG CELL ADHESION MOLECULES CAMS 0.02 0.14 
REACTOME SPHINGOLIPID METABOLISM 0.02 0.14 
REACTOME PLATELET ACTIVATION SIGNALING AND AGGREGATION 0.00 0.14 
BIOCARTA LAIR PATHWAY 0.03 0.14 
BIOCARTA SPPA PATHWAY 0.01 0.15 
REACTOME REGULATION OF INSULIN LIKE GROWTH FACTOR IGF ACTIVITY BY INSULIN LIKE GROWTH 
FACTOR BINDING PROTEINS IGFBPS 0.03 0.15 
KEGG FOCAL ADHESION 0.01 0.15 
BIOCARTA INFLAM PATHWAY 0.05 0.15 
REACTOME GLOBAL GENOMIC NER GG NER 0.01 0.16 
REACTOME EXTRACELLULAR MATRIX ORGANIZATION 0.05 0.16 
KEGG LEUKOCYTE TRANSENDOTHELIAL MIGRATION 0.00 0.18 
PID TCR PATHWAY 0.02 0.18 
BIOCARTA HIVNEF PATHWAY 0.01 0.18 
PID SYNDECAN 1 PATHWAY 0.06 0.19 
PID A6B1 A6B4 INTEGRIN PATHWAY 0.02 0.19 
KEGG REGULATION OF ACTIN CYTOSKELETON 0.01 0.19 
REACTOME GLYCOSPHINGOLIPID METABOLISM 0.06 0.19 
REACTOME LAGGING STRAND SYNTHESIS 0.03 0.19 
BIOCARTA DEATH PATHWAY 0.04 0.19 
KEGG LYSOSOME 0.03 0.19 
REACTOME ASPARAGINE N LINKED GLYCOSYLATION 0.03 0.19 
BIOCARTA NFKB PATHWAY 0.05 0.19 
PID TAP63PATHWAY 0.05 0.19 
PID DELTANP63PATHWAY 0.04 0.19 
REACTOME HS GAG DEGRADATION 0.06 0.19 
PID ILK PATHWAY 0.02 0.20 
KEGG PRIMARY IMMUNODEFICIENCY 0.07 0.20 
REACTOME COLLAGEN FORMATION 0.08 0.20 
PID MYC REPRESSPATHWAY 0.03 0.20 
KEGG ARACHIDONIC ACID METABOLISM 0.04 0.21 
PID FRA PATHWAY 0.09 0.22 
KEGG P53 SIGNALING PATHWAY 0.04 0.22 
PID AR PATHWAY 0.04 0.22 
PID P53DOWNSTREAMPATHWAY 0.04 0.22 
REACTOME COSTIMULATION BY THE CD28 FAMILY 0.02 0.22 
PID AVB3 OPN PATHWAY 0.03 0.22 
BIOCARTA DC PATHWAY 0.09 0.22 
BIOCARTA RHO PATHWAY 0.03 0.23 
REACTOME DNA STRAND ELONGATION 0.07 0.23 
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REACTOME NCAM1 INTERACTIONS 0.08 0.23 
REACTOME NUCLEOTIDE EXCISION REPAIR 0.02 0.23 
BIOCARTA UCALPAIN PATHWAY 0.05 0.23 
KEGG SMALL CELL LUNG CANCER 0.04 0.23 
KEGG DNA REPLICATION 0.07 0.24 
GENE-SETS ENRICHED IN THE ST DNTs        
 
REACTOME POST NMDA RECEPTOR ACTIVATION EVENTS 
 
 
 
0.00 
 
 
 
0.08 
REACTOME NEUROTRANSMITTER RELEASE CYCLE 0.01 0.08 
BIOCARTA NO1 PATHWAY 0.01 0.08 
REACTOME NEUROTRANSMITTER RECEPTOR BINDING AND DOWNSTREAM TRANSMISSION IN THE 
POSTSYNAPTIC CELL 0.00 0.08 
REACTOME TRANSMISSION ACROSS CHEMICAL SYNAPSES 0.00 0.09 
BIOCARTA NOS1 PATHWAY 0.00 0.09 
REACTOME NITRIC OXIDE STIMULATES GUANYLATE CYCLASE 0.00 0.11 
REACTOME PLC BETA MEDIATED EVENTS 0.00 0.13 
REACTOME OPIOID SIGNALLING 0.00 0.13 
REACTOME CA DEPENDENT EVENTS 0.01 0.14 
REACTOME DAG AND IP3 SIGNALING 0.01 0.14 
REACTOME ACTIVATION OF NMDA RECEPTOR UPON GLUTAMATE BINDING AND POSTSYNAPTIC EVENTS 0.00 0.14 
KEGG LONG TERM POTENTIATION 0.00 0.14 
KEGG OLFACTORY TRANSDUCTION 0.00 0.15 
KEGG CARDIAC MUSCLE CONTRACTION 0.01 0.15 
PID RAS PATHWAY 0.00 0.16 
REACTOME PHOSPHOLIPASE C MEDIATED CASCADE 0.02 0.16 
BIOCARTA GPCR PATHWAY 0.00 0.16 
REACTOME DARPP 32 EVENTS 0.01 0.16 
REACTOME ION CHANNEL TRANSPORT 0.01 0.16 
REACTOME CREB PHOSPHORYLATION THROUGH THE ACTIVATION OF RAS 0.02 0.16 
BIOCARTA PGC1A PATHWAY 0.01 0.17 
BIOCARTA VIP PATHWAY 0.00 0.17 
KEGG GAP JUNCTION 0.01 0.17 
REACTOME NEURONAL SYSTEM 0.00 0.20 
REACTOME POTASSIUM CHANNELS 0.02 0.22 
REACTOME SIGNALING BY FGFR IN DISEASE 0.01 0.23 
BIOCARTA AT1R PATHWAY 0.03 0.24 
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3.3. Variations in expression patterns by tumor location  
 
 We also observe significant differences in expression between ST and IT tumors 
on both a global scale (p=0.0001; Figure 26A) and at the individual gene level, after 
controlling for histology. We compared Euclidean distances within and between the two 
groups, controlling for histology by maintaining histology class labels. We also found 
significant differences after restricting the analysis to PAs (p=0.02). These differences 
can be visualized using the first three principle components of a Principal Components 
Analysis (PCA) across the whole cohort (Figure 26A) and across the PAs (Figure 26B).  
Among PAs, 31 genes and 21 gene-sets were significantly differentially expressed 
between ST and IT tumors (Figure 26C, Table 10A-B).  All 21 differentially expressed 
gene-sets were enriched among the ST tumors, including three that were associated 
with IL12 pathway activation (out of four total; p<0.0001; Figure 26D).  
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Figure 26: ST and IT PAs exhibit different molecular patterns 
A-B. PCA analyses comparing ST and IT PLGGs (A) and ST and IT PAs (B).  C. Heat-map of 
genes found to be differentially expressed between ST and IT PAs. D. Enrichment plot of an 
IL12 gene-set found to be significantly enriched in ST PAs relative to IT PAs. E. HLA-DRA 
immunohistochemical staining of individual ST and IT PAs (top) and summary results across 8 
ST and 8 IT tumors (bottom).  The y-axis represents the area under the curve (AUC) metric from Cell 
Profiler. * p<0.05. 
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Among our ST tumors, 58 were cortical and 15 were midline. After controlling for 
histology as a confounder, we observed 73 genes and 3 gene-sets significantly 
differentially expressed between the two ST regions (Table 10D and 10E). 
These differences between ST and IT tumors appear to be tumor-specific and not 
reproduced in normal brain tissue. We compared ST and IT expression profiles from 12 
children’s brains in the publicly available BRAINSPAN dataset332. Among the 31 genes 
that were differentially expressed between ST and IT PAs, 30 were also included in the 
BRAINSPAN dataset.  Among these, 14 genes were differentially expressed in the same 
direction and 16 in the opposite direction between tumors and normal brains (p = 0.29). 
We also performed GSEA on 12 ST and 12 IT normal samples from children in the 
BRAINSPAN database (Table 10C).  We did not observe significant enrichment in either 
direction of any inflammatory pathways. 
However, we did find indications of increased IL12 pathway activation in ST tumors in 
expression data from an independent set of 16 ST and 30 IT PAs229. We evaluated all 
four IL12 gene-sets that are included in the C2 CP set.  One of these was enriched in 
the ST PAs (p=0.03); the other three exhibited trends in that direction (p=0.0984, 
0.1262, and 0.2350, respectively). 
We further evaluated this finding by performing immunohistochemistry for HLA-DRA in 
an independent set of 8 ST and 8 IT PAs. HLA-DRA is a major effector in immune 
response and was one of the genes overexpressed in ST relative to IT PAs. We 
observed significantly higher expression of HLA-DRA in the ST (Figure 26E, p = 0.007). 
The cells that stained positive for HLA-DRA included cells within vessels (possibly 
lymphocytes) and also cells with glial morphology within the tumor, suggesting that both 
populations may contribute to the increase in inflammatory signatures in ST PAs. 
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Table 10: 
 
A. List of the genes significantly differentially expressed between ST and IT PAs. 
 
Upregulated 
in Name p value FDR 
Difference mean                 
z-score ST – IT PAs 
ST PA GFPT2 0.00 0.14 1.23 
ST PA RARRES1 0.00 0.20 0.91 
ST PA LYZ 0.00 0.13 0.80 
ST PA F13A1 0.00 0.09 0.75 
ST PA CD74 0.00 0.24 0.67 
ST PA SIX1 0.00 0.09 0.62 
ST PA LAMB1 0.00 0.14 0.60 
ST PA TRIM22 0.00 0.19 0.59 
ST PA IGJ 0.00 0.09 0.58 
ST PA SLIT1 0.00 0.19 0.58 
ST PA HLA-DRA 0.00 0.11 0.54 
IT PA NOS1 0.00 0.16 -0.51 
IT PA KLHDC3 0.00 0.09 -0.53 
IT PA GRIA4 0.00 0.09 -0.53 
IT PA CHAD 0.00 0.14 -0.53 
IT PA ABAT 0.00 0.09 -0.55 
IT PA NTRK2 0.00 0.19 -0.61 
IT PA TRH 0.00 0.19 -0.65 
IT PA CSMD1 0.00 0.09 -0.69 
IT PA EDIL3 0.00 0.09 -0.70 
IT PA RHOB 0.00 0.20 -0.71 
IT PA PCDH17 0.00 0.09 -0.76 
IT PA AGT 0.00 0.19 -0.76 
IT PA FGF12 0.00 0.09 -0.79 
IT PA CPE 0.00 0.09 -0.81 
IT PA CNTN1 0.00 0.09 -0.81 
IT PA RIT2 0.00 0.16 -0.99 
IT PA COL9A1 0.00 0.19 -1.03 
IT PA CDH19 0.00 0.09 -1.03 
IT PA AGTRL1 0.00 0.09 -1.30 
IT PA S100A1 0.00 0.21 -1.54 
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C. Gene sets significantly enriched in ST PAs in comparison with IT PAs 
NAME P value FDR 
PID IL12 STAT4PATHWAY 0.00 0.01 
KEGG ALLOGRAFT REJECTION 0.01 0.05 
BIOCARTA CTLA4 PATHWAY 0.00 0.05 
KEGG SYSTEMIC LUPUS ERYTHEMATOSUS 0.00 0.06 
KEGG AUTOIMMUNE THYROID DISEASE 0.01 0.06 
KEGG VIRAL MYOCARDITIS 0.00 0.06 
PID IL12 2PATHWAY 0.00 0.07 
KEGG INTESTINAL IMMUNE NETWORK FOR IGA  
PRODUCTION 0.00 0.07 
KEGG ASTHMA 0.01 0.08 
BIOCARTA SPRY PATHWAY 0.01 0.08 
BIOCARTA IL12 PATHWAY 0.00 0.09 
KEGG GRAFT VERSUS HOST DISEASE 0.01 0.11 
BIOCARTA TH1TH2 PATHWAY 0.01 0.12 
KEGG CYTOKINE CYTOKINE RECEPTOR INTERACTION 0.01 0.16 
KEGG LEISHMANIA INFECTION 0.00 0.16 
REACTOME IMMUNOREGULATORY INTERACTIONS BETWEEN A LYMPHOID AND A 
NON LYMPHOID CELL 0.02 0.17 
KEGG TYPE I DIABETES MELLITUS 0.02 0.19 
PID TCR PATHWAY 0.01 0.20 
PID INTEGRIN3 PATHWAY 0.02 0.24 
BIOCARTA CSK PATHWAY 0.01 0.24 
REACTOME DOWNSTREAM TCR SIGNALING 0.03 0.24 !!
D. List of the 30 genes significantly differentially expressed between ST and IT PAs 
related to the expression in the Brainspan dataset  
 
Gene Expression in normal brain (BRAINSPAN) 
CDH19 OPPOSITE 
CHAD SAME 
FGF12 OPPOSITE 
HLA-DRA OPPOSITE 
KLHDC3 OPPOSITE 
PCDH17 OPPOSITE 
RHOB SAME 
RIT2 SAME 
AGT SAME 
COL9A1 OPPOSITE 
F13A1 SAME 
RARRES1 SAME 
TRH OPPOSITE 
CNTN1 SAME 
EDIL3 OPPOSITE 
GRIA4 SAME 
LAMB1 OPPOSITE 
NOS1 OPPOSITE 
NTRK2 OPPOSITE 
S100A1 OPPOSITE 
SLIT1 SAME 
ABAT OPPOSITE 
CD74 OPPOSITE 
CPE SAME 
CSMD1 OPPOSITE 
GFPT2 OPPOSITE 
IGJ SAME 
LYZ SAME 
SIX1 SAME 
TRIM22 SAME 
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D. List of the 73 genes significantly differentially expressed between midline and cortical 
tumors  !
Upregulated in Name p value FDR 
Difference mean 
Zscore midline - 
cortex 
midline LMOD1 0,01 0,21 1,33 
midline FOS 0,00 0,10 1,31 
midline CD44 0,00 0,14 1,18 
midline AEBP1 0,00 0,10 1,13 
midline CAV1 0,01 0,22 1,12 
midline AGTRL1 0,01 0,24 1,10 
midline C1R 0,01 0,21 1,09 
midline ID4 0,00 0,10 0,98 
midline RARRES3 0,00 0,10 0,95 
midline ZFP36L2 0,00 0,14 0,94 
midline ECM2 0,00 0,11 0,82 
midline GYPC 0,01 0,22 0,81 
midline LGALS3BP 0,00 0,14 0,80 
midline SIX1 0,00 0,10 0,77 
midline PRRX1 0,00 0,20 0,76 
midline NFIL3 0,01 0,22 0,74 
midline CHPF 0,01 0,21 0,73 
midline S100A10 0,00 0,10 0,72 
midline SLC39A14 0,00 0,15 0,71 
midline FCGBP 0,00 0,15 0,71 
midline GLUL 0,01 0,21 0,70 
midline PRSS23 0,00 0,10 0,69 
midline AHNAK 0,01 0,23 0,68 
midline ARHGDIA 0,00 0,16 0,67 
midline COL6A1 0,00 0,13 0,66 
midline FMOD 0,00 0,20 0,66 
midline TRPM8 0,01 0,22 0,65 
midline CP 0,00 0,20 0,64 
midline HCLS1 0,00 0,20 0,63 
midline MVP 0,00 0,10 0,61 
midline PLTP 0,01 0,22 0,61 
midline PLAU 0,00 0,10 0,59 
midline DDR1 0,00 0,16 0,59 
midline CTNNB1 0,00 0,14 0,57 
midline EMP2 0,00 0,17 0,57 
midline RFX1 0,00 0,10 0,56 
midline PKM2 0,01 0,24 0,56 
midline SPARC 0,00 0,11 0,55 
midline NFE2L1 0,01 0,23 0,51 
midline SERPINA5 0,00 0,11 0,51 
cortex NFYB 0,00 0,17 -0,51 
cortex RGS5 0,01 0,22 -0,52 
cortex CPSF6 0,00 0,14 -0,54 
cortex SLC1A3 0,00 0,18 -0,54 
cortex C11orf8 0,00 0,16 -0,54 
cortex PPP2CA 0,00 0,19 -0,55 
cortex COX7B 0,00 0,20 -0,58 
cortex NRGN 0,00 0,20 -0,58 
cortex R3HDM 0,01 0,22 -0,58 
cortex SKP1A 0,00 0,14 -0,59 
cortex DBI 0,00 0,14 -0,60 
cortex RGS7 0,00 0,10 -0,60 
cortex CTNND2 0,01 0,22 -0,61 
cortex FOXG1B 0,00 0,10 -0,62 
cortex ACSL3 0,00 0,19 -0,63 
cortex GPM6A 0,00 0,10 -0,65 
cortex NPY 0,01 0,22 -0,66 
cortex NGFRAP1 0,01 0,22 -0,68 
cortex AES 0,00 0,20 -0,68 
cortex NM 001069 0,01 0,24 -0,70 
cortex GP1BB 0,01 0,24 -0,73 
cortex PC4 0,00 0,20 -0,76 
cortex PIP5K1B 0,00 0,14 -0,78 
cortex PBP 0,00 0,14 -0,80 
cortex PLS3 0,00 0,19 -0,81 
cortex CAMK4 0,00 0,10 -0,83 
cortex ATP5G3 0,01 0,24 -0,85 
cortex DLGAP1 0,00 0,14 -0,91 
cortex SLC17A7 0,00 0,14 -0,92 
cortex ST13 0,01 0,22 -0,95 
cortex GABRB1 0,00 0,13 -0,98 
cortex SNAP25 0,00 0,10 -1,12 
cortex VSNL1 0,00 0,10 -1,26 !!!!
! 119 
E. List of the gene-sets significantly differentially expressed between midline and cortical 
tumors  !!
Enriched in Name p value FDR 
midline REACTOME MEMBRANE BINDING AND TARGETTING OF GAG PROTEINS 0,00 0,18 
cortex KEGG PARKINSONS DISEASE 0,00 0,18 
cortex REACTOME POST NMDA RECEPTOR ACTIVATION EVENTS 0,00 0,18 
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3.4. Molecular differences associated with BRAF alterations 
 
 We observed significant differences in levels of individual genes and gene-sets 
between BRAF-duplicated and BRAF-V600E mutated tumors. We performed 
Comparative Marker Selection between the BRAF-duplicated or mutated tumors and WT 
tumors, controlling for both location and histology as possible confounders by 
maintaining these class labels during all permutations. We evaluated both individual 
gene scores and sums of scores across all genes within the gene-sets listed in the 
MSigDBC2P database335. No genes or gene-sets were significantly differentially 
expressed between the BRAF-duplicated tumors and WT tumors or between BRAF-
V600E mutated and WT tumors. We did find 15 genes that were differentially expressed 
between the BRAF-duplicated and -V600E mutated tumors (Figure 27A, Table 11). 
Eleven genes were overexpressed in BRAF-duplicated tumors, including the calcium-
binding protein S100A1, involved in the regulation of cell cycle progression and 
differentiation, and the transcription factor ID4. Four genes were overexpressed in 
BRAF-V600E-mutant tumors, including ANK1, an ankyrin involved in cell motility and 
proliferation, and the tyrosine kinase PTK2B, which regulates neuronal activity. 
To evaluate global differences, we compared the Euclidean distances between BRAF-
duplicated, BRAF-V600E mutated, and BRAF-WT tumors to Euclidean distances 
between tumors within each of these classes, after controlling for location and histology. 
We found no significant differences between any of these groups (p=0.15, p=0.40, 
p=0.26, respectively; Figure 27B).  
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Figure 27: Variation in gene expression between BRAF-KIAA duplicated and 
BRAF-V600E mutated tumors  
A. Heat-map representing genes found to be differentially expressed between BRAF-
duplicated and V600E-mutated tumors.  
B. Histogram representing the Euclidean distances between and within BRAF-duplicated 
and WT tumors, between and within BRAF-V600E mutated and WT tumors, and 
between and within BRAF-duplicated tumors and BRAF-V600E mutated tumors.  
P-values represent the probability that the Euclidean distances between tumor groups are 
significantly higher than distances within tumor groups.  
 
 
  
! 122 
Table 11: Genes exhibiting significantly different expression between BRAF-duplicated 
and V600E-mutated tumors. 
 !
Upregulated 
in gene p value FDR 
Difference mean  
z-score  
BRAF DUP - 
BRAF MUT 
DUP S100A1 0.00 0.23 2.57 
DUP ID4 0.00 0.17 1.24 
DUP ABAT 0.00 0.24 1.00 
DUP NEBL 0.00 0.17 0.84 
DUP PCP4 0.00 0.17 0.80 
DUP AGT 0.00 0.21 0.77 
DUP LSAMP 0.00 0.23 0.74 
DUP NTRK2 0.00 0.17 0.73 
DUP NOS1 0.00 0.20 0.64 
DUP CNTN1 0.00 0.17 0.64 
DUP ADCYAP1R1 0.00 0.17 0.54 
MUT PTK2B 0.00 0.20 -0.53 
MUT ANK1 0.00 0.23 -0.90 
MUT POSTN 0.00 0.17 -0.91 
MUT PHLDA2 0.00 0.21 -0.98 
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3.5. Differences between primary and recurrent tumors 
 
 Our cohort included 31 primary tumors from children who went on to have 
recurrences and 16 recurrent tumors, with overlap in nine cases. We observed no 
significant differences in the overall Euclidean distances between primary and recurrent 
tumor samples or between the 104 primary tumors with no record of recurrence and the 
31 tumors that went on to progress (p=0.12, p=0.9, respectively; Figures 28A-B). We 
also found no genes or gene-sets whose expression differed significantly between 
primary and recurrent PLGGs after controlling for location and histology.   
 
Compared to primary tumors from the same patients, recurrent tumors exhibited 
enrichment of two genes: the zinc finger ZNF652 and the kinase anchor protein AKAP9, 
which interacts with signaling proteins from various signal transduction pathways. 
However, there was no significant difference in overall Euclidean distances between the 
paired primary and recurrent tumors (p=0.28), and the changes between them did not 
favor any direction or magnitude (Figure 28C). 
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Figure 28: Recurrent and primary PLGGs do not exhibit clearly distinct molecular 
patterns. 
A-C. PCA analysis comparing the expression pattern of primary and recurrent PLGGs 
(A), the 104 primary tumors that have no record of recurrence and the 31 primary tumors 
that have relapsed or progressed (B), and the nine paired primary and recurrent 
samples (C). Arrows match each primary to its recurrent pairs. 
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3.6. Similar expression patterns in childhood and adolescent PAs 
 
 Tumors that occurred in young children also exhibited no significant differences 
compared to adolescents approaching adulthood. We evaluated both individual genes 
and gene-sets, and controlled for location and histology by selecting only IT PAs for 
comparison. 
 
 
4. Discussion 
 
 
PLGGs are characterized by a spectrum of histological subtypes, different ages and 
locations of development within the brain, and varied genetic alterations. We examined 
how expression profiles of PLGGs are shaped by their clinical, histopathological, and 
BRAF genomic characteristics, and whether differences associated with age and 
location were reflected in expression profiles from normal brain. 
 
We identified substantial differences between ST and IT tumors after controlling for 
histology, indicating that tumor location significantly influences controlling for histology, 
indicating that tumor location significantly influences PLGG expression profiles. Only 
tumors with purities greater than 70% were included in this analysis, however. The 
differences were also not significantly similarly reflected in ST and IT normal brain 
expression, suggesting that the differences were specific to the cancer cells or to their 
interactions with normal cells within the tumor. ST and IT PAs have previously been 
found to harbor distinct expression 319,320 and methylation profiles336. However, the 
! 126 
genes found to be differentially expressed in the prior study319,320 did not overlap with 
our gene set. Among the 15 genes reported to be differentially expressed in that study 
that were represented in our DASL platform, two-thirds were similarly differentially 
expressed between normal brain ST and IT regions (p=0.3). 
 
ST PAs are enriched for IL12 pathway activity compared to IT PAs. IL12 activates T-
cells and regulates the production of IFN-γ via JAK2 and STAT4337,338. HLA-DRA, which 
drives various inflammatory pathways, was specifically enriched among ST PAs339. 
These findings suggest either an inflammatory signal in ST PA tumor cells or 
inflammatory activation in the tumor microenvironment. HLA-DRA expression in 
colorectal cancer has been reported to reflect an immunologic response in the tumor 
bed that is associated with a better outcome340,341.  
 
We identified molecular differences between PAs and DAs and between PAs and DNTs, 
even after controlling for location. Although DAs and PAs are both classified as 
astrocytic tumors by the WHO consensus, the differences we detect suggest either that 
they arise from distinct cells of origin or the distinct genomic abnormalities that drive 
these tumor subtypes are reflected in their expression profiles. Conversely, other PLGG 
subtypes such as PAs and GGs tend to cluster together in the same SOM group and did 
not exhibit statistically significant differences using a distance permutation test. This was 
surprising, as their morphologies and BRAF alterations differ.  It is possible that 
differences will be revealed by larger tumor cohorts with increased statistical power. 
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NOS tumors distributed equally across the 3 clusters in our unsupervised analyses, 
suggesting that they do not constitute a unified molecular class.  The finding that their 
distribution was dependent on their BRAF alteration status suggests the NOS class 
includes tumors with strong molecular similarities to existing histologic classes (eg PAs 
and GGs).  It may be appropriate to include such molecular features in the diagnostic 
criteria for these tumors so as to reclassify the NOS tumors among the well-defined 
histologic groups with which they are most similar. 
 
BRAF-duplicated and BRAF-V600E mutated tumors exhibited differences after 
controlling for location and histological subtype, including differences in expression 
levels of genes involved in cell development and differentiation. However, these 
differences were not extensive. These tumors also tended to cluster separately in our 
unsupervised analysis, but not to a statistically significant degree. It is possible that we 
would detect greater differences in a larger cohort or using an assay that evaluates 
larger numbers of genes.  However, the minimal differences between these tumor 
subsets, as compared to the differences between ST and IT tumors, may indicate that 
these alterations lead to similar downstream effects.  Similarly, our inability to detect 
substantial differences in gene expression profiles of BRAF-altered tumors compared to 
wild-type tumors might be related to a lack of power to detect small differences in our 
dataset, to a minimal impact of BRAF alterations on gene expression profiles or to the 
existence of genomic alterations in the wild-type tumors that lead to similar downstream 
effects. These alterations might include mutations or copy-number alterations of FGFR1 
or NTRK2 rearrangements, all of which have recently been described in PLGGs and 
shown to lead to lead to MAPK activation228,229. 
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We find that PLGG expression patterns do not substantially evolve with progression. 
This is consistent with clinical observations that although PLGGs do often progress or 
recur, they rarely undergo malignant transformation100 and often respond to the same 
chemotherapy regimen117.   
 
We also found no significant differences in outcome between the three different clusters 
of primary tumors, possibly due to lack of power as PLGGs grow slowly. 
 
A significant complication in the analysis of bulk gene expression profiles, as obtained 
here, is that they reflect the sum of profiles across the many subclones and cell states of 
both tumor and normal cells within the sample342,343.  For example, the finding that ST 
PAs exhibit enhanced inflammatory pathways may reflect changes within the cancer 
cells or an increased inflammatory response.  Single-cell expression profiling344,345 may 
enable us to disentangle these different contributions to the bulk profile, thereby 
providing important information about the molecular programs that are altered 
specifically in the tumor cells and in their microenvironment. 
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Chapter 4: Single cell expression profiling 
 
1. Introduction 
 
One major limitation of bulk expression profiling is the impurity of the signal 
obtained. Indeed, in a standard punch biopsy, several cell types are mixed and 
contribute to the overall expression pattern. Using high purity samples decreases the 
fraction of contaminating normal cells in the analyses. However, beside the cancer cells 
that are analyzed, there is a mixture of interstitial cells, vascular cells, and epithelial cells 
that might influence the overall expression signal343,346,347. Additionally, a same cell type 
might present a different expression signal due to the stochastic process of those 
cells343.  The cancer cells themselves may also reside in a number of different 
differentiation states. 
 
Recent advances in cell isolation and sequencing have enabled the possibility to isolate 
and extract RNA and sequence the transcriptome of single cells348. This progress has 
enabled analyses of the transcriptome with higher resolution to understand deeper the 
biology of distinct cell types in cells and tumors. However these techniques have never 
been applied to a pediatric tumor type. We have previously performed FFPE bulk 
expression profiling on more than 150 PLGGs that revealed substantial tumor 
heterogeneity on the level of gene expression. We therefore wanted to test this cutting 
edge procedure to PLGG tumors in order to explore the gene expression profiles of 
individual cells from dissociated tumors obtained by flow cytometry.  
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This project was conducted with different steps. We first tested the hypothesis that we 
can dissociate and sort pediatric glial cells from a LGG tumor with good viability. We 
then tested different antibodies to explore the expression of those markers in several 
tumors. We then optimized the extraction, transcriptome amplification and library 
preparation protocols to our PLGG cells. Here we describe the results of single cell 
RNA-sequencing originated from 3 fresh PLGG tumors.  
 
2. Methods 
 
The main steps of the protocol are summarized in Figure 29.  
 
2.1. Tumor dissociation, antibody staining and single-cell lysate preparation 
 
Fresh PLGG tumor was collected from the operating room with a maximum delay of 4 
hours after surgical resection. Tumor dissociation was then performed using the Miltelyi 
Brain Tumor Dissociation Kit protocol (MACS, Miltenyi Biotec). After two filtering-
washing steps (using a 70 µm filter), we prepared the cell suspension at a concentration 
of 1x106 cells/ml. We then stained the fresh dissociated cells using various antibodies 
(Abs) reflecting different developmental stages in the glioneuronal differentiation 
process. Anti-A2B5 Ab (staining glial precursor cells) conjugated with APC, anti-GLAST 
Ab (also know as ACSA-1 for astrocyte cell surface antigene 1, expressed 
predominantly expressed at the surface of differentiated astrocytes) conjugated with PE, 
anti-O4 Ab (expressed predominantly at the surface of differentiated oligodendrocytes) 
conjugated with biotin and anti-PSA-NCAM Ab (linked to the extra-cellular domain of 
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neural adhesion molecule, staining preferentially neuronal progenitor as well as more 
differentiated neuronal tissues) were used at 1/10 concentration (MACS, Miltenyi 
Biotec). Anti-FGFR1 (fibroblast growth factor receptor 1) antibody (D8E4) was used at 
1:250 concentration (Cell Signaling Technology).  
For the PLGG tumors that we evaluated without further single cell sorting, we used the 
LSRFortressa Analyzer (BD Biosciences, Dana-Farber Cancer Institute Flow Cytomtry 
Core, Boston, USA).  
Single cells were sorted using an Astrios FACS sorter (Beckman Coulter, Bauer Flow 
Cytometry, Harvard University, Cambridge, USA) in 96-cell plates containing 5µl of TCL 
buffer with 1% 2-mercaptoethanol. To improve the yield of the viable cells we used two 
cells death-viability markers; we gated the cells based on the positive viability marker 
Calcein AM (Life Technologies) and the absence of the cell death marker Near-IR (Life 
Technologies). After a short spin (800g, 1 min), plates were immediately freezed at  
- 80°C. Additional samples containing 200-5000 cells (depending on the yield) were 
sorted in 1,5ml lysis buffer as bulk controls. 
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Figure 29: 
Summary of the workflow from the tumor to single cell RNA-sequencing 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fresh resected PLGG tumor 
A2B5 and viability markers staining  
FACS sorting in lysis buffer  
- single cells 
- bulk populations (5,000-10,000 cells) 
Tumor dissociation 
(MACS protocol)  
Quality control 
- qPCR (hauskeeping genes) 
- Bioanlyzer checkup for 20 samples 
- Picogreen quantification 
Library preparation and double index barcoding  
on 96 selected single cells 
(Illumina Nextera XT protocol) 
Sequencing of the pooled cells (one lane) 
Illumina HiSeq  
Reverse transcriptase and 
Whole transcriptase amplification 
(Clontech protocol) 
Data analyses 
(Prada, Picard) 
! 133 
2.2. Reverse transcriptase and whole transcriptome amplification  
 
We first performed a lysate purification using beads technology (Agencourt 
RNAClean XP SPRI beads). We added 2,2 volumes of RNA-SPRI beads to each well of 
lysate. After 10 min incubation we placed the 96-well plate on an adapted magnet (Life 
Technologies DynaMagTM-96 side skirted magnet) and incubated for 5 min. After three 
steps of washing with ethanol 80% we allowed beads to dry at room temperature for 
approximately 10 minutes and eluted the pellet with the 3’ SMART CDS Primer II A 
(according to the protocol, SMARTer ultra Low Input RNA Kit, Clontech®). We then 
followed the reverse transcriptase and the whole transcriptome amplification (WTA) 
protocols (Advantage 2 Polymerase Kit) according to the manufacture 
recommendations. We then purified the amplified cDNA using the DNA SPRI beads 
(Agencourt AMPure XP). We added 0.8 volumes of the DNA SPRI beads buffer to the 
WTA solution. After three steps of washing with ethanol 80% we allowed beads to dry at 
room temperature for approximately 10 minutes and eluted the pellet with 20µl of TE 
buffer and transferred the eluent in a new 96-well plate.  
For the bulk controls, we purified the RNA using the RNEasy Plus Micro Kit (Qiagen) 
according to the manufacturers recommendations. We then substitute the 1L purified 
RNA in place of H2O at the first step of the reverse transcriptase buffer preparationl. We 
then followed the same procedure as for the single cells. 
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2.3. Quality control steps 
 
We used three independent methods to evaluate the size and the quality of the 
purified cDNA from the single cells as well as the bulk controls. We used 1µL of the 
purified WTA product to measure the fragment size distribution with the Agilent HS DNA 
BioAnalyzer. Figure 30 shows 11 profiles obtained on SC after WTA, describing good 
and bad profiles reflecting various yields obtained after the WTA protocol. 
To estimate the library concentration, we used the Quant-iT™ PicoGreen® dsDNA 
Assay Kit (as per manufacturer’s recommendations, Life Technologies) using 1µL of the 
purified WTA product.  
We finally estimated the single cell and the bulk control viability with the Taqman qPCR 
assay, using well described housekeeping genes (B2M, ACTB or RPLP0). We then 
compared results from the three tests in order to select the best single cell candidates 
for the library construction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 135 
Figure 30: 
Bioanalyzer results of 11 samples selected among the 96 SC A2B5 positive from tumor 
PLGG 22 !!
!
!
 
 
 
2.4. Library construction procedure 
 
We performed library preparation of 48 A2B5 positive cells and 48 A2B5 negative 
cells (on a same 96-well plate) using a double indexing strategy according to the 
Nextera XT sequencing-library construction protocol (Illumina). This protocol performs a 
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first step sharing the double strand DNA and followed by attaching a 8bp index AA 
sequence at the 3’ and 5’ end of the small strand DNA before performing PCR 
amplification. We used 1.2 L of the diluted PCR product from SMART RT-PCR for the 
library construction (as per manufacturer’s recommandations). 
We then pooled 2.5L from each well containing the product of the amplified library into 
a single 1.5mL tube and purified a last time the cDNA using the DNA SPRI beads 
(Agencourt AMPure XP). After three washing steps with ethanol 80% we allowed the 
beads to dry at room temperature for approximately 10 minutes and eluted the DNA with 
30µl of TE buffer and repeated the DNA SPRI beads cleanup a last time. We finally 
measured the average sized of the library obtained using the Agilent HS DNA 
BioAnalyzer.  
 
2.5. Sequencing and data analyses 
 
We sequenced the libraries on a Illumina sequencer (HiSeq 2500, 2 x 25 cycles) 
using one lane for the 96 pooled single cells and another line for the pooled bulk 
controls of the corresponding tumor. After demultiplexing the FASTQ files, we matched 
each of the paired-end reads with its mate and aligned the reads to reference genome 
hg19 using TopHat349. Gene-expression profiles were then assessed using a built Picard 
tool inside the Broad Institute Firehose environment. Z-scores were generated for each 
gene across samples. Self Organizing Maps326, hierarchical clustering202, Comparative 
Marker Selection Analysis (CMS)327,328, Support Vector Machine (SVM) algorithm and 
Gene-set Enrichment Analysis (GSEA)206,329 were performed using GenePattern330 
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(Broad Institute, http://genepattern.broadinstitute.org). Principal Component Analysis 
(PCA) plots were generated in Matlab. For CMS analyses, genes that described p<0.01, 
FDR<0.1 and fold-change > 500 were considered significant. For GSEA analysis, gene-
sets that showed p<0.01 and FDR<0.1 were only considered significant. For those two 
later analyses, we used non z-scored matrix. 
 
3. Results 
 
3.1 Profiling of glioneuronal markers in PLGGs 
 
We first analyzed by flow cytometry the fraction of PLGG cells expressing various 
glioneuronal markers. We profiled in total 26 PLGG tumors from different ages, 
locations, and histological subtypes as well as various BRAF genomic statuses (Table 
12 and Figure 31) and tested different glioneuronal markers. We used glioneuroanl Ab 
available on the market and expressed at the membrane of cells in order to allow further 
potential nucleic acid extraction.  Most of the cells tested were obtained from freshly 
dissociated PLGG tumors (20/26 tumors, 77%).  Six samples (23%) were from frozen 
cells and one case was an autopsy.   
We observed important variability in terms of the fraction of positive glioneuronal staining 
across the PLGG tumors. We were able to assess the expression of the early glial 
progenitor marker A2B5 in 21/26 tumors (81% of tumors) and found a wide range of 
A2B5 expression (mean 27%, range 1-88%). Among the 17 tumors analyzed for the 
astrocyte marker GLAST (63%), we observed similar important variability in the fraction 
of positive PLGG cells (mean 28%, range 0-90%). O4 was tested in 10 tumors (37%) 
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and was expressed between 0.5-30% of the cells (mean 7%). FGFR1 was expressed at 
a lower amplitude, 0.5-30% of the PLGG cells (mean 7%). The neuronal marker N-CAM 
was globally poorly expressed in the 4 tumors analyzed (mean 1% of positive cells).  
For the single-cell sorting and sequencing experiment we decided to focus our analysis 
using the anti-A2B5 Ab, as we have optimized the use this Ab with a positive control 
(cultured mouse neural stem cells, staining the A2B5 Ab between 10-20%, Figure 32A-
C) and a negative control (cultured 3T3-cells, Figure 32D and E). 
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Table 12: 
Summary of the glioneuronal profling in the 26 PLGG tumors analyzed by flow 
cytometry The three tumors highlighted in orange are the ones that have been 
processed for single cell sorting and RNA-sequencencing 
 
PLGG ID 
Age at 
surgery 
(years) 
Histo Location BRAF status 
Fresh/ 
frozen A2B5 + N-CAM GLAST O4 FGFR1 
PLGG 1 5 GG ST ND fresh 76 3 73 3 ND 
PLGG 2 0.6 PMA ST V600E neg fresh 1 2 1.5 0,5 ND 
PLGG 3 1.4 PA IT BRAF DUP fresh 88 0 48 3 ND 
PLGG 3 1.4 PA IT BRAF DUP frozen 50 0 35 5 ND 
PLGG 4 1.9 PA IT no BRAF alteration frozen 15 ND 83 13 75 
PLGG 5 2.5 PMA ST V600E neg frozen ND ND 76 4 ND 
PLGG 6 1 PMA ST BRAF DUP fresh ND ND 3 6 ND 
PLGG 7 2.5 LGG NOS IT V600E neg frozen 30 ND 2 30 60 
PLGG 8 5.5 LGG NOS IT V600E neg fresh ND ND 1 1,5 ND 
PLGG 9 13 DNT ST ND fresh 9 ND 0.5 2 21 
PLGG 10 6 PA recurrent ST ND frozen ND ND 1.5 2 ND 
PLGG 11 13.1 DNT  ST ND fresh 2 ND ND ND 10 
PLGG 12 10 DNT  ST ND fresh 63 ND ND ND ND 
PLGG 13 5 PA IT BRAF DUP fresh 11 ND 22 ND ND 
PLGG 14 3.4 PA IT BRAF DUP fresh 8 ND 90 ND 80 
PLGG 15 10.8 DA ST IDH1+ fresh 0 ND 2 ND 1,8 
PLGG 16 16 DNT ST ND fresh 0 ND 2 ND 0 
PLGG 17 14.5 GG ST no BRAF alteration frozen 18.5 ND 7.5 ND 0 
PLGG 18 5 PA IT BRAF DUP fresh 13 ND ND ND ND 
PLGG 19 6.4 LGG NOS ST 
no BRAF 
alteration fresh 6.5 ND ND ND ND 
PLGG 20 10.3 DNT ST no BRAF alteration fresh 6.5 ND ND ND ND 
PLGG 21 13.1 PA recurrent IT BRAF DUP fresh 35 ND ND ND ND 
PLGG 22 16 GG recurrent ST V600E mut fresh 6 ND 0 ND ND 
PLGG 23 6.1 PA IT ND fresh 47 ND ND ND ND 
PLGG 24 4 LGG NOS ST ND autopsia ND ND ND ND ND 
PLGG 25 7 
LGG 
NOS 
recurrent 
IT BRAF DUP fresh 40 ND ND ND ND 
PLGG 26  PLGG   fresh 65 ND ND ND ND 
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Figure 31: 
Graphical representation of flow cytometry results from 26 tumors  
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Figure 32: 
Immunofluorescence and flow cytometry profiles of the positive (mouse neural 
stem cells, A, B and C) and negative controls (NIH 3T3 cells, D and E) for the A2B5 
antibody 
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3.2. Single-cell profiling results 
 
Among the 26 PLGGs that we analyzed by flow cytometry, we sorted 6 tumors at 
a single cell level by collecting separately A2B5 positive and negative cells. Among 
those 6 PLGGs, we processed the single cells RNA until the library preparation step for 
sequencing in 3 tumors. We then sequenced the RNA of these cells in order to analyze 
their genome-wide transcriptome. 
 
The first tumor analyzed (PLGG 18) had 46 A2B5 positive and 46 A2B5 negative single 
cells (SC) that met these criteria. We observed for both A2B5 positive and negative SC 
a good correlation between the mean gene expression of the SC to the gene expression 
in the corresponding bulk control (Figure 33A and 33B). PCA revealed that the A2B5 
positive SC clustered separately from the A2B5 negative cells (Fig 33C).  SOM 
consensus clustering showed that two clusters best segregated the 91 SC (Figure 33D). 
Strikingly, the clusters obtained by SOM were significantly strongly enriched with A2B5 
positive and negative cells, respectively (Figure 33F and 33E, p<0.0001).  
 
We then performed comparative marker selection (CMS) and GSEA analyses 
comparing both clusters in order to identify the molecular differences between the A2B5 
positive and negative cells. We found 709 genes significantly overexpressed in the 
cluster 1 dominated by the A2B5 positive cells and 312 genes significantly 
overexpressed in cluster 2 enriched with the A2B5 negative cells. Among the top 100 
genes that describe the highest fold-change in cluster 1 relative to cluster 2, we found 
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genes involved in intracellular metabolic regulation such as GNG3 (guanine nucleotide 
binding protein 3), STK32A (serine-threonine kinase 32A), LDLRAD3 (low-density 
lipoprotein receptor class A domain containing 3) and RRP9 (ribosomal RNA processing 
9) and genes coding proteins involved in cytoskeletal organization such as MARCKSL1 
(myristoylated alanie-rich C-kinase substrate-like 1), ECM1 (extracellular matrix 1) and 
KIF1A (kinesin family member 1) (Table 13A). Among the top 10% genes that describe 
the highest fold-change in cluster 2, dominated by the A2B5 relative to cluster 1, we 
found genes essentially genes involved in inflammatory mechanisms, such as CCRL2 
(chemokine receptor-like 2), essential for the recruitment of immune cells to the site of 
inflammation, TLR-7 (toll-like receptor 7) mediating the production of cytokines and 
HPGDS (hematopoietic prostaglandin D synthase) playing a role in the production of 
prostanoids in the immune system and mast cells (Table 13B).  
 
The same molecular patterns were found in GSEA between cluster 1 and 2. Among the 
151 gene-sets significantly enriched in the A2B5 positive cells (cluster 1), we found that 
58/151 (38%) of the gene-sets were represented by metabolic process and mitosis 
related pathways (such as KEGG OXIDATIVE PHOSPHORYLATION, REACTOME 
MITOTIC G2 M PHASES) and 21/151 (14%) were represented by cell mobility and 
intracellular communications (such as KEGG GAP JUNCTION, REACTOME 
COLLAGEN FORMATION, KEGG ECM RECEPTOR INTERACTION or REACTOME 
CELL CELL JUNCTION ORGANIZATION, Table 14A). 68/90 (75%) of the gene-sets 
enriched in cluster 2 were related to inflammatory pathways (Table 14B and Figure 
33G). We then wanted to explore the degree of heterogeneity within each subcluster. 
SOM consensus clustering performed on the cluster 1 SC revealed two major groups 
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whereas cluster 2 segregated in 3 groups (Figure 33H), suggesting that the 
heterogeneity within the A2B5 negative cells is significantly higher than the A2B5 
positive SC. 
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Figure 33: Results of PLGG 18 single-cell RNA-sequencing experiment 
! 
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Figure 33 (legend) 
A-B, graphical representation of the correlation between the average gene expression of 
SC relative to the bulk gene expression for the positive A2B5 cells (A) and negative cells 
(B). C, PCA analysis showing the three first components of the SC A2B5 positive (red)  
and negative (blue). D, graphical representation of the delta-gini index variation obtained 
by SOM clustering, E, heat-map of the SOM clustering (red represents A2B5 SC positive 
cells, blue the A2B5 negative cells). F, summary table of the distribution of the different 
SC by SOM clustering. G, GSEA enrichment plots significantly enriched in cluster 1 and 
2. H, summary table of the distribution of the different sublclusters of SC by SOM 
clustering 
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Table 13: Genes significantly overexpressed in cluster 1 (A) and 2 (B) 
 
                                A. 
 
Genes%upregulated%%
in%Cluster%1% FDR% Fold%change%
!!GNG3! 5,51E%04( 28225(
C1orf198! 5,51E%04( 15586(
STK32A! 5,51E%04( 11705(
RP11%342M3.5( 5,51E%04( 8476(
MARCKSL1! 5,51E%04( 8467(
LDLRAD3! 5,51E%04( 8370(
NOVA1! 5,51E%04( 7727(
ECM1! 5,51E%04( 7241(
RRP9! 5,51E%04( 5605(
KIF1A! 5,51E%04( 5434(
BHLHB9! 5,51E%04( 5291(
NSDHL! 5,51E%04( 5280(
CDR1! 5,51E%04( 5188(
KIF5C! 5,51E%04( 5093(
ACTL6A! 5,51E%04( 4924(
RP3?398G3.3! 5,51E%04( 4924(
RP11?161M6.2! 5,51E%04( 4632(
IFIT3! 5,51E%04( 4491(
CHAD! 5,51E%04( 4450(
ALDH1A3! 5,51E%04( 4330(
RP11?547I7.2! 5,51E%04( 4099(
USP30! 5,51E%04( 4009(
GRM5?AS1! 5,51E%04( 3946(
IFI27L2! 5,51E%04( 3924(
RP11?480D4.3! 5,51E%04( 3800(
EPN2! 5,51E%04( 3782(
RP5?1177M21.1! 5,51E%04( 3750(
SPATA6L! 5,51E%04( 3562(
GRIK1! 5,51E%04( 3548(
C8orf46! 5,51E%04( 3464(
CCDC28B! 5,51E%04( 3408(
IGSF9B! 5,51E%04( 3368(
JAM3! 5,51E%04( 3363(
MORN2! 5,51E%04( 3343(
RP3?412A9.11! 5,51E%04( 3325(
PABPC5! 5,51E%04( 3318(
TSPAN12! 5,51E%04( 3296(
FLRT3! 5,51E%04( 3251(
FSTL1! 5,51E%04( 3250(
TMEM231! 5,51E%04( 3235(
RP11?548C21.1! 5,51E%04( 3143(
DNALI1! 5,51E%04( 3116(
TMEM132C! 5,51E%04( 3112(
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SWI5! 5,51E%04( 3075(
CPE! 5,51E%04( 3041(
BBS10! 5,51E%04( 3038(
AP3M2! 5,51E%04( 2959(
RP11?508N12.4! 5,51E%04( 2860(
LMCD1! 5,51E%04( 2835(
BNIP3P1! 5,51E%04( 2771(
GLIPR1L2! 5,51E%04( 2716(
DIRAS3! 5,51E%04( 2698(
BAMBI! 5,51E%04( 2688(
CDO1! 5,51E%04( 2685(
BTBD8! 5,51E%04( 2677(
RP4?788L13.1! 5,51E%04( 2675(
KLHL32! 5,51E%04( 2663(
AMPH! 5,51E%04( 2652(
ARC! 5,51E%04( 2652(
C12orf29! 5,51E%04( 2630(
PNMAL1! 5,51E%04( 2610(
SORCS3! 5,51E%04( 2595(
AEBP1! 5,51E%04( 2589(
BBS7! 5,51E%04( 2571(
TAGLN3! 5,51E%04( 2568(
TRMT61B! 5,51E%04( 2533(
THBS2! 5,51E%04( 2519(
ZCCHC24! 5,51E%04( 2505(
NRSN2! 5,51E%04( 2487(
CTD?2033A16.3! 5,51E%04( 2450(
ZNF521! 5,51E%04( 2448(
POP7! 5,51E%04( 2436(
C14orf132! 5,51E%04( 2418(
PRPF31! 5,51E%04( 2399(
TIAM2! 5,51E%04( 2356(
Y!RNA! 5,51E%04( 2337(
POMGNT1! 5,51E%04( 2305(
sept?08! 5,51E%04( 2288(
GPD1! 5,51E%04( 2288(
APBA2! 5,51E%04( 2255(
MTSS1L! 5,51E%04( 2208(
AC015936.3! 5,51E%04( 2206(
ASAP3! 5,51E%04( 2188(
KLHL23! 5,51E%04( 2173(
CHST3! 5,51E%04( 2157(
NKAIN4! 5,51E%04( 2156(
TXNL4A! 5,51E%04( 2117(
CDCA7L! 5,51E%04( 2112(
SLC24A2! 5,51E%04( 2111(
AKAP12! 5,51E%04( 2103(
TECPR2! 5,51E%04( 2097(
MASP1! 5,51E%04( 2090(
MLLT11! 5,51E%04( 2084(
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ACAN! 5,51E%04( 2050(
SHISA4! 5,51E%04( 2048(
DHCR24! 5,51E%04( 2045(
snoU13! 5,51E%04( 2040(
PRRX1! 5,51E%04( 1979(
ATCAY! 5,51E%04( 1977(
NAP1L3! 5,51E%04( 1964(!!!!
B. 
 
Genes%upregulated%
in%Cluster%2% FDR% Fold%change%
CCRL2! 5,51E%04( 30825(
ACSL5! 5,51E%04( 13643(
LGALS9! 5,51E%04( 12737(
FOLR2! 5,51E%04( 10297(
TLR7! 5,51E%04( 9619(
HPGDS! 5,51E%04( 8571(
VTRNA1?3! 5,51E%04( 6975(
C1orf162! 5,51E%04( 6496(
HAMP! 5,51E%04( 6054(
U6! 5,51E%04( 5802(
LILRA1! 5,51E%04( 5791(
TNFAIP3! 5,51E%04( 5418(
TRBJ2?1! 5,51E%04( 5225(
AP000908.1! 5,51E%04( 5217(
RP11?1094M14.3! 5,51E%04( 5063(
AC005232.1! 5,51E%04( 4837(
MIR335! 5,51E%04( 4813(
AC090282.1! 5,51E%04( 4645(
FCGBP! 5,51E%04( 4478(
TRAJ42! 5,51E%04( 4478(
RP11?489O18.1! 5,51E%04( 4168(
ABI3! 5,51E%04( 4084(
PIK3R5! 5,51E%04( 4058(
CRYBB1! 5,51E%04( 4056(
TNF! 5,51E%04( 3842(
AC006953.1! 5,51E%04( 3829(
TRAV1?2! 5,51E%04( 3787(
RP11?300J18.2! 5,51E%04( 3711(
EMR1! 5,51E%04( 3397(
CEACAM21! 5,51E%04( 3395(
TRAV12?2! 5,51E%04( 3349(
CD300C! 5,51E%04( 3315(
CTD?2616J11.3! 5,51E%04( 3253(
snoU13! 5,51E%04( 2984(
S100A4! 5,51E%04( 2964(
PLCG2! 5,51E%04( 2860(
TRAV36DV7! 5,51E%04( 2853(
SAMD9L! 5,51E%04( 2840(
AC069363.1! 5,51E%04( 2762(
TBXAS1! 5,51E%04( 2738(
SNORD119! 5,51E%04( 2735(
RNASE2! 5,51E%04( 2683(
CALHM2! 5,51E%04( 2676(
LILRA2! 5,51E%04( 2647(
CD48! 5,51E%04( 2645(
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RP11?493L12.2! 5,51E%04( 2642(
TRBJ2?4! 5,51E%04( 2555(
PTGER4! 5,51E%04( 2462(
RP11?750H9.5! 5,51E%04( 2450(
VSIG4! 5,51E%04( 2407(
U4! 5,51E%04( 2393(
ITPRIP! 5,51E%04( 2377(
NFKBID! 5,51E%04( 2363(
GPR65! 5,51E%04( 2345(
TNFSF13! 5,51E%04( 2341(
CD163L1! 5,51E%04( 2332(
RN5S226! 5,51E%04( 2331(
AREG! 5,51E%04( 2326(
NCKAP1L! 5,51E%04( 2315(
RP4?612C19.2! 5,51E%04( 2295(
MS4A4A! 5,51E%04( 2269(
CMKLR1! 5,51E%04( 2267(
CTD?2616J11.2! 5,51E%04( 2233(
IL4R! 5,51E%04( 2210(
LILRB4! 5,51E%04( 2195(
RN5S498! 5,51E%04( 2175(
TRBV20?1! 5,51E%04( 2165(
TRAJ16! 5,51E%04( 2070(
TRAJ26! 5,51E%04( 1988(
RILPL2! 5,51E%04( 1957(
AL118508.1! 5,51E%04( 1946(
NAPSB! 5,51E%04( 1885(
CSF2RA! 5,51E%04( 1816(
PTAFR! 5,51E%04( 1776(
CXorf21! 5,51E%04( 1764(
DLEU7?AS1! 5,51E%04( 1763(
ITGAM! 5,51E%04( 1740(
TNFSF18! 5,51E%04( 1735(
FMNL1! 5,51E%04( 1734(
ADORA3! 5,51E%04( 1725(
GS1?526D21.5! 5,51E%04( 1712(
CD300LB! 5,51E%04( 1706(
IRAK3! 5,51E%04( 1705(
FILIP1L! 5,51E%04( 1688(
SIGLEC10! 5,51E%04( 1675(
TRAJ9! 5,51E%04( 1648(
RNASE3! 5,51E%04( 1620(
F11R! 5,51E%04( 1612(
CD84! 5,51E%04( 1578(
STAT6! 5,51E%04( 1557(
MRC1L1! 5,51E%04( 1545(
NCF2! 5,51E%04( 1539(
SH3TC1! 5,51E%04( 1483(
TLR4! 5,51E%04( 1470(
RP11?394B5.2! 5,51E%04( 1429(
RP5?1073O3.7! 5,51E%04( 1389(
AC010518.3! 5,51E%04( 1386(
C1orf38! 5,51E%04( 1364(
SNORD58C! 5,51E%04( 1356(
F13A1! 5,51E%04( 1345(
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Table 14: Gene-sets enriched in cluster 1 (A) and 2 (B) in PLGG 18. 
 
A. 
NAME( FDR(
KEGG(OXIDATIVE(PHOSPHORYLATION( 0,00(
REACTOME(GLUCOSE(METABOLISM( 0,00(
KEGG(PARKINSONS(DISEASE( 0,00(
KEGG(HUNTINGTONS(DISEASE( 0,00(
KEGG(ALZHEIMERS(DISEASE( 0,00(
REACTOME(MITOCHONDRIAL(PROTEIN(IMPORT( 0,00(
REACTOME(RESPIRATORY(ELECTRON(TRANSPORT( 0,00(
REACTOME(TCA(CYCLE(AND(RESPIRATORY(ELECTRON(TRANSPORT( 0,00(
REACTOME(RESPIRATORY(ELECTRON(TRANSPORT(ATP(SYNTHESIS(BY(CHEMIOSMOTIC(COUPLING(AND(
HEAT(PRODUCTION(BY(UNCOUPLING(PROTEINS(( 0,00(
REACTOME(ABORTIVE(ELONGATION(OF(HIV1(TRANSCRIPT(IN(THE(ABSENCE(OF(TAT( 0,00(
KEGG(PROPANOATE(METABOLISM( 0,00(
KEGG(CITRATE(CYCLE(TCA(CYCLE( 0,00(
REACTOME(TRANSMISSION(ACROSS(CHEMICAL(SYNAPSES( 0,00(
REACTOME(UNBLOCKING(OF(NMDA(RECEPTOR(GLUTAMATE(BINDING(AND(ACTIVATION( 0,00(
REACTOME(NEUROTRANSMITTER(RECEPTOR(BINDING(AND(DOWNSTREAM(TRANSMISSION(IN((
THE(POSTSYNAPTIC(CELL( 0,00(
KEGG(VALINE(LEUCINE(AND(ISOLEUCINE(DEGRADATION( 0,00(
REACTOME(ACTIVATION(OF(KAINATE(RECEPTORS(UPON(GLUTAMATE(BINDING( 0,00(
REACTOME(ELONGATION(ARREST(AND(RECOVERY( 0,00(
REACTOME(TRAFFICKING(OF(AMPA(RECEPTORS( 0,00(
KEGG(PYRUVATE(METABOLISM( 0,00(
KEGG(BUTANOATE(METABOLISM( 0,00(
REACTOME(MICRORNA(MIRNA(BIOGENESIS( 0,00(
KEGG(RNA(POLYMERASE( 0,00(
REACTOME(REGULATORY(RNA(PATHWAYS( 0,00(
REACTOME(PEROXISOMAL(LIPID(METABOLISM( 0,00(
REACTOME(GLYCOLYSIS( 0,00(
REACTOME(RECRUITMENT(OF(MITOTIC(CENTROSOME(PROTEINS(AND(COMPLEXES( 0,00(
REACTOME(NEUROTRANSMITTER(RELEASE(CYCLE( 0,00(
KEGG(GLYCINE(SERINE(AND(THREONINE(METABOLISM( 0,00(
REACTOME(GABA(SYNTHESIS(RELEASE(REUPTAKE(AND(DEGRADATION( 0,00(
REACTOME(LOSS(OF(NLP(FROM(MITOTIC(CENTROSOMES( 0,00(
REACTOME(NCAM1(INTERACTIONS( 0,00(
PID(NCADHERINPATHWAY( 0,00(
PID(P75NTRPATHWAY( 0,00(
REACTOME(ADHERENS(JUNCTIONS(INTERACTIONS( 0,00(
KEGG(GLYCOLYSIS(GLUCONEOGENESIS( 0,00(
REACTOME(GLYCOGEN(BREAKDOWN(GLYCOGENOLYSIS( 0,00(
REACTOME(MRNA(SPLICING(MINOR(PATHWAY( 0,00(
REACTOME(CREB(PHOSPHORYLATION(THROUGH(THE(ACTIVATION(OF(CAMKII( 0,00(
KEGG(BIOSYNTHESIS(OF(UNSATURATED(FATTY(ACIDS( 0,01(
REACTOME(BRANCHED(CHAIN(AMINO(ACID(CATABOLISM( 0,01(
REACTOME(A(TETRASACCHARIDE(LINKER(SEQUENCE(IS(REQUIRED(FOR(GAG(SYNTHESIS( 0,01(
REACTOME(FORMATION(OF(RNA(POL(II(ELONGATION(COMPLEX(( 0,01(
REACTOME(GLUCONEOGENESIS( 0,01(
ST(DIFFERENTIATION(PATHWAY(IN(PC12(CELLS( 0,01(
REACTOME(TRAFFICKING(OF(GLUR2(CONTAINING(AMPA(RECEPTORS( 0,01(
REACTOME(NEURONAL(SYSTEM( 0,01(
KEGG(UBIQUITIN(MEDIATED(PROTEOLYSIS( 0,01(
REACTOME(FORMATION(OF(THE(HIV1(EARLY(ELONGATION(COMPLEX( 0,01(
REACTOME(INHIBITION(OF(INSULIN(SECRETION(BY(ADRENALINE(NORADRENALINE( 0,01(
KEGG(CARDIAC(MUSCLE(CONTRACTION( 0,01(
REACTOME(REGULATION(OF(INSULIN(SECRETION( 0,01(
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KEGG(PURINE(METABOLISM( 0,01(
REACTOME(METABOLISM(OF(AMINO(ACIDS(AND(DERIVATIVES( 0,01(
KEGG(PENTOSE(PHOSPHATE(PATHWAY( 0,01(
REACTOME(NETRIN1(SIGNALING( 0,01(
KEGG(ALANINE(ASPARTATE(AND(GLUTAMATE(METABOLISM( 0,01(
REACTOME(TRNA(AMINOACYLATION( 0,01(
REACTOME(METABOLISM(OF(CARBOHYDRATES( 0,01(
PID(NETRIN(PATHWAY( 0,01(
REACTOME(PYRUVATE(METABOLISM(AND(CITRIC(ACID(TCA(CYCLE( 0,01(
REACTOME(MITOTIC(G2(G2(M(PHASES( 0,01(
REACTOME(FORMATION(OF(TUBULIN(FOLDING(INTERMEDIATES(BY(CCT(TRIC( 0,01(
PID(P38(MKK3(6PATHWAY( 0,01(
BIOCARTA(NOS1(PATHWAY( 0,01(
REACTOME(ACTIVATION(OF(NMDA(RECEPTOR(UPON(GLUTAMATE(BINDING(AND(POSTSYNAPTIC(
EVENTS( 0,01(
REACTOME(INSULIN(SYNTHESIS(AND(PROCESSING( 0,01(
KEGG(FRUCTOSE(AND(MANNOSE(METABOLISM( 0,01(
PID(NOTCH(PATHWAY( 0,01(
PID(BMPPATHWAY( 0,01(
REACTOME(INTEGRATION(OF(ENERGY(METABOLISM( 0,01(
KEGG(AMINOACYL(TRNA(BIOSYNTHESIS( 0,01(
PID(SYNDECAN(3(PATHWAY( 0,01(
REACTOME(CITRIC(ACID(CYCLE(TCA(CYCLE( 0,02(
REACTOME(INTERACTION(BETWEEN(L1(AND(ANKYRINS( 0,02(
REACTOME(CHONDROITIN(SULFATE(DERMATAN(SULFATE(METABOLISM( 0,02(
ST(WNT(CA2(CYCLIC(GMP(PATHWAY( 0,02(
ST(JNK(MAPK(PATHWAY( 0,02(
REACTOME(NCAM(SIGNALING(FOR(NEURITE(OUT(GROWTH( 0,02(
REACTOME(EXTRACELLULAR(MATRIX(ORGANIZATION( 0,02(
REACTOME(ANTIGEN(PROCESSING(UBIQUITINATION(PROTEASOME(DEGRADATION( 0,02(
REACTOME(PREFOLDIN(MEDIATED(TRANSFER(OF(SUBSTRATE(TO(CCT(TRIC( 0,02(
KEGG(PEROXISOME( 0,02(
KEGG(TRYPTOPHAN(METABOLISM( 0,02(
REACTOME(PROTEIN(FOLDING( 0,02(
REACTOME(PYRUVATE(METABOLISM( 0,02(
REACTOME(GENERIC(TRANSCRIPTION(PATHWAY( 0,02(
ST(GRANULE(CELL(SURVIVAL(PATHWAY( 0,02(
REACTOME(CELL(CELL(JUNCTION(ORGANIZATION( 0,02(
REACTOME(CHONDROITIN(SULFATE(BIOSYNTHESIS( 0,02(
KEGG(ECM(RECEPTOR(INTERACTION( 0,03(
REACTOME(INWARDLY(RECTIFYING(K(CHANNELS( 0,03(
PID(BETACATENIN(NUC(PATHWAY( 0,03(
REACTOME(CHOLESTEROL(BIOSYNTHESIS( 0,03(
PID(A6B1(A6B4(INTEGRIN(PATHWAY( 0,03(
REACTOME(ION(CHANNEL(TRANSPORT( 0,03(
REACTOME(RAS(ACTIVATION(UOPN(CA2(INFUX(THROUGH(NMDA(RECEPTOR( 0,03(
REACTOME(SMOOTH(MUSCLE(CONTRACTION( 0,03(
REACTOME(HEPARAN(SULFATE(HEPARIN(HS(GAG(METABOLISM( 0,03(
REACTOME(GLYCOSAMINOGLYCAN(METABOLISM( 0,03(
REACTOME(COLLAGEN(FORMATION( 0,03(
KEGG(PROTEIN(EXPORT( 0,03(
REACTOME(RNA(POL(III(TRANSCRIPTION( 0,03(
PID(AR(PATHWAY( 0,03(
KEGG(PYRIMIDINE(METABOLISM( 0,03(
KEGG(LONG(TERM(POTENTIATION( 0,03(
REACTOME(RNA(POL(III(TRANSCRIPTION(TERMINATION( 0,03(
REACTOME(METABOLISM(OF(LIPIDS(AND(LIPOPROTEINS( 0,03(
REACTOME(FATTY(ACID(TRIACYLGLYCEROL(AND(KETONE(BODY(METABOLISM( 0,03(
REACTOME(BILE(ACID(AND(BILE(SALT(METABOLISM( 0,03(
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REACTOME(G(BETA(GAMMA(SIGNALLING(THROUGH(PLC(BETA( 0,04(
REACTOME(GABA(RECEPTOR(ACTIVATION( 0,04(
REACTOME(MUSCLE(CONTRACTION( 0,04(
REACTOME(BASE(EXCISION(REPAIR( 0,04(
REACTOME(AQUAPORIN(MEDIATED(TRANSPORT( 0,04(
PID(PS1PATHWAY( 0,04(
BIOCARTA(GPCR(PATHWAY( 0,04(
KEGG(GAP(JUNCTION( 0,04(
REACTOME(G(PROTEIN(ACTIVATION( 0,05(
KEGG(MELANOMA( 0,05(
REACTOME(REGULATION(OF(WATER(BALANCE(BY(RENAL(AQUAPORINS( 0,05(
REACTOME(OPIOID(SIGNALLING( 0,05(
KEGG(VASOPRESSIN(REGULATED(WATER(REABSORPTION( 0,05(
PID(AR(TF(PATHWAY( 0,05(
REACTOME(GABA(B(RECEPTOR(ACTIVATION( 0,05(
PID(TRKRPATHWAY( 0,05(
REACTOME(MRNA(SPLICING( 0,05(
KEGG(PPAR(SIGNALING(PATHWAY( 0,06(
REACTOME(NUCLEAR(SIGNALING(BY(ERBB4( 0,06(
PID(TAP63PATHWAY( 0,06(
REACTOME(CELL(JUNCTION(ORGANIZATION( 0,06(
REACTOME(DEVELOPMENTAL(BIOLOGY( 0,06(
REACTOME(RESPONSE(TO(ELEVATED(PLATELET(CYTOSOLIC(CA2(( 0,06(
KEGG(RNA(DEGRADATION( 0,06(
PID(AURORA(B(PATHWAY( 0,06(
PID(FOXOPATHWAY( 0,06(
REACTOME(P75(NTR(RECEPTOR(MEDIATED(SIGNALLING( 0,07(
REACTOME(AXON(GUIDANCE( 0,07(
REACTOME(RNA(POL(II(TRANSCRIPTION( 0,07(
BIOCARTA(AGR(PATHWAY( 0,07(
ST(FAS(SIGNALING(PATHWAY( 0,07(
REACTOME(TRANSCRIPTION( 0,07(
PID(ERA(GENOMIC(PATHWAY( 0,07(
WNT(SIGNALING( 0,08(
PID(ECADHERIN(STABILIZATION(PATHWAY( 0,08(
KEGG(WNT(SIGNALING(PATHWAY( 0,08(
REACTOME(METABOLISM(OF(PROTEINS( 0,08(
KEGG(MELANOGENESIS( 0,09(
REACTOME(BIOLOGICAL(OXIDATIONS( 0,09(
REACTOME(PHOSPHOLIPID(METABOLISM( 0,10(
REACTOME(POTASSIUM(CHANNELS( 0,10(
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B.  
NAME( FDR(
KEGG(LEISHMANIA(INFECTION( 0,00(
KEGG(ALLOGRAFT(REJECTION( 0,00(
KEGG(INTESTINAL(IMMUNE(NETWORK(FOR(IGA(PRODUCTION( 0,00(
KEGG(AUTOIMMUNE(THYROID(DISEASE( 0,00(
REACTOME(GENERATION(OF(SECOND(MESSENGER(MOLECULES( 0,00(
KEGG(HEMATOPOIETIC(CELL(LINEAGE( 0,00(
KEGG(TYPE(I(DIABETES(MELLITUS( 0,00(
BIOCARTA(TH1TH2(PATHWAY( 0,00(
KEGG(ANTIGEN(PROCESSING(AND(PRESENTATION( 0,00(
KEGG(GRAFT(VERSUS(HOST(DISEASE( 0,00(
PID(TCR(PATHWAY( 0,00(
PID(IL12(2PATHWAY( 0,00(
REACTOME(TCR(SIGNALING( 0,00(
REACTOME(CHEMOKINE(RECEPTORS(BIND(CHEMOKINES( 0,00(
KEGG(VIRAL(MYOCARDITIS( 0,00(
REACTOME(COSTIMULATION(BY(THE(CD28(FAMILY( 0,00(
REACTOME(PD1(SIGNALING( 0,00(
KEGG(ASTHMA( 0,00(
REACTOME(IMMUNOREGULATORY(INTERACTIONS(BETWEEN(A(LYMPHOID(AND(A(NON(LYMPHOID(
CELL( 0,00(
REACTOME(INTERFERON(GAMMA(SIGNALING( 0,00(
BIOCARTA(NKT(PATHWAY( 0,00(
KEGG(NATURAL(KILLER(CELL(MEDIATED(CYTOTOXICITY( 0,00(
BIOCARTA(DC(PATHWAY( 0,00(
BIOCARTA(CTLA4(PATHWAY( 0,00(
REACTOME(PHOSPHORYLATION(OF(CD3(AND(TCR(ZETA(CHAINS( 0,00(
BIOCARTA(LAIR(PATHWAY( 0,00(
REACTOME(PEPTIDE(LIGAND(BINDING(RECEPTORS( 0,00(
REACTOME(DOWNSTREAM(TCR(SIGNALING( 0,00(
KEGG(PRIMARY(IMMUNODEFICIENCY( 0,00(
PID(IL23PATHWAY( 0,00(
REACTOME(DEFENSINS( 0,00(
REACTOME(CLASS(A1(RHODOPSIN(LIKE(RECEPTORS( 0,00(
BIOCARTA(NO2IL12(PATHWAY( 0,00(
PID(IL12(STAT4PATHWAY( 0,00(
PID(CD8TCRPATHWAY( 0,00(
KEGG(FC(GAMMA(R(MEDIATED(PHAGOCYTOSIS( 0,00(
SA(MMP(CYTOKINE(CONNECTION( 0,00(
REACTOME(IL(2(SIGNALING( 0,00(
BIOCARTA(INFLAM(PATHWAY( 0,00(
BIOCARTA(TOB1(PATHWAY( 0,00(
KEGG(B(CELL(RECEPTOR(SIGNALING(PATHWAY( 0,00(
REACTOME(IL(RECEPTOR(SHC(SIGNALING( 0,00(
PID(PI3KCIPATHWAY( 0,00(
PID(CXCR4(PATHWAY( 0,00(
REACTOME(IL(3(5(AND(GM(CSF(SIGNALING( 0,00(
REACTOME(INNATE(IMMUNE(SYSTEM( 0,00(
KEGG(SYSTEMIC(LUPUS(ERYTHEMATOSUS( 0,00(
PID(FCER1PATHWAY( 0,01(
REACTOME(CELL(SURFACE(INTERACTIONS(AT(THE(VASCULAR(WALL( 0,01(
REACTOME(GPVI(MEDIATED(ACTIVATION(CASCADE( 0,01(
KEGG(CYTOKINE(CYTOKINE(RECEPTOR(INTERACTION( 0,01(
PID(IL27PATHWAY( 0,01(
REACTOME(CYTOKINE(SIGNALING(IN(IMMUNE(SYSTEM( 0,01(
REACTOME(MHC(CLASS(II(ANTIGEN(PRESENTATION( 0,01(
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PID(BCR(5PATHWAY( 0,01(
REACTOME(INTERFERON(SIGNALING( 0,01(
KEGG(NOD(LIKE(RECEPTOR(SIGNALING(PATHWAY( 0,02(
KEGG(TOLL(LIKE(RECEPTOR(SIGNALING(PATHWAY( 0,02(
REACTOME(GPCR(LIGAND(BINDING( 0,03(
KEGG(CHEMOKINE(SIGNALING(PATHWAY( 0,03(
KEGG(LEUKOCYTE(TRANSENDOTHELIAL(MIGRATION( 0,04(
PID(TXA2PATHWAY( 0,04(
REACTOME(TOLL(RECEPTOR(CASCADES( 0,05(
BIOCARTA(IL17(PATHWAY( 0,00(
BIOCARTA(CYTOKINE(PATHWAY( 0,00(
REACTOME(G(ALPHA(I(SIGNALLING(EVENTS( 0,07(
BIOCARTA(IL7(PATHWAY( 0,01(
PID(CMYB(PATHWAY( 0,06(
BIOCARTA(CSK(PATHWAY( 0,00(
ST(INTERLEUKIN(4(PATHWAY( 0,01(
PID(IL2(STAT5PATHWAY( 0,01(
BIOCARTA(IL10(PATHWAY( 0,01(
KEGG(FC(EPSILON(RI(SIGNALING(PATHWAY( 0,02(
KEGG(CELL(ADHESION(MOLECULES(CAMS( 0,02(
ST(T(CELL(SIGNAL(TRANSDUCTION( 0,04(
KEGG(T(CELL(RECEPTOR(SIGNALING(PATHWAY( 0,01(
REACTOME(SIGNALING(BY(ILS( 0,03(
BIOCARTA(NKCELLS(PATHWAY( 0,01(
REACTOME(THE(ROLE(OF(NEF(IN(HIV1(REPLICATION(AND(DISEASE(PATHOGENESIS( 0,00(
KEGG(JAK(STAT(SIGNALING(PATHWAY( 0,10(
BIOCARTA(MPR(PATHWAY( 0,04(
BIOCARTA(NTHI(PATHWAY( 0,02(
REACTOME(NUCLEOTIDE(BINDING(DOMAIN(LEUCINE(RICH(REPEAT(CONTAINING(RECEPTOR(NLR(
SIGNALING(PATHWAYS( 0,03(
KEGG(CYTOSOLIC(DNA(SENSING(PATHWAY( 0,04(
BIOCARTA(IL2RB(PATHWAY( 0,06(
SIG(IL4RECEPTOR(IN(B(LYPHOCYTES( 0,05(
REACTOME(NOD1(2(SIGNALING(PATHWAY( 0,06(
PID(PTP1BPATHWAY( 0,06(
PID(INTEGRIN2(PATHWAY( 0,02(
BIOCARTA(CDC42RAC(PATHWAY( 0,01(
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The second tumor analyzed (PLGG 21) contained 44 A2B5 positive and 28 A2B5 
negative SC that each exhibited expression of at least 1500 genes. Similarly to PLGG 
19, we observed for both A2B5 positive and negative SC a good correlation between the 
mean gene expression of the SC to the gene expression in the corresponding bulk 
control (Figure 34A and 34B). PCA revealed that the A2B5 positive SC clustered 
separately from the A2B5 negative cells (Figure 34C).  SOM consensus clustering 
showed that two clusters best segregated the 82 SC (Figure 34D). Strikingly, we 
observed that the clusters obtained by SOM segregated strongly A2B5 positive and 
negative SC, respectively (Figure 34F and 34E, p<0.0001).  
 
Using CMS and GSEA analyses, we found that 3,420 genes and 283 gene-sets were 
significantly differentially expressed between the A2B5 positive and negative SC. 
Among the top 100 genes significantly overexpressed in the A2B5 positive cells relative 
to the negative SC and harboring the highest fold-change, we noticed a predominance 
of genes mostly involved in metabolic pathways, such as PLPP (plasmolipin), 
considered as a myelin protein involved in human hereditary demyelinating 
neuropathies, NDUFA1 (NADH dehydrogenase (ubiquinone) 1 alpha subcomplex), 
involved in the proton translocation process in the respiratory chain, ALDOC (aldolase 
C, fructose-bisphosphate), a glycolytic enzyme specifically expressed in the 
hippocampus and Purkinje cells of the brain and COX8A (cytochrome c oxidase subunit 
VIIIA), involved in the catalytic function of the terminal steps in the respiratory chain 
(Table 15). Conversely, among the top 100 genes significantly overexpressed in the 
A2B5 negative SC relative to the positive SC, we found a enrichment in genes involved 
in inflammatory pathways, such as C1QB (complement component 1, q subcomponent, 
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B chain), a major constituent of the human complement subcomponent C1q), CCL3L3 
(chemokine ligand 3-like 3), HLA-DQB1 (major histocompatibility complex, class II, DQ 
beta 1), CD69 and RFPL4A (ret finger protein-like 4A) (Table 15).  
 
Similar patterns were also observed in the GSEA results. The three first gene-sets 
significantly enriched in the cluster 1 were represented by respiratory electron transport 
(Figure 34G and Table 16). We also noticed a significant enrichment in NOTCH 
pathways gene-sets in the A2B5 positive cells (7 NOTCH related gene-sets were 
enriched, p<0.012). 9/14 (64%) gene-sets significantly enriched in the A2B5 negative 
population were directly related to inflammatory pathways. We then wanted to explore 
the degree of heterogeneity within each subgroup of SC. SOM consensus clustering 
performed on the A2B5 positive SC revealed two major groups whereas the A2B5 
negative SC segregated in 3 groups (Figure 34H), suggesting that the heterogeneity 
within the A2B5 negative cells is significantly higher than the A2B5 positive SC in this 
tumor. 
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Figure 34: Results of PLGG 21 single-cell RNA-sequencing experiment 
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Figure 34 (legend):  
A-B, graphical representation of the correlation between the average gene expression of 
SC relative to the bulk gene expression for the positive A2B5 cells (A) and negative cells 
(B). C, PCA analysis showing the three first components of the SC A2B5 positive (red)  
and negative (blue). D, graphical representation of the delta-gini index variation obtained 
by SOM clustering, E, heat-map of the SOM clustering (red represents A2B5 SC positive 
cells, blue the A2B5 negative cells). F, summary table of the distribution of the different 
SC by SOM clustering. G, GSEA enrichment plots significantly enriched in cluster 1 and 
2. H, summary table of the distribution of the different sublclusters of SC by SOM 
clustering 
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Table 15: List of the top 100 genes that are significantly differentially expressed 
between A2B5 positive cells (POS) and negative cells (NEG) with the fold change 
of gene expression. 
Overexpressed in gene FDR Fold-change 
POS PLLP 0,0 50429,2 
POS AL132780.1 0,0 48890,6 
POS RP11-701H24.3 0,0 34673,1 
POS NDUFA1 0,0 32654,1 
POS ALDOC 0,0 27847,4 
POS AC012379.1 0,0 24540,7 
POS AL590762.1 0,0 23715,0 
POS RP3-398G3.3 0,0 22231,1 
POS NDUFB7 0,0 22040,3 
POS SNX22 0,0 20967,8 
POS COX8A 0,0 20374,7 
POS MRPS18A 0,0 20075,9 
POS BEX4 0,0 19319,9 
POS RP11-566K8.1 0,0 19264,8 
POS COPS6 0,0 18834,6 
POS NDUFB11 0,0 18260,1 
POS PSMB5 0,0 17889,7 
POS RP11-512N4.2 0,0 16823,3 
POS PEPD 0,0 16815,1 
POS RP11-599J14.2 0,0 16511,0 
POS PSMC4 0,0 15986,2 
POS NNMT 0,0 15963,8 
POS BEX1 0,0 15361,1 
POS RABAC1 0,0 14655,1 
POS RP11-21N7.2 0,0 14426,1 
POS RP11-728F11.6 0,0 14314,1 
POS EIF3G 0,0 14293,1 
POS SLC25A35 0,0 14161,5 
POS TMEM179B 0,0 13936,6 
POS CTD-2206G10.2 0,0 13917,7 
POS MAGEH1 0,0 13759,2 
POS HIST1H3A 0,0 13610,5 
POS ATP5J 0,0 13536,1 
POS AC004797.1 0,0 13171,0 
POS CNBP 0,0 13083,1 
POS NDUFB9 0,0 13045,6 
POS SNORA11 0,0 12904,4 
POS TCEB2 0,0 12899,3 
POS NDUFA6 0,0 12703,6 
POS MT1M 0,0 12188,6 
POS UBA3 0,0 11784,5 
POS HIRIP3 0,0 11756,3 
POS FAM127A 0,0 11737,6 
POS OAT 0,0 11591,0 
POS PRDX2 0,0 11554,6 
POS DCXR 0,0 11552,7 
POS HIGD2A 0,0 11434,5 
POS SLC25A4 0,0 11366,2 
POS RP11-354M1.3 0,0 11329,4 
POS RP3-525N10.2 0,0 10852,7 
POS SARS 0,0 10672,6 
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POS RP4-604K5.1 0,0 10650,3 
POS EDF1 0,0 10474,3 
POS RP11-342M3.5 0,0 10282,7 
POS HINT1 0,0 10244,8 
POS SSBP1 0,0 10196,8 
POS MRPL51 0,0 10141,4 
POS RP3-330M21.5 0,0 10113,6 
POS BEX2 0,0 10075,1 
POS AC006195.2 0,0 9885,3 
POS C6orf108 0,0 9851,4 
POS ACTRT2 0,0 9843,1 
POS RP11-216M21.1 0,0 9828,1 
POS LRRC14 0,0 9734,5 
POS AC138744.2 0,0 9685,6 
POS AC009948.3 0,0 9610,2 
POS NDUFA13 0,0 9524,8 
POS RP11-230C9.1 0,0 9360,1 
POS OR51D1 0,0 9159,4 
POS S100A10 0,0 8887,5 
POS CHST12 0,0 8876,7 
POS ZMAT5 0,0 8834,9 
POS PSMD8 0,0 8808,6 
POS SEPP1 0,0 8747,2 
POS FIBP 0,0 8694,3 
POS PRNP 0,0 8620,8 
POS RP11-801I18.1 0,0 8578,8 
POS RPS15 0,0 8558,4 
POS C16orf80 0,0 8552,6 
POS APOA1BP 0,0 8494,1 
POS RP11-474L23.3 0,0 8479,2 
POS EFNA1 0,0 8376,0 
POS GALT 0,0 8351,8 
POS RCBTB1 0,0 8346,9 
POS APEH 0,0 8345,4 
POS TUBG2 0,0 8131,1 
POS DHPS 0,0 8127,9 
POS FAM127B 0,0 8113,8 
POS RP11-453M1.1 0,0 8088,6 
POS PEF1 0,0 8066,4 
POS RP11-63M22.2 0,0 8043,6 
POS SNX3 0,0 7951,6 
POS TH1L 0,0 7807,7 
POS FAM96B 0,0 7794,6 
POS MIR593 0,0 7792,9 
POS HIGD1B 0,0 7756,2 
POS RP3-388M5.8 0,0 7727,8 
POS BRP44L 0,0 7606,1 
POS RP11-447H19.3 0,0 7564,4 
POS AL445309.1 0,0 7533,7 
NEG RN5S151 0,0 114386,0 
NEG C1QB 0,0 46165,0 
NEG AC112165.1 0,0 45406,6 
NEG MIR30E 0,0 32716,1 
NEG CCL3L3 0,0 26970,7 
NEG OR8Q1P 0,0 22624,7 
NEG Y RNA 0,0 21421,8 
NEG APOC1 0,0 21140,8 
NEG AC022201.5 0,0 20234,2 
NEG U6 0,0 19247,0 
NEG CYBB 0,0 18433,4 
NEG OR13C3 0,0 15062,2 
NEG AL162430.1 0,0 14237,6 
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NEG AC108696.1 0,0 14015,9 
NEG AC073352.1 0,0 13635,8 
NEG RP11-2A1.1 0,0 12488,6 
NEG HPDL 0,0 12222,6 
NEG RP11-299L17.3 0,0 11632,0 
NEG Y RNA 0,0 11503,6 
NEG RP13-128O4.3 0,0 10936,3 
NEG RNASE1 0,0 10097,8 
NEG RP11-456A14.1 0,0 10097,6 
NEG ADORA3 0,0 9666,2 
NEG SNORA51 0,0 9250,3 
NEG RN5S98 0,0 9200,9 
NEG FAM71E1 0,0 8879,5 
NEG HLA-DQB1 0,0 8012,9 
NEG CD69 0,0 7345,0 
NEG RFPL4A 0,0 7336,3 
NEG RP11-1085N6.5 0,0 7254,9 
NEG C11orf52 0,0 7152,5 
NEG CXCR4 0,0 7054,4 
NEG SRGN 0,0 6947,7 
NEG VSIG4 0,0 6834,7 
NEG SNORA81 0,0 6815,4 
NEG XX-CR54.1 0,0 6511,9 
NEG AIF1 0,0 6466,1 
NEG CCL3 0,0 5780,3 
NEG U6 0,0 5670,9 
NEG MS4A6A 0,0 5415,7 
NEG RGS1 0,0 5240,0 
NEG U6 0,0 5129,0 
NEG U6atac 0,0 4954,6 
NEG MIR548E 0,0 4864,4 
NEG RP11-25K21.1 0,0 4647,5 
NEG CTD-3195I5.1 0,0 4640,1 
NEG P2RY12 0,0 4635,2 
NEG AC007163.3 0,0 4509,2 
NEG snoU13 0,0 4345,3 
NEG CCL4 0,0 4183,2 
NEG RP11-147K6.2 0,0 4052,7 
NEG RP11-505P4.7 0,0 4032,8 
NEG RP11-867G2.5 0,0 4023,7 
NEG PRICKLE4 0,0 4020,9 
NEG RP11-379P15.1 0,0 3892,4 
NEG OR4F6 0,0 3880,1 
NEG RP11-667M19.1 0,0 3856,4 
NEG Y RNA 0,0 3785,8 
NEG OR52S1P 0,0 3506,9 
NEG AC005005.1 0,0 3423,9 
NEG RP11-64K12.4 0,0 3267,1 
NEG C2orf70 0,0 3263,8 
NEG C3 0,0 3257,4 
NEG RP11-445H22.4 0,0 3155,7 
NEG PARVG 0,0 3118,9 
NEG ZAR1L 0,0 3061,7 
NEG RP11-930O11.1 0,0 3045,1 
NEG SNORA79 0,0 2881,7 
NEG RN5S226 0,0 2779,4 
NEG Y RNA 0,0 2729,5 
NEG RP11-404P21.1 0,0 2407,9 
NEG TAAR5 0,0 2401,6 
NEG OR10V3P 0,0 2344,6 
NEG AC015987.1 0,0 2324,5 
NEG RP11-66H6.3 0,0 2257,9 
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NEG U6 0,0 2218,9 
NEG RP11-49O14.2 0,0 2122,8 
NEG FBXO46 0,0 2016,8 
NEG CTSS 0,0 1966,8 
NEG ATP8B5P 0,0 1914,8 
NEG AC140120.1 0,0 1900,4 
NEG RP11-52I18.1 0,0 1839,3 
NEG RNU5A-6P 0,0 1741,2 
NEG IL8 0,0 1651,6 
NEG TNFAIP3 0,0 1591,5 
NEG C12orf35 0,0 1591,1 
NEG CD2 0,0 1562,2 
NEG TRNAQ36P 0,0 1562,0 
NEG LAPTM5 0,0 1502,3 
NEG XAGE1E 0,0 1499,5 
NEG U6 0,0 1368,1 
NEG SNORD56 0,0 1367,4 
NEG REM1 0,0 1318,4 
NEG AL049831.1 0,0 1216,8 
NEG CEBPB 0,0 1211,4 
NEG RP11-108K3.1 0,0 1140,6 
NEG BX255972.1 0,0 1138,3 
NEG SPINK14 0,0 996,9 
NEG TRAV38-2DV8 0,0 986,2 
NEG CTD-2316B1.2 0,0 969,1 
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Table 16: GSEA results for cluster 1 (A) and 2 (B) in PLGG 21 tumor. 
A.  
NAME FDR 
REACTOME RESPIRATORY ELECTRON TRANSPORT 0,00 
REACTOME RESPIRATORY ELECTRON TRANSPORT ATP SYNTHESIS BY CHEMIOSMOTIC COUPLING AND 
HEAT PRODUCTION BY UNCOUPLING PROTEINS  0,00 
REACTOME TCA CYCLE AND RESPIRATORY ELECTRON TRANSPORT 0,00 
KEGG PARKINSONS DISEASE 0,00 
KEGG OXIDATIVE PHOSPHORYLATION 0,00 
KEGG HUNTINGTONS DISEASE 0,00 
KEGG ALZHEIMERS DISEASE 0,00 
REACTOME MRNA SPLICING 0,00 
BIOCARTA PROTEASOME PATHWAY 0,00 
REACTOME NGF SIGNALLING VIA TRKA FROM THE PLASMA MEMBRANE 0,00 
REACTOME REGULATION OF ORNITHINE DECARBOXYLASE ODC 0,00 
REACTOME PROCESSING OF CAPPED INTRON CONTAINING PRE MRNA 0,00 
REACTOME HIV INFECTION 0,00 
REACTOME MRNA PROCESSING 0,00 
REACTOME DOWNSTREAM SIGNALING EVENTS OF B CELL RECEPTOR BCR 0,00 
REACTOME ER PHAGOSOME PATHWAY 0,00 
KEGG ENDOCYTOSIS 0,00 
REACTOME LATE PHASE OF HIV LIFE CYCLE 0,00 
REACTOME PREFOLDIN MEDIATED TRANSFER OF SUBSTRATE TO CCT TRIC 0,00 
KEGG VIBRIO CHOLERAE INFECTION 0,00 
PID REG GR PATHWAY 0,00 
REACTOME MRNA SPLICING MINOR PATHWAY 0,00 
REACTOME SIGNALING BY THE B CELL RECEPTOR BCR 0,00 
REACTOME MRNA CAPPING 0,00 
REACTOME SIGNALING BY WNT 0,00 
BIOCARTA MEF2D PATHWAY 0,00 
REACTOME ACTIVATION OF KAINATE RECEPTORS UPON GLUTAMATE BINDING 0,00 
KEGG PEROXISOME 0,00 
REACTOME AUTODEGRADATION OF CDH1 BY CDH1 APC C 0,00 
REACTOME REGULATION OF MRNA STABILITY BY PROTEINS THAT BIND AU RICH ELEMENTS 0,00 
REACTOME CROSS PRESENTATION OF SOLUBLE EXOGENOUS ANTIGENS ENDOSOMES 0,00 
REACTOME GLUCOSE METABOLISM 0,00 
REACTOME RNA POL II TRANSCRIPTION 0,00 
REACTOME HIV LIFE CYCLE 0,00 
PID ERBB1 DOWNSTREAM PATHWAY 0,00 
REACTOME RNA POL II PRE TRANSCRIPTION EVENTS 0,00 
PID MTOR 4PATHWAY 0,00 
PID ECADHERIN STABILIZATION PATHWAY 0,00 
REACTOME FORMATION OF RNA POL II ELONGATION COMPLEX  0,00 
REACTOME SIGNALING BY ERBB4 0,00 
BIOCARTA GPCR PATHWAY 0,00 
REACTOME VIF MEDIATED DEGRADATION OF APOBEC3G 0,00 
REACTOME FORMATION OF THE HIV1 EARLY ELONGATION COMPLEX 0,00 
BIOCARTA NOS1 PATHWAY 0,00 
REACTOME DOWNSTREAM SIGNAL TRANSDUCTION 0,00 
REACTOME PEROXISOMAL LIPID METABOLISM 0,00 
KEGG PROTEASOME 0,00 
KEGG SPLICEOSOME 0,00 
REACTOME REGULATION OF APOPTOSIS 0,00 
REACTOME FORMATION OF TRANSCRIPTION COUPLED NER TC NER REPAIR COMPLEX 0,00 
REACTOME NUCLEOTIDE EXCISION REPAIR 0,00 
KEGG BIOSYNTHESIS OF UNSATURATED FATTY ACIDS 0,00 
REACTOME RNA POL II TRANSCRIPTION PRE INITIATION AND PROMOTER OPENING 0,00 
PID HDAC CLASSIII PATHWAY 0,00 
REACTOME ACTIVATION OF NF KAPPAB IN B CELLS 0,00 
REACTOME P53 INDEPENDENT G1 S DNA DAMAGE CHECKPOINT 0,00 
REACTOME MITOCHONDRIAL PROTEIN IMPORT 0,00 
REACTOME SIGNALING BY NOTCH 0,00 
REACTOME SCF BETA TRCP MEDIATED DEGRADATION OF EMI1 0,00 
PID TELOMERASEPATHWAY 0,00 
REACTOME SCFSKP2 MEDIATED DEGRADATION OF P27 P21 0,00 
REACTOME SIGNALLING BY NGF 0,00 
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REACTOME DARPP 32 EVENTS 0,00 
REACTOME HOST INTERACTIONS OF HIV FACTORS 0,00 
REACTOME NOTCH1 INTRACELLULAR DOMAIN REGULATES TRANSCRIPTION 0,00 
REACTOME GLYCOLYSIS 0,00 
KEGG PROPANOATE METABOLISM 0,00 
REACTOME DESTABILIZATION OF MRNA BY AUF1 HNRNP D0 0,00 
REACTOME FORMATION OF INCISION COMPLEX IN GG NER 0,00 
KEGG VALINE LEUCINE AND ISOLEUCINE DEGRADATION 0,00 
REACTOME CYCLIN E ASSOCIATED EVENTS DURING G1 S TRANSITION  0,00 
REACTOME ANTIGEN PROCESSING UBIQUITINATION PROTEASOME DEGRADATION 0,00 
KEGG PROTEIN EXPORT 0,00 
KEGG CARDIAC MUSCLE CONTRACTION 0,00 
REACTOME ABORTIVE ELONGATION OF HIV1 TRANSCRIPT IN THE ABSENCE OF TAT 0,00 
REACTOME GLUCAGON SIGNALING IN METABOLIC REGULATION 0,00 
REACTOME CDK MEDIATED PHOSPHORYLATION AND REMOVAL OF CDC6 0,00 
REACTOME CLASS I MHC MEDIATED ANTIGEN PROCESSING PRESENTATION 0,00 
PID TRKRPATHWAY 0,00 
KEGG ADHERENS JUNCTION 0,00 
REACTOME ACTIVATION OF CHAPERONE GENES BY XBP1S 0,00 
REACTOME AUTODEGRADATION OF THE E3 UBIQUITIN LIGASE COP1 0,00 
REACTOME DIABETES PATHWAYS 0,00 
REACTOME TRANSCRIPTION COUPLED NER TC NER 0,00 
KEGG GLIOMA 0,00 
REACTOME MEMBRANE TRAFFICKING 0,00 
BIOCARTA MPR PATHWAY 0,00 
REACTOME MAPK TARGETS NUCLEAR EVENTS MEDIATED BY MAP KINASES 0,00 
PID HDAC CLASSI PATHWAY 0,00 
REACTOME CHOLESTEROL BIOSYNTHESIS 0,00 
REACTOME APC C CDC20 MEDIATED DEGRADATION OF MITOTIC PROTEINS 0,00 
BIOCARTA MTA3 PATHWAY 0,00 
KEGG INSULIN SIGNALING PATHWAY 0,00 
KEGG LYSINE DEGRADATION 0,00 
KEGG GAP JUNCTION 0,00 
REACTOME NEUROTRANSMITTER RECEPTOR BINDING AND DOWNSTREAM TRANSMISSION IN THE 
POSTSYNAPTIC CELL 0,00 
REACTOME TRANSMISSION ACROSS CHEMICAL SYNAPSES 0,00 
REACTOME SIGNALING BY ERBB2 0,00 
KEGG RNA POLYMERASE 0,00 
KEGG LONG TERM POTENTIATION 0,00 
REACTOME METABOLISM OF CARBOHYDRATES 0,00 
BIOCARTA CARM ER PATHWAY 0,00 
REACTOME PYRUVATE METABOLISM AND CITRIC ACID TCA CYCLE 0,00 
REACTOME PROCESSING OF CAPPED INTRONLESS PRE MRNA 0,00 
REACTOME ACTIVATION OF NMDA RECEPTOR UPON GLUTAMATE BINDING AND POSTSYNAPTIC EVENTS 0,00 
PID RAC1 REG PATHWAY 0,00 
KEGG CITRATE CYCLE TCA CYCLE 0,00 
REACTOME TRANSPORT OF MATURE MRNA DERIVED FROM AN INTRONLESS TRANSCRIPT 0,00 
BIOCARTA NDKDYNAMIN PATHWAY 0,00 
REACTOME SMOOTH MUSCLE CONTRACTION 0,00 
REACTOME SIGNALING BY FGFR IN DISEASE 0,00 
KEGG UBIQUITIN MEDIATED PROTEOLYSIS 0,00 
BIOCARTA EIF PATHWAY 0,00 
REACTOME NUCLEAR SIGNALING BY ERBB4 0,00 
BIOCARTA AKAPCENTROSOME PATHWAY 0,00 
KEGG OOCYTE MEIOSIS 0,00 
KEGG PYRIMIDINE METABOLISM 0,00 
REACTOME FATTY ACID TRIACYLGLYCEROL AND KETONE BODY METABOLISM 0,00 
REACTOME CDT1 ASSOCIATION WITH THE CDC6 ORC ORIGIN COMPLEX 0,00 
REACTOME BMAL1 CLOCK NPAS2 ACTIVATES CIRCADIAN EXPRESSION 0,00 
REACTOME ASSEMBLY OF THE PRE REPLICATIVE COMPLEX 0,00 
PID BETACATENIN NUC PATHWAY 0,00 
REACTOME REGULATION OF WATER BALANCE BY RENAL AQUAPORINS 0,00 
REACTOME PRE NOTCH EXPRESSION AND PROCESSING 0,00 
REACTOME OPIOID SIGNALLING 0,00 
REACTOME METABOLISM OF AMINO ACIDS AND DERIVATIVES 0,00 
KEGG GLYCOLYSIS GLUCONEOGENESIS 0,00 
REACTOME CIRCADIAN REPRESSION OF EXPRESSION BY REV ERBA 0,00 
REACTOME PI3K EVENTS IN ERBB2 SIGNALING 0,00 
BIOCARTA CALCINEURIN PATHWAY 0,00 
REACTOME MITOTIC G1 G1 S PHASES 0,00 
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REACTOME CIRCADIAN CLOCK 0,00 
PID PDGFRBPATHWAY 0,00 
PID ERA GENOMIC PATHWAY 0,00 
REACTOME FORMATION OF TUBULIN FOLDING INTERMEDIATES BY CCT TRIC 0,00 
REACTOME METABOLISM OF NON CODING RNA 0,00 
REACTOME ANTIGEN PROCESSING CROSS PRESENTATION 0,00 
REACTOME DOWNSTREAM SIGNALING OF ACTIVATED FGFR 0,00 
SIG INSULIN RECEPTOR PATHWAY IN CARDIAC MYOCYTES 0,00 
PID HES HEYPATHWAY 0,00 
KEGG RENAL CELL CARCINOMA 0,00 
REACTOME SIGNALING BY PDGF 0,00 
REACTOME PRE NOTCH TRANSCRIPTION AND TRANSLATION 0,00 
REACTOME TRANSFERRIN ENDOCYTOSIS AND RECYCLING 0,00 
REACTOME METABOLISM OF LIPIDS AND LIPOPROTEINS 0,00 
KEGG NUCLEOTIDE EXCISION REPAIR 0,00 
REACTOME SIGNALING BY NOTCH1 0,00 
REACTOME P53 DEPENDENT G1 DNA DAMAGE RESPONSE 0,00 
REACTOME TRAFFICKING OF AMPA RECEPTORS 0,00 
REACTOME DNA REPAIR 0,00 
REACTOME AXON GUIDANCE 0,00 
REACTOME GLUCONEOGENESIS 0,00 
BIOCARTA CREB PATHWAY 0,00 
REACTOME APOPTOSIS 0,00 
REACTOME CA DEPENDENT EVENTS 0,00 
REACTOME SIGNALING BY EGFR IN CANCER 0,00 
REACTOME CELL CYCLE CHECKPOINTS 0,00 
REACTOME PKA MEDIATED PHOSPHORYLATION OF CREB 0,00 
REACTOME PLC BETA MEDIATED EVENTS 0,00 
PID NOTCH PATHWAY 0,00 
PID BMPPATHWAY 0,00 
REACTOME ELONGATION ARREST AND RECOVERY 0,00 
REACTOME PI3K AKT ACTIVATION 0,00 
REACTOME INTEGRATION OF ENERGY METABOLISM 0,00 
REACTOME REGULATION OF INSULIN SECRETION 0,00 
REACTOME SIGNALING BY FGFR 0,00 
REACTOME RORA ACTIVATES CIRCADIAN EXPRESSION 0,00 
REACTOME GENERIC TRANSCRIPTION PATHWAY 0,00 
REACTOME MRNA 3 END PROCESSING 0,00 
REACTOME PIP3 ACTIVATES AKT SIGNALING 0,00 
REACTOME S PHASE 0,00 
BIOCARTA BCR PATHWAY 0,00 
BIOCARTA GATA3 PATHWAY 0,00 
PID IL6 7PATHWAY 0,00 
REACTOME GLOBAL GENOMIC NER GG NER 0,00 
KEGG CYSTEINE AND METHIONINE METABOLISM 0,00 
REACTOME APC C CDH1 MEDIATED DEGRADATION OF CDC20 AND OTHER APC C CDH1 TARGETED 
PROTEINS IN LATE MITOSIS EARLY G1 0,00 
PID TGFBRPATHWAY 0,00 
REACTOME REGULATORY RNA PATHWAYS 0,00 
BIOCARTA ERK PATHWAY 0,00 
REACTOME INSULIN RECEPTOR RECYCLING 0,00 
BIOCARTA RHO PATHWAY 0,00 
REACTOME REGULATION OF INSULIN SECRETION BY GLUCAGON LIKE PEPTIDE1 0,00 
REACTOME SIGNALLING TO ERKS 0,00 
BIOCARTA PPARA PATHWAY 0,00 
REACTOME RECRUITMENT OF MITOTIC CENTROSOME PROTEINS AND COMPLEXES 0,00 
REACTOME CLEAVAGE OF GROWING TRANSCRIPT IN THE TERMINATION REGION  0,00 
REACTOME GAB1 SIGNALOSOME 0,00 
REACTOME METABOLISM OF RNA 0,00 
REACTOME SYNTHESIS SECRETION AND DEACYLATION OF GHRELIN 0,00 
KEGG NOTCH SIGNALING PATHWAY 0,00 
REACTOME REGULATION OF MITOTIC CELL CYCLE 0,00 
REACTOME TRAFFICKING OF GLUR2 CONTAINING AMPA RECEPTORS 0,00 
KEGG MISMATCH REPAIR 0,00 
REACTOME G1 S TRANSITION 0,00 
REACTOME M G1 TRANSITION 0,00 
REACTOME DAG AND IP3 SIGNALING 0,00 
REACTOME NEURONAL SYSTEM 0,00 
PID PS1PATHWAY 0,00 
REACTOME MITOTIC G2 G2 M PHASES 0,00 
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REACTOME DEVELOPMENTAL BIOLOGY 0,00 
REACTOME PROTEIN FOLDING 0,00 
REACTOME CELL CYCLE 0,00 
REACTOME ORC1 REMOVAL FROM CHROMATIN 0,00 
REACTOME INTERACTIONS OF VPR WITH HOST CELLULAR PROTEINS 0,00 
REACTOME TRANSPORT OF MATURE TRANSCRIPT TO CYTOPLASM 0,00 
PID ERBB1 INTERNALIZATION PATHWAY 0,00 
REACTOME TRANSCRIPTION 0,00 
PID HIF1 TFPATHWAY 0,00 
PID MET PATHWAY 0,00 
KEGG VASOPRESSIN REGULATED WATER REABSORPTION 0,00 
REACTOME SIGNALING BY INSULIN RECEPTOR 0,00 
REACTOME MUSCLE CONTRACTION 0,00 
SA TRKA RECEPTOR 0,00 
REACTOME METABOLISM OF PROTEINS 0,00 
 
B. 
 
NAME FDR 
BIOCARTA TH1TH2 PATHWAY 0,00 
KEGG ASTHMA 0,00 
BIOCARTA NKT PATHWAY 0,00 
REACTOME PHOSPHORYLATION OF CD3 AND TCR ZETA CHAINS 0,00 
REACTOME PD1 SIGNALING 0,00 
KEGG INTESTINAL IMMUNE NETWORK FOR IGA PRODUCTION 0,00 
REACTOME CHEMOKINE RECEPTORS BIND CHEMOKINES 0,01 
REACTOME GENERATION OF SECOND MESSENGER MOLECULES 0,01 
REACTOME DOWNSTREAM TCR SIGNALING 0,01 
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The third tumor analyzed (PLGG 25) contained 22 A2B5 positive SC and 15 A2B5 
negative SC that exhibited expression of at least 1500 genes. Similarly to PLGG 19 and 
PLGG 22, we observed for both A2B5 positive and negative SC a good correlation 
between the mean gene expression of the SC to the gene expression in the 
corresponding bulk control (Figure 35A and 35B).  
 
Although the segregation between A2B5 positive and negative SC was not as striking as 
the two previous tumors, PCA showed relatively distinct distributions between the two 
clusters for the A2B5 positive SC and the A2B5 negative cells (Fig 35C).  SOM 
consensus clustering performed on the 37 SC showed that 2 clusters distinguished the 
best the matrix (Figure 35D). We observed a significant enrichment of the A2B5 positive 
and negative cells in cluster 1 and 2, respectively (Figure 35F and 35E, p<0.0001).  
 
Using CMS and GSEA analyses, we found that 1,637 genes and 19 gene-sets were 
significantly differentially expressed between cluster 1 and 2. Beside the pseudogenes 
and small RNA molecules, we found S100A9 (S100 calcium binding protein A9) involved 
in the regulation of a number of cellular processes such as cell cycle progression and 
differentiation, CLEC18C and CLEC18A (C-type lectin domain family 18) that belong to 
the superfamily of proteins containing C-type lectin-like domains proteins, harboring 
various cell functions such as cell trafficking350 that are among the top 100 genes 
overexpressed in the cluster 1 (Table 17A). Among the top 100 genes overexpressed in 
cluster 2, we found APOC1 (apolipoprotein C-I) activated in the transformation of 
monocytes into macrophages, EVI2B (ecotropic viral integration site 2B) overexpressed 
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in cells derived from NF1 neurofibromas351 and SYNDIG1 (synapse differentiation 
inducing 1) involved in the development of the central nervous system352 (Table 17B). 
 
GSEA analysis revealed that 13/18 gene-sets (72%) significantly enriched in the cluster 
2 were involved in inflammatory processes (Figure 35G and Table 18). We performed 
SOM consensus clustering on the cluster 1 and 2 separately and observed that both 
clusters segregated preferentially in 2 groups (Figure 35H).  
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Figure 35: Results of PLGG 25 single-cell RNA-sequencing experiment.  
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Figure 35 (legend):  
A-B, graphical representation of the correlation between the average gene expression of 
SC relative to the bulk gene expression for the positive A2B5 cells (A) and negative cells 
(B). C, PCA analysis showing the three first components of the SC A2B5 positive (red) 
and negative (blue). D, graphical representation of the delta-gini index variation obtained 
by SOM clustering, E, heat-map of the SOM clustering (red represents A2B5 SC positive 
cells, blue the A2B5 negative cells). F, summary table of the distribution of the different 
SC by SOM clustering. G, GSEA enrichment plots significantly enriched in cluster 2. H, 
summary table of the distribution of the different sublclusters of SC by SOM clustering 
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Table 17: Comparative marker selection results in A2B5 positive (A) and negative 
(B) cells for PLGG 25 tumor (top 100 genes with highest fold-change are represented) 
 
A.  
overexpressed gene FDR Fold-change 
pos RN5S87 0,00 827228 
pos KRTAP21-3 0,00 795687 
pos AL132855.1 0,00 738701 
pos 7SK 0,01 364228 
pos AC105383.1 0,00 236174 
pos MRPL20P1 0,00 185028 
pos S100A9 0,00 150278 
pos RN5S447 0,00 148862 
pos AC073352.1 0,00 132915 
pos OR5R1 0,00 109973 
pos AC114491.2 0,00 96716 
pos snoU13 0,00 96247 
pos TRNAK42P 0,00 62721 
pos RP11-411D10.1 0,00 60619 
pos AC103783.1 0,00 57426 
pos AC022027.1 0,00 39078 
pos RP11-115C10.1 0,00 38046 
pos RP11-353N14.4 0,00 37676 
pos DDX18P6 0,00 30109 
pos RP11-312P12.2 0,00 29363 
pos CLEC18B 0,00 29169 
pos Y RNA 0,00 28435 
pos Y RNA 0,00 27373 
pos SNORD112 0,00 26066 
pos RP11-95K23.7 0,00 25218 
pos GCOM1 0,00 25023 
pos snoU13 0,00 24775 
pos AC024367.1 0,00 23170 
pos AC000111.4 0,00 22689 
pos CLEC18C 0,00 21097 
pos AC126365.7 0,00 20799 
pos Y RNA 0,00 20733 
pos Y RNA 0,00 20530 
pos RNU7-55P 0,00 20180 
pos U6atac 0,00 20019 
pos AL162415.1 0,00 19628 
pos AL606830.1 0,01 19279 
pos snR39B 0,00 18133 
pos CLEC18A 0,00 17822 
pos RP11-5N11.5 0,00 17527 
pos Y RNA 0,00 17289 
pos TRIM47 0,01 17126 
pos CD52 0,00 17123 
pos U3 0,00 16794 
pos U6 0,00 16513 
pos RP11-379H8.1 0,00 16345 
pos AC104456.2 0,00 16042 
pos AC127391.3 0,00 15019 
pos U6 0,00 14735 
pos TRNAK37P 0,00 14129 
pos U6 0,00 13882 
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pos TRBJ2-2 0,00 13329 
pos Y RNA 0,00 13105 
pos ZBTB20-AS2 0,00 12740 
pos RP11-365D9.1 0,00 12613 
pos Y RNA 0,00 12512 
pos Y RNA 0,00 12379 
pos snoU13 0,00 12296 
pos snoU13 0,00 12266 
pos snoU13 0,00 12030 
pos RP11-12D24.6 0,00 11934 
pos U6 0,00 11693 
pos UBQLN4P1 0,00 11454 
pos TMIE 0,00 11391 
pos SNORD42 0,00 11073 
pos MIR297 0,00 10576 
pos AC018607.3 0,01 10176 
pos RNU7-23P 0,00 10090 
pos LCK 0,01 10023 
pos Y RNA 0,00 9926 
pos RP11-554D15.4 0,00 9890 
pos CSRP2 0,00 9689 
pos AC026992.1 0,00 9474 
pos CTD-2542O7.2 0,00 9455 
pos AL022344.4 0,00 9342 
pos AC011453.1 0,00 9330 
pos UBL7 0,00 9304 
pos RP11-85G21.2 0,00 9196 
pos ELL2P2 0,00 9014 
pos RNU7-26P 0,00 9009 
pos AP003402.1 0,00 8937 
pos DGCR6L 0,00 8883 
pos OR4A40P 0,00 8767 
pos AC026406.1 0,00 8719 
pos TRNAQ41P 0,00 8649 
pos SNORA44 0,00 8624 
pos PIK3CA 0,00 8493 
pos RBM22P3 0,00 8395 
pos SNORD60 0,00 8330 
pos AC092966.1 0,00 8112 
pos CTD-2530H12.2 0,00 8036 
pos Y RNA 0,00 7882 
pos AP002982.1 0,00 7861 
pos AC012485.2 0,00 7778 
pos snoU13 0,00 7702 
pos TMEM194B 0,00 7666 
pos AC004673.1 0,00 7481 
pos RP11-390D11.2 0,00 7466 
pos SNORD113 0,00 7275 
pos Y RNA 0,00 7192 
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B.  
overexpressed gene FDR Fold-change 
neg APOC1 0,00 35141 
neg TMEM11 0,00 14192 
neg SYNDIG1 0,00 14084 
neg MIR616 0,00 11837 
neg U6 0,00 10385 
neg EVI2B 0,01 10099 
neg CYB561D2 0,00 9738 
neg SPA17P1 0,00 8357 
neg RP11-407G23.3 0,00 7584 
neg RP11-96D1.7 0,00 7488 
neg AC019131.1 0,00 7391 
neg DOK1 0,01 6602 
neg FCGR1B 0,00 6397 
neg U6 0,00 5983 
neg CTD-2647E9.3 0,00 5868 
neg SRA1 0,00 5623 
neg SHC1P1 0,00 5368 
neg BHLHE41 0,01 5354 
neg ADPGK 0,00 4930 
neg RP1-20B21.4 0,00 4642 
neg AC011754.1 0,01 4491 
neg EDDM3A 0,01 4478 
neg DLEU7-AS1 0,00 4438 
neg RP11-423H2.1 0,00 4242 
neg RP11-63M22.2 0,00 4233 
neg PCDH12 0,00 4201 
neg OR6A2 0,00 4185 
neg AF240627.2 0,00 4117 
neg AC091177.1 0,00 4110 
neg GPN3 0,01 3967 
neg FAN1 0,01 3960 
neg SIGLEC9 0,01 3928 
neg IL10RB 0,00 3911 
neg ACSF3 0,00 3667 
neg BLCAP 0,01 3652 
neg 7SK 0,00 3646 
neg C1QC 0,00 3397 
neg RP1-257A7.4 0,00 3362 
neg SNORD13 0,00 3331 
neg FTSJ2 0,00 3298 
neg ZNF846 0,00 3258 
neg RABIF 0,00 3144 
neg RP13-644M16.3 0,00 3024 
neg EFTUD1 0,00 2942 
neg 7SK 0,00 2928 
neg S100A11P1 0,00 2896 
neg TMEM109 0,00 2839 
neg MTIF3 0,01 2790 
neg U6 0,00 2749 
neg RN5S477 0,00 2641 
neg RP11-641C17.4 0,00 2619 
neg 7SK 0,00 2614 
neg RP11-181C21.4 0,01 2597 
neg snoU13 0,01 2570 
neg AC006483.5 0,00 2557 
neg snoU13 0,00 2541 
neg RP11-950C14.8 0,00 2531 
neg AL592166.1 0,00 2504 
neg RP11-160E2.11 0,00 2459 
neg S100A11P2 0,00 2440 
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neg RP11-25J3.2 0,00 2415 
neg CEBPG 0,00 2357 
neg ELMO1-AS1 0,00 2357 
neg RP11-685N10.1 0,00 2324 
neg SNRPA1 0,01 2280 
neg RN5S194 0,00 2244 
neg MIR29B2 0,00 2227 
neg RP3-417O22.1 0,00 2214 
neg RP5-886K2.3 0,00 2176 
neg OR2AG1 0,00 2133 
neg RP11-452F19.3 0,01 2112 
neg HPGDS 0,01 2084 
neg RP11-536L15.1 0,00 2078 
neg RP4-760C5.3 0,00 2064 
neg AC079140.1 0,00 2058 
neg CTD-2272D18.1 0,02 2047 
neg Y RNA 0,00 2039 
neg RP4-686C3.7 0,00 2008 
neg RP5-881L22.5 0,00 1982 
neg CTD-2001E22.1 0,01 1966 
neg AC073063.10 0,01 1937 
neg RP11-49O14.2 0,00 1900 
neg ATP8B4 0,00 1886 
neg RAB1C 0,00 1871 
neg RP13-192B19.2 0,00 1871 
neg AL137798.1 0,00 1854 
neg RP11-313E4.1 0,00 1842 
neg RN5S89 0,00 1836 
neg RAB15 0,00 1775 
neg RP11-582E3.2 0,02 1740 
neg LY96 0,01 1726 
neg TDGF1P6 0,01 1725 
neg COG6 0,01 1625 
neg 5S rRNA 0,02 1608 
neg AC004979.2 0,02 1608 
neg AC093484.4 0,01 1599 
neg U4atac 0,01 1514 
neg SNORA20 0,00 1511 
neg RP11-438F14.3 0,02 1489 
neg PCNA 0,01 1475 
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Table 18: GSEA results for cluster 1 (A) and 2 (B) in PLGG 25 tumor. 
 
A. 
 
NAME FDR 
REACTOME CLASS B 2 SECRETIN FAMILY RECEPTORS 0,20 
REACTOME A TETRASACCHARIDE LINKER SEQUENCE IS REQUIRED 
FOR GAG SYNTHESIS 0,24 
 
 
B. 
 
NAME FDR 
KEGG VIRAL MYOCARDITIS 0,00 
KEGG AUTOIMMUNE THYROID DISEASE 0,00 
KEGG LEISHMANIA INFECTION 0,00 
KEGG ASTHMA 0,00 
KEGG ALLOGRAFT REJECTION 0,00 
KEGG TYPE I DIABETES MELLITUS 0,01 
KEGG ANTIGEN PROCESSING AND PRESENTATION 0,01 
KEGG INTESTINAL IMMUNE NETWORK FOR IGA PRODUCTION 0,01 
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3.3. A2B5 positive cells appear as a homogeneous population across 
different PLGG tumors 
 
 In order to evaluate whether the molecular patterns of A2B5 positive and negative 
cells were reproducible across different tumors we performed SOM consensus 
clustering including all the SC originated from the 3 tumors analyzed. We observed that 
the SC clustered preferentially in two groups (Figure 36A) and that the clusters were 
significantly enriched in A2B5 positive and negative cells, respectively (p<0.0001, Figure 
36B). We further performed SVM analysis to evaluate how predictive was the molecular 
profile of A2B5 positive and negative SC across different individuals. We observed that 
100% of the positive A2B5 SC were successfully predicted by the algorithm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
! 178 
Figure 36: 
SOM clustering results performed on all the SC across the 3 tumors tested 
A. Delta Gini Index graph obtained by SOM analysis including all the SC from the 3 
tumors 
B. Heat-map of the SOM clustering (legend: red represents A2B5 SC positive cells, blue 
the A2B5 negative cells). 
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3.4. Discussion 
 
 In the first part of this section we presented the profiling of 26 PLGG tumors from 
different ages, locations, histological subtypes as well as BRAF genomic statuses using 
different markers of glioneuronal differentiation. Besides N-CAM that was uniformly 
poorly expressed across the tumors tested, we noticed a high degree of heterogeneity of 
expression of the different markers tested, as it has been described353,354. Although our 
cohort of tumors was composed with different histological subtypes, we could not 
distinguish distinct level of expression of GLAST, A2B5, FGFR1 or O4 according to a 
specific tumor type or location. The fact that we observed such important variability of 
the level of expression of the different glial differentiation markers can be related either 
by a lack of specificity of the different antibodies used or by an extreme heterogeneity of 
the populations of cells inside the tumors between different individuals.  
 
We decided to perform the sorting experiment for SC RNA-sequencing using the A2B5 
Ab as we had a higher confidence of the specificity of the staining of the Ab. Indeed for 
every sorting experiment we used mouse neural stem cells that stained the A2B5 Ab by 
flow cytometry as well as immunohistochemistry between 10-20%, which is similar to 
what has been previously reported355. We also used NIH 3T3 cells that systematically 
did not show any positive staining for the Ab as a negative control. Furthermore, A2B5 is 
well-recognized as a cancer stem cell marker. Several studies have shown that A2B5 
isolated cells from human high grade gliomas were able to generate highly infiltrative 
tumors, suggesting that this population might be important in the initiation and the 
maintenance of tumors356. 
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We then showed that we were able to dissociate PLGG tumors and sort successfully 
A2B5 positive and negative SC to perform genome wide RNA-sequencing analysis. 
Single-cell RNA-sequencing has recently been described in normal human and bacterial 
cells357-359 as well as several cancer models such as prostate360 and higher grade 
gliomas361. This represents a new opportunity to study in detail, cell by cell, the degree 
of heterogeneity of PLGGs and understand what major patterns are expressed in the 
different cells.  
 
Unsupervised hierarchical clustering performed successively on the 3 tumors revealed 
strong similarities in terms of the significant clustering between positive and negative 
SC. Indeed, all cells originated from the 3 distinct tumors clustered preferentially in 2 
major clusters characterized for one by A2B5 positive cells and for the other cluster the 
A2B5 negative cells. We showed that A2B5 positive cells were enriched in various 
metabolic processes pathways as well as cell-to-cell interaction pathways, compared to 
the A2B5 negative SC. Additionally, we observed that in the PLGG 18 tumor cells the 
expression of MKI67IP, associated with mitosis and cell cycle progression, was 
significantly higher in the A2B5 positive population relative to the negative population 
(p< 0.0001, Mann-Whitney test).  
 
Even when combining the 3 tumors cells originated from different individuals, we were 
able to observe the similar pattern. This suggest that the A2B5 positive cells can be 
considered as a distinct population of cells among PLGGs, and especially PAs, as 2/3 
tumors tested were PAs.  
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These results suggest that the results are accurate enough to reliably detect differences 
between cell types across different tumors and experiments.  
 
One next important question is to understand how the BRAF duplicated cells are defined 
in our SC. Indeed, the 3 tumors tested have been diagnosed by FISH as BRAF 
duplicated. Based on the RNA-seq results, we have not been able to distinguish the SC 
that harbor the BRAF duplication, as the coverage of the gene was not sufficient. We are 
currently sequencing the transcriptome of the bulk tumors in order to identify the exact 
BRAF rearrangement type in order to validate by classical RT-PCR the mutation in our 
SC cDNAs left before library preparation. This information will allow us to observe 
whether the BRAF duplicated SC are preferentially A2B5 positive cells or not.  
 
The other important finding was the importance of immunological perturbations enriched 
in the cluster dominated by the A2B5 negative cells across all 3 tumors. This suggests 
that within the tumors, there is a high degree of immunologic perturbation related 
probably to an important inflammatory cell infiltration within the tumor that might activate 
several cascades responsible of the tumor behavior.  
 
Looking individually at the different subclusters of SC, we also discovered that the 
clusters dominated by the A2B5 negative cells were segregating in three distinct groups, 
whereas the A2B5 positive cells were only clustering in two groups. This pattern has not 
been observed in the last tumor, probably due to a lack of power (the number of single 
cells expressing at least 1500 genes was significantly reduced compared to the two first 
tumors analyzed).  
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This altogether suggests that PLGGs are characterized by a ‘stem cell-like’ population of 
A2B5 positive cells that might play a role in the initiation and the maintenance of PLGG 
tumors. The other cells are more heterogeneous and are highly characterized by an 
activation of inflammatory processes that are activated probably in response of the 
tumor growth but also causing itself damages to the normal CNS. 
 
Limitations of the current study are represented by the bias of the sorting upfront. The 
cells are sorted based on their viability by a double staining strategy by flow cytometry. It 
is possible that not all the cells representative of the tumors are sorted and therefore are 
limiting the exhaustive landscape of the tumors cells. The other bias might be related to 
the tumor dissociation process that may cause damage to cells, especially glial cells. 
One last bias might be related by the RNA-sequencing protocol. We observed a non-
negligible number of single cells that harbor a low number of genes expressed with poor 
overall coverage. This might be due to the cDNA and PCR steps that are not uniformly 
performed and generating preferential amplifications of regions, whereas other regions 
are not covered enough. All those steps require further closer optimization of the current 
protocol in order to increase the yield of the cDNA and PCR steps across the genome. 
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Chapter 5: General discussion and conclusion 
 
 
We have explored the alterations of both DNA and RNA of PLGGs. A strength of this 
study is the size of the cohorts analyzed. Both the sequencing meta-analysis as well as 
the gene expression profiling study benefit from a large number of samples. The 
statistical power to detect rare events across samples is therefore partially reached and 
enables further discovery of new insights in the biology of PLGGs such as MYB-QKI 
recurrent alterations in AGs or specific immunologic alterations is the ST PAs. This work 
has been possible only through multi-institutional efforts. As we understand even more 
that PLGGs are very heterogeneous tumors, this effort of collecting and profiling more 
tumors is still needed in order to apprehend better the characteristics of each tumor 
subtypes.  
 
Another important aspect that is highlighted in this work is the exploration of new paths 
through innovative techniques to apprehend the biology of PLGGs. The single cell 
expression profiling in PAs illustrates this effort. This study shows for the first time 
reliable results of transcriptomic patterns of SCs in PLGGs. These results represent a 
great opportunity to benefit such technological advances in order to study at a single cell 
level the biological patterns that are dominant in tumors and driving those cells. We have 
showed that A2B5 positive cells represent a distinct population in the tumor. The 
identification that BRAF duplication in specifically described in that population of cells 
would further reinforce the hypothesis that A2B5 positive cells are the “cancer cells” 
within the tumors. The expression results generated in our experiments would then 
represent a precious resource to explore the molecular patterns of the PA cancer cells in 
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comparison to the other cells represented in the tumor. Additionally, the biology of A2B5 
positive cells needs to be explored further. After FACS sorting A2B5 positive cells, they 
can be cultured in vitro and also be implanted as xenograft in order to explore their 
potential oncogenic properties. Furthermore, cultured A2B5 positive cells could 
represent a precious resource to test candidate drugs in order to accelerate the 
discovery of efficient therapies against AGs. In parallel of functional developments, 
further efforts are needed to improve the quality and the reliability of the results in order 
to built strong biological conclusions.  
 
This work underlines also the desperate need to link closely clinical features and 
genomic profiles of PLGGs in order to provide a better global definition of what is a 
PLGG. The latest WHO classification of PLGGs is still only based on clinical features of 
the cells identified in the tumor. The last decade has brought a new dimension in the 
field: genetic alterations. BRAF duplications and point mutation is certainly dominating 
the landscape of PLGGs alterations. This work is confirming and highlighting the fact 
that other genetic events such as FGFR1 duplication and mutation, MYB/MYBL1 
alteration, IDH1 mutation, MYB-QKI rearrangement need to be considered as actors in 
the physiopathology of those tumors. Based on morphological features, PLGGs are 
often difficult to classify into a specific diagnosis group. The contribution of genetic 
features will therefore help clinicians to better define the type of low-grade tumor. 
Indeed, such as BRAF duplication identified in a posterior fossa tumor speaks strongly in 
favor of a PA, the discovery that MYB-QKI alteration is only represented in AG tumors 
might represent a strong biological feature to define AGs and might be used as a 
diagnostic test in routine clinic.  
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Another aspect highlighted by our study is the relative low number of DNA alterations 
observed in PLGG tumors. Furthermore, those genetic alterations (such as BRAF-KIAA 
duplications, FGFR1 alterations, MYB alterations) have not been described in the 
literature as transforming cells into a cancer cell, part due to a desperate lack of relevant 
model. Those few alterations need to be further explored in better models to understand 
their exact contribution in the physiopathology of PLGGs. Alternatively, the fact that 
those genetic alterations are yet not defined as clear drivers in in vitro and in vivo 
models argues in favor of another level of biological regulation that interplays in the 
biology of PLGGs. Epigenetic and environmental influences can certainly be considered 
as important contributors in the physiopathology of PLGGs. Our bulk gene expression 
study has shown that specific molecular patterns characterize distinct tumor subtypes 
(histology and location mainly), suggesting that distinct biological perturbations are 
causing distinct tumor phenotypes. However we were not able to define clear patterns 
between the different PLGG tumor types, partially due to the mixed cell populations 
represented in the bulk expression profiling. To that extent, the SC profiling work opens 
new avenues of research as it allows dissecting the expression patterns of the “tumor 
cells” (ie presumably A2B5 cells) relative to “non-tumor cells” and thus understanding 
which molecular perturbations are acting in the transformation of PLGG tumor cells. 
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APPENDIX I – Résumé en Français 
 
 
CONTEXTE SCIENTIFIQUE ET DEFINITIONS 
 
Les gliomes de bas-grade représentent la tumeur cérébrale la plus fréquente 
chez l’enfant. Leur définition actuelle est basée sur l’aspect morphologique des tumeurs. 
Elles sont caractérisées par un très large spectre de sous-types tumoraux, très 
hétérogènes tant cliniquement que radiologiquement.  
 
Leur définition actuelle est principalement basée sur des critères histologiques, en 
fonction de la prédominance et de l’architecture des sous-types cellulaires décrits dans 
la tumeur. Il existe deux principales classifications histologiques couramment utilisées ; 
la première est définie par l’Organisation Mondiale de la Santé (OMS) et la seconde est 
celle définie par la classification de Sainte-Anne, plus fréquemment utilisée en France. 
Elles sont dites de bas-grade car elles correspondent à un grade I ou II selon la 
classification OMS. Ces classifications ont l’avantage de répertorier les multiples 
tumeurs en différentes catégories afin d’harmoniser leur appellation à travers le monde. 
Leur principale limite est qu’elles se basent uniquement sur l’architecture cellulaire au 
microscope. Ces classifications souffrent ainsi d’un manque de consensualisme et de 
précision due à la variabilité interindividuelle lors de l’appellation d’une tumeur dans une 
certaine catégorie.  
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Les astrocytomes pilocytiques (PA) sont les gliomes de bas-grade les plus fréquents 
chez l’enfant. Dans la majorité des cas, les PA sont aisément diagnostiqués car leur 
architecture tumorale est relativement typique et caractérisée par une la présence de 
fibres de Rosenthal, d’une prolifération vasculaire et de corps éosinophiles fréquemment 
localisés en bordure des régions kystiques qui sont caractéristiques de ces tumeurs. 
Elles sont caractérisées par une expression constante de Glial Fibrillary Acid Protein 
(GFAP) en immunohistochimie. Elles expriment également typiquement le marqueur de 
différenciation OLIG2 et la myelin basic protein (MBP).  
Les gangliogliomes (GG) sont également des gliomes de grade I et se caractérisent 
typiquement par une prolifération de neurones binuclés, d’une inflammation 
périvasculaire, de calcifications et de kystes.  
Les tumeurs neuroépithéliales dysembryoplastiques (DNT) et les gliomes 
angiocentriques (AG ou ANET) sont des tumeurs de grade I qui ont été récemment 
décrites et reconnues comme entité histologique à part. Les DNT se caractérisent par 
des cellules apparentées aux oligodendrocytes, GFAP négatives associées à des 
neurones immergés dans un environnement éosinophile. Les AGs décrits initialement 
par Lellouch-Tubiana et al. sont composés d’astrocytomes fusiformes et bipolaires fixant 
la GFAP se disposant classiquement en palissade autour des structures vasculaires. 
Les gliomes de grade II selon l’OMS sont définis essentiellement par les astrocytomes 
diffus (DA), les astrocytomes pilomixoides (PMA), les xanthoastrocytomes pleomorphic 
(PXA) et les tumeurs oligodendrogliales (OD).  
Globalement, l’index de prolifération cellulaire MIB est faible avec moins de 10%. 
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Sur le plan clinique, les gliomes de bas-grade ont un comportement tumoral intriguant. 
Leur croissance tumorale est lentement progressive, marquée par des phases de 
croissance puis de « quiescence » probable. Leur traitement actuel est principalement 
basé sur la chirurgie et la chimiothérapie. La radiothérapie tend à être moins utilisée 
compte tenu des complications à long terme. Malgré une excellente survie globale dans 
la population pédiatrique, ces tumeurs rechutent ou progressent fréquemment et sont 
responsables d’une comorbidité importante liée aux différents traitements utilisés. 
Malgré un manque de preuve formelle sur le plan scientifique, ces tumeurs ont une 
tendance à entrer dans une phase de quiescence définitive lors de la transition à l’âge 
adulte, expliquant ainsi leur excellente survie globale. Les raisons physiopathologiques 
à l’origine de ce phénomène d’arrêt de croissance tumorale demeurent inconnues et 
interpellent les scientifiques. 
 
Les progrès récents de la biologie moléculaire et de la génomique, avec l’expansion des 
techniques de séquençage à haut débit et le développement de plateformes permettant 
l’exploration à haute résolution du génome tumoral ont permis d’approfondir la biologie 
de nombreux types de cancers. Dans les gliomes de bas-grade de l’enfant, ces 
techniques modernes nous permettent premièrement d’approfondir considérablement 
les connaissances sur la biologie de ces tumeurs afin d’enrichir et compléter leur 
classification morphologique actuelle. Elles permettent également d’appréhender des 
questions plus fondamentales comme celle du type cellulaire initial à l’origine de ces 
tumeurs multiples et des voies de différenciation cellulaires responsables du 
développement puis du ralentissement de la croissance tumorale. 
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CHAPITRE 1 : REVUE DE LA LITTERATURE 
 
Dans le premier chapitre, ce travail résume de façon détaillée les connaissances 
actuelles sur la prise en charge clinique de ces tumeurs. Il décrit ensuite toutes les 
différentes technologies d’exploration de l’ADN tumoral (détection des altérations de 
nombre, des mutations ponctuelles, des insertions, délétions, réarrangements 
chromosomiques) et de l’ARN tumoral (étude du transcriptome par méthodes array ou 
par séquençage direct de l’ARN tumoral) ainsi que les outils bioinformatiques 
actuellement disponibles pour exploiter l’ensemble de ces ressources. 
Sur la base d’une revue de la bibliographie, ce travail décrit l’ensemble des altérations 
génétiques qui ont été récemment découvertes grâce aux progrès des techniques de 
séquençage à haut débit.   
Sur le plan génétique, plusieurs facteurs influencent la probabilité de découvrir de 
nouvelles altérations potentiellement oncogéniques. La fréquence des mutations au sein 
d’un sous-type tumoral, le taux de mutation somatique tumoral, et surtout le nombre de 
tumeurs utilisées sont importants. L’importance de la cohorte de tumeurs étudiée est 
donc un aspect primordial. Compte tenu de leur faible prévalence à travers le monde, 
l’accessibilité à un grand nombre de gliomes de bas-grade pédiatriques représente un 
obstacle important dans les études de séquençage du génome. Par conséquent, les 
collaborations et le partage des résultats sont nécessaires afin d’augmenter la cohorte 
des tumeurs et de bénéficier de conditions optimales pour découvrir de nouvelles 
altérations génétiques à l’origine de ces tumeurs.    
! 212 
Ce travail bénéficie directement de cet effort de collecter un maximum de tissu et 
d’information sur le séquençage tumoral afin de réaliser une analyse approfondie des 
altérations génomiques de l’ADN et l’ARN des gliomes de bas-grade pédiatriques. 
 
CHAPITRE 2 : ETUDE DES ALTERATIONS DE L’ADN  
 
Dans le deuxième chapitre, notre travail se base sur la description des altérations de 
l’ADN des gliomes de bas-grade de l’enfant à partir des données de séquençage à haut 
débit récemment publiées par des équipes de chercheurs aux USA (Washington 
University et St-Jude Hospital, Tenesse) et en Europe (DKFZ, Heidelberg) ainsi que des 
tumeurs nouvellement séquencées au Dana-Farber Cancer Institute et au Children’s 
Hospital of Philadelphia et des tumeurs originaires de l’Hôpital Necker à Paris. Nous 
avons analysé au total le génome de 169 gliomes de bas-grade de l’enfant, comprenant 
138 whole genome sequencing (WGS) et 53 RNA-sequencing (parmi lesquelles 22 
tumeurs ont également bénéficié de whole exome sequencing (WES)).  
 
Le taux médian de mutation dans les régions exoniques était de 1.02x10-5 mutations 
/base. Nous avons pu confirmer que les mutations du gène BRAF sont les plus 
fréquentes. 98 tumeurs (57%) présentent un des 7 différents isoformes de duplication de 
BRAF. 12 tumeurs présentent une mutation BRAF (V600E, insertion p.599 599T>TT, 
insertion VLR à la position 506 et une mutation ponctuelle p.E451D). Les altérations du 
gène FGFR1 ont été retrouvées dans 12 tumeurs (5 tumeurs avec une mutation faux-
sens, 4 duplications dans la région exonique du gène et 3 duplication-inversions entre 
FGFR1 et TACC1). Nous avons également identifié un réarrangement chromosomique 
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entre FGFR3 et TACC4 dans un PA. Les réarrangements du gène codant pour le 
récepteur à la Tyrosine kinase NTRK2 ont été retrouvés dans 4 tumeurs. Deux de ces 
tumeurs présentent un réarrangement identique entre l’exon 15 du gène NTRK2 et 
l’exon 6 de QKI. Nous avons également identifié un réarrangement entre NTRK3 et 
NAV6 dans une tumeur PXA analysée par RNA-sequencing. 
NF1 était muté dans 5 tumeurs.  
Nous avons observé des mutations dans les gènes codant pour les histones (H3F3A et 
HIST1H3B) dans 5 tumeurs. 80% de ces mutations ont également été décrites dans les 
gliomes de haut-grade pédiatriques.  
 
Notre travail présente pour la première fois un réarrangement chromosomique 
prédominant de façon quasi exclusive dans les AGs. Parmi les 6 AGs analysés dans 
notre cohorte, nous avons découvert que 5 présentaient une translocation entre le gène 
MYB et QKI.  Au total nous avons décrit 4 différents types de réarrangements entre 
MYB et QKI, résultant tous en une perte de l’extrémité 3’ end de MYB et 5’ de QKI. 
Deux de ces tumeurs ont pu être analysées par WGS ayant permis d’identifier de façon 
précise la cartographie des cassures chromosomiques. Dans la première tumeur, la 
cassure chromosomique se situe entre l’exon 9 et 10 de MYB et entre l’exon 4 et 5 de 
QKI. La seconde tumeur décrit un réarrangement complexe entre le gène EYA4, MYB et 
QKI  résultant à la perte du dernier exon de MYB accolé aux exons 5-7 de QKI. Les 
quatre premiers exons de QKI sont accolés aux 11 premiers exons de EYA4. De façon 
intéressante, MYB (activateur transcriptionnel) et QKI (protéine se liant à l’ARN) ont été 
décrits dans d’autres études génétiques comme potentiels oncogène et gène 
suppresseur de tumeur, respectivement. 
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Des études complémentaires dans divers modèles in vitro and in vivo  réalisées 
principalement par Bandopahhayay et Ramkisson, deux collaboratrices dans le 
laboratoire, ont permis d’appréhender les répercussions fonctionnelles de ce 
réarrangement particulier. Elles ont pu décrire que le réarrangement entre MYB et QKI  
entrainait entre autre trois potentiels mécanismes à l’origine des mécanismes 
d’oncogenèse ; la création d’une protéine oncogénique MYB-QKI, l’augmentation de 
l’expression de MYB en partie lié à la translocation des enhancers présents à l’extrémité 
3’ de QKI proches des domaines de transactivation de MYB et enfin par une perte 
hétérozygote de QKI.  
 
CHAPITRE 3 : ETUDE DES ALTERATIONS DE L’ARN DANS LE BULK TUMORAL 
 
Dans le troisième chapitre, ce travail décrit les résultats d’analyses des profils 
d’expression génétiques de 151 gliomes de bas grade pédiatriques extraits à partir de 
tissu conservé en paraffine. Les tumeurs pédiatriques sélectionnées reflètent en partie 
l’hétérogénéité clinique et génétique avec une bonne représentativité des différents 
sous-types histologiques. Nous avons pu analyser le profil d’expression de 6100 gènes 
de 76 PAs, 17 GGs, 11 DAs, 12 DNTs, 2 ODs et 33 tumeurs NOS (histologie 
indifférenciée). 48% de ces tumeurs étaient localisées dans des régions 
supratentorielles (cortex cérébral, région hypothalamo-chiasmatiques) et 52% 
provenaient de la fosse postérieure. Nous avons également pu déterminer le statut 
BRAF (91% pour la duplication BRAF-KIAA1549 et 62% pour la mutation V600E) des 
tumeurs. Nous disposions également d’une répartition homogène des âges au sein de 
la population pédiatrique avec 13 tumeurs développées dans la petite enfance (entre 0 
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et 18 mois), 89 tumeurs dans l’enfance (entre 19 mois et 11 ans) et 49 tumeurs dans 
l’adolescence (entre 12 et 19 ans). Nous avons pu mettre en évidence des différences 
moléculaires en fonction de leur sous-type histologique, de la localisation tumorale et de 
leur statut BRAF.  
 
Grâce aux différentes techniques de clustering non supervisées, nous avons identifié 
que les 151 gliomes de bas-grade pédiatriques se distribuaient majoritairement en 3 
groupes moléculaires. Le premier cluster moléculaire était significativement composé de 
DA et DNT et d’autres tumeurs supratentotorielles. Ce cluster était enrichi avec des 
tumeurs portant la mutation V600E. Le deuxième cluster était significativement enrichi 
de PAs développés dans la fosse postérieure comportant la duplication BRAF-
KIAA1549. Le troisième cluster, groupe mixte, se composait majoritairement de PA, GG 
et NOS provenant des régions supra ou infratentorielles. L’étude de la survie sans 
événement des patients portant ces tumeurs n’a pas permis d’identifier de différence 
significative en fonction des trois clusters moléculaires. 
 
En comparant les profils d’expression des différents sous-types histologiques, nous 
avons observé que certains sous-types histologiques divergeaient, comme les PA des 
DA ou les PA des DNT, alors que d’autres sous-types ne présentaient pas de 
différences moléculaires significatives, comme les PA et les GG. 
 
Nous avons également observé que les tumeurs développées dans les régions 
supratentorielles divergeaient clairement des tumeurs naissant dans la fosse 
postérieure. De façon complémentaire, nous avons pu démontrer que les PAs 
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développés dans les régions corticales surexprimaient notamment un grand nombre de 
gènes impliqués dans les voies de signalisation de l’inflammation, par rapport aux PAs 
de la fosse postérieure. Ces résultats suggèrent que selon la localisation tumorale, les 
patterns d’activation moléculaires divergent au sein d’une même entité histologique.  
 
Nous avons également observé certaines différences moléculaires entre les tumeurs 
primitives et les tumeurs lors de la rechute ainsi qu’entre les tumeurs BRAF V600E 
mutées et BRAF-KIAA1549 dupliquées. 
 
Enfin, nous n’avons pas observé de différences moléculaires significatives entre les 
tumeurs développées dans la petite enfance avec celles diagnostiquées dans l’enfance 
ou l’adolescence. De façon opposée, en comparant le profil d’expression génétique de 
20 gliomes de bas-grade de l’adulte nous avons observé que celles-ci divergent de 
façon importante avec celles développées chez l’enfant. 
 
CHAPITRE 4 : ETUDE DES ALTERATIONS DE L’ARN A L’ECHELLE D’UNE 
CELLULE UNIQUE 
 
Un des obstacles de l’analyse du transcriptome en cancérologie est la contamination 
des cellules tumorales par du tissu conjonctif normal. Dans le dernier volet de ce travail, 
nous avons pu tester la faisabilité d’isoler successivement par cytométrie en flux des 
cellules uniques issues de la dissociation tumorale provenant d’une exérèse chirurgicale 
récente. Afin de distinguer deux sous-types de population cellulaire au sein de la tumeur 
dissociée, nous avons initialement testé le taux d’expression dans les tumeurs 
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fraichement dissociées de plusieurs marqueurs membranaires de différentiation neuro-
gliale, comme N-CAM, A2B5, GLAST, O4, FGFR1. Après avoir optimisé les contrôles 
positifs et négatifs pour ces anticorps membranaires, nous avons privilégié l’utilisation 
de l’anticorps A2B5 qui nous semblait le plus robuste. Nous avons pu ensuite dissocier 
trois PAs et trier à l’échelle de la cellule unique des populations de cellules A2B5 
positives et négatives. 
 
En parallèle, nous avons bénéficié de l’expertise technologique du Broad Institute qui 
nous a permis d’optimiser les étapes d’extraction d’ARN, de génération de cDNA suivi 
d’amplification du cDNA et de la préparation des librairies en vue d’une analyse 
transcriptomique à haut-débit de l’ARN d’une cellule unique A2B5 positive et négative. 
Notre hypothèse de travail était que ces deux sous-populations cellulaires exprimaient 
des profils différents. Nous souhaitions ensuite étudier leur degré d’hétérogénéité au 
sein de chaque population cellulaire (A2B5 positives ou négatives) et entre ces deux 
sous-populations.  
 
L’analyse des données de RNA-sequencing des cellules A2B5 positives et négatives 
issues des trois PAs nous a permis de confirmer notre hypothèse que ces deux sous-
populations cellulaires divergeaient significativement. Nous avons pu décrire de façon 
exhaustive les gènes et voies de signalisations divergentes entre ces deux sous-
populations dans les trois PAs analysés.  
 
Nous avons observé que le degré d’hétérogénéité semblait plus important pour la 
population cellulaire A2B5 négatif et que les voies de signalisation de l’inflammation 
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prédominaient fréquemment dans ces cellules, en comparaison avec celles exprimant 
A2B5. Des études complémentaires de validation sont nécessaires pour consolider ces 
premiers résultats.  
 
De façon complémentaire, il serait nécessaire d’identifier parmi les cellules uniques 
étudiées celles qui revêtent les altérations génétiques de BRAF afin d’observer si celles-
ci sont majoritairement caractérisées par l’expression membranaire de A2B5. Ces 
résultats pourront fortement suggérer que les cellules exprimant le marqueur de 
différentiation A2B5 représentent la fraction de cellules cancéreuses responsable de la 
croissance et du développement tumoral. 
 
Ces premiers résultats soulignent l’intérêt d’exploiter des nouvelles technologies de 
pointe pour servir de base à l’étude des caractéristiques biologiques des cellules 
tumorales ouvrant de nouvelles perspectives sur la compréhension fine des 
mécanismes moléculaires à l’origine des tumeurs. 
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Cancer Therapy: Preclinical
BET Bromodomain Inhibition of MYC-Amplified
Medulloblastoma
Pratiti Bandopadhayay1,3,5, Guillaume Bergthold1,5, Brian Nguyen6, Simone Schubert6, Sharareh Gholamin7,
Yujie Tang6, Sara Bolin11, Steven E. Schumacher1,5, Rhamy Zeid2, Sabran Masoud6, Furong Yu6,
Nujsaubnusi Vue6, William J. Gibson1,5, Brenton R. Paolella1,5, Siddhartha S. Mitra7, Samuel H. Cheshier7,
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James E. Bradner2,5, Rameen Beroukhim1,2,4,5, and Yoon-Jae Cho6,7,8
Abstract
Purpose: MYC-amplified medulloblastomas are highly lethal tumors. Bromodomain and extraterm-
inal (BET) bromodomain inhibition has recently been shown to suppress MYC-associated transcrip-
tional activity in other cancers. The compound JQ1 inhibits BET bromodomain-containing proteins,
including BRD4. Here, we investigate BET bromodomain targeting for the treatment of MYC-amplified
medulloblastoma.
Experimental Design: We evaluated the effects of genetic and pharmacologic inhibition of BET
bromodomains on proliferation, cell cycle, and apoptosis in established and newly generated patient-
and genetically engineered mouse model (GEMM)-derived medulloblastoma cell lines and xenografts that
harbored amplifications ofMYC orMYCN.We also assessed the effect of JQ1 onMYC expression and global
MYC-associated transcriptional activity. We assessed the in vivo efficacy of JQ1 in orthotopic xenografts
established in immunocompromised mice.
Results: Treatment ofMYC-amplifiedmedulloblastoma cells with JQ1 decreased cell viability associated
with arrest at G1 and apoptosis. We observed downregulation of MYC expression and confirmed the
inhibition of MYC-associated transcriptional targets. The exogenous expression of MYC from a retroviral
promoter reduced the effect of JQ1 on cell viability, suggesting that attenuated levels of MYC contribute to
the functional effects of JQ1. JQ1 significantly prolonged the survival of orthotopic xenograft models of
MYC-amplified medulloblastoma (P < 0.001). Xenografts harvested from mice after five doses of JQ1 had
reduced the expression of MYC mRNA and a reduced proliferative index.
Conclusion: JQ1 suppresses MYC expression and MYC-associated transcriptional activity in medullo-
blastomas, resulting in an overall decrease in medulloblastoma cell viability. These preclinical findings
highlight the promise of BET bromodomain inhibitors as novel agents for MYC-amplified medulloblas-
toma. Clin Cancer Res; 20(4); 912–25. !2013 AACR.
Introduction
Medulloblastoma is the most common malignant brain
tumor of childhood (1). Patients with local disease receive
surgical resection, radiotherapy, and chemotherapy, with
5-year overall survival exceeding 80% (2). These treat-
ments cause significant therapy-related morbidity, includ-
ing disabling cognitive deficits (3), growth failure, and
increased risk of secondary malignancies (4). However,
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despite intensive chemotherapy and radiotherapy, the over-
all survival of "high-risk" patients remains dismal, with
10-year overall survival rates as low as 20% (5). Thus,
tremendous impetus exists for the development of more
effective treatments, based on known molecular targets, in
medulloblastoma.
Medulloblastoma is a genetically heterogeneous disease,
composed of molecular subtypes characterized by differing
transcriptional signatures, genomic alterations, and clinical
courses (6–9). The current consensus is of at least four
distinct subtypes, including Wingless (WNT), Sonic Hedge-
hog (SHH), and groups 3 and 4 (10). Group 3 medullo-
blastomas have the worst prognosis, and are commonly
metastatic and refractory to standard therapy, with 10-year
overall survival rates of 39% (5, 6, 10). Amplifications of
one of three members of the MYC family of genes (MYC,
MYCN, andMYCL1) are found in several subtypes. Group 3
tumors are often associatedwith amplificationofMYC (11),
which is the most frequently observed amplification
observed acrossmultiple cancer types (12). Group 3 tumors
withoutMYC amplification are often characterized by over-
expression of MYC (6) or amplification of MYCN (11).
MYCL1 amplifications have been reported in a few SHH
tumor cases whereas SHH and group 4 tumors are enriched
with amplifications of MYCN (11).
MYC and other transcription factors complicit in cancer
are poor targets for small molecule inhibition. Alternative
strategies target MYC through epigenetic modulation of
MYC transcription itself or of MYC target genes (13, 14).
In particular, bromodomain and extraterminal (BET)–con-
taining proteins, which recognize and engage side-chain
acetylated lysine on open chromatin to facilitate gene
transcription (15), have been identified as novel targets for
small molecule development (13). The evidence that tran-
scription of MYC and MYCN and subsequent activation of
their downstream transcriptional programs can be targeted
by BET bromodomain inhibition (13, 16, 17) presents a
novel therapeutic strategy for patients withMYC-amplified
medulloblastoma.
Materials and Methods
Ethics statement
Ethics approval was granted by the relevant human
Institutional Review Board and/or animal ethics Institu-
tional Animal Care and Use Committee (IACUC) research
committees of Dana-Farber Cancer Institute (Boston, MA)
and Stanford University (Stanford, CA).
Cell lines and culture
D283, D425, D458, and D556 were generously provided
byDr.Darrell Bigner (DukeUniversity, Durham,NC).Daoy
cells were obtained from the American Type Culture Col-
lection. Cell lines were maintained in Dulbecco’s Modified
Eagle Medium (Gibco) supplemented with 10% FBS
(100106; Benchmark) and 1%penicillin–streptomycinwith
1%glutamine (Gibco).UW228, R256, R262, andR308were
a kind gift fromMichael Bobola (University of Washington,
Seattle, WA). MB002 cells were derived from an autopsy
specimen of the leptomeningeal compartment from a child
with metastatic, treatment-refractory (chemotherapy only)
medulloblastoma. The MB002 primary tumor displayed
histologic features of large-cell medulloblastoma and gene
expression markers consistent with group 3 medulloblasto-
ma (Supplementary Fig. S1A; ref.11). MB004 cells were
derived from the primary surgical resection of a tumor in
a child whose tumor recurred after therapy. The MB004
primary tumor displayed focal anaplasia and gene expres-
sion markers consistent with group 3 and 4 medulloblasto-
mas (see Supplementary Fig. S1; ref. 6).MYC amplification
in the MB002 and MB004 cells was confirmed with Nano-
String nCounter v2 Cancer CN Codeset, which estimates a
copy number of 86 genes commonly amplified or deleted in
cancer (Supplementary Table S1). Human neural stem cells
were derived from subventricular zone tissue surgically
excised during a functional hemispherectomy in a child
with refractory seizures.MB002 andMB004 cells weremain-
tained in culture media with 1:1 Dulbecco’s Modified Eagle
Medium (Gibco) and neural stem cell media (Gibco) sup-
plemented with B27 (Gibco) EGF (02653, StemCell), fibro-
blast growth factor (GF003; Millipore), Heparin (07980,
Stem Cell), and leukemia inhibitory factor (LIF; LIF1010;
Millipore). The subventricular zone (SVZ)–derived neural
stem cells were maintained similarly, with the exception of
the LIF supplement. The MYC- and MYCN-driven medullo-
blastoma GEMM cell lines were derived and cultured as
previously described (18, 19). Briefly, for Myc-amplified
GEMM lines, cerebellar stem cells infected with Myc and
DNp53 retroviruses were transplanted into cerebella of
NOD-SCID-IL2Rgammanull (NSG) mice. When mice
became symptomatic, tumors were harvested and disso-
ciated into single cell suspensions.
Translational Relevance
Collectively, MYC, MYCN, and MYCL1 are the most
commonly amplified oncogenes in medulloblastoma,
and are associated with a dismal prognosis. The recent
development of strategies to blockMYC activity through
the inhibitionof bromodomain andextraterminal (BET)
bromodomain proteins represents a possible novel ther-
apeutic strategy for these tumors. Here, we report that
JQ1, a potent inhibitor of BET bromodomain proteins,
results in both reduced cell proliferation and prominent
apoptosis using in vitromodels ofMYC-amplifiedmedul-
loblastoma, and prolongs survival in xenograft models.
We confirm effective downregulation of MYC-related
pathways with JQ1 and suppression of the expression
of MYC. We also show reduced cell proliferation with
JQ1 treatment of cells derived from MYCN-driven
tumors harvested from a genetically engineered mouse
model. BET bromodomain inhibition, therefore, repre-
sents a novel therapeutic strategy for children withMYC-
amplified medulloblastoma. These data support further
evaluation in early-phase clinical trials.
BET Inhibition Medulloblastoma
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Patient-derived cell lines MB002 and MB004 were
authenticated using sequence-tagged site (STS) fingerprint-
ing. Cell lines obtained from the Bigner and Babola labo-
ratories were authenticated using SNP250k or SNP6.0
arrays, which revealed copy-number alterations consistent
with previously published karyotypes (12, 20).
Short hairpin RNA suppression
Lentiviral vectors encoding short hairpin RNAs (shRNA)
specific for BRD4, MYC, and the control LACZ were obt-
ained from The RNAi Consortium (Clones and sequence:
shBRD4 TRCN0000021426, 50CGTCCGATTGATGTTCT-
CCAA; shMYC TRCN0000039640, 50CAGTTGAAACACA-
AACTTGAA; and shLacZ TRCN0000231726, 50TGTTCGC-
ATTATCCGAACCAT). Lentivirus was produced by the
transfection of 293T cells with vectors encoding each
shRNA (2 mg) with packaging plasmids encoding PSPAX2
and VSVG using Lipofectamine (Invitrogen, 56532). Len-
tivirus-containing supernatant was collected 48 and 72
hours after transfection, pooled, and stored at!80"C. Cells
were infected (a ratio of 1:4 virus media) in polybrene-
containing media (2.5 mg/mL), and incubated overnight.
Cells were selected in puromycin (2.0 mg/mL) starting 48
hours after infection.
Overexpression of MYC in D283 for MYC rescue
experiments
293T cells were transfected with 2 mg retroviral pBabe
expression vectors (empty vector or pBabeMYC) with pack-
aging plasmids encoding gag-pol and VSVG using Lipofec-
tamine. Retrovirus containing supernatant was collected 48
and 72 hours after transfection, and was pooled and stored
at !80"C. D283 ells were infected (a ratio of 1:4 virus
media) in polybrene-containing media (2.5 mg/mL). Treat-
ment with 1 mmol/L JQ1R or JQ1Swas commenced 6 hours
after infection. Cell viability was assessed 24 hours after
treatment with JQ1.
Cell viability assays following treatment with JQ1 or
shRNA suppression
To assess responsiveness to JQ1, 1,000 cells were plated in
96-well plates in serial dilutions of either JQ1R or JQ1S, in
triplicate. Cell viability was measured by assessing ATP
content at 0, 24, 48, 72, 96, and 120 hours using Cell
Titre-Glo (Promega) according to themanufacturer’s instruc-
tions. Mean# SD was calculated. Nonlinear dose–response
curves were applied to the data using GraphPad Prism.
To assess the dependence of cells on BRD4 or MYC, cells
were infected with lentiviral plasmids encoding shRNA.
Forty-eight hours after infection, 1,000 cells were plated in
each well of 96-well plates, in triplicate, inmedia containing
puromycin (1 mg/mL). Cell viability was measured by asses-
sing ATP content using Cell Titre-Glo (Promega), and results
were normalized to baseline. Mean # SD was calculated.
Flow cytometry
Cell-cycle analysis was performed by measuring DNA
content by propidium iodide (PI)–stained cells treated
with 1 mmol/L of JQ1R or JQ1S for 72 hours. Apoptosis
was measured with Annexin V/PI staining. The Annexin V
was labeled with Alexa Fluor (A13201; Invitrogen) and
flow cytometry was performed per the manufacturer’s
guidelines.
Protein extraction and immunoblotting
MYC-amplified cells were lysed in boiling RIPA (radio-
immunoprecipitation assay) lysis buffer containing pro-
tease and phosphatase inhibitors, and centrifuged at
13,000 $ g for 10 minutes. For MYCN-amplified lines,
Western blot analysis was performed as previously
described (19) with the following modification: lysis buff-
er with 1% SDS. Supernatant was mixed with 4$ SDS
sample buffer, boiled for 10 minutes, and subjected to
SDS-PAGE on 4% to 12% gradient gels. Blots were probed
with antibodies against BRD4 (12183; Cell Signaling
Technology), MYC (sc-764; Santa Cruz Biotechnology),
MYCN (ab-16898; Abcam), b-tubulin (MAB 3408; Milli-
pore), and actin (sc-1615; Santa Cruz).
RNAextractionand real-time reverse transcriptasePCR
RNA was extracted with the RNeasy Kit (Qiagen). cDNA
was synthesized from 1 mg RNA using High Capacity
RNA-to-cDNA kits (Applied Biosystems). Real-time
reverse transcriptase (RT-PCR) was performed using SYBR
Green master mix (Applied Biosystems). Cycling was
performed as follows: 50"C for 2 minutes and 95"C for
10 minutes, followed by 40 cycles of 95"C for 15 seconds
and 60"C for 30 seconds. This was followed with a
dissociation stage of 95"C for 15 seconds, 60"C for 30
seconds, and 95"C for 15 seconds. Primers for BRD4,
MYC, and b-actin are listed in Supplementary Table S2.
Samples were amplified in triplicate and data were ana-
lyzed using the DDCT method.
Copy-number analysis
Relative copy-number estimates were generated from
published Affymetrix SNP 6.0 data for 1,073 tumors
(11) using comparison data from 131 normal samples
and an analytic pipeline described in detail elsewhere
(Tabak and colleagues, in preparation). Briefly, signal
intensities for each probe were normalized to uniform
intensity values and merged to form probe set–level
values using SNPFileCreator, a Java implementation of
dChip (21, 22). Marker-level intensities were calibrated
to DNA copy-number levels using Birdseed for single-
nucleotide polymorphism (SNP) markers (23) and
using the results of experiments with cell lines with
varied copy numbers of the X chromosome for copy-
number probes (Tabak and colleagues, in preparation).
Regions of frequent germline copy-number variation
were identified using a large bank of normal tissue
samples and excluded from the data (Tabak and collea-
gues, in preparation). Noise was reduced by applying
tangent normalization (12), followed by circular binary
segmentation (24, 25). Data were mean centered for
each sample. Amplifications were defined as greater than
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a relative copy number of 2.4. For samples with a
relative copy number of 2.4 to 3, we applied the ABSO-
LUTE algorithm (26), and confirmed that each of these
samples had an absolute copy number of greater than
three copies.
Genome-wide expression analysis
Previously published microarray expression and copy-
number data (11) were obtained from the Gene Expression
Omnibus (GEO; GSE37385 and GSE37382). The expres-
sion data were obtained using the GEOImporter module in
GenePattern. Z scores of gene expression values of genes
within samples were calculated.
For analyses of gene sets enriched among samples exhi-
biting high expression of MYC family members (z score > 1
for MYC, z score > 0.85 for MYCL1, and z score > 1.5 for
MYCN), gene set enrichment analysis (GSEA; refs. 27, 28)
was performed using the C2 canonical pathway (CP) gene
sets and seven additional gene sets from The Molecular
Signatures Database (MSigDB) that represent MYC activa-
tion signatures (Supplementary Table S2). Gene sets with
a nominal P value of less then 0.05 were considered
significant.
To examine the effect of JQ1 on global gene transcrip-
tion, cell lines were treated with JQ1R or JQ1S (1 mmol/L
for 24 hours) and RNA was extracted. Gene expression
profiles were assayed using Affymetrix Human Gene 1.0
ST microarrays (Affymetrix). Affymetrix CEL files were
normalized using Robust Multi-Array average (RMA)
(29). Expression-array data have been deposited in the
GEO portal under the accession number GSE51020.
Comparative marker selection analysis (30) between
JQ1S- and JQ1R-treated cells was performed in GenePat-
tern using the default settings.
The recently described JQ1 consensus signature (16) was
applied to the gene expression profiles using the 52 genes
identified as being significantly differentially expressed fol-
lowing treatment with JQ1. Agglomerative hierarchical
clustering was performed using pairwise complete linkage
and a Pearson correlation metric across both samples and
genes.
To identify gene sets differentially expressed following
treatment with JQ1, GSEA was performed using the same
customized C2 (CP) gene sets (MSigDB) with the seven
additional MYC activation gene sets. Gene sets with a
nominal P value of less then 0.05 were considered
significant.
In vivo experiments
In vivo efficacy studies were performed in accordance
with protocols approved by the IACUC at Stanford Uni-
versity. Briefly, MB002 cells were transduced with a GFP-
luciferase lentiviral expression construct and FACS sorted
to obtain 30,000 GFP-luciferase–positive cells that were
then injected with stereotaxic guidance into the cerebella
of 4- to 6-week-old NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
mice (The Jackson Laboratory). To confirm engraftment,
mice were administered D-luciferin (75 mg/kg; Promega)
and imaged on a Xenogen IVIS2000 (PerkinElmer) 14
days after injection. Mice were randomized into treat-
ment and control groups (n ¼ 5 mice/group) and admin-
istered JQ1-S (50 mg/kg in 1:10 solution of DMSO:10%
cyclodextrin) or vehicle alone (1:10 solution of
DMSO:10% cyclodextrin), daily via intraperitoneal injec-
tion, until euthanasia was required. Tumor growth was
monitored by in vivo imaging systems (IVIS) imaging at
14 and 21 days of treatment. Statistical significance for
Kaplan–Meier analysis was determined by the log-rank
(Mantel–Cox) test.
For immunohistochemistry analysis of xenografted
medulloblastomas, 4- to 6-week-old NSG mice received
intracerebellar injections of MB002 cells (30,000 cells) and
were administered JQ1-S (50 mg/kg twice daily; n ¼ 3) or
vehicle (n ¼ 3), for five doses and then euthanized. Brains
were carefully dissected and either frozen in RNAlater
(Qiagen) or preserved in 4% paraformaldehyde and sub-
sequently embedded in paraffin. RNA was extracted from
frozen cerebellum using the RNeasy Kit (Qiagen) as per the
manufacturer’s instructions.
Immunohistochemistry
JQ1- and vehicle-treated MB002 xenografts were
harvested, rinsed in PBS, and fixed in 4% paraform-
aldehyde overnight at 4"C. Then, 5-mm-thick sections
were mounted on poly-D-lysine–coated slides and trea-
ted with xylene, followed by several changes of graded
alcohol. Antigen retrieval was performed by application
of citrate buffer pH 6.00 for 20 minutes. Slides were
then incubated with anti-Ki67 (Lab Vision; SP6 RM-
9106-S, lot 9106S1210D) overnight at 4"C. Cells were
washed with several changes of PBS, and secondary
antibody conjugated to horseradish peroxidase was
applied and detected using the Dako Envision Kit for
3,30-diaminobenzidine.
Immunofluorescence
Primary medulloblastoma cells (MB002) were cul-
tured in 12-well plates at a density of 1 # 105 cells per
well and treated with vehicle, (S)-JQ1 (500 nmol/L and
1 mmol/L for 6 and 12 hours). Cells were centrifuged
at 1,000 rpm for 5 minutes, washed in PBS, and mechan-
ically dissociated for 5 minutes at 37"C. Single cell
suspensions were transferred to coverslips precoated
with poly-L-lysine (10 mg/mL in double-distilled
water, catalog number P6516; Sigma-Aldrich) and then
fixed with 4% paraformaldehyde for 15 minutes. Immu-
nolabeling was carried out with the antibody anti-BAD
(C-7; 1:400, SC8044; Santa Cruz), detected by Cy3-
conjugated secondary Donkey anti-mouse antibody
(1:200; JacksonImmuno Research) and visualized by
confocal fluorescence microscopy (Leica DM5500 B;
Leica Microsystems).
For statistical analysis, P values were calculated using
the Fisher, t tests, or Pearson, as appropriate. ANOVA
with correction was used for the comparison of multiple
groups.
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Results
Medulloblastomas exhibit several indicators of MYC
pathway activation
We evaluated indicators ofMYC pathway activation using
integrated data sets of genome-wide copy-number estimates
from 1,071 medulloblastomas and corresponding gene
expression data for 282 medulloblastomas (11). These
tumors comprised 79 Wnt subgroup medulloblastomas,
265 SHH subgroup tumors, 168 group 3medulloblastomas,
and 313 group 4 tumors, as determined by exon array or
nanoString analysis (11). Subtype designation was not
available for 245 tumors. We evaluated copy numbers and
expression of all three MYC family members (MYC,MYCN,
andMYCL1) andnine signatures ofMYCpathway activation
obtained from the Gene Set Enrichment Database.
We found that 23% of all medulloblastomas exhibit
amplifications of one or more of MYC, MYCN, or MYCL1
(9%, 12%, and 2% of all tumors, respectively; Fig. 1A).
Group 3 tumors exhibit amplifications of MYC family
members approximately three times as frequently (44% of
cases) as the other subtypes (13%, 19%, and 16% among
Wnt, SHH and group 4 tumors, respectively). This enrich-
ment was most profound for MYC; group 3 tumors
accounted for 70% of medulloblastomas exhibiting MYC
amplifications. Amplifications of MYCN were observed
slightly more often in SHH and group 4 tumors (38% and
35% of all MYCN amplifications, respectively) than in
group 3 tumors (10%).
Amplifications of MYC and MYCN were anticorrelated
(P < 0.05; Fig. 1B), suggesting that they have similar
functional effects. Anticorrelated genetic alterations often
indicate functional redundancies (31–33) because redun-
dant alterations are not required by the same tumor.
Although there was a trend toward anticorrelation bet-
ween amplification of MYCL1 and either MYC or MYCN,
this did not reach significance (P ¼ 0.8 and 0.8, respec-
tively), perhaps because MYCL1 amplifications were
observed so infrequently.
Amplifications of each MYC family member were also
associated with increased expression of its gene transcript
(P < 0.0001 in all cases). Indeed, high expression ofMYCN
or MYCL1 tends to be found exclusively in medulloblasto-
mas with amplification of those genes. High MYC expres-
sion, however, is often present in samples without MYC
amplification, suggesting alternative mechanisms for
increased MYC expression. Increased expression of MYC
andMYCN was anticorrelated (P ¼ 0.007; Fig. 1B), as were
MYC and MYCN amplifications. Increased expression of
MYCL1 trended toward a similar anticorrelation with the
other MYC family members, but did not reach statistical
significance.
Amplification and overexpression of each MYC family
member was also associated with increased expression of
genes upregulated byMYC (P < 0.05 in all cases; Fig. 1C).
We assessed MYC pathway activation by summing the
expression levels of 68 previously published genes known
to be upregulated by MYC (14). We obtained similar
results with GSEA using nine signatures ofMYC activation
(Supplementary Table S2) and comparing tumors with
high expression of any MYC to tumors with low expres-
sion of all MYCs. Among the nine MYC activation sig-
natures present in our gene sets, six were significantly
associated with high MYC expression, five with MYCN,
and four with MYCL1, respectively (Supplementary
Table S3).
Medulloblastomas that exhibited indicators of MYC
activation also exhibited high expression of genes observed
to be downregulated with treatment with the BET bromo-
domain inhibitor JQ1 (16). Genes downregulated by JQ1
werepreviously identified in tumors frommultiple lineages,
including multiple myeloma, leukemia, and neuroblasto-
ma (16). We found a positive correlation between the
expression of genes that are targeted by JQ1 (and thus
opposite to the signature following treatment with JQ1)
and MYC activation signatures in medulloblastoma (Fig.
1D).We also observedpositive correlations between expres-
sion of genes targeted by JQ1 and amplifications of MYC
(P ¼ 0.003) and MYCN (P < 0.05). The finding that
medulloblastomas with indicators of MYC activation
exhibit gene expression profiles that are opposite to the
signature of JQ1 is not surprising, because the JQ1 signa-
ture has already been shown to reflect the downregula-
tion of MYC activity (16). Nevertheless, these findings
raise the hypothesis that treatment with JQ1 may limit
MYC activity and suppress the proliferation of MYC-driven
medulloblastomas.
JQ1 reduces cell proliferation in MYC- and MYCN-
amplified medulloblastoma cells
We examined the efficacy of treatment with JQ1S in six
patient-derived medulloblastoma cell lines documented
to haveMYC amplification relative to five non-MYC–ampli-
fied medulloblastoma lines, and human neural stem cells
(34, 35). Western immunoblotting of the patient-derived
cell lines confirmed increased expression of MYC in lines
with MYC amplification (Supplementary Fig. S1B). No
patient-derived MYCN-amplified medulloblastoma cell
lines have been generated to date; therefore, we evaluated
JQ1 activity in the setting ofMycn amplification using tumor
cells derived from recently developed mouse models of
group 4 MYNC–amplified medulloblastomas (18, 36). We
also evaluated JQ1 activity in a murine model of group
3 MYC–driven medulloblastomas. The activity of JQ1 was
initially assessed by comparing proliferation rates in the
presence of the active stereoisomer of JQ1 (JQ1S) to pro-
liferation rates in the presence of an inactive stereoisomer,
JQ1R (13).
In allMYC-amplified patient-derived cell lines, treatment
with JQ1S for 48 hours at doses less than 1 mmol/L resulted
in 57% to 69% reduction in cell viability compared with
treatment with JQ1R (Fig. 2A). Each MYC-amplified line
had an IC50 of less than 1 mmol/L. In contrast, cell viability
of non-MYC–amplified cell lines (Fig. 2B) and neurons
derived from the SVZ (Fig. 2C) was not substantially altered
by treatment with either JQ1S or JQ1R. Cells with MYC
amplification exhibited up to 5-fold increases in cell
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number by day 4 of treatment with JQ1R, but showed no
increase in cell numbers with JQ1S treatment over the same
time period (Supplementary Fig. S2A).
Treatment with JQ1S also reduced the proliferation of
cells derived from a murine model of group 3–4 medul-
loblastoma with MYCN overexpression. In these cells,
treatment with JQ1 reduced viability by 75% compared
with treatment with JQ1R (Fig. 2D). Medulloblastoma
cells from a mouse model with MYC overexpression
exhibited an even greater (91%) sensitivity to treatment
with JQ1S (Fig. 2D). Taken together, these data show that
JQ1 is efficacious in reducing cell viability in medullo-
blastoma cell lines driven byMYC and also in cells from a
murine model of MYCN-driven medulloblastoma, with
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minimal effect observed in non-MYC–amplified medul-
loblastoma cells or neural stem cells.
JQ1 reduces cell viability by inducing G1 arrest and
apoptosis inMYC-amplifiedmedulloblastomacell lines
Treatment with JQ1S significantly affected cell cycling of
the MYC-driven cell lines. We profiled cell cycling by flow-
cytometry measurement of PI-stained cells treated for 72
hours with either 1 mmol/L of JQ1S or JQ1R. In six patient-
derived MYC-amplified cell lines, and one Mycn-driven
GEMM-derived cell line, we observed that treatment with
JQ1S resulted in G1 arrest, with an increased percentage of
cells in G1 and reduction of cells in S phase (Fig. 3A). Across
all MYC-amplified lines, treatment with JQ1S reduced the
number of cells in S phase by approximately 50%compared
with JQ1R (21% ! 3% vs. 43% ! 5%; P < 0.001) and
increased the number of cells in G1 (73 ! 4% vs. 51 ! 6%;
P < 0.001; Fig. 3B).
Treatment with JQ1S also induced apoptosis in patient-
derived MYC-amplified cells. We assessed the induction of
apoptosis in cells treatedwith 1mmol/L JQ1S or JQ1R for 72
hours by flow cytometry analysis of Annexin V/PI staining
(Fig. 3C). MB004 was observed to have an increase in the
number of necrotic cells, whereas in all other cell lines, there
was a clear increase in apoptosis noted. When the results of
all cell lines were pooled (including MB004), JQ1S almost
tripled the number of apoptotic cells (8%! 2%vs. 22.5%!
4%, P ¼ 02; Fig. 3D). As an independent correlation of
induction of apoptosis, we treated MB002 cells with JQ1
and observed induction of the apoptotic protein, BAD,
within 6 hours of treatment (Fig. 3D. right panel). These
data suggest that JQ1S reduces the cell viability of MYC-
drivenmedulloblastoma cell lines by inducingG1 arrest and
apoptosis.
BRD4 suppression attenuates expression of MYC in
medulloblastoma cells
We hypothesized that the effects of JQ1 in the medullo-
blastoma cells were mediated in large part by the decreased
activity ofMYC through inhibitionofBRD4. BRD4hasbeen
shown to be a cofactor for MYC-dependent transcription
in multiple cell types (13), and JQ1 has previously been
shown to have higher affinity for binding domains of
BRD4 than other bromodomain-containing proteins (13).
Figure 2. JQ1 reduces cell proliferation inMYC-amplified medulloblastoma cell lines and murine models ofMYC- andMYCN-amplified medulloblastoma. A,
dose–response curves of patient-derived MYC-amplified medulloblastoma cell lines treated with JQ1S and JQ1R for 48 hours. The percentage of cell
viability is relative to untreated cells. Values, mean!SD. B, dose–response curves of patient-derived non-MYC–amplifiedmedulloblastoma cell lines treated
with JQ1S for 72 hours. The percentage of cell viability is relative to untreated cells. Values, mean ! SD. C, dose–response curves of neural stem cells
derived from the SVZ treated with JQ1S and JQ1R. Values, mean!SD. D, dose–response curves of cancer cells from genetically engineered micemodels of
group 3 and 4 medulloblastoma with Myc or Mycn overexpression, after treatment with JQ1S. Values, mean ! SD.
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We, therefore, suppressed the expression of eitherMYCor
BRD4 in each of the sixMYC-amplified patient-derived cell
lines usingMYC- andBRD4-directed shRNAs.Wemeasured
the proliferation and compared the results with controls
treated with LacZ-targeted shRNAs. Suppression of MYC
andBRD4protein levelswas confirmedby immunoblotting
(Fig. 4A and Supplementary Fig. S3).
In all cell lines, suppression of either MYC or BRD4
resulted in greater than 50% reductions in proliferation
relative to cells treated with LacZ-targeted shRNAs (Fig.
4B). We observed absolute decreases in cell numbers
among four lines with both MYC suppression and BRD4
suppression.
In all cell lines, suppression of BRD4 was also associated
with a reduction of MYC mRNA, by an average of 45%
relative to the LacZ-suppressed controls (P < 0.0001; Fig.
4C). We also observed a reduction in MYC protein levels in
cells following suppression of BRD4 (Fig. 4A and Supple-
mentary Fig. S3). This was most pronounced in the D425
and D556 cell lines. Suppression of BRD4 has previously
been shown to decrease the MYC expression in other cell
types (13). The finding that BRD4 suppression resulted in
attenuation ofMYCmRNA and protein suggested that JQ1
also exerted its effects in part through suppression of MYC.
JQ1 suppresses MYC activation pathways and
expression of MYC and MYCN themselves
To determine the transcriptional effects of JQ1 treatment,
we performed genome-wide expression profiling of five
patient-derived MYC-amplified cell lines treated with 1
mmol/L of either JQ1S or JQ1R for 24 hours. We identified
43 genes that were significantly downregulated by JQ1S
(false discovery rate (FDR) < 0.1; Supplementary Table S4).
No genes were significantly upregulated at this significance
threshold.
The JQ1S-treated cells exhibited significant enrichment of
a signature of JQ1 treatment derived from multiple mye-
loma, leukemia, and neuroblastoma cells (P < 0.0001;
Fig. 5A; 16), and significant attenuation of MYC activity
(P < 0.05 in all cases; Fig. 5B). An unbiased screen of
pathways altered by treatment with JQ1S (using the gene
set enrichment algorithm and the C2 (CP) set of signatures)
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indicated significant alteration of 46 pathways (P < 0.05;
Supplementary Table S5). Four of these 46 pathways repre-
sentedMYC activation signatures (Fig. 5B), andwere down-
regulated following treatment with JQ1S (compared with
cells treated with JQ1R).
In all patient-derived MYC-amplified cell lines, treat-
ment with 1 mmol/L of JQ1S also led to decreased expres-
sion of MYC itself. Levels of MYC mRNA declined by an
average of 46% (range, 29%–78%; P < 0.0001; Fig. 5C),
and these changes were associated with decreased exp-
ression of the MYC protein. We also examined the expres-
sion of MYC mRNA in three cell lines treated with lower
doses of JQ1S, and found attenuation of MYC mRNA
expression at doses of JQ1S as low as 125 nmol/L (Sup-
plementary Fig. S2B). Treatment of Mycn-overexpressing
cells derived from tumors from the Glt1 Mycn GEMM
model with 0.5 mmol/L of JQ1 for 72 hours was associ-
ated with the suppression of Mycn mRNA and protein
expression (Fig. 5C).
We next overexpressed MYC from an exogenous retro-
viral promoter in D283 cells and treated them with JQ1
to assess whether forced expression of MYC could rescue
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the cells from the effects of JQ1 (Fig. 5D). In cells infected
with the empty pBabe retroviral vector, we observed
reduced cell viability following treatment with JQ1S.
In contrast, in cells infected with pBabe MYC, we
observed minimal effect on cell viability following treat-
ment with JQ1S.
Taken together, these results confirm that BET bromo-
domain inhibition with JQ1 results in the downregulation
of MYC and MYC activation pathways, resulting in reduced
cell proliferation. JQ1 treatment also reduces MYC and
MYCN expression in patient-derived MYC-amplified med-
ulloblastoma cell lines and in cells derived from a MYCN-
driven medulloblastoma mouse model. Forced expression
of MYC from an exogenous promoter rescues D283 cells
from the effects of JQ1S.
Treatment with JQ1 prolongs survival of MYC-
amplified medulloblastoma xenografts
We examined the efficacy of JQ1 in vivo, using ortho-
topic xenografts generated by intracerebellar injections of
MB002 cells. Compared with vehicle control, mice under-
going daily treatment with JQ1 (50 mg/kg/d) exhibited a
significantly prolonged survival (Fig. 6A) with a slower
rate of tumor growth at 14 and 21 days postinjection
as indicated by bioilluminescence (Fig. 6B). This was
statistically significant on day 14 (P, 0.03). A cohort of
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mice was sacrificed following five doses of JQ1 or vehicle
treatment. We extracted RNA from the cerebellum of
vehicle- or JQ1-treated mice and assessed the expression
of MYC mRNA (Fig. 6C). We observed significant down-
regulation ofMYCmRNA expression following treatment
with JQ1. Ki67 immunostaining confirmed a reduced
proliferative index in tumors treated with JQ1 compared
with vehicle controls (82% vehicle vs. 27% JQ1 treated, P
< 0.0001; Fig. 6D).
Discussion
Our data provide the first preclinical evidence for a
potential therapeutic role of BET bromodomain inhibition
for MYC-amplified medulloblastoma. Furthermore, we
show redundancy between amplification of the different
MYC genes. We observed responsiveness to JQ1 therapy of
all patient cell lines harboringMYC amplifications, and in a
murine cell line of aMycn-driven medulloblastoma model.
MYC-amplified medulloblastomas are characteristically
resistant to conventional treatments, including radiothera-
py and chemotherapy. In this study, the use of JQ1 as a
single agent was able to reduce cell proliferation and tumor
growth and prolong the survival of mice with intracranial
xenografts. Thus, our data provide rationale for the devel-
opment of clinical trials to assess the role of these agents in
the treatment of patients with medulloblastoma.
Ongoing work, however, is required to determine opti-
mal strategies to incorporate these agents into upfront
therapy for children with newly diagnosed MYC-amplified
medulloblastoma. Specifically, further work is required to
assess strategies to combine BET bromodomain inhibition
with other treatment modalities such as radiotherapy and
chemotherapy. Specific predictors of sensitivity and resis-
tance to JQ1 remain to be elucidated.
The anticorrelation between amplifications of MYC and
MYCN, and the correlations between these amplifications
(and amplifications of MYCL1) and expression of genes
upregulated by MYC, indicate that these amplifications are
associated with increased MYC activity. However, some
samples withoutMYC amplification had high expression of
MYCorofother genesupregulatedbyMYC. Thisobservation
Figure 6. JQ1 prolongs survival of xenograft models of group 3 medulloblastoma. A, Kaplan–Meier curves of mice with intracranial xenograft injections of
MB002 treated with JQ1 or vehicle. B, rate of tumor growth in NSG mice with orthotopic MB002 xenografts following treatment with JQ1 as monitored by
bioilluminescence detection. C, quantitative PCR of MYC mRNA levels (normalized to b-actin) in cerebellar xenografts of MB002 following treatment
with either vehicle control or JQ1. Values, mean! SD of six replicate measurements. D, representative images of Ki67 staining of MB002 xenografts treated
with vehicle control andJQ1 (top). Thepercentage ofKi67positivity in tumors frommice treatedwith either vehicle control (n¼2) or JQ1 (n¼3). Values,mean!
SD of three replicate measurements for each animal.
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suggests that other factors are also involved in the regulation
of MYC activation pathways, and that some tumors without
MYC amplification may benefit from therapeutics targeting
MYC, including BET bromodomain inhibition.
Although we observed minimal responsiveness of the
non-MYC–amplified medulloblastoma cell lines to JQ1, it
is possible that these lines may not represent the full
spectrum of non-MYC--amplified medulloblastomas. For
example, none of our non-MYC–amplified lines included
either theWnt or SHH subtypes. We are unable to speculate
whether these subtypes may also have sensitivity to treat-
ment with BET bromodomain inhibition.
Importantly, the inhibition of MYC family members
and activation pathways may result in downregulation of
other cell-signaling pathways in tumors that do not
harbor amplification of MYC isoforms. This is particu-
larly relevant in the SHH subtype. Both MYC (37) and
MYCN (38–40) have been reported to interact with
and regulate transcription factors involved in SHH
signaling, raising the possibility that inhibition of MYC
activation may also result in inhibition of the SHH
pathway, and other pathways important in the patho-
genesis of medulloblastoma.
We show that MYC-amplified medulloblastomas can be
targeted by epigeneticmodulation of oncogenes. BRD4 is an
epigenetic reader that binds to e-N-lysine acetylation motifs
(41). It is increasingly recognized that genomic alterations
may result in global epigenetic dysregulation in pediatric
brain tumors (42–44). Indeed, group 3 medulloblastomas
have been found to harbor somatic copy-number alterations
of genes involved in chromatin modeling (45, 46). These
alterations frequently affect genes of modifiers of H3K27
methylation (46). Thus, it is possible that targeting other
chromatin modifiers may also have activity in this group of
tumors. Further work is required to define the interplay
betweenmethylation and acetylation of these histonemarks
to help determine whether the combination of different
classes of epigenetic modulators may improve their efficacy.
We were unable to obtain any patient-derived medul-
loblastoma cell lines that harbor amplifications of either
MYCN or MYCL1. Our integrative analysis of copy num-
ber and expression profiles suggest that both isoforms are
associated with increased expression of MYC activation
pathways, suggesting that BET bromodomain inhibition
may be effective in tumors that harbor these amplifica-
tions. Indeed, BET bromodomain inhibition has been
shown to suppress MYCN expression in patient-derived
neuroblastoma cell lines (16). We have shown efficacy of
JQ1 treatment in a cell line generated from a MYCN-
driven mouse model; however, ideally this should be
validated in patient-derived MYCN-amplified medullo-
blastoma cell lines.
In summary, we show that BET bromodomain inhibi-
tion results in the suppression of MYC activation path-
ways in MYC-driven medulloblastoma models, resulting
in reduced cell viability, induction of G1 arrest, and
apoptosis with prolongation of survival in xenograft
models. These data provide a rationale for early-phase
clinical trials for BET bromodomain inhibitors for chil-
dren with this aggressive disease.
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The Hedgehog (Hh) pathway is an evolutionarily conserved sign-
aling axis that directs embryonic patterning through strict tempo-
ral and spatial regulation of cell proliferation and differentiation1. 
Developmental aberrations in Hh signaling result in dysmorphology, 
such as cyclopism, holoprosencephaly and limb deformity, when its 
output is absent or decreased2 and in cancer predisposition, as is seen 
in nevoid basal cell carcinoma syndrome (Gorlin syndrome)3, when 
its output is increased or unchecked1,4.
In canonical Hh signaling, several morphogens (sonic hedgehog 
(SHH), Indian hedgehog (IHH) and desert hedgehog (DHH))5,6 
have been identified that bind to the multipass cell-surface receptor 
Patched (PTCH1)1. When not bound by Hh ligand, PTCH1 inhibits 
the G protein–coupled receptor, SMO7. Once bound by ligand, how-
ever, PTCH1 no longer inhibits SMO, allowing SMO to positively 
regulate mobilization of the otherwise latent zinc finger transcription 
factor GLI2, residing in the cilia, to the nucleus, where GLI2 transac-
tivates the GLI1 promoter8–10. GLI1 and GLI2 directly transactivate 
transcription of Hh target genes, several of which are involved in 
proliferation, such as MYCN and CCND1 (ref. 11). GLI1 also serves 
to amplify the output of Hh signaling in a positive feedback loop 
by activating transcription of GLI2, albeit indirectly12. Ultimately, 
the transcriptional programs mediated by Hh signaling orchestrate 
an array of events based on cellular, temporal and spatial context, 
with perhaps the most phenotypically consequential event being an 
increase in cell proliferation.
Inappropriate activation of Hh signaling results in tumor formation 
in several tissue lineages, including skin, brain, muscle, breast and 
pancreas13–15. The tumors most commonly associated with aberrant 
Hh signaling are basal cell carcinoma (BCC) and medulloblastoma, 
given their prevalence in individuals with germline mutations in 
PTCH1 (Gorlin syndrome)3,4. However, the overwhelming major-
ity of Hh-driven BCCs and medulloblastomas activate Hh signaling 
through sporadic somatic mutations in PTCH1 or other components 
of the Hh pathway14,16,17. These include activating mutations in SMO 
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Hedgehog signaling drives oncogenesis in several cancers, and strategies targeting this pathway have been developed, most 
notably through inhibition of Smoothened (SMO). However, resistance to Smoothened inhibitors occurs by genetic changes of 
Smoothened or other downstream Hedgehog components. Here we overcome these resistance mechanisms by modulating GLI 
transcription through inhibition of bromo and extra C-terminal (BET) bromodomain proteins. We show that BRD4 and other 
BET bromodomain proteins regulate GLI transcription downstream of SMO and suppressor of fused (SUFU), and chromatin 
immunoprecipitation studies reveal that BRD4 directly occupies GLI1 and GLI2 promoters, with a substantial decrease in 
engagement of these sites after treatment with JQ1, a small-molecule inhibitor targeting BRD4. Globally, genes associated with 
medulloblastoma-specific GLI1 binding sites are downregulated in response to JQ1 treatment, supporting direct regulation of GLI 
activity by BRD4. Notably, patient- and GEMM (genetically engineered mouse model)-derived Hedgehog-driven tumors (basal cell 
carcinoma, medulloblastoma and atypical teratoid rhabdoid tumor) respond to JQ1 even when harboring genetic lesions rendering 
them resistant to Smoothened antagonists. Altogether, our results reveal BET proteins as critical regulators of Hedgehog pathway 
transcriptional output and nominate BET bromodomain inhibitors as a strategy for treating Hedgehog-driven tumors with emerged 
or a priori resistance to Smoothened antagonists.
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or inactivating mutations in SUFU, which negatively regulates Hh 
output downstream of SMO17,18. Genomic amplification of GLI2, and 
more rarely GLI1, has also been reported and is associated with a more 
aggressive clinical course16,19–21. In addition, noncanonical activation 
of the Hh pathway can occur through loss of SMARCB1, a component 
of the SWI/SNF chromatin remodeling complex, which results in 
derepression of transcriptional activity at the GLI1 locus in malignant 
rhabdoid tumors22. Similarly, the EWS-FLI fusion oncogene respon-
sible for Ewing sarcoma has been shown to directly transactivate the 
GLI1 promoter23.
The identification of SMO as the main pharmacological target of 
cyclopamine24, a natural compound found in wild corn lily (Veratrum 
californicum)2, fostered the development of clinically optimized 
compounds with potent activity against SMO25–27. Some of these 
compounds have shown clinical efficacy against BCC, medulloblas-
toma and other cancers28–30. However, emergence of resistance and 
a priori resistance have been encountered25,29,31, prompting investi-
gations into alternate strategies targeting new sites on SMO and Hh 
pathway components downstream of SMO32,33 or signaling pathways 
that cooperate with Hh activation in development and disease25,34,35. 
High-throughput screens have also identified scaffolds that regulate 
GLI processing and its translocation to or from the cilia and nucleus36. 
However, the effectiveness of these strategies against Hh-driven can-
cers with MYCN amplification, such as SHH-subtype medulloblas-
tomas, is unclear, as MYCN appears to be epistatic to the targets of 
many of these drugs.
A new class of drugs targeting BET bromodomain proteins (BRD2–
BRD4 and BRDT) was described recently37. Bromodomains recognize 
and bind to E-N-lysine acetylation motifs on open chromatin, such 
as those found on K27 residues of H3 histone N-terminal tails38,39. 
The BET proteins also interact with the positive transcription elonga-
tion factor (P-TEFb)40,41 and phosphorylate Ser2 of RNA polymer-
ase II (PolII), facilitating gene transcription at ‘super-enhancer’ sites 
across the genome42,43. BRD-containing complexes that bind at these 
super-enhancer sites often localize to promoter regions of key tran-
scription factors such as MYC, and disruption of these complexes by 
BET inhibitors has produced substantial responses in mice bearing 
xenografts of treatment-refractory cancers driven by MYC and other 
previously ‘untargetable’ oncogenes, with limited or no toxicity to 
normal tissues44–47.
Here we aimed to identify whether inhibition of BET bromo-
domain proteins could provide a strategy for treating Hh-driven 
tumors, including those resistant to SMO antagonists. We provide 
evidence that BRD4 is a critical regulator of GLI1 and GLI2 tran-
scription through direct occupancy of their promoters. Furthermore, 
we show that occupancy of GLI1 and GLI2 promoters by BRD4 and 
transcriptional activation at cancer-specific GLI promoter–binding 
sites are markedly inhibited by the BET inhibitor JQ1. In GEMM- and 
patient-derived tumors with constitutive Hh pathway activation, JQ1 
effectively decreases tumor cell proliferation and viability in vitro and 
in vivo, even when genetic lesions conferring resistance to SMO inhi-
bition (SMOi) are present. Notably, the inhibition of cell proliferation 
by JQ1 can be rescued by GLI2 expression driven by a plasmid-based 
cytomegalovirus (CMV) promoter, which, in contrast to endog-
enous GLI promoters, is not under direct transcriptional regulation 
by BET proteins. In sum, our study identifies BET proteins as epige-
netic regulators of Hedgehog transcriptional output and establishes a 
rationale for the use of BET inhibitors in cancers with evidence of Hh 
pathway activation.
RESULTS
BRD4 is required for ligand-induced Hh transcriptional output
The BET protein BRD4 enhances the transcription of key genes 
involved in embryonic stem cell maintenance42 and oncogenesis43. 
Therefore, we hypothesized that BRD4 is a transcriptional cofactor 
for Hh-responsive genes. In the mouse 3T3 cell–based Hh-Light2 
reporter line containing a stably integrated Gli-luciferase reporter 
construct48, ligand-induced activation of Hh-Light2 cells with either 
Shh-N conditioned medium (CM)49 or Smoothened agonist (SAG)48 
resulted in an expected increase in Gli1-luciferase activity and Gli1 
mRNA levels, which were both potently inhibited by increasing 
doses of the BET inhibitor JQ1 (Fig. 1a and Supplementary Fig. 1). 
Upregulation of other Hh target genes such as Ptch1 and Gli2 was also 
inhibited by JQ1 (Fig. 1b). In contrast, Smo expression was modestly 
influenced, and expression of Sufu and Brd4 was not substantially 
altered by JQ1 (Fig. 1b). Notably, the inhibition of Gli1 expression by 
JQ1 equaled that by SMO inhibitors (GDC-0449, LDE225 or SANT-1) 
(Fig. 1c,d). Additionally, shRNA-mediated knockdown of Brd4 in 
Hh-Light2 cells followed by Shh-N CM or SAG stimulation resulted 
in marked inhibition of ligand-induced Gli-luciferase activity and Hh 
target gene expression, directly supporting an essential role of Brd4 
in Hh signaling (Fig. 1e,f).
To further assess inhibition of Hh transcriptional output by JQ1, 
we used zebrafish harboring a ptc2:GFP reporter transgene, a well-
described canonical Hh pathway reporter in zebrafish50,51. Embryos 
exposed to JQ1 from 2 to 30 hours post fertilization (hpf) showed 
decreased expression of GFP mRNAs, similar to the results seen in 
cyclopamine-exposed fish (Fig. 1g). We also assessed whether JQ1 
could revert abnormal phenotypes caused by aberrant Hh signaling 
in a temperature-sensitive transgenic fish line harboring an hsp70l:
Shha–enhanced GFP (eGFP) transgene51, which overexpresses Shh 
and produces a reliable and well-described dysgenic eye phenotype 
that often includes a ventral coloboma, a structural defect in the eye 
resulting from improper closure of gaps located between various eye 
structures during embryonic development52,53. As predicted, heat-
shocked transgenic fish treated with vehicle alone (DMSO) developed 
abnormally shaped eyes with diminished diameter relative to their 
heat-shocked nontransgenic siblings (Fig. 1h). However, fish exposed 
to JQ1 immediately after heat shock trended toward more normal-
appearing eyes with statistically significant increases in eye diameter, 
suggesting that BET inhibition countered the effects of aberrant Hh 
signaling in vivo in this model (Fig. 1h).
BRD4 regulates Hh signaling at Gli1 and Gli2 promoters
We next examined the effects of JQ1 on Hh signaling in Sufu−/− 
mouse embryonic fibroblasts (MEFs)54 and Hh-Light2 cells over-
expressing GLI2. SUFU positively regulates the degradation of GLI 
proteins54, and thus loss of SUFU activity results in stabilization of 
GLI and constitutive Hh signaling downstream of SMO. As expected, 
we observed markedly increased Gli1 mRNA and protein levels in 
Sufu−/− MEFs, which were substantially downregulated by JQ1 
(Fig. 2a,c and Supplementary Fig. 2a,b). We also noted decreased 
transcription of Gli2, as well as Smo to a lesser extent, after JQ1 treat-
ment, whereas Brd4 mRNA levels remained unchanged (Fig. 2a). 
In stark contrast to JQ1 treatment, we observed little to no effect 
on Gli transcripts or Gli1 protein levels in Sufu−/− MEFs after treat-
ment with the SMO inhibitors (LDE225, GDC-0449 or SANT-1) 
(Fig. 2b,c). Consistent with pharmacological inhibition of Brd4, 
shRNA-mediated knockdown of Brd4 in Sufu−/− MEFs resulted in 
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decreased Gli1 and Gli2 mRNA levels (Fig. 2d). It is worth noting 
that Brd4 knockdown did not abrogate GLI-luciferase activity or 
Gli expression as effectively as did JQ1 treatment. This result could 
be explained by incomplete knockdown of Brd4, or it could suggest 
that other BET proteins (all targets of JQ1) may also contribute to 
the transcriptional regulation of Gli genes. Indeed, knockdown of 
either Brd2 or Brd3 resulted in a substantial decrease of Gli mRNA 
levels in Sufu−/− MEFs (Supplementary Fig. 2c).
In Hh-Light2 cells, forced expression of full-length mouse Gli2 
(hemagglutinin (HA)-Gli2-FL) or an N-terminally truncated active 
form of human GLI2 (Myc-GLI2-DN)55 resulted in an increase in Gli1 
mRNA levels, which was inhibited by JQ1 but not SMO inhibitors 
(GDC-0449, LDE225 or SANT-1) (Fig. 2e). Notably, we did not observe 
any decrease in ectopic GLI2 expression driven by the CMV promoter 
expression construct after JQ1 treatment, in contrast to the marked 
decrease in endogenous Gli transcripts (Figs. 1b and 2f). Additionally, 
upregulation of Ptch1, another Hh target gene, was not inhibited by 
JQ1, suggesting that not all Hh target genes are directly dependent on 
Brd4, as Gli genes themselves are (Supplementary Fig. 2d).
In Sufu−/− cells, JQ1 decreased Gli1 and Gli2 levels as early as 3 h 
after treatment, supporting a role for Brd4 as a transcriptional 
cofactor that directly regulates transactivation of Gli promoters 
(Supplementary Fig. 2e). Chromatin immunoprecipitation followed 
by quantitative PCR (ChIP-qPCR) using antibody to Brd4 of regions 
flanking the transcription start sites of Gli1 and Gli2 promoters con-
firmed increased Brd4 occupancy at both Gli promoters after SAG-
mediated activation of Hh signaling in Hh-Light2 cells (Fig. 2g,h). 
Accordingly, ChIP-qPCR with antibody to PolII showed engagement 
of both Gli promoters by PolII after SAG stimulation. Notably, both 
Brd4 and PolII interactions at the Gli promoters were blocked by the 
addition of JQ1 (Fig. 2g,h). Similarly, in Sufu−/− MEFs, we observed 
increased baseline occupancy of Gli promoters by Brd4 and PolII rela-
tive to that in wild-type (WT) MEFs, which was markedly inhibited 
by JQ1 (Fig. 2i,j).
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Figure 1 BRD4 is necessary for GLI transcription. (a) Gli-luciferase  
reporter activity in Hh-Light2 cells treated with Hh ligand (Shh-N CM  
or SAG) alone or in combination with increasing amount of JQ1. Data  
represent the mean of triplicates o s.d. (b) qRT-PCR of Hh target genes  
(Gli1, Gli2 and Ptch1), Hh pathway components (Sufu and Smo) and  
Brd4 in Hh-Light2 cells treated with Hh ligand (Shh-N CM or SAG)  
alone or in combination with JQ1 (1 MM). Data represent the mean of  
triplicates o s.d. (c) qRT-PCR of Gli1 mRNA levels in Hh-Light2 cells  
treated with Hh ligand (Shh-N CM or SAG) alone or in combination with  
1 MM of JQ1, GDC-0449, LDE225 or SANT-1. Data represent the mean  
of triplicates o s.d. (d) Immunoblot detecting Gli1 expression in cell  
lysates from Hh-Light2 cells treated with Hh ligand (Shh-N CM or SAG)  
alone or in combination with 1 MM of JQ1, GDC-0449, LDE225 or  
SANT-1. An anti–B-tubulin (B-tub) immunoblot is shown as a loading  
control. The immunoblot shown represents a typical result from an  
experiment performed in duplicate. (e) Gli-luciferase reporter activity in  
Hh-Light2 cells treated with Hh ligand (Shh-N CM or SAG) in combination  
with shRNAs against Brd4 (shBrd4-1 and shBrd4-2) or scrambled shRNA (shCtrl). Data represent the mean of quadruplicates o s.d. (f) qRT-PCR of 
Hh target genes (Gli1, Gli2 and Ptch1), Hh pathway components (Sufu and Smo) and Brd4 after treatment with Hh ligand (Shh-N CM or SAG) alone 
or in combination with shBrd4-1, shBrd4-2 or shCtrl. Data represent the mean of triplicates o s.d. (g) In situ hybridization detecting GFP mRNA levels 
in transgenic (Tg) zebrafish (ptc2:GFP) treated with JQ1 (0.6 MM), cyclopamine (25 MM) or vehicle (veh) controls (DMSO or EtOH). The fraction of 
zebrafish with decreased GFP expression is shown. Fisher’s exact test was used for statistical analysis. *P < 0.05. Scale bar, 100 Mm. (h) Images of a 
heat-shocked + Tg(hsp70l:Shha-eGFP) zebrafish or a nontransgenic sibling treated with JQ1 (0.6 MM) or DMSO. The eye diameter of each group (n = 12)  
was measured and is shown. Data represent the group means o s.d. The P value shown was generated using Student’s t test. Scale bar, 100 Mm.
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JQ1 inhibits Ptch-deficient medulloblastoma and BCC
We investigated the efficacy of JQ1 in Hh-driven tumors using cell 
lines derived from autochthonous medulloblastomas (SmoWT-MB 
and Med1-MB) arising in Ptch+/−; Trp53−/− and Ptch+/−; lacZ mice, 
respectively32,56, and BCC (ASZ001)57, also derived from Ptch+/− 
mice. JQ1 treatment resulted in marked downregulation of Gli mRNA 
and protein expression with little to no effect on Smo, Sufu or Brd4 
(Fig. 3a–d and Supplementary Fig. 3a). Again, we observed a rapid 
decrease of Gli gene expression after JQ1 treatment (as early as 3 h), 
supporting a direct effect of BET inhibition on Gli promoters 
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Figure 2 JQ1 inhibits Hh target gene activation at the level of the GLI1 and GLI2 promoters. (a) qRT-PCR showing Gli1, Gli2, Smo and Brd4 mRNA 
levels in Sufu−/− MEFs treated with JQ1. Data represent the mean of triplicates o s.d. (b) Gli1 and Gli2 mRNA levels in Sufu−/− MEFs treated with 
DMSO, JQ1, GDC-0449, LDE225 or SANT-1. Data represent the mean of triplicates o s.d. (c) Immunoblot detecting GLI1 expression in cell lysates 
from Sufu−/− MEFs treated with DMSO, JQ1, GDC-0449, LDE225 or SANT-1. An anti–B-tubulin immunoblot is shown as a loading control. The 
immunoblots in c and f represent a typical result from each experiment performed in duplicate. (d) qRT-PCR showing Gli1, Gli2 and Brd4 mRNA levels 
in Sufu−/− cells expressing shBrd4-1, shBrd4-2 or shCtrl. Data represent the mean of triplicates o s.d. (e) qRT-PCR showing Gli1 mRNA levels in  
Hh-Light2 cells transiently transfected with HA-Gli2-FL or Myc-GLI2-DN and their responses to JQ1, GDC-0449, LDE225 or SANT-1. Data represent 
the mean of triplicates o s.d. (f) Anti-HA and anti-Myc immunoblots on cell lysates from Hh-Light2 cells transfected with HA-Gli2-FL or Myc-GLI2-DN 
and treated with DMSO, JQ1, GDC-0449, LDE225 or SANT-1. An anti–B-tubulin immunoblot is shown as a loading control. (g–j) Schematic of regions 
flanking the Gli1 and Gli2 promoter transcription start sites (TSS) analyzed by ChIP-qPCR of Brd4 and PolII occupancies in Hh-Light2 cells treated with 
SAG and JQ1 (g,h) and in Sufu−/− MEFs treated with JQ1 (i,j). Data represent the mean of triplicates o s.d. Except where indicated, cells were treated 
with 1 MM of JQ1, GDC-0449, LDE225 or SANT-1.
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(Supplementary Fig. 3b). Accordingly, ChIP-qPCR using antibodies 
to Brd4 and PolII showed potent inhibition of Brd4 and PolII 
occupancy at Gli promoters in all cell lines after exposure to JQ1 
(Supplementary Fig. 3c,d).
In Med1-MB and SmoWT-MB cells, JQ1 treatment resulted in 
dose-responsive decreases in cell viability to a much greater extent 
than those observed in Hh-Light2 or Sufu−/− MEFs (Supplementary 
Fig. 4a). Potent growth inhibition was achieved (half-maximum 
inhibitory concentration (IC50) ~50–150 nM; Supplementary 
Fig. 4b,c) with marked decreases of proliferation (Fig. 3e–h), induc-
tion of apoptosis (Supplementary Fig. 4d,e) and, in Med1-MB cells, 
an increased fraction of cells in G1 and a decreased fraction of cells 
transitioning through S phase (Supplementary Fig. 4f). Notably, in 
SmoWT-MB cells, the inhibitory effects of JQ1 on Gli expression, cell 
viability and proliferation were equivalent to those of SMO inhibitors 
(GDC-0449 or LDE225) (Fig. 3a,e,g and Supplementary Figs. 3a and 
4d), and these effects were enhanced when we exposed cells to both 
JQ1 and GDC-0449 in combination (Supplementary Fig. 4g).
Using microarray analysis, we assessed changes in global gene 
expression in JQ1-treated SmoWT-MB cells compared with 
DMSO- and GDC0449-treated cells. We observed a substan-
tial overlap between significantly differentially expressed genes 
(P < 0.0001) or gene sets (P < 0.0001; Supplementary Dataset) 
by JQ1 and GDC0449 in both cell lines compared with DMSO-
treated controls, including the anticipated GLI target genes Gli2, 
Ptch1, Ccnd1, Ccnd2, Hhip and Cdk6 (Supplementary Fig. 5a–c). 
We next compared JQ1-induced gene expression profiles with 
gene sets derived from previously published ChIP-chip studies, 
which indexed gene promoters with Gli1-binding sites in normal 
granule neuron precursor cells (GNPs) and Ptch+/− medulloblas-
toma cells58. Specifically, we analyzed for enrichment of ChIP-chip 
peaks associated with GNPs, medulloblastoma, the overlap of both 
and peaks associated with GNPs alone or medulloblastoma alone 
(Supplementary Table 1). Gene set enrichment analysis (GSEA) 
revealed that only genes with Gli1 promoter–binding sites associ-
ated with medulloblastoma were significantly enriched (P < 0.0001) in 
JQ1-treated cells (Supplementary Fig. 5d). These results confirm the 
disruption of Gli1-mediated transcription by JQ1 and the preferential 
targeting of Gli1 transcriptional activity in tumor cells43.
Ectopic GLI2 expression rescues growth inhibition by JQ1
We tested whether knockdown of Brd4 could phenocopy the effects 
of JQ1 in Hh-driven medulloblastoma cells. As expected, knock-
down of Brd4 resulted in decreased Gli expression (Fig. 4a,b) and 
cell proliferation (Fig. 4c,d), suggesting that the inhibitory effect of 
JQ1 was through targeting of Brd4. Furthermore, to directly assess 
whether BET inhibition blocked cell proliferation in Hh-driven tumor 
cells through targeting of Gli transcription, we used plasmid-based 
expression of GLI2 (Myc-GLI2-DN; Fig. 2f) in SmoWT-MB cells and 
monitored its ability to rescue the inhibition of proliferation by JQ1 
(Fig. 4c). Notably, ectopic expression of GLI2 inhibited the effects 
of JQ1 on 5-ethynyl-2`-deoxyuridine (EdU) incorporation, resulting 
in levels of EdU incorporation that were nearly equivalent to levels 
in DMSO-treated control cells (Fig. 4e,f). This result indicates that 
inhibition of proliferation by JQ1 is mediated largely through inhi-
bition of Gli transcription and, intriguingly, that Brd4-independent 
transcriptional targets of Gli transcription factors are sufficient to 
overcome BET inhibition.
SMOi-resistant Hh-driven tumors are inhibited by JQ1
Given the documented mechanisms of resistance to current, clinically 
available SMO inhibitors25,31 and the potential of BET inhibitors as 
a strategy to overcome this resistance, we examined the efficacy of 
JQ1 in Hh-driven cancers with either acquired or a priori resistance 
to SMO inhibitors (Fig. 5a). We analyzed the efficacy of JQ1 and SMO 
inhibitors (GDC-0449 and LDE225) against medulloblastoma cells 
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Gli1 expression in response to JQ1 treatment over time. An anti–B-tubulin immunoblot is shown as a loading control. The immunoblots represent a 
typical result from each experiment performed in duplicate. (e,f) Cell viability detection over time with increasing doses of JQ1 or SMO inhibitors.  
Data represent the group means o s.d. (g,h) Proliferative index in response to JQ1 (1 MM) or SMO inhibitors (GDC-0449 or LDE225 at 0.1 MM) as 
measured by EdU incorporation. Data represent the group means o s.d.
©
20
14
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
A R T I C L E S
6 ADVANCE ONLINE PUBLICATION NATURE MEDICINE
carrying an aspartate-to-glycine substitution at amino acid residue 
477 in Smo that results in decreased sensitivity to SMO antagonists 
(SmoD477G-MB) (Fig. 5b)32; patient-derived SUFU-mutated primary 
SHH-subtype medulloblastoma cells (RCMB025); patient-derived 
primary atypical teratoid rhabdoid tumor (ATRT) cells (CHB_ATRT1 
and SU_ATRT2) with derepression of GLI1 transcription through 
loss of SMARCB1 (also called SNF5 or INI1) (ref. 22); and patient-
derived MYCN-amplified primary SHH-subtype medulloblastoma 
cells (RCMB018). Cell viability (Fig. 5b–f, top), Gli and GLI  
levels (Fig. 5b–f, bottom) and EdU incorporation (Supplementary 
Fig. 6a–c) were markedly decreased in response to JQ1 in all of these 
cells, and we observed little or no effect with the SMO inhibitors 
GDC-0449 and LDE225. Additionally, we examined Myc, MYC, Mycn 
and MYCN expression in SmoWT-MB, SmoD477G-MB, RCMB025, 
CHB_ATRT1 and RCMB018 cells and found that Mycn and MYCN 
expression was consistently inhibited by JQ1 (Fig. 5f, bottom and 
Supplementary Figs. 4h and 6d–f), suggesting that JQ1 targets at least 
two important driver oncogenes (GLI and MYCN) in these tumors.
In vivo inhibition of Hh-driven tumors by JQ1
To support a therapeutic role for BET inhibition in Hh-driven tumors, 
we assessed the in vivo efficacy of JQ1 against medulloblastomas and 
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BCCs. We treated flank and intracranial allografts of Med1-MB cells 
stably expressing a firefly luciferase reporter in immunodeficient NSG 
mice with either JQ1 (50 mg per kg body weight per day intraperito-
neally (i.p.)) or vehicle control. We observed a significant reduction 
in flank tumor growth in JQ1-treated mice, as well as an increase 
in overall survival in JQ1-treated mice harboring intracranial allo-
grafts (Fig. 6a,b and Supplementary Fig. 7a). Additionally, we treated 
medulloblastoma flank allografts of SmoWT-MB or SmoD477G-MB 
cells with vehicle control, JQ1 (50 mg per kg body weight per day 
i.p.) or GDC-0449 (100 mg per kg body weight per day orally (p.o.)). 
We observed marked decreases in the growth of SmoD477G-MB 
flank allografts in response to JQ1 but not GDC-0449, whereas 
SmoWT-MB flank allografts responded to both GDC-0449 and JQ1 
(Fig. 6c,d). To evaluate the efficacy of JQ1 against BCCs in vivo, we used 
an allograft model of Ptch+/−; K14-creER2; p53flox/flox–derived mouse 
BCC cells34. JQ1 treatment (50 mg per kg body weight per day i.p.) 
a
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Figure 5 JQ1 inhibits Hh pathway activity and cell viability and proliferation in SMOi-resistant Hh-driven tumors. (a) Schematic depicting mechanisms 
of resistance to Smoothened antagonists in Hh-driven cancers. (b–f, top) Cell viability in SMOi-resistant medulloblastoma cells (SmoD477G-MB; b), 
patient-derived SUFU mutant medulloblastoma cells (RCMB025; c), patient-derived ATRT cells (CHB_ATRT1 and SU_ATRT2; d,e) and patient-derived 
MYCN-amplified medulloblastoma cells (RCMB018; f) treated with increasing doses of JQ1, GDC-0449 or LDE225. Data represent the group  
means o s.d. (b–f, bottom) qRT-PCR of Gli1, GLI1, Gli2, GLI2, Brd4 and BRD4 (plus MYC and MYCN levels for RCMB018) in SmoD477G-MB (b), 
RCMB025 (c), CHB_ATRT1 (d), SU_ATRT2 (e) and RCMB018 (f) cells in response to JQ1 (1 MM), GDC-0449 or LDE225 (0.1 MM for SmoD477G-MB 
and 1 MM for the other groups). Data represent the mean of triplicates o s.d.
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Figure 6 JQ1 inhibits Hh-driven tumor growth in vivo. (a,b) Med1-MB cells transduced with a lentiviral  
luciferase reporter were used for flank (a) or cerebellum (b) injections of NSG mice, which were then  
randomized for treatment with either JQ1 (50 mg per kg body weight daily i.p.) or vehicle. (a) Tumor growth  
of Med1-MB allografts assessed by IVIS imaging and presented as the average radiance. (b) Survival curve  
of the mice injected with Med1-MB cells in the cerebellum. (c,d) Tumor growth, assessed by caliper  
measurement, after SmoWT-MB (c) and SmoD477G-MB (d) cells were injected into the flanks of NSG mice  
(both flanks of each mouse) followed by treatment with JQ1 (50 mg per kg body weight daily i.p.), GDC-0449  
(100 mg per kg body weight daily p.o.) or vehicle. (e) Tumor growth, assessed by caliper measurement,  
of SMOi-naive mouse BCC tumors generated under the dermis of NSG mice that were treated with JQ1  
(50 mg per kg body weight daily i.p.), BMS-833293 (100 mg per kg body weight daily i.p.) or vehicle. Data on tumor  
growth represent the group means o s.e.m. Two-way analysis of variance (ANOVA) was used for comparing tumor growth curves. Log-rank test was used 
for comparing survival curves. The results shown are from two separate experiments testing JQ1 and BMS-833293, independently, but are presented on 
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resulted in significant growth inhibition of BCCs but was not as 
effective as the clinically optimized SMO inhibitor BMS-833293 
(ref. 34) (Fig. 6e). Nonetheless, in all Hh-driven tumor models 
tested, we observed reduction of Gli mRNA levels after JQ1 treat-
ment regardless of whether allografts were sensitive or resistant to 
SMO inhibition (SMOi) (Supplementary Fig. 7b–f). Together these 
results demonstrate in vivo efficacy of JQ1 against Hh-driven tumors, 
even those with acquired or a priori resistance to clinically available 
SMO inhibitors.
DISCUSSION
We have shown that BRD4 and other BET proteins are critical regu-
lators of GLI1 and GLI2 transcription and that BET inhibition pro-
vides a new therapeutic strategy against Hh-driven tumors. Notably, 
as BET proteins regulate the far-downstream transcriptional output 
of Hh signaling, BET inhibition was effective against tumor cells that 
evade Smoothened antagonists through mutation of SMO or amplifi-
cation of nodes downstream of SMO. Our study is clinically relevant 
for patients who have a priori resistance to SMO inhibitors and in 
cases in which the emergence of resistance develops after an initial 
response to such therapy. By acting directly on the GLI1 and GLI2 
promoters, BET inhibition circumvents all SMOi resistance mecha-
nisms that have been reported so far, which include mutations of 
SMO or SUFU or amplifications in GLI2 or MYCN16,17,20,25,31. The 
response to JQ1 observed in MYCN-amplified SHH medulloblastoma 
cells (RCMB018), in terms of both decreased cell viability and MYCN 
levels, is similar to the results of a recent study showing the efficacy 
of BET inhibitors in MYCN-amplified neuroblastoma46. However, in 
Hh-driven tumors, it is likely that decreased MYCN levels in response 
to JQ1 treatment reflect the role of GLI in directly transactivating the 
MYCN promoter, in addition to the role of JQ1 in directly regulating 
expression of Mycn and MYCN.
Given the importance of Hh signaling in normal development, it 
will be essential to understand and anticipate potential toxicities of 
BET inhibitor therapies as they enter into clinical trials. We observed 
developmental anomalies at very high doses of JQ1 in our zebrafish 
studies (data not shown), consistent with those seen in Brd4 hetero-
zygous mice, which display a multitude of defects that overlap with 
cyclopamine-treated or Hh-deficient mice59,60. Of note, however, Brd4 
heterozygous mice develop craniofacial but not overt axial skeletal 
phenotypes59, unlike cyclopamine-exposed embryos2,60, suggesting 
lineage-specific differences of Hh pathway dependency on Brd4. Our 
finding that plasmid-driven GLI2 expression can rescue the prolifera-
tion defect induced by JQ1 supports the existence of GLI-responsive 
promoters that do not require BRD4 for their transactivation. Notably, 
such genes appear to be either individually or collectively sufficient to 
mediate part, if not all, of the oncogenic phenotype associated with 
Hh-GLI signaling.
Investigating how BRD4 regulates normal Hh-mediated biological 
processes and documenting BRD4-related changes that occur dur-
ing Hh-mediated oncogenic transformation could potentially elu-
cidate factors essential for tumor development that are independent 
of normal development. Our analysis of gene expression changes in 
JQ1-treated medulloblastoma supports observations by Lee et al.58, 
who identified marked shifts in Gli1 occupancy across the genome in 
medulloblastoma compared to GNPs. An unbiased characterization of 
Brd4 binding across the genome in GNPs and medulloblastomas will 
clarify whether the genomic footprint of Brd4 overlaps with Gli occu-
pancy in the oncogenic state relative to the normal developmental 
state. Related to this point, emerging evidence suggests BET proteins 
converge on super-enhancer sites across the genome and that these 
super-enhancer sites help transactivate promoters of key regulators of 
cellular identity in normal and pathogenic contexts42,43. Whether GLI 
transactivates super enhancer–related promoters and, accordingly, 
whether super-enhancer sites are positioned over GLI promoters is 
currently under active investigation.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Gene expression profiling data has been deposited 
into the National Center for Biotechnology Information (NCBI) Gene 
Expression Omnibus (GEO) with accession code GSE58185.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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SUMMARY
Smoothened (SMO) inhibitors recently entered clinical trials for sonic-hedgehog-driven medulloblastoma
(SHH-MB). Clinical response is highly variable. To understand the mechanism(s) of primary resistance and
identify pathways cooperating with aberrant SHH signaling, we sequenced and profiled a large cohort of
SHH-MBs (n = 133). SHH pathway mutations involved PTCH1 (across all age groups), SUFU (infants,
including germline), and SMO (adults). Children >3 years old harbored an excess of downstream MYCN
and GLI2 amplifications and frequent TP53 mutations, often in the germline, all of which were rare in infants
and adults. Functional assays in different SHH-MB xenograft models demonstrated that SHH-MBs harboring
aPTCH1mutation were responsive to SMO inhibition, whereas tumors harboring an SUFUmutation orMYCN
amplification were primarily resistant.
INTRODUCTION
Medulloblastoma (MB) comprises a collection of clinically and
molecularly distinct tumor subgroups that arise either in the cer-
ebellum or brainstem (Grammel et al., 2012; Louis et al., 2007;
Taylor et al., 2012). In children, they comprise the most frequent
embryonal brain tumor, whereas in adults the disease is relatively
rare, accounting for less than 1% of all intracranial malignancies
(Louis et al., 2007). Current therapy regimens including surgery,
cranio-spinal radiotherapy, and chemotherapy, may cure 70%–
80% of patients with MB. Most survivors, however, suffer from
long-term sequelae because of the intensive treatment, demon-
strating that less toxic treatments are urgently needed. Molecu-
lar analyses have shown that there are four major MB subgroups
(WNT, Sonic Hedgehog [SHH], Group 3, and Group 4; Taylor
et al., 2012). They are highly distinct in tumor cell histology and
biology, and in addition show divergent clinical phenotypes
such as patient demographics, tumor dissemination, and patient
outcome (Kool et al., 2012; Northcott et al., 2012a; Taylor et al.,
2012). Recent studies, largely focusing on pediatric MB, have
utilized next-generation sequencing technologies to map the
genomic landscape of MB and to identify novel driver mutations
in each molecular subgroup (Jones et al., 2012; Northcott et al.,
2012a, 2012b; Parsons et al., 2011; Pugh et al., 2012; Rausch
et al., 2012; Robinson et al., 2012). Due to the infrequent occur-
rence of this disease in adulthood, little is known about the
biology and genetics of MB in adults. This also explains why
there are few prospective phase III trials for this age group.
Most centers treat adult patients with MB either using glioblas-
toma protocols (which are largely ineffective) or, alternatively,
using pediatric MB protocols, although toxicity profiles differ
greatly between children and adults, leading to dose-limiting
toxicity in a high proportion of adults treated on pediatric proto-
cols (Brandes et al., 2009; Padovani et al., 2007; Spreafico et al.,
2005).
Targeted therapy as an alternative treatment option for
patients with MB is especially interesting for SHH-MBs. SHH
pathway antagonists, primarily those inhibiting at the level of
smoothened (SMO), are currently a major area of interest in the
pharmaceutical industry because they can potentially be applied
in multiple cancers with activated SHH signaling (Lin andMatsui,
2012). Some of these drugs are already in clinical trials for MB
(Low and de Sauvage, 2010; Ng and Curran, 2011). SHH-MBs
with alterations in downstream SHH pathway genes, however,
such as SUFU, GLI2, orMYCN, may demonstrate primary resis-
tance to SMO inhibition (Lee et al., 2007). Furthermore, as has
been shown in both humans and mice, tumors may also rapidly
acquire secondary resistance to treatment (Dijkgraaf et al., 2011;
Rudin et al., 2009; Yauch et al., 2009), suggesting that such in-
hibitors might be ineffective as a curative option when adminis-
tered as monotherapy. SHH-MBs present the most common
subgroup in infants (%3 years old) and adults (R18 years old),
Significance
Our data show that most adults, but only half of the pediatric patients, with SHH-MB will likely respond to SMO inhibition as
predicted by molecular analysis of the primary tumor and tested in the SHH xenografts, demonstrating that the next gen-
eration of SMO inhibitor trials should be based on these predictive biomarkers. Recurrent mutations in additional pathways
suggest rational combination therapies including epigeneticmodifiers and PI3K/AKT inhibitors, especially in adults.We also
show that tumor predisposition (Gorlin syndrome and Li-Fraumeni syndrome) is highly prevalent in patients with SHH-MB.
Each patient with SHH-MB, especially those 4–17 years old with LCA histology, should be tested for germline TP53 muta-
tions. Separate LFS-MB trials should be considered, sparing radiotherapy and excluding alkylating drugs.
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whereas in children (4–17 years old) other subgroups are more
prevalent (Kool et al., 2012). Transcriptome analyses and whole
genome sequencing have already shown that SHH-MBs are
quite heterogeneous (Northcott et al., 2011a; Rausch et al.,
2012). Childhood SHH-MBs, for instance, are genetically distinct
from those in infants, because they frequently harbor TP53
mutations and as a result of chromothripsis, their genomes are
often dramatically rearranged (Rausch et al., 2012). To preselect
patients who might qualify for clinical trials using SMO antago-
nists or future combination therapies, a better understanding of
the biology of SHH-MBs across different age groups is required.
We have therefore sequenced the genomes of 133 cases of
SHH-MB, including 50 adult and 83 pediatric cases. In addition,
we analyzed the tumors for DNA methylation and gene
expression.
RESULTS
SHH-MBs in Infants, Children, and Adults Are
Genomically Distinct
Unsupervised k-means consensus cluster analysis of DNA
methylation data (n = 129) identified two major clusters, mainly
separating infant from childhood and adult SHH-MB tumors (Fig-
ure 1A, left panel). Unsupervised cluster analysis of gene expres-
sion data (n = 103) showed similar results, with the infant cases
again being the most distinct (Figure 1A, right panel). GISTIC2
analysis of somatic copy number aberrations in all SHH-MB
cases (n = 266) reported by MAGIC (Northcott et al., 2012b),
however, showed that childhood SHH-MBs are very different
from both infant and adult SHH-MBs (Figure 1B). Childhood
SHH-MBs typically show much greater genomic instability and
are characterized by frequent amplifications of oncogenes
includingGLI2,MYCN, andPPM1D,most likely due to underlying
chromosome shattering (chromothripsis; Rausch et al., 2012).
Next-Generation Sequencing of SHH-MB
To determine the mutational landscape of SHH-MBs across age
groups, we sequenced a large series of SHH-MB tumors from
infants (%3 years old; n = 50), children (4–17 years old; n = 33),
and adults (R18 years old; n = 50; Table 1; Table S1 available on-
line). In the discovery cohort of 67 SHH-MBs, analyzed by whole
genome or whole exome sequencing, we identified 1,090 non-
synonymous somatic single nucleotide variants (SNVs) and
155 small insertions or deletions (indels), 89 of which introduced
translational frameshifts and 9 affected splice sites. In total,
1,054 geneswere found to be somatically mutated in this discov-
ery cohort, including 78 with alterations in more than one tumor.
In the two replication cohorts (43 pediatric and 23 adults), we
identified another 666 nonsynonymous SNVs and 76 indels.
For the combined 133 SHH-MBs, we found mutations in 1,156
genes, 215 of which were recurrently altered. All coding somatic
SNVs/indels identified are listed in Table S2.
As previously reported (Jones et al., 2012), pediatric SHH-
MBs harbored very few nonsynonymous SNVs (infants, 0–13,
median 3.0; children [TP53 wild-type], 1–26, median 9.5; Table
S2; Figures 2A and 2B). Exceptions were the eight TP53mutated
tumors in children, in this discovery cohort all between 9.5 and
14 years old, which harbored on average many more mutations
(7–29, median 19.5). WGS data showed that adult SHH-MBs
also containedmanymore nonsynonymous SNVs (9–48, median
25.0), in linewith other adult solid tumors. The average number of
small indels was also higher in adults (0–10, median 3.0) than in
children (0–4, median 1.0) and infants (0–3, median 1.0). Interest-
ingly, there was a much stronger correlation between somatic
mutation rate and patient age, both genome-wide (r2 = 0.58,
p = 1.6 3 10!9, Pearson’s product moment correlation), and
for coding mutations (r2 = 0.62, p = 2.23 10!15), than previously
reported across all MB subgroups (Figures 2A and 2B; Jones
et al., 2012). Assessment of mutation classes revealed a pre-
dominance of cytosine to thymine (C > T) transitions in a CpG
context (likely due to deamination of methylated cytosines), as
expected for an age-related background mutation pattern (Fig-
ures 2C and 2D; Welch et al., 2012). Interestingly, the C > T
fraction in the TP53 mutated cases appeared to be much lower,
with a relatively higher proportion of cytosine to adenosine (C >
A) transitions. Whether this can be explained by the TP53muta-
tion itself remains elusive.
Mutations in the SHH Pathway
Overall, we detected mutations in known SHH pathway genes
(116/133 cases; 87%), further substantiating the tumor-driving
role of the SHH pathway in this medulloblastoma subgroup
(Table S3). As expected, among the most frequently mutated
genes were PTCH1 (60 cases), SMO (19 cases), and SUFU
(10 cases), all mutually exclusive (Figure 3A; Figures S1A–
S1C). In addition, we found two PTCH1 and six SUFUmutations
in the germlines of eight pediatric patients, including two twin
brothers with an identical small indel in SUFU (Table S3). The
second replication cohort (for which germline controls were un-
available) contained another two cases from twin brothers both
with the same inactivating SUFU mutation, strongly suggesting
that this was also a germline event. For all other samples in
this replication cohort, it remains unknown whether any of the
identified PTCH1 or SUFU mutations were germline events.
Interestingly, while PTCH1 mutations were found at roughly
equal frequency in infants (42.0%), children (36.4%), and adults
(54.0%), SMO mutations were highly enriched in adult patients
(15/19 mutations; p = 1.8 3 10!4), while SUFU mutations were
almost exclusively found in infants %3 years old (16/18 muta-
tions; p = 8.43 10!6). Mutations in SMO and SUFUwere absent
or extremely rare in children (4–17 years old; Figures 3A and 3B).
Instead, they frequently harbored TP53 mutations (16/33 chil-
dren; p = 1.2 3 10!11), all found in children between 8 and 17
years old. The TP53 mutations were mutually exclusive with
PTCH1 mutations but often co-occurred with amplifications of
GLI2 (p = 2.5 3 10!6) and MYCN (p = 2.8 3 10!8), three events
that were rare in infants, young children, and adults (Figures 3A
and 3B). In addition, we identified four cases, including three
children with a TP53 mutation, with an amplification of the
SHH gene. These results show that activating mutations in the
SHH pathway are detectable in almost all SHH-MBs, but
the type of mutation and targeted genes are largely variable in
the different age groups (Figure 3C).
Large Cell/Anaplastic Histology and 17p Loss Are
Strongly Associated with TP53 Mutated SHH-MBs
Losses of 9q, 10q, and/or 17p are the most common copy num-
ber aberrations associated with SHH-MBs (Kool et al., 2012). All
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three were most frequent in childhood cases, with 17p loss
highly enriched in TP53 mutant cases (14/17 had 17p loss; p =
7.8 3 10!8; Figures 3A and 3B). Histology was also unequally
distributed between the three age groups, with most large cell/
anaplastic (LCA) cases found in childhood (15/21; p = 4.1 3
10!9). Thirteen of these 15 had a TP53 mutation. Nodular/
desmoplastic MB variants were most prevalent in infant cases.
Moreover, all four MBs with extensive nodularity (MBEN) were
found in infants (Figures 3A and 3B). In contrast to a recent report
(Brugie`res et al., 2012), which was, however, reporting on a
larger number of MBENMBs, only 1/4 MBEN cases in our series
had an SUFU mutation, while two harbored a PTCH1, and one
displayed an SMO mutation (Figure 3A).
TERT Promoter Mutations Are Highly Recurrent in Adult
SHH-MBs
Recently, several groups have reported that TERT promoter
mutations that drive telomerase activity are frequently found in
various cancers, including medulloblastoma, of mainly adult
patients (Killela et al., 2013; Koelsche et al., 2013; Remke
et al., 2013). Two mutually exclusive hotspot mutations in the
promoter region have been reported: C228T and the less
frequent C250T. Using our WGS data and data from the replica-
tion cohort in which the TERT promoter region was analyzed by
PCR and Sanger sequencing (Remke et al., 2013), we found that
indeed these mutations almost exclusively and with high fre-
quency occur in adult SHH-MBs (Table S1). Strikingly, almost
all adult patients for which we had data available had a somatic
TERT promoter mutation (43/44, 98%; 40 had the C228T muta-
tion and 3 had the C250T mutation). In contrast, in infants and
children, only 3/24 (13%) and 3/14 (21%) SHH-MBs, respec-
tively, had a TERT mutation (five C228T and one C250T).
DDX3X and Chromatin Modifiers Are Frequently
Mutated in Adult SHH-MBs
Other genes previously reported as being recurrently mutated in
pediatric SHH-MBs (MLL2,BCOR, and LDB1) were also found in
adult SHH-MBs (Figures 4A–4C). Interestingly, however, we
identified several recurrent mutations in adult SHH-MBs that
were completely absent or very rare in pediatric SHH-MBs,
including BRPF1, KIAA0182, TCF4, CREBBP, NEB, LRP1B,
PIK3CA, FBXW7, KDM3B, XPO1, PRKAR1A, and PDE4D (Fig-
ures 4A–4C; Figures S1D–S1I). Another striking example is the
gene encoding the RNA helicase DDX3X, which was mutated
in 27 adult SHH-MBs (54%) and only 6 pediatric MBs (7.2%,
p = 4.5 3 10!9). DDX3X was among the new genes identified
in recent sequencing studies of pediatric MB (Jones et al.,
2012; Pugh et al., 2012; Robinson et al., 2012). Notably, whereas
mutations were found in 50% ofWNT-MBs in children (Northcott
et al., 2012a), few DDX3X mutations were seen in SHH-MBs in
these studies (Pugh et al., 2012; Robinson et al., 2012). All iden-
tifiedmutations affected one of the two helicase domains with no
difference in their distribution between WNT- and SHH-MBs
(Figure S1D). Interestingly, mutations affecting the SWI-SNF
complex, also mainly found in the WNT-MBs in children (Jones
et al., 2012; Northcott et al., 2012a; Pugh et al., 2012; Robinson
et al., 2012), were also frequently seen in adult SHH-MBs.
Pathway analyses, performed separately for the three age
groups, showed marked differences in altered processes. In
infant cases, developmental processes and DNA/histone
methylation are prominently affected. Both in children and in
adults, chromatin organization is also affected, but especially
in adults many more chromatin modifiers and/or transcription
regulators were additionally altered, as well as different and
larger gene sets involved in brain development (Figure S2 and
Table S4). Remarkably, most of the mutations in chromatin
modifiers in adults were found to be mutually exclusive (Fig-
ure 4D). Interestingly, some of these mutations in chromatin
Figure 1. Genetic and Epigenetic Differences between SHH-MBs from Infants, Children, and Adults
(A) Cluster analysis of DNA methylation and gene expression data of SHH-MB. Both methylation profiling (left; n = 129) and gene expression profiling (right;
n = 103) reveal two SHH-MB subgroups identified by unsupervised k-means consensus clustering. Each row represents a methylation probe/expression pro-
beset, each column represents a sample. The level of DNAmethylation (b value) is represented with a color scale as depicted. For each sample patient age (blue,
infants; yellow, children; and pink, adults) and clustering according to expression data or methylation data (when available) is shown. Grey indicates that no data
were available.
(B) GISTIC2 significance plots of amplifications (red) and deletions (blue) observed in SHH-MB infants, children, and adults. Candidate genesmapping significant
regions have been indicated.
Table 1. SHH-MB Patient Cohorts
Cohort Number of Patients
Whole genome sequencinga n = 45
Infantsb 5
Childrenc 13
Adultsd 27
Whole exome sequencinga n = 22
Infants 13
Children 9
Adults 0
Targeted sequencing 2734 genesa 12 n = 12
Infants 7
Children 5
Adults 0
Targeted sequencing 400 genese n = 54
Infants 25
Children 6
Adults 23
Immunohistochemistry n = 155
Infants 31
Children 54
Adults 70
See also Tables S1, S2, S3, and S4.
aTumor-normal pairs were sequenced.
bInfants: 0–3 years of age.
cChildren: 4–17 years of age.
dAdults:R 18 years of age.
eOnly tumors were sequenced.
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modifiers were more closely associated with SMO mutations,
like the ones in BRPF1/3, while mutations in CREBBP or
KDM3B were more often found in PTCH1-mutated tumors.
PI3K/AKT Signaling Activated in Adult SHH-MB
Associates with Poor Outcome
As we identified recurrent mutations affecting the PI3K/AKT/
mTOR-pathway in SHH-MBs (PIK3CA, PTEN, and PIK3C2G
are all mutated in >5% of SHH-MBs; Figures 4A–4C), which
could lead to GLI activation independent of SMO (Wang et al.,
2012), targeting this pathway could be an option for combination
therapies. To investigate which SHH patients would be most
suitable for targeting PI3K/AKT/mTOR-signaling, we examined
activation of the pathway in a large series of SHH-MBs
(n = 155) by immunohistochemistry using antibodies for p-AKT
and p-S6. p-AKT and p-S6 positivity were each detected in
17% of cases, with 12% positive for both (Figures 5A–5F).
Surprisingly, the vast majority of positive cases were tumors
from adult patients, with 31% and 30% of the adult SHH-MBs
staining positive for p-AKT or p-S6, respectively. Moreover,
survival analysis showed that both p-AKT and p-S6
positivity were strongly associated with a poor outcome in adult
patients with SHH-MB (Figure 5G). Other factors shown to be
associated with a poor outcome in SHH-MB patients, like
A B
C D
Figure 2. Number and Type of Somatic Mutations in Medulloblastoma Tumors in Relation to the Age of the Patient
(A) Total number of somatic mutations genome wide correlates with age of the patient. Plotted are the total number of somatic SNVs identified genome wide
versus age of the patient for all cases for which we performed whole genome sequencing (WGS; n = 45). Red indicates patients harboring a TP53 mutation.
(B) Same as in (A), but only the total number of coding SNVs is plotted versus age for all cases for which we performed either whole genome or whole exome
sequencing (WGS and WES, n = 67).
(C) Mutation signatures. Plotted are the total numbers of somatic mutations genome wide sorted by age of the patient. Coloring of bars represents the ratio of the
six possible nucleotide changes (C > A, C > G, C > T, T > A, T > C, and T > G) for each sample.
(D) Normalized mutation signatures sorted by age.
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MYCN or GLI2 amplification, LCA histology or metastasis at
diagnosis, are all exceptionally rare in adult SHH-MB patients
(Figures 1C and 3A; Kool et al., 2012), and could therefore
not explain the poor outcome of these p-AKT/p-S6-positive
subgroup of patients. Our results suggest that adult
patients with SHH-MB may be the best group to benefit
from combination therapies of SMO inhibitors with PI3K/AKT/
mTOR inhibition.
A
B C
Figure 3. Genetic and Histological Differences between SHH-MBs from Infants, Children, and Adults
(A) SHH pathway mutations, gender, histology and 9q/10q/17p aberrations in all sequenced 133 SHH-MB. Cases have been split up in infants, children and
adults, and are sorted based on type of mutation in the SHH-pathway. Potential response to SMO inhibition: cases with SHH amplifications, PTCH1mutations, or
SMO mutations will likely respond to SMO inhibition (indicated in green). Cases with SUFU mutations or MYCN or GLI2 amplifications will likely not respond to
SMO inhibition (indicated in red). In cases for which no mutations in the SHH pathway were detected, it is not clear whether they will respond to SMO inhibitors
(indicated in yellow). Percentages indicate fraction of infants, children, or adults, respectively, of each category. p Values indicate whether distributions are
significantly different among infants, children, and adults.
(B) Pie charts showing in infants, children, and adults with SHH the distribution of gender (male, blue; female, pink; unknown, gray), histology (classic, dark red;
nodular/desmoplastic, green; large cell/anaplastic LCA, orange; MBEN, yellow; and unknown, gray), 9q loss (yes, black; no, gray), 10q loss (yes, black; no, gray),
17p loss (yes, black; no, gray), and type of SHH pathway mutation (SHH amp, purple; PTCH1 mut, red; SMO mut, green; SUFU mut, orange; GLI2/MYCN amp,
blue; and unknown, gray).
(C) Trimodal age distribution of patients with SHH-MB. Red line indicates age distribution of all patients with SHH-MB. Three subgroups make up this age
distribution: young children with PTCH1 and SUFUmutations (blue line), older children with PTCH1 and TP53mutations (purple line), and adults whomostly have
PTCH1 or SMO mutations (green line).
See also Figure S1.
Cancer Cell
Genome Sequencing of SHH Medulloblastoma
Cancer Cell 25, 393–405, March 17, 2014 ª2014 Elsevier Inc. 399
SHH Medulloblastomas with Mutations Downstream of
SMO Are Resistant to LDE-225
Assuming a linear pathway, we anticipate that patients with
mutations in the SHH pathway downstream of SMO (e.g.,
SUFU, GLI2, and MYCN) show primary resistance to targeted
SMO inhibition. To test this hypothesis, we used xenografts
from three SHH-associated MBs (DMB-012, RCMB-018, and
RCMB-025; Yeh-Nayre et al., 2012). These xenografts were
generated by stereotaxic orthotopic xenotransplantation of
cells immediately after surgical resection, maintained by serial
intracranial transplantation, and harvested only for use in
short-term experiments, allowing them to maintain the charac-
teristics of the original tumors (Shu et al., 2008; Zhao et al.,
2012). WES showed that each xenograft harbored a different
alteration in the SHH pathway (Figure 6A). Cells from each
xenograft line were treated in vitro with NVP-LDE225, an SMO
inhibitor that is currently being applied in phase III clinical trials
for relapsed childhood and adult SHH-MB (Geoerger et al.,
2012). Proliferation was measured based on incorporation of
tritiated thymidine. Treatment with LDE225 significantly in-
hibited the proliferation of DMB-012 cells (PTCH1 mutant), but
did not affect the proliferation of RCMB-018 (MYCN amplifica-
tion) or RCMB-025 cells (SUFU deletion; Figures 6B–6D). Pre-
clinical testing in vivo also demonstrated a strong inhibition of
tumor growth by LDE225 in DMB-012 (Figure 6E), but not
RCMB-018 (Figure 6F and Figure S3), confirming the in vitro
data. Survival analyses indeed show that mice with DMB-012
tumors live longer when treated with LDE-225 (Figure 6G), but
mice with RCMB-018 tumors do not (Figure 6H). Finally, we
have tested whether RCMB-018 cells, resistant to LDE-225,
are responsive to arsenic trioxide (ATO) targeting cells at the
level of GLI (Beauchamp et al., 2011). Figure 6I illustrates that
RCMB-018 cells are responsive to ATO. At concentrations of
5–10 mM, cells are markedly inhibited in growth. Our data
A B C
D
Figure 4. Most Frequently Mutated Genes in SHH-MB and the Mutual Exclusivity of Mutations in Chromatin Modifier Genes
(A–C)Mutation frequencies of 33 genes that aremutated either inR5%of all SHH-MB cases or inR10%of SHH-MB cases in one of the age categories. Mutation
frequencies for these 33 genes are shown in infants (A), children (B), and adults (C). Black indicates the fraction of mutations that is found in the germline.
(D) Mutations in chromatin modifiers in infants, children, and adults with SHH-MB. The top line shows the mutations in the SHH pathway for each case.
See also Figure S2.
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show that classification as an SHH-MB using a five-gene
expression signature currently being applied in clinical trials is
not sufficient as a predictive biomarker for response to SMO
antagonists, because all SHH-MBs are detected by this signa-
ture, regardless of their underlying genetic makeup (Amakye
et al., 2012).
DISCUSSION
Herein we have shown that genetic hits in SHH-MBs are very
heterogeneous. Tumors in infants, children, and adults strongly
differ in transcriptome, methylome, and copy-number aberra-
tions as well as in number and type of mutations they contain.
Hereditary predisposition syndromes involving germline muta-
tions of SUFU (or rarely PTCH1; Gorlin syndrome) are highly
prevalent in infant (0–3 years old) SHH-MBs, while germline
TP53 mutations (Li-Fraumeni syndrome) are common in older
children (>3 years old), especially in children between 8 and 17
years old. Strikingly, almost all adults harbored somatic muta-
tions in the TERT promoter, whereas they were much less com-
mon in pediatric patients. Our data show that three groups of
SHH-MBs should be considered: young children with mostly
PTCH1 orSUFUmutations, older children with frequent germline
TP53 mutations and chromothripsis-associated amplifications
of SHH pathway genes, and adults harboring mostly PTCH1
and SMO mutations (Figure 3C). Recent data showing that
SHH-MBs can arise from different precursor cells in the cere-
bellum or brainstem (Grammel et al., 2012) suggest that infant
SHH-MBs may have a different cellular origin or hit the same
progenitor cell at a different stage of differentiation than child-
hood or adult SHH-MBs (which were more similar at the tran-
scriptome/methylome levels).
Most importantly, our results show that patients with different
underlying SHH mutations should be stratified accordingly. We
have demonstrated that targeting the SHH pathway in SHH-MB
using SMO antagonists will most likely give the best results in
adult patients. A vast majority (82%) of adult patients harbor
tumors with mutations in either PTCH1 or SMO, rendering
them likely responsive to these drugs. In contrast, infant (36%)
and childhood (45%) SHH-MBs frequently have mutations
downstream of SMO, which makes these tumors intrinsically
resistant to drugs targeting SMO. Indeed, SHH-MB xenografts
harboring these downstream mutations did not respond to
SMO antagonists. The impact of bone developmental toxicity
may additionally limit the use of SMO inhibitors in infants (Kimura
et al., 2008).
A
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Figure 5. Immunohistochemical Staining of MB Tissue Arrays for p-AKT and p-S6
(A) Example of positive p-AKT MB.
(B) Example of negative p-AKT MB.
(C) Example of positive p-S6 MB.
(D) Example of negative p-S6 MB.
(E) Overlap in staining results between p-AKT and p-S6.
(F) Frequencies of p-AKT and p-S6 staining in infants, children, and adults.
(G) Survival analysis for p-AKT and p-S6 in all SHH patients and in adults only. Numbers on the y-axis indicate the fraction of surviving patients. Numbers on the
x-axis indicate the follow-up time in months. The number of patients per group is indicated next to the graphs plus the number of events within that group
(between brackets). For infants and children, the number of patients staining positive was too low to draw conclusions from separate survival analyses.
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Furthermore, our results strongly suggest that each patient
with a SHH-MB, but especially those between 4 and 17 years
of age with LCA histology, should be tested for germline TP53
mutations. Currently, these patients with Li-Fraumeni syndrome
(LFS)-MB are often not recognized and therefore treated with
standard protocols, including ionizing radiotherapy and alkylat-
ing chemotherapy. Moreover, as almost all patients with germ-
line TP53 mutations have tumors with LCA histology, they are
often stratified as high risk and will therefore get even higher
doses of radiotherapy and chemotherapy. It seems that these
patients are often cured of their MB, but frequently die of
secondary malignancies induced by previous radio-chemo-
therapy. This may partly explain why TP53 mutations in SHH-
MBs are associated with a particularly poor outcome (Zhukova
et al., 2013), and is also in line with the finding thatMYCN ampli-
fication in SHH-MBs is associated with an inferior prognosis
(Kool et al., 2012; Korshunov et al., 2012; Ryan et al., 2012).
We therefore strongly suggest that separate LFS-MB trials
A
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I
Figure 6. SMO Antagonists Do Not Suppress Proliferation of All SHH-Associated MB Tumors
(A) Characteristics of SHH-MB models treated with LDE225.
(B–D) Cells from patient-derived xenografts of SHH-associated MB were treated with DMSO (0.05% [hatched bars] or 0.25% [solid bars]) or LDE-225 (100
[hatched bars] or 500 nM [solid bars]). Cells were pulsedwith [methyl-3H]thymidine (3H-Td) after 48 hr and harvested for analysis of 3H-Td incorporation at 66 hr. In
DMB-012 (B), LDE-225 significantly inhibited 3H incorporation compared to DMSO control (p < 0.01 based on paired two-tailed t test). In RCMB-018 (C) and
RCMB-025 (D), LDE-225 did not significantly inhibit 3H incorporation (p > 0.5 and p > 0.1, respectively). Data represent means of triplicate samples ± SD.
(E and F) Cells from MB xenograft DMB-012 (E) or RCMB-018 (F) were infected with luciferase virus and transplanted into NSG mice. Bioluminescence images
were taken pretreatment (day 0) and at different time points after daily treatment with vehicle or SHH antagonist (LDE-225, 5 or 20 mg/kg/day). Five mice per
group were used. Representative examples from each group are shown. Other examples are shown in Figure S3. A red cross indicates when mice were
sacrificed.
(G and H) Kaplan-Meier survival plots for the mice harboring DMB-012 tumors (G) or RCMB-018 tumors (H) and treated with vehicle or LDE-225.
(I) RCMB-018 cells were treated with DMSO (0.25%; gray bar), LDE-225 (500 nM; red bar), vehicle (PBS + 0.01 N NaOH; light blue bars), or increasing
concentrations of ATO (dark blue bars). Cells were pulsed with [methyl-3H]thymidine (3H-Td) after 48 hr and harvested for analysis of 3H-Td incorporation at 66 hr.
LDE-225 did not inhibit 3H incorporation compared to DMSO control, but ATO did at 5 and 10 mM concentrations. Data represent means of triplicate
samples ± SD.
See also Figure S3.
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should be developed using chemotherapy-only protocols and
excluding alkylating drugs.
We further strongly advocate that the next generation
of SMO inhibitor trials should be based on underlying tumor
genetics because many patients with SHH-MB will not respond
to these inhibitors. Alternative treatment options could include
arsenic trioxide (ATO) targeting GLI transcription factors by
degrading the protein (Figure 7; Kim et al., 2010, 2013). ATO
and the antifungal agent itraconazole (which acts on SMO)
have also been suggested in preclinical experiments for use
in SHH-MBs that become resistant after treatment with
SMO antagonists (Kim et al., 2013) or in combination with
SMO inhibitors upfront knowing that GLI2 amplifications
comprise a common mechanism of secondary resistance
to SMO inhibition in preclinical models (Buonamici et al.,
2010; Dijkgraaf et al., 2011). Other options for combination
therapies to avoid or delay the development of resistance
include drugs targeting PI3K/AKT/mTOR- or PKA-signaling
pathways (Figure 7), both mutated in a subset of patients
with SHH and both also leading to GLI activation (Metcalfe
et al., 2013; Milenkovic and Scott, 2010; Wang et al., 2012),
or epigenetic drugs.
EXPERIMENTAL PROCEDURES
Patient Samples
Patient materials were collected after receiving informed consent according to
International Cancer Genome Consortium guidelines (http://www.icgc.org)
and as approved by the institutional review board of contributing centers.
DNA derived from SHH-MBs and matched normal blood from 45 patients
was subjected to whole genome sequencing (WGS) using Illumina technolo-
gies. Two additional tumor-normal pairs were sequenced by whole exome
sequencing (WES). WGS data for 13/45 andWES data for another 20 pediatric
tumor-normal pairs were previously reported (Jones et al., 2012; Pugh et al.,
2012). All patients in this discovery cohort (n = 67) were confirmed to have a
MB of the SHH subtype by either gene expression profiling, DNA methylation,
or immunohistochemistry (SFRP1 Northcott et al., 2011b and GAB1 Ellison
et al., 2011). In addition, we used data from 12 pediatric SHH-MB tumor-
normal pairs that were sequenced for 2,734 genes as part of a previously
reported replication cohort (Jones et al., 2012). Finally, a set of 400 genes,
including those identified as recurrently mutated in SHH-MBs in our discovery
cohort, was investigated in another independent set of pediatric (31) and adult
Figure 7. Schematic Overview of SHH-, PI3K/AKT/mTOR-, and PKA Pathways and How They Interact
Genes that were found in the genomic analyses of SHH-MBs to harbor activating mutations (green stars), inactivating mutations (red stars), or were found to be
amplified (MYCN andGLI) are indicated. All thesemutations lead to activation of GLI proteins and their downstream pathways. Options for targeted treatment are
indicated. Patients harboring mutations in either PTCH1 or SMO should be responsive to SMO inhibitors, whereas patients harboring mutations more down-
stream in the SHH pathway (SUFU,MYCN, and GLI) or in the PI3K/AKT/mTOR and/or PKA-pathways may be treated using arsenic trioxide (ATO) or other more
specific GLI-inhibitors or PI3K/AKT/mTOR inhibitors.
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(23) SHH-MBs, for which only tumor DNA was available. In total, sequencing
data for 133 (83 pediatric and 50 adult) SHH-MBs are presented in this study.
Patient details are listed in Table S1.
Animals
Immunocompromised (NOD-scid IL2Rgammanull or NSG) mice used for
transplantation were purchased from Jackson Labs. Mice were maintained
in the Animal Facility at Sanford-Burnham. All experiments were performed
in accordance with national guidelines and regulations, and with the approval
of the animal care and use committee at Sanford-Burnham.
The experimental procedures used in this study are described in more detail
in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
The Gene Expression Omnibus accession numbers for the complete CpG
methylation values are GSE49576 and GSE49377; for the complete gene
expression values, the number is GSE49243. The European Genome-
phenome Archive accession number for the sequencing data is
EGAS00001000607.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.02.004.
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INTRODUCTION
Children with PLGGs have been reported to have superior 10-
year overall survival (OS) rates compared to adults diagnosed with
low-grade gliomas during adulthood (ALGG) [1]. While children
have an excellent 10-year OS, adult patients diagnosed with low-
grade gliomas have amore aggressive clinical course and poor long-
term survival rates, with a high incidence of malignant transforma-
tion and death [2,3]. PLGGs have been reported to spontaneously
stabilize or regress [4,5], particularly in children with neurofibro-
matosis type 1 [6,7], a phenomenon which is rare in ALGG.
Although small case series and anecdotal evidence have suggested
that PLGGs rarely undergo malignant transformation [8–10], long-
term outcomes of PLGG remain unknown. In particular, it remains
unclear whether these tumors undergo malignant transformation to
cause death in adulthood. We performed a comparative retrospec-
tive analysis of survival of patients with PLGG diagnosed between
1973 and 2008 as identified in the National Institute Surveillance,
Epidemiology and End Results (SEER) database of the National
Cancer Institute (NCI), to analyze the survival rates of adult
survivors of pediatric low-grade gliomas.
MATERIALS AND METHODS
Approval to access the SEER data was granted by the NCI to use
all datasets up until 2011 [11]. Pediatric patients (0–19 years of age)
diagnosed with a grade I or II glioma between 1973 and 2008 were
identified. Variables recorded for each patient included age, year of
diagnosis, race, sex, location of tumor, histological diagnosis and
grade of tumor, extent of surgery, and whether the child received
radiation therapy. Histological groupings used to identify patients
included pilocytic astrocytoma, diffuse astrocytoma, astrocytoma
not otherwise specified (NOS), glioma NOS, mixed glioma, or
unique astrocytoma variants. Only tumors classified as grade I or II
were included. Outcomes were recorded for status (alive or dead),
time from diagnosis to last follow-up or death, and cause of death.
Deaths were classified as death due to glioma, or death not due to
glioma. Secondary malignancies, such as radiation induced tumors,
were not classified as deaths due to glioma.
Background. Children with pediatric low-grade gliomas (PLGG)
are known to have excellent 10-year survival rates; however the
outcomes of adult survivors of PLGG are unknown. We identified
patients diagnosed with PLGG diagnosed between 1973 and 2008
through the Surveillance Epidemiology and End Results (SEER)
database to examine outcomes of adult survivors of PLGG.
Procedure. Four thousand and forty patients with either WHO grade
I or II PLGG were identified and outcome data retrieved. Two
analyses were performed to assess survival and risk of death from
tumor. Competing risks analysis was conducted and cumulative
incidence curves of death due to disease were generated. Cox
proportional hazards regression was performed, with adjustment for
non-disease death. Kaplan–Meier curves for overall cancer specific
survival (OS) were also generated. Results. The 20-year OS was
87%!0.8% and the 20-year cumulative incidence of death due to
glioma was 12%!0.8%. The incidence of death after transition to
adulthood (age greater than 22 years)was slightly lower,with 20-year
cumulative incidence of disease death of 7%!1.8%. Year of
diagnosis, age of diagnosis, histology, WHO grade, primary site,
radiation, and degree of initial resection were prognostic in
univariate analysis, while the administration of radiation was the
greatest risk of death in multivariate analysis of OS (hazard
ratio¼3.9). Conclusions. PLGGs are associated with an excellent
long-term survival, with a low likelihood of PLGG related death in
adult survivors. Treatment strategies for pediatric tumors should
therefore aim for disease control during childhood and adolescence
with an emphasis on minimizing long-term treatment induced
toxicities. Pediatr Blood Cancer 2014;61:1173–1179.
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A competing risks analysis was conducted according to the
methods of Pepe and Mori [12]. With adjustment for non-disease
deaths, cumulative incidence curves of death due to disease were
plotted for the overall cohort and for subgroups of each potential
prognostic factor: age, sex, year of diagnosis, histology, WHO
grade of differentiation, primary site, extent/type of radiation
therapy, and degree of initial resection. The prognostic ability of
the factors was tested using a Cox proportional hazards
regression model (univariate and multivariate) for competing
risks, according to Rosthoj et al. [13], with adjustment for non-
disease death. This method allows for separate estimation/
quantification of (i) risk for death due to disease; and (ii) risk for
death from non-disease causes. Kaplan–Meier curves of OS were
generated to determine overall survival including all causes of
death. Cancer specific survival was performed by generating
Kaplan–Meier curves including glioma related deaths. Non-
disease deaths were censored [3].
To compare the risk of death from disease prior to transition to
adulthood (age 22 years) versus after transition to adulthood, a time-
dependent covariate for the occurrence of a patient’s 22nd birthday
was included in the Cox model. The age of 22 was chosen to allow
for the examination of the natural history of PLGG after the age at
which the majority of brain maturation during the transition from
adolescence to adulthood has been completed [14].
RESULTS
A total of 4,040 patients aged !19 years of age (median age at
diagnosis: 9 years, range 0–19 years) at time of diagnosis of a PLGG
between 1973 and 2008were identified (Table I). The 30-year OS of
the 4,040 patients was 74.8%" 2%, including all causes of death.
We were unable to determine progression-free survival from the
available data. Of the 4,040 patients, 347 patients died as a result of
PLGG and 78 patients died of other causes. Cause of death was
unknown in 17 patients. Median time of follow-up was 6.9 (0–36.5)
years. Importantly, the cohort included 875 patients with at least
15 years of follow-up from diagnosis.
The Kaplan–Meier estimate of overall cancer specific OS at
20 years was 87%" 0.8% (Fig. 1A), and the 20-year overall
survival of the 875 patients for which there was at least 15 years
follow-up was 92%" 3% (Fig. 1B). Pepe–Mori 20-year cumulative
incidence of death due to disease was 12%" 0.8% (Fig. 1C). We
examined the overall survival of adult survivors of pediatric low-
grade gliomas by calculating OS after transition to adulthood. This
analysis included children diagnosed with all subtypes of PLGG.
After reaching adulthood (defined as age 22), survivors of PLGG
(including all histological subtypes) had a 30-year OS of 93%" 1.7
(Fig. 1D). These patients had a 20-year cumulative incidence of
death due to disease of 7%" 1.8% (Fig. 1E). For patients prior to
reaching their 22nd birthday, the risk of death due to disease is
slightly higher (HR¼ 1.37, P¼ 0.24) than the risk of death from
any cause (HR¼ 1.20, P-value¼ 0.40) in comparison to patients
after age 22 years, though not significantly higher in either case.
Univariate analysis of risk of death identified age <2 years at
diagnosis (P< 0.0001, Fig. 2A), year of diagnosis between 1970
and 1989 (P< 0.0001, Fig. 2B), histology other than pilocytic
astrocytoma (P< 0.0001, Fig. 2C), tumor site other than cerebel-
lum (P< 0.0001, Fig. 2D) andWHO grade II (P< 0.0001, Fig. 2E)
as prognostic of increased risk of death. There was no significant
difference in overall survival between childrenwho had a gross total
surgical resection and children with residual disease (P¼ 0.4,
Fig. 2F).
We performed a multivariate Cox model analysis (Table II) and
identified an increased risk of cancer-specific death in children who
were treated with radiation therapy (HR¼ 3.9, P< 0.0001).
Children who did not have cerebellar disease (HR¼ 2.3,
P< 0.0001) or had non-pilocytic astrocytoma histology (HR¼ 2.2,
P< 0.0001) also had increased risk of disease-related death.
Despite this, children with all histological subtypes of pediatric
low-grade gliomas still had an excellent long-term overall survival
(Fig. 3). Children who were less than 2 years of age had greater risk
of disease-related death compared to older children (HR¼ 2,
P< 0.0001). Although not significant on univariate analysis,
patients with subtotal or no resection had a small but statistically
TABLE I. Demographics of Pediatric Patients in Cohort
Category Number (%)
Gender
Male 2,059 (51)
Female 1,981 (49)
Age (median) 9 years
Histology
Pilocytic astrocytoma 2,648 (65)
Astrocytoma NOS 841 (21)
NOS grade I 227
NOS grade II 614
Diffuse astrocytoma 260 (6)
Glioma NOS (total) 189 (5)
Grade I 68
Grade II 121
Mixed glioma (total) 75 (2)
Grade I 16
Grade II 59
Unique astrocytoma variant 27 (1)
Grade I 12
Grade II 15
Grade (all histologies)
Grade I 2,971 (74)
Grade II 1,069 (26)
Location
Supratentorial 1,264 (31)
Ventricular 189 (5)
Cerebellum 1,170 (29)
Brainstem 504 (12)
Overlapping or NOS 718 (18)
Spinal cord 195 (5)
Extent of resection
No resection 373 (9)
Biopsy 9 (0.2)
Subtotal resection 1,769 (44)
Gross total 1,094 (27)
Not otherwise specified 593 (15)
Unknown 202 (5)
Radiation
No radiation therapy 3,235 (80)
Radiation therapy 736 (18)
Unknown 69 (2)
Number of deaths 442 (11)
PLGG 347
Non-PLGG 78
Unknown 17
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significant increase in risk of disease-related death compared to
those with total resection on multivariate analysis (HR¼ 1.5, 95%
CI: 1.01, 2.1, P¼ 0.04).
Treatment with radiation therapy was an adverse prognostic
factor. Regardless of the extent of surgical resection, children who
were treated with radiation therapy had a worse OS and greater risk
of disease death compared to those that were not treated with
radiation therapy (HR¼ 3.9, P< 0.0001; Fig. 4, respectively).
Within each treatment group (radiation or no radiation), there was
no difference in OS or cumulative incidence of disease death in
children who had received a gross total resection in comparison to
children who had residual tumor. Further, children in whom only a
subtotal resection was achieved but did not undergo radiation had a
significantly superior outcome compared to children who had a
gross total resection but treated with radiation. The hazard ratio of
death due to glioma in patients who were treated with radiation was
3.9 (P-value< 0.0001). Data were not available in the SEER
database to permit a determination of the incidence of radiation-
induced secondary malignancies; however the hazard ratio of death
due to non-glioma related causes of 2.4 (P-value¼ 0.0006) in
patients treated with radiation suggests that radiation-induced
mortality may have accounted for some of the deaths that were not
directly due to glioma.
The risk of death due to disease was slightly higher for patients
before age 22 compared to after age 22 (hazard ratio¼ 1.37),
although not statistically significant (P¼ 0.24). The risk of death
from any cause was slightly higher for patients before age 22
compared to after age 22 (hazard ratio¼ 1.20), although not
statistically significant (P¼ 0.40). Within the group that had
received radiation, the hazard ratio of dying from causes all causes
compared to patients less than 22 years of age was 1.59 (P-
value¼ 0.1) and from tumor 1.74 (P-value¼ 0.1).
DISCUSSION
Our outcome analysis is the largest ever reported for very long-
term survivors of PLGGs, and confirms the excellent prognosis of
PLGG.While it is known that patients with PLGGs have superior 5-
and 10-year OS [15,16] the data presented here confirm for the first
time that adult survivors of pediatric disease have a low incidence of
glioma related death. Importantly this highlights that PLGGs are
very unlikely to undergo malignant transformation resulting in
tumor-related death, which contrasts with the natural history of
ALGGs [1,3]. Further, the data show that children who are treated
with radiation therapy, regardless of their surgical status, have
significantly inferior outcomes compared to those children who are
not treated with radiation therapy.
We have found that children whowere treated with radiation had
inferior outcomes. It is however important to acknowledge that it is
difficult to determine from the SEER data howmuch of this is due to
radiation itself and howmuch is a reflection of selection bias.While
some degree of selection bias is likely, the finding that children in
whom a gross total resection was achieved and were irradiated had
an inferior outcome compared to those children with a subtotal
resection who were not irradiated suggests that radiation induced
mortality (rather than PLGG related mortality) also accounts for a
Fig. 1. Adult survivors of pediatric low-grade gliomas have excellent overall survival with low rates of mortality after patients transition into
adulthood. A: Kaplan–Meier overall survival curve of patients with PLGG including only tumor related deaths. B: Kaplan–Meier overall survival
curve of patients for which there is at least 15 years of follow-up. C: Pepe–Mori cumulative incidence of tumor specific death curve of patients
diagnosed with PLGG. D, A: Kaplan–Meier overall survival curve of patients with PLGG showing survival starting from the patient’s 22nd
birthday. E: Pepe–Mori cumulative incidence of tumor specific death curves of patients starting from patient’s 22nd birthday.
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number of these deaths. The HR of dying from disease after
radiation was 3.9 and the HR of dying from non-glioma related
disease after radiation was 2.4. These data suggest that the observed
increased in mortality in children treated with radiation therapy is
likely to be a combination of both selection bias (i.e., children with
harder to control disease are more likely to have received radiation)
and radiation induced mortality, such as the increased risk for
secondary malignancies and vasculopathy. Due to the inherent
Fig. 2. Pepe–Mori cumulative incidence of death curves depicting univariate analysis including A, age at diagnosis B, year of diagnosis C,
histology D, location of primary tumor E, grade and F, extent of resection. Number of patients at each time point are shown below.
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limitations associated with SEER database, we are unable to
determine the proportion of children who were treated with
radiation after failing chemotherapeutic approaches.
GTR of PLGGs have been associated with superior event free
and overall survival [16]. In the SEER cohort of PLGG we have
found that children who do not have a GTR also have an excellent
overall survival. This analysis included all histological subtypes of
pediatric low-grade gliomas. Thus, the aim of surgery for these
children should be to resect the maximal amount of tumor that can
be safely resected while minimizing the risk of long-term
neurological sequalae.
The overall long-term survival of patients diagnosed with
PLGGs including all causes of death is superior to the outcomes of
patients diagnosed with glioma as adults [3]. Our analysis, using
two methodologies to examine disease-specific deaths of patients
with PLGG, confirms that PLGG infrequently causes death in adult
survivors. In fact, the risk of death decreases once patients reach
adulthood.
Our study reports outcomes of grade II low-grade gliomas in a
large SEER-based cohort of pediatric patients, and our finding of
excellent overall survival in this cohort has important clinical
implications. Many physicians have been concerned that residual
grade II PLGGs may undergo malignant transformation later in life,
and have thus advocated potentially morbid therapies including
radical surgical resection and/or radiation therapy. However, in our
series, the majority of children with grade II PLGGs also had
excellent overall survival, and we did not observe increased rates of
deathwith time as have been reported in low-grade gliomas that arise
in adults, and which are prone to undergo malignant transformation.
Unfortunately, data to perform progression-free survival
analysis are not available from the SEER database; however, the
observation of a very low mortality in adult survivors supports the
hypothesis that PLGG become stable, possibly quiescent as
children transition into their early adult years. It is possible that
loss of follow-up of adult survivors of PLGG may have affected
outcome measures in this study and may result in under-estimation
of overall survival as adult survivors who are well and not requiring
medical assistance may not be captured in follow-up data while
adult survivors who have disease recurrence and subsequent death
are more likely to have been reported.
The confirmation that the majority of adult survivors of
PLGG do not eventually succumb to their disease is an important
TABLE II. Multivariate Analysis of Risk Factors in Patients With Pediatric Low-Grade Glioma
Factor (reference level)
Death due to disease Death from non-disease causes
HR (95% CI) P-value HR (95% CI) P-value
Beam radiation, with or without implants or isotopes (no radiation) 3.9 (3.0, 4.9) <0.0001 2.4 (1.4, 3.9) 0.0006
Degree of radiation unknown (no radiation) 3.1 (1.7, 5.8) 0.0003 NA 1.0
Primary site (cerebellum) 2.3 (1.6, 3.2) <0.0001 NA 1.0
Histology group (pilocytic astrocytoma) 2.2 (1.7, 2.8) <0.0001 NA 0.05
Age of diagnosis (!2 years old) 2.0 (1.5, 2.8) <0.0001 2.2 (1.1, 4.5) 0.03
Subtotal resection, biopsy or no resection (total resection) 1.5 (1.01, 2.1) 0.04 3.0 (1.1, 8.6) 0.04
HR, hazard ratio (increased risk of death due to disease for the Factor in comparison to the reference level); CI, confidence interval.
Fig. 3. Patients with all histological subtypes of PLGG have excellent very long-term overall survival. Kaplan–Meyer curves of outcomes of
patients diagnosed with different histological subtypes of PLGG.
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observation that must be taken into account when considering
therapeutic options for children with low-grade gliomas. Given
these children are expected to survive into adulthood, the aim of
treatment should be to control disease and minimize long-term
morbidity from both the tumor itself and treatment. This can be
achieved with surgery if the tumor can be safely resected without
resulting in neurological sequelae, chemotherapy or novel targeted
therapeutic agents. Treatment strategies should aim to minimize
treatment induced long-term morbidity such as those associated
with radiation therapy, including neuro-cognitive deficits [17–20],
hormone deficiencies and secondary malignancies [20,21]. Al-
though some groups are currently using radiation therapy as first-
line therapy [22], the data we present suggest that treatment with
radiation therapy should be reserved for the small number of
children in whom tumor control cannot be achieved with surgery,
chemotherapy or targeted agents.
These data confirm that the natural history of PLGGs is distinct
from their adult counterparts [1,3], and it is likely that this is a
reflection of differences in the underlying biology of the tumors.
Although histologically these tumors have the same characteristics
in children and adults, the higher rate of genetic alterations observed
in ALGGs compared to pediatric low-grade gliomas suggest a
difference in genomic stability. While mutations of IDH [23] and
p53 [24] are reported in ALGGs and predict malignant transforma-
tion, these are rare in their pediatric counterparts, which more
commonly harbor alterations of BRAF [25–28]. While the
propensity of ALGGs to slowly progress and undergo malignant
transformation is secondary to the acquisition of driver mutations, it
remains to be determined why PLGGs do not also acquire these
alterations with time to cause transformation. It can be hypothesized
that normal processes that guide development and maturation of the
brain, for example, epigenetic processes, may cause PLGGs to
become quiescent as children transition into adulthood. The factors
that govern the stability of PLGG remain unknown.
There are limitations to the data obtainable from the SEERs
database. In particular, the quality of the data extracted is dependent
on how the data are entered into the database, histology and
radiology results have not been centrally reviewed, and interpreta-
tion of the grading of low-grade gliomas according to the current
WHO classification can vary. The limitations of the WHO
classification are highlighted by the finding that a significant
proportion of PLGG in the SEER database are designated as “not
otherwise specified,” rather than given a distinct classification
according to the WHO criteria. This suggests a need for better
molecular markers to diagnose and stratify these gliomas. Further, it
is possible that some of the tumors that have been designated as
pediatric low-grade gliomas not otherwise specified may have
represented higher-grade gliomas, thus accounting for the inferior
survival of those children whose tumors could not be classified
according to the WHO classification. This may have resulted in an
over-estimation of the actual death rate of children with true low-
grade gliomas.
In addition, the SEER database lacks information about
chemotherapy regimens that were used, and how many courses
of chemotherapy children were treated with prior to radiation
therapy. This information would have been important for those
patients in whom a subtotal resection was achieved, in determining
whether radiation therapy was used more frequently in tumors in
which control had not been achieved with radiation therapy.
In conclusion, we show that PLGGs are not the cause of death in
the majority of adult survivors and that patients diagnosed with
PLGGs have excellent long-term survival. This holds true for both
grade (I or II) and degree of resection (GTR or STR) in pediatric
low-grade gliomas. Therapeutic strategies should be designed to
provide tumor control while avoiding those that cause irreversible
long-term toxicity should be avoided as patients can be expected to
survive long into adulthood.
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Pediatric low-grade gliomas (PLGGs) are among the most common
solid tumors in children but, apart from BRAF kinase mutations or
duplications in specific subclasses, few genetic driver events are
known. Diffuse PLGGs comprise a set of uncommon subtypes that
exhibit invasive growth and are therefore especially challenging
clinically. We performed high-resolution copy-number analysis on
44 formalin-fixed, paraffin-embedded diffuse PLGGs to identify re-
current alterations. Diffuse PLGGs exhibited fewer such alterations
than adult low-grade gliomas, but we identified several signifi-
cantly recurrent events. The most significant event, 8q13.1 gain,
was observed in 28% of diffuse astrocytoma grade IIs and resulted
in partial duplication of the transcription factorMYBL1 with trunca-
tion of its C-terminal negative-regulatory domain. A similar recurrent
deletion-truncation breakpoint was identified in two angiocentric gli-
omas in the related gene v-myb avian myeloblastosis viral oncogene
homolog (MYB) on 6q23.3. Whole-genome sequencing of a MYBL1-
rearranged diffuse astrocytoma grade II demonstrated MYBL1 tan-
dem duplication and few other events. Truncated MYBL1 tran-
scripts identified in this tumor induced anchorage-independent
growth in 3T3 cells and tumor formation in nude mice. Truncated
transcripts were also expressed in two additional tumors withMYBL1
partial duplication. Our results define clinically relevantmolecular sub-
classes of diffuse PLGGs and highlight a potential role for the MYB
family in the biology of low-grade gliomas.
cancer | aCGH | A-myb
Pediatric low-grade gliomas (PLGGs) are the most commonbrain tumors in children and, collectively with other CNS
tumors, have surpassed leukemias as the leading cause of cancer-
related deaths in children and young adults (1). PLGGs are
generally categorized as “nondiffuse” or “diffuse” based on their
extent of brain infiltration. Nondiffuse tumors exhibit minimal
infiltration and are predominantly benign World Health Orga-
nization (WHO) grade I pilocytic astrocytomas (PAs), which are
most often cured by surgery alone. In contrast, diffuse gliomas
are associated with less favorable clinical outcomes, including
recurrence after initial resection, by virtue of their extensive in-
filtration and invasion into the brain. These tumors are also more
likely to progress to glioblastoma. PLGGs with diffuse growth
patterns are further subclassified histologically as diffuse astro-
cytoma grade IIs (DA2s), gangliogliomas (GGs), angiocentric
gliomas (AGs), pleomorphic xanthoastrocytomas (PXAs), and
several other rare glioma types (2). However, these subclasses
exhibit extensive heterogeneity and histologic overlap, often
precluding categorical diagnosis. PLGGs that cannot be cate-
gorized are often referred to as low-grade gliomas, not otherwise
specified (LGG-NOS) and represent nearly one-third of all
PLGGs. Moreover, these histologic categories do not reliably
predict biologic behavior and risk of malignant transformation.
Unifying genetic events have been identified in some PLGG
subtypes, including v-raf murine sarcoma viral oncogene homolog
B1 (BRAF) fusions in PAs and BRAF V600E mutations in PXAs
and GGs, with substantial diagnostic, prognostic, and therapeutic
implications (3–9). Identification of genetic alterations in diffuse
PLGGs would increase biologic understanding of tumor behav-
ior as well as define diagnostic molecular subclasses. However,
unlike pilocytic astrocytomas, the rarity and diversity of diffuse
PLGGs combined with the scarcity of frozen tissue available for
genomic analyses has historically impeded identification of ge-
netic alterations specific to these tumors. Prior studies have
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found that BRAF-KIAA1549 fusions are rare to nonexistent in
diffuse PLGGs, particularly in DA2s (10). Diffuse PLGGs in-
cluded in large cohorts of low- and high-grade gliomas were
suggested to have increased expression of the proto-oncogene
v-myb avian myeloblastosis viral oncogene homolog (MYB),
including rare cases with genomic aberrations involving the
gene (11), but no unifying recurrent genetic events have been
identified.
Here we describe high-resolution copy-number profiles of 44
diffuse PLGGs, the largest collection ever to have been analyzed,
and whole-genome sequencing of a diffuse PLGG. These studies
reveal a recurrent rearrangement of the transcription factor
v-myb avian myeloblastosis viral oncogene homolog-like 1 (MYBL1)
that induces anchorage-independent growth of 3T3 cells as well
as tumor growth in vivo. These findings indicate oncogenic events
that define subclasses of diffuse PLGGs.
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Fig. 1. CNAs among diffuse PLGGs. (A) Fraction of the genome altered by CNAs is lower among diffuse PLGGs compared with adult LGGs and high-grade
gliomas (P < 10−6). Blue bars indicate medians. (B) Amplifications (red) and deletions (blue) among 44 diffuse PLGGs (x axis) across the genome (y axis) ordered
by copy-number status. Significance (x axis) of (C) arm-level and (D) focal deletions (Left, blue) and amplifications (Right, red) across the genome (y axes).
Putative gene targets within the peak regions are indicated where known.
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Results
Characteristics of the Diffuse PLGG Cohort. To focus our studies on
diffuse PLGGs, we collected a diverse set of carefully screened
tumors through an international consortium of seven institutions
(Table S1 and Fig. S1). Our cohort specifically excluded the more
common, nondiffuse pilocytic astrocytomas, which are known to
be driven primarily by BRAF alterations and are the focus of
separate ongoing international collaborative sequencing efforts
[International Cancer Genome Consortium (Germany)]. Our co-
hort included 18 DA2, three AG, three desmoplastic infantile
ganglioglioma, nine GG, one subependymal giant cell astrocy-
toma, and 10 LGG-NOS tumors. Given the infiltrative growth and
rarity of certain categories of diffuse PLGGs, the samples that we
acquired were mostly archival formalin-fixed, paraffin-embedded
(FFPE) tissue. We recently developed a method for reliable per-
formance of array comparative genomic hybridization (aCGH) on
FFPE archival samples (12) and used this technique to determine
copy-number status at 1 million loci genome-wide. We also per-
formed deep whole-genome or whole-exome sequencing to define
and validate recurrent genetic events that drive tumorigenesis in
these rare pediatric cancers.
Genomic Identification of Significant Targets in Cancer Analysis
Identifies Significant Recurrent Events in Specific PLGG Subtypes.
The percentage of the genome altered by copy-number alter-
ations (CNAs) in diffuse PLGGs was significantly lower than
among previously profiled adult low- and high-grade gliomas
(P < 10−6, Mann–Whitney test, Fig. 1A) (13, 14). Few (12/44;
27%) of these tumors harbored alterations affecting more than
90% of the length of a chromosome arm (Fig. 1B), compared with
an 83–97% rate among adult low- and high-grade tumors (15).
One of the PLGG samples exhibited chromothripsis on chromo-
some 8 (chr8) (highlighted in Fig. 2A, PLGG27). The most sig-
nificantly recurrent arm-level CNAs were gains of chromosomes 7
(11% of tumors), 8 (7%), and 5q (5%) and loss of 1p (2%) (Fig.
1C). These events have all been described in pediatric high-grade
gliomas and adult gliomas with varying frequencies (15, 16).
We found 6 significantly recurrent regions of focal deletion
and 17 significantly recurrent regions of focal amplification (Fig.
1D and Table S2). One deleted region on 9p21.3 contained
cyclin-dependent kinase inhibitor 2A and 2B (CDKN2A and
CDKN2B), known tumor suppressors that had previously been
reported in diffuse PLGGs (17); a second region was immedi-
ately adjacent to this one. A third region (6q26) contained 252
genes, including the proto-oncogene MYB. Two regions
(10q21.3 and 8p22) contained single genes with no known re-
lation to cancer or neural development, catenin (cadherin-associated
protein), alpha 3 (CTNNA3) and zeta sarcoglycan (SGCZ), re-
spectively. The sixth region (13q31.3) contained 48 genes and
was adjacent to the known tumor suppressor RB1. We did not
identify any focal deletions of other known tumor suppressors
involved in adult or pediatric brain tumors such as neurofibromin 1
(NF1), phosphatase and tensin homolog (PTEN), or cyclin-dependent
kinase inhibitor 1C (CDKN1C).
One of the 17 focally gained regions contained BRAF. How-
ever, the canonical BRAF-KIAA1549 duplication-fusion was
detected in only four samples: two GGs and two LGG-NOS. This
is in contrast to pilocytic astrocytomas, among which >80% of
tumors harbor a BRAF duplication (18) (P < 0.0001, Fisher’s
exact test). We also determined BRAF V600E mutation status
in 24 tumors with sufficient DNA for sequencing. We found
mutations in 54% of the diffuse PLGGs (Fig. 1A and Table S1),
consistent with previously published rates for diffuse PLGGs (8).
A second focally gained region (3q26.33) contained the stem
cell and glial transcription factor sex determining region Y-box 2
(SOX2), which is amplified in adult glioblastomas (19). Two ad-
ditional regions (2q12.1 and 5q14.3) contained factors that control
telencephalic neural progenitor proliferation and differentiation:
POU class 3 homeobox 3 (POU3F3) (also known as BRN1) and
microRNA 9-2 (20, 21). A fifth region (1q21.3) contained myeloid
cell leukemia sequence 1 (MCL1), a known oncogene amplified in
several cancer types (22). Twelve regions either contained over
150 genes or did not contain genes with known roles in cancer or
neural development. We did not observe any high-level amplifi-
cation of receptor tyrosine kinases (e.g., EGFR, PDGFRA), which
are observed frequently in both adult and pediatric high-grade
gliomas (19, 23).
The most statistically significant recurrent focal aberration (q =
3.37 × 10−6) was a gain on chromosome 8q involving the tran-
scription factor MYBL1. Although MYBL1 is not a known onco-
gene, it is closely related to the proto-oncogeneMYB. In contrast to
prior reports (11), no amplifications or gains of the proto-oncogene
MYB were identified in our study set. All of the focal 8q gains
occurred in DA2s (P = 0.0057, Fisher’s exact test), comprising 28%
(5/18) of this histologic subtype. In contrast, MYBL1 was not in
a significant amplification peak across 3,131 cancers comprising
multiple other cancer types that we had previously analyzed (22) or,
specifically, among adult low- or high-grade gliomas (15).
All five DA2 samples with 8q focal gains exhibited a common
centromeric breakpoint within MYBL1 after exon 9, including
the sample with chromothripsis of chr8 (Fig. 2A). To confirm the
MYBL1 centromeric breakpoint, we performed fluorescence in
situ hybridization (FISH) using a probe slightly telomeric to the
breakpoint on all eight DA2 samples with sufficient tissue
available (Fig. 2B and Fig. S2). All DA2 samples with 8q gain (3/3)
demonstrated duplication of one allele in more than 60% of the
nuclei in each tumor whereas none of the other DA2 samples
showed duplication (0/5) (P = 0.018, Fisher’s exact test).
The tight clustering of these breakpoint sites, and particularly
their location immediately preceding the C-terminal negative
regulatory domains of MYBL1 and MYB, suggested a mecha-
nism for rearrangement and creation of functional, truncated
genes reminiscent of the viral oncogene v-MYB (Fig. 2C). In-
deed, we also identified a homologous breakpoint between
exons 10 and 11 of MYB on 6q in one angiocentric glioma with
a focal 6q deletion (Fig. S3) similar to that previously reported
in a single angiocentric glioma with a 6q deletion (11). An ad-
ditional angiocentric glioma (PLGG45), not included in our
initial diffuse PLGG cohort and genomic identification of sig-
nificant targets in cancer (GISTIC) analysis, also exhibited
a deletion in 6q at the same location inMYB as seen in PLGG29
(Fig. S3).
Whole-Genome Sequencing of a DA2 with 8q Focal Gain Defines
a Tandem Duplication–Truncation of MYBL1. To further character-
ize the MYBL1 amplicon and its genetic context, we performed
90× whole-genome sequencing of a DA2 sample with MYBL1
gain but no other CNAs (PLGG24, Table S3). Whole-genome
sequencing of PLGG24 determined the centromeric breakpoint
of the 8q amplicon to single-base resolution between exons 9
and 10 of MYBL1 (Fig. 3A). The telomeric sequence was lo-
cated in an intergenic region 38 kb from matrix metallopeptidase
16 (MMP16). We validated the breakpoint locations in this
sample using PCR on native genomic DNA from the same
tumor (Fig. S2 C and D). Taken together, our data define
a tandem duplication–truncation of MYBL1.
Apart from this event, whole-genome sequencing of PLGG24
revealed a sparsely altered genome. No other CNAs or fusion
events were identified, and the BRAF V600E mutation was not
present. Three nonsynonymous mutations in exons were identified
(Table S4); none of these have been reported in association with
cancer. The genome-wide mutation rate (1.48/Mb) and the
number of nonsynonymous mutations in exons (three per ge-
nome) were low compared with pediatric and adult high-grade
astrocytomas (mutation count means: 15 and 47.3 per genome,
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respectively) (16). The low rate of CNAs, mutations, and trans-
locations in this sample highlight the potential biological impact
of MYBL1 duplication–truncation.
Tandem Duplication–Truncation of MYBL1 Results in Expression of
Oncogenic Transcripts. To determine whether the MYBL1 dupli-
cation–truncation resulted in expression of fused transcripts, we
performed 3′-rapid amplification of cDNA ends (3′-RACE) on
cDNA generated from RNA of PLGG24. We identified two
populations of MYBL1 transcripts, both of which contained
MYBL1 exons 1–9 but also acquired short noncanonical
sequences fused to the 3′ ends, leading to premature translation
stops (Fig. 3B). The first transcript (MYBL1-trunc1) contained
an additional 15 bp of intronic sequence, and the second tran-
script (MYBL1-trunc2) acquired 36 bp from the intergenic region
near MMP16. MYBL1-trunc1 was retrieved more frequently
(74%) than MYBL1-trunc2 (26%); the wild-type transcript was
not observed. We then performed RT-PCR to detect MYBL1-
trunc1 and MYBL1-trunc2 in the two other PLGGs with 8q focal
amplification for which we had sufficient RNA (PLGG25 and
PLGG28). We detected MYBL1-trunc2 in both of these samples
(Fig. 3C), indicating that this transcript is recurrently expressed
in DA2s.
To assess the oncogenic potential of these transcripts, we
transduced 3T3 cells with lentiviruses containing MYBL1-trunc1,
MYBL1-trunc2, full-length MYBL1-wt, or GFP control con-
structs and plated them in soft agar. Both aberrantly truncated
MYBL1 sequences produced soft agar colony growth indicative
of transformation (Fig. 4A). No evidence of colony formation
was noted with full-length MYBL1-wt or GFP control. Both
MYBL1-trunc1– and MYBL1-trunc2–transformed 3T3 cells were
also able to form tumors with malignant histology in Nude mice,
whereas cells transduced with full-length MYBL1-wt constructs
showed no evidence of tumor formation (Fig. 4 B–D). These
results suggest that the truncation of MYBL1 is oncogenic.
Discussion
Our data identify several recurrent somatic genetic events in
PLGG, some of which track with specific histologic types. The
most significant of these was recurrent focal amplification of
MYBL1, found exclusively in DA2 samples, none of which had
other PLGG-associated lesions such as a BRAF duplication.
Focal deletion of 6q involving the MYB locus was also observed
in two angiocentric gliomas in our dataset, similar to deletions in
two individual cases of angiocentric glioma noted in prior stud-
ies. Such aberrations may therefore be useful in identifying this
tumor type (11, 24). In other cases, genetic events span histologic
subtypes and tumor grades, such as duplications of BRAF in GG
and NOS samples in our diffuse PLGG cohort as well as dele-
tions involving CDKN2A/B (Fig. 5). Although previous work had
identified high-level amplification of MYB and 6q deletions in-
volving MYB in several DA2 tumors, we detected no such events
in our DA2 cohort (11).
These findings provide genetic and functional evidence of a role
for MYBL1 and the MYB proto-oncogene family of transcription
factors in low-grade gliomagenesis. MYB transcription factors are
known to regulate cell-cycle progression in multiple cellular con-
texts, and MYB has been identified as an oncogene in T-ALL and
adenoid cystic carcinomas (25). The MYB family members share
extensive homology in their DNA-binding domains; however, they
differ in their C-terminal domains. In vitro and in vivo studies have
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demonstrated roles for each transcription factor in cell-cycle reg-
ulation mediated by interactions with and modifications of the C
terminus (26). Truncating deletions may affect the transcriptional
activity of MYB transcription factors by loss of a conserved neg-
ative regulatory domain or may result in increased gene expression
due to loss of a 3′ UTR targeted by microRNA 15a/16 and
microRNA 150 (25). Our results suggest that truncations affecting
the C terminus of MYB family transcription factors may be suf-
ficient to drive oncogenesis in a discrete molecular subclass of
diffuse PLGGs by acting as gain-of-function mutations.
Methods
Patients and Samples. Institutional review board approval from all institu-
tions (Boston Children’s Hospital, Dana-Farber Cancer Institute, The Univer-
sity of Texas School of Medicine Southwestern, Children’s Cancer Hospital-
Egypt, The Johns Hopkins University School of Medicine, Children’s National
Medical Center, Hospital for Sick Children, and the Mayo Clinic) was
obtained, and all samples were from patients who provided informed con-
sent or were studied with waiver of the requirement for informed consent
by the Dana-Farber Cancer Institutional review board. Samples of various
histologic subtypes were identified, collected at multiple institutions, and
central histopathologic review was performed by at least three board-cer-
tified neuropathologists using WHO criteria (K.L.L., S.S., S.H.R., or J.A.C.).
aCGH and Data Processing. DNA extraction from archival FFPE samples and
aCGH were performed as previously described (12). GC-normalized copy-
number data for the samples were then cleaned of known germ-line copy-
number variations. Circular Binary Segmentation was used to segment the
copy-number data, using parameters (α = 0.001, undo.splits = sdundo, undo.
SD = 1.5, minimum width = 5). Segmented data were analyzed with GISTIC
2.0 to determine statistically significant recurrent broad and focal CNAs
using the following parameters: minimum segment size = 8, lesion ampli-
tude threshold = 0.2, focal/broad cutoff = 0.9× chromosome arm length,
q-value threshold = 0.10, and gene confidence level = 0.95. For comparison
of diffuse PLGG data to previously published adult low-grade glioma (LGG)
and high-grade glioma (HGG) data (13, 14), previously segmented copy-
number data were subjected to the same GISTIC analysis parameters
as above.
Whole-Genome Sequencing and Data Processing. DNA from fresh-frozen tissue
from PLGG24 and paired blood was extracted using the QIAGEN DNA Blood
and Tissue kit. A target depth of 90× in blood and tumor was set for Illumina
sequencing, using two different insert-size libraries (500 and 800 bp) to
maximize detection of rearrangements (27). Sequencing quality control (QC)
metrics are shown in Table S3.
Sequence data were aligned to the hg19 (b37) reference genome with the
Burrows-Wheeler Aligner (28) with parameters [-q 5 -l 32 -k 2 -t 4 -o 1].
Aligned data were sorted, normalized, mate-fixed, duplicate-marked, and
indexed with Samtools and Picard tools (29). Base-quality score recalibration
and local realignment around insertions and deletions was achieved with
the Genome Analysis Toolkit (30, 31).
Somatic mutations and small insertions-deletions were called with MuTect
and Indelocator, filtered against a panel of normals, and annotated to genes
with Oncotator (29, 32, 33). CNAs were called with SegSeq and standard
parameters (34). Somatic rearrangements were identified with dRanger and
BreakPointer algorithms (32, 33) with the cutoff SN parameter increased to
1,000 bp (reflecting the larger-than-normal insert sizes used for sequencing).
Results are reported with high confidence if the dRanger score was ≥8 and
the BreakPointer algorithm identified the exact breakpoints on both ends
(equivalent to 8× high-confidence coverage of read pairs spanning the
breakpoint).
Whole-Exome Sequencing. DNAwas extracted from tumors as above, and 250-
bp libraries were prepared by Covaris sonication, followed by double-size
selection (Agencourt AMPure XP beads) and ligation to specific barcoded
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adaptors (Illumina TruSeq) for multiplexed analysis. Exome hybrid capture
was performed with the Agilent Human All Exon v2 (44 Mb) or Illumina
TruSeq bait sets, and samples were sequenced as above. Tumors were
manually reviewed for the presence of the BRAF V600E mutation.
FISH and PCR. FISH was performed on 4-μm tissue sections using methods
described previously (35) and Homebrew probes RP11-110J18 (5′ toMYBL1;
directly labeled in SpectrumOrange) and RP11-707M3 (3′ to MYBL1; di-
rectly labeled in SpectrumGreen) that map to 8q13.1. MYBL1 status was
assessed in 50 tumor nuclei per sample. PCR was performed on genomic
DNA from PLGG0024 and control samples to confirm breakpoint sequences
identified by dRanger. Primer sequences (5′-AATGCTATCCCTCCCCACTC-3′
and 5′-GAGGGAGCTTGGAAATTTGA-3′) targeting MYBL1 and intergenic
sequences, respectively, amplified a 450-bp fragment. The band was gel-
purified, cloned (TOPO TA Cloning; Invitrogen, and sequenced by Sanger
sequencing to validate the fusion.
RT-PCR and 3′-RACE. MYBL1-trunc1 and MYBL1-trunc2 were cloned from
PLGG24 frozen tumor tissue using a 3′ RACE kit (Invitrogen) per manu-
facturer’s instructions. To amplify all MYBL1 specific transcripts, primers
targeting the 5′ end of MYBL1 (5′-AAAACCCTGCAGGAGACTG-3′) were
used in conjunction with a universal amplification primer (UAP). A second
PCR was performed using a nested MYBL1 primer (5′-TGCGGTACTTGAAG-
GATGG-3′) along with the UAP. PCR products were subjected to Sanger
sequencing, and results were aligned to the hg19 reference genome. For RT-
PCR reactions, RNA was extracted from FFPE samples of PLGG09, PLGG25,
and PLGG28 using RNeasy FFPE kit (Qiagen). cDNA was generated from
500 ng RNA using the iScript cDNA synthesis kit (Bio-Rad). PCR to detect
the presence of MYBL1-trunc2 was performed using primers targeting the
MYBL1 exon 7–8 junction (5′-ATTGTATAGAACATGTTCAGCCT-3′) and the
MYBL1-trunc2 sequence (5′-GGTCCTCTGCCTCTAGAATAGATTC-3′).
Expression Constructs and Lentiviral Production. Full-length MYBL1-wt (Open
Biosystems),MYBL1-trunc1, andMYBL1-trunc2 cDNA sequences were subcloned
into the pLenti7.3/V5 vector using the Gateway system (Invitrogen). For retroviral
production, 293FT packaging cells were cotransfected with pBabe expression
clones, Gag-pol, and vs.v-g. Viral supernatant was harvested 48 h after trans-
fection, filtered through a 45-μm filter, and concentrated by ultracentrifugation.
Anchorage-Independent Growth Assay. Wild-type 3T3 mouse embryonic fibro-
blasts (ATCC) were transduced by addition of viral supernatant to the growth
medium. Twenty-four hours later, infection efficiency was evaluated based on
GFP expression and determined to be >80%. Cells were harvested and mixed
with growth medium containing 0.33% bactoagar, and 1 × 104 cells were
plated in triplicate onto a bottom layer of medium with 0.5% agar in a six-
well plate. Soft agar colonies were counted 2 wk later. Images were acquired
using the AlphaInnotch FluorChem HD2 Imager.
Flank Tumor Growth Assay. The Institutional Animal Care and Use Committee
at Dana-Farber Cancer Institute preapproved all animal experiments. 3T3-
MYBL1-wt, 3T3-MYBL1-trunc1, or 3T3-MYBL1-trunc2 cells (106) were sus-
pended in 150 μL PBS, mixed with 150 μL Matrigel (BD Biosciences), and then
injected into the flank of 6-wk-old male Nude (NU-Foxn1, Charles River)
mice. Mice were then monitored for signs of distress or tumor growth. Six
weeks post injection the mice were euthanized and analyzed for tumor
growth. Tumors were subjected to standard histologic analysis.
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The ability to predict patient tumour response to cytotoxicor target defined therapeutic agents remains a holy grail.While molecular and genetic profiling is driving the
evolution of subtype-specific personalized therapy1,2, the
presence of a biomarker often does not translate into a
successful clinical outcome3–5. For example, epidermal growth
factor receptor (EGFR) inhibitors, cetuximab and panitumumab,
are approved for metastatic colorectal carcinoma with wild-type
KRAS, but provide clinical benefit in only 10–20% of selected
patients1,6,7. A technology that can identify drug sensitivity and
predict clinical benefit can significantly advance the clinical
management of cancer.
Emerging evidence implicates intratumoral heterogeneity, both
hierarchical and stochastic, in the variability of response to
chemotherapy, which is not captured by the existing cancer cell
biomarker-based approaches. Genetic and epigenetic distinctions
within clonal populations could critically determine whether a
particular drug combination will benefit a patient or result in
resistance8–13. In addition, the contribution of the tumour
microenvironment to these phenotypes is increasingly being
appreciated9,10,14,15. Indeed, the spatial distribution of cancer and
stromal cells within the tumour microenvironment can affect how
they interact with each other and their microenvironment, which
in turn can impact proliferation, differentiation, morphology and
a range of cellular functions16–18. We rationalized that to predict
the clinical outcome of chemotherapy with high accuracy, it is
therefore important to conserve this clinical ‘global’ heterogeneity
with high fidelity in terms of cancer and stromal cells, tumour
microenvironment and architecture. Unfortunately, current gold-
standard in vitro and ex vivo preclinical approaches that employ
cell lines and spheroids3,12,19 or ex vivo organotypic tumour
models are all limited by their inability to capture the full
biological approximation of the native tumour, resulting in poor
mapping to clinical outcomes19–22.
To create a clinically relevant predictive model, here we
engineered an ex vivo tumour ecosystem, where thin tumour
sections with conserved cellular and microenvironmental hetero-
geneity and architecture were cultured in tissue culture wells
coated with grade-matched tumour matrix support in the
presence of autologous serum (AS) containing endogenous
ligands. The integration of the tumour ecosystems with a
novel machine learning algorithm formed the CANScript
platform, which reliably predicted the therapeutic efficacy
of targeted and cytotoxic drugs in patients with head and
neck squamous cell carcinoma (HNSCC) and colorectal cancer
(CRC). The robustness of this platform in predicting clinical
response could potentially be useful for personalizing cancer
treatment.
Results
Role of matched tumour matrix proteins in CANScript platform.
We depict the schematic for the development and validation of
the CANScript platform in Fig. 1. A detailed patient demography
and tumour subtypes used in this study are provided in
Supplementary Table 1. As a first step towards mimicking the
patient tumour ecosystem, we studied the contribution of cancer
and grade-specific human tumour-stromal matrix proteins
(TMPs) in preserving tumour morphology of HNSCC and CRC
explants in an ex vivo setting. Indeed, three-dimensional (3D)
matrix support is emerging as a critical factor that dynamically
determines the fate of tumours in terms of integrity, survival,
metastasis and response to chemotherapy23–25. We isolated and
characterized the matrix components from clinical HNSCC
and CRC tumours using processes described in detail in
Supplementary Methods and Supplementary Fig. 1. The overall
relative abundance of different TMP in tumour (both HNSCC
and CRC) biopsies was analysed by liquid chromatography–mass
spectrometry (LCMS/MS; Fig. 2a). Interestingly, a systematic
analysis of the major TMP components not only revealed distinct
compositions between the two tumour types and between high-
and low-grade tumours of the same type (Fig. 2b,c), but also
heterogeneity within the patient population as demonstrated
using heat maps (Supplementary Figs 2a,d and 3a,d). Venn
diagrams reveal unique matrix proteins that were conserved
across the patient cohort within each tumour type and grade
(Supplementary Figs 2b,e and 3b,e), which together with their
abundance (median) (Supplementary Figs 2c,f and 3c,f) formed
the basis for selection of the proteins to create the tumour- and
grade-matched cocktails (listed in Supplementary Figs 2,3). We
coated tissue culture microwells with these defined cancer- and
grade-specific TMPs, which was confirmed using scanning
electron microscopy and matrix proteins-specific immuno-
fluorescence (Fig. 2d). Thin section tumour explants were then
cultured in these TMP-coated wells. As compared with uncoated
control, type- and grade-matched TMP showed a dose-dependent
improvement in the maintenance of tissue morphology,
proliferation and cell viability of the tumour explants (Fig. 2e,f).
Furthermore, scanning electron microscopy analysis of native
tumour extracellular matrix structure post culture indicated that
integrity was better preserved in tumour explant tissues that were
provided with TMP support (Fig. 2g). To further understand the
role of grade-matched TMP cocktail, we did a cross-comparison
analysis where high- and low-grade tumours were cultured in
matched and unmatched TMP-coated plates. As shown in Fig. 2h,
explants cultured on matched TMPs better retained native (T0)
proliferation (Ki-67) state compared with the corresponding
unmatched counterparts and no matrix controls. As expected,
high-grade tumours did exhibit a greater capacity to preserve
the proliferation profile even in low-grade TMP. Low-grade
tumours in high-grade matrix performed poorly (Fig. 2h and
Supplementary Fig. 4a). Next we compared the effects of different
commercially available matrix proteins with TMP coating in
maintaining the proliferation, viability and signalling activation of
the explants to the native state (T0 baseline). As shown in Fig. 2i–j
and Supplementary Fig. 4b, explants cultured in non-coated wells
lost tumour architecture and exhibited decreased viability,
proliferation and activation of oncogenic pathways compared
with T0 baseline. While gelatin coating was no better than
non-coated condition, collagen partially supported tumour
proliferation, tumour area and phosphorylation of ERK1/2 but
not cell viability. Interestingly, Matrigel, a widely used murine
tumour-derived matrix, resulted in increased cell viability,
tumour area and phospho-ERK but not in proliferation (Fig. 2j
and Supplementary Fig. 4b). In contrast, explants cultured
in matched TMPs retained tumour morphology, viability,
proliferation and phospho-ERK1/2 status similar to the T0
baseline parameters. This observation is consistent with recent
reports that highlight context-dependent stromal-epithelial
interaction as a critical requirement of tumour cell survival and
maintenance10.
Autologous ligands maintain the signalling and phenotypes.
A heterogenous tumour microenvironment represents a diverse
network of oncogenic signalling pathways, which are activated in
both ligand-dependent and -independent manner and can spa-
tiotemporally and dynamically cross-talk26–30. Indeed, a reverse
phase phosphoprotein array (RPPA)-based profiling of key
receptor tyrosine kinases (RTKs) and their nodal proteins in
the tumour biopsies revealed a heterogeneity in the baseline
activation levels of these receptors and downstream signals
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(Fig. 3a and Supplementary Fig. 5a,b). This led us to hypothesize
that a balanced induction of these receptors using their original
ligands in an individualized setting is critical to mimic the
baseline networks of the parent tumour ex vivo.
Autocrine–paracrine loops of growth factors enriched in
patient sera contribute to the activation of signalling networks
and survival cascades in cancer cells10,31,32. As the second step
towards fabricating the CANScript platform, we therefore studied
the functional attributes of AS. As shown in Fig. 3b a number of
growth factors (represented by EGF, hepatocyte growth factor
(HGF), vascular endothelial growth factor (VEGF) and
macrophage colony-stimulating factor (MCSF)) were found to
be within clinically detectable ranges in patient sera. The
variability in the levels of these growth factors that exists
between individuals further underlined the importance of using
the complete AS for a balanced induction of signal transduction
pathways as opposed to an artificial combination of growth
factors. We first performed a dose–response analysis, where
increasing concentrations of AS was used in combination with a
reducing percentage of fetal bovine serum (FBS) in the culture for
72 h. A concentration dependent increase in cell proliferation in
the explants was observed while supplementing the system with
AS that attained the peak at 2% (Fig. 3c). Concomitantly, 2% AS
also mimicked the native state (morphology and proliferation) of
tumours at T0 baseline (Fig. 3d). The decline above this
concentration is consistent with earlier observations with
growth factor ligands and possibly arises due to the
downregulation of targets33. In addition, 2% AS (þ 8% FBS)
resulted in significant increase in ATP utilization and cell
proliferation compared with 10% FBS or recombinant EGF
alone (Fig. 3e,f). Furthermore, compared with exogenous EGF
controls, the addition of AS significantly preserved the major
signalling networks as measured by phosphorylation of EGFR,
Met and downstream target, ERK1/2. It is interesting to note that
1 ngml" 1 concentration of EGF predominantly activates EGFR
pathway alone. In contrast, 2% AS showed the capacity to activate
both EGFR and HGFR/Met pathways along with downstream
ERK1/2 comparable to the T0 baseline, consistent with the
balanced effect of patient-derived ligands in its natural milieu.
The enhanced response to AS was reduced to T72 h baseline (that
is, no AS control) using neutralizing antibodies to EGFR, which is
consistent with the aberrant activation of EGFR pathway in a
majority of HNSCC and other cancers of epithelial origin27,29.
However, the neutralizing antibody failed to fully abrogate the
proliferation below the level of T72 h control, suggesting that
despite the predominant role of EGFR in some individual
tumours additional constitutive mechanisms exist that might
contribute to minimal maintenance of these tumours (Fig. 3g–i).
It is obvious that the survival of tumour is not a consequence of
dependency on single pathway lineage or network.
To further validate the contribution of autologous sera in
personalizing the explant culture, we compared the individual
effects of heterologous/allogenic sera (HS) obtained from
treatment naı¨ve patients (age, sex and cancer-type matched)
with AS and recombinant EGF. As shown in Fig. 3j,k, while
EGF resulted in the maximum effect in inducing EGFR
phosphorylation, 2% AS efficiently maintained both EGFR and
Met phosphorylation. In contrast, 2% HS, while exerting a greater
effect than no ligand (T72 h) control, was significantly inferior to
AS. Similar pattern was observed for Ki-67 (Supplementary
Fig. 6a). Taken together, these results indicate that presenting the
entire repertoire of growth-promoting ligands by using AS is
critical to fully capture the parental activation status of important
receptors in the personalized explant setting. Indeed, RPPA array-
based analysis of the parent HNSCC tumours (T0 baseline)
showed that a bulk of the proteins in RTK cascades that were
upregulated are largely conserved in the tumour explants cultured
in 2% AS (Fig. 3l and Supplementary Fig. 6b).
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Figure 1 | Schematic showing the development and validation of the CANScript technology. Four critical modules were integrated in generating and
validating the CANScript platform. The first module involved collecting tumour core or surgical biopsy with tumour staging and pathology information
besides clinical/treatment history. In the second module, tumour biopsy was rapidly processed into thin explants. Tumour biopsies were also used to
generate either in vivo implants in mice, or processed for isolation and analysis of tumour matrix, which was used to develop the TMP cocktail. The explants
were cultured in tumour- and grade-matched TMP and AS and incubated with selected drug regimens. While multiple drug regimens can be used, the one
used by the oncologist for the patient was always included in the tumour explant culture. Functional outcome of treatment in terms of cell viability,
pathological and morphological analysis, cell proliferation and cell death was quantified. In module three, these quantitative scores from the explants were
aggregated using a machine learning algorithm to assign a final score, which helped rank the outcomes as CR,PR or NR. The learning algorithm was trained
on data from 109 patients. In the final module, these predictions were tested against clinical outcomes from 55 new patients to validate the approach.
D1, D2, D3 and D4 indicate different drug regimens.
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Reconstructing a tumour ecosystem. As the final step towards
constructing the CANScript tumour ecosystem, both conditions
(that is, TMP and AS) were contextually integrated in the
explant system. Immunohistochemistry (IHC) labelling was
used to evaluate a number of static and dynamic phenotypic
markers associated with functional heterogeneity of tumour
microenvironment. Profiling for CD68 (marker for immune
component)34, VEGFR (marker for angiogenesis), CD34 (marker
for angiogenesis and progenitors)35, E-Cadherin and Vimentin
(markers for epithelial mesenchymal transition (EMT)) revealed
that the combination of AS and TMP conserved the parental (T0)
phenotypes better than T72 h control or EGFþTMP(Fig. 4a,b).
Similar effects of AS and TMP were also observed for EMT-
specific markers (Fig. 4c). Furthermore, cell viability, proliferation
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Figure 2 | TMPs are critical for conserving primary tumour characteristics in explants. (a) The average composition and abundance range of key
components of TMP. Abundance range was measured based on area under the peak using Pearson’s correlation for clustering of protein features. The line
within each notch box represents the median, and the lower and upper boundaries of the box indicate first and third quartiles, respectively (n¼ 24), of
some of the key TMPs isolated from (b) HNSCC (n¼ 12) and (c) CRC tumours (n¼ 12) (d) scanning electron microscopy (SEM) images of plastic surface
precoated with Collagen-I (top) or TMP cocktails (bottom). Scale bars, 1 mm. Adherence of the component proteins to the surface and their ability to form
networks is shown following immunofluorescence (IF) staining using human Collagen-I antibody. Adherence was measured by detecting specific
fluorescence signal in coated area contrasting to uncoated area of the same surface. Scale bars, 200mm (right). (e) HNSCC explants were cultured for 72 h
in plates coated with different concentrations of TMP as indicated. Maintenance of overall intratumoral heterogeneity and integrity was determined by
hematoxylin and eosin staining (H&E; top) and tumour cell proliferation by Ki-67 staining (bottom). Scale bar, 100mm. (f) Tumours from HNSCC patients
were sliced. Explants were cultured for 72 h in plates coated with different concentrations of TMP as indicated. Percent tumour area, cell viability and
Ki-67þ cells per field was measured (mean±s.d.). *Pr0.05 compared with uncoated control using paired t-test. Data represent one of the five
independent experiments performed in triplicates. (g) HNSCC tumour slices cultured for 72 h with or without TMP were subjected to extraction of native
extracellular matrix (ECM). Preservation of ECM 72h post culture was determined by IF staining of extracted ECM parallel to SEM imaging (inset).
(h) HNSCC tumours of high and low grades were sectioned cultured for 72 h in plates coated with matched and unmatched TMP (high and low grade)
Scatter plot indicates the effects of grade-matched and unmatched TMP on retaining the proliferation profile. Percent Ki–67–positive cells from HNSCC
explants were calculated at the end of 72 h based on T0 score. **Po0.0002, #Po0.05 for the high-grade tumours cultured in presence of low-grade
TMP by paired Student’s t-test. NS, not significant (n¼ 12). (i) Representative images show the effects of CRC-specific TMP and other coating materials
on pERK status (top), proliferation (middle) and morphology (bottom) of tumour explants. Scale bar, 100 mm. (j) Quantitative analysis of TMP on
proliferation, tumour area and pERK status in CRC explants. **P o0.01 compared with T72 control (analysis of variance, n¼ 8).
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index, and metabolic state of the explants in the CANScript
tumour ecosystem was similar to native (parent/T0 baseline)
tumour and significantly enhanced compared with control
explants cultured without AS and TMP, or with either AS or
TMP alone. The pattern of augmentation of Ki-67 upon
ASþTMP was found to be consistent and significant
(Fig. 4d,e). Together these results indicate that the native
tumour-stromal micro-architecture and phenotypic features
were largely conserved in the CANScript tumour ecosystem
compared with the culture conditions with only TMP or AS or
EGF-supplemented TMP. Next, we used microarray profiling to
compare the transcriptome of primary tumours at baseline (T0)
and serially sectioned tumour explants cultured under different
conditions. Indeed, a high degree of conserved global
transcriptomic profile consistent with the primary tumour was
observed only in the case of the CANScript platform that
integrated both TMP and AS, while supplementing the explant
cultures with either AS or TMP(þ EGF) alone resulted in distinct
transcriptomic signatures (Fig. 4f,g). Concurrent to the
phenotypic expression as shown in Fig. 4a,b, conservation of
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stromal gene expression signatures, specifically linked to tumour-
associated macrophages and angiogenesis were also observed
(Fig. 4g). To further confirm these results, a selected panel of
genes relevant to TAM (that is, PDGFA, DUSP1 and STAT3) and
angiogenesis (that is, FABP4 and ITSN1) signatures
(Supplementary Table 2) was analysed under different
conditions using qRT–PCR. As shown in Fig. 4i, the expression
of these markers were conserved only under ASþTMP condition
but not when either is absent. In addition, expression of tumour-
associated key cytokine/chemokines, such as interleukin-6,
interleukin- 8 and CXCR-4, matrix degrading enzyme matrix
metallopeptidase 9 (MMP-9) and cancer stem cell markers like
CD44 and ALDH1 observed in the parent HNSCC tumours were
also preserved in the CANScript tumour ecosystem
(Supplementary Fig. 7a–c). It is important to note that unlike
common synthetic organotypic inserts, the CANScript platform
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Figure 4 | Integration of both TMP and AS in the CANScripts maintains the tumour ecosystem. (a) Representative IHC images show the effect of AS
and matchedTMP on the phenotypic stability of tumour explants 72 h post culture. Tumour sections were stained for CD68, VEGFR and CD34. Scale bar,
100mm. (b) Quantitative IHC based box plot indicates CD68, VEGFR and CD34-positive cells in the explants maintained under different conditions.
Horizontal line represents median and error bars indicate the interquartile range. *Po0.05 and **Po0.001, respectively (paired t-test, n¼8).
(c) Representative IHC images show EMTrelated markers of tumour microenvironment in the CANScript explants. Scale bar, 100mm. (d) Graph shows the
combined effects of AS and TMP on the functional integrity of the explants. Tumour sections were cultured for 72 h. Number of Ki-67-positive cells
were counted and plotted along with percent viability and ATP utilization per section in triplicates (mean±s.d.). **Po 0.01 (by analysis of variance).
(e) The combined effects of AS and TMP on the functional integrity of explants are represented as scatter plot (n¼ 8). Number of Ki-67-positive cells were
counted and plotted. HS was run as a control. *Po 0.05 (by paired t-test). (f) 3D-PCA plot showing global gene expression patterns between different
culture conditions (that is, no AS and no TMP, EGFþTMP, ASþTMP and T0 baseline) obtained from HNSCC tumour explants after 12 h. After initial
normalization of data analysis was performed compared with baseline. (g) Heat map analysis of the microarray data showing the genes related to
TAM (top) and angiogenesis (bottom). Tumours explants were cultured in TMP-coated plates with AS (ASþTMP, lane 2) or EGF (EGFþTMP, lane 3) or
in uncoated plates without AS (No TMP and no AS Control, lane 4) and transcriptomic pattern was compared with base line tumour (lane 1). Heat map
scale indicates the expression range. Clustering of genes was performed by k- means algorithm. Distance was measured by Euclidean distance metric.
(h) Venn diagram showing number of overlapped genes related to TAM and angiogenesis between the three culture conditions. (i) Validation of microarray
gene signature by qRT–PCR for TAM (left) and angiogenesis (right); selected genes from each signature was run in triplicates (technical replicates)
normalized to baseline expression (biological replicates) and compared between conditions as indicated in the scatter plot (n¼ 5).
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exhibited enhanced preservation of native tumour morphology
and proliferation status (Supplementary Fig. 7d). Taken together,
these results suggest that a number of phenotypic markers
characteristic of EMT, immune cells and cytokines as well as
cancer stem cell phenotypes are more consistently and collectively
better conserved in this platform compared with culture
conditions with either TMP or AS or EGF-supplemented TMP.
CANScript predicts response to cytotoxic and targeted drugs.
The conservation of patient tumour heterogeneity in the
CANScript tumour ecosystem prompted us to explore the
possibilities of using this as a preclinical tool to predict anticancer
drug response. To assess this, we first compared drug response in
human tumour-derived xenotransplants (HTX) and in matched
CANScripts explants (constructed from passage 2, that is,
P2-HTX). Primary HNSCC tissues were propagated in severe
combined immunodeficiency mice up to second passage
(P2-HTX). Since response and resistance to a particular drug
combination can be intrinsically controlled by deregulation at the
genetic and epigenetic levels,11,36–38 we first mapped the degree
to which a xenotransplanted tumour (at P2) conserves the
descriptors of the primary tumour. Interestingly, exome data
from three different primary samples, HNSCC-1, HNSCC-2 and
HNSCC-3, and their matched P2-HTX, showed that while the
overall events of mutation and translocation of primary tumours
were largely preserved when passaged in immunocompromised
mice, there were mutations that were unique to original parental
P0 and P2-HTX, respectively (Fig. 5a,b and Supplementary
Table 3). However, global transcriptome pattern showed a
good association between P0 and matched HTXs (Fig. 5c,d).
Furthermore, histopathological characterization of P2-HTX
revealed that the HTX successfully conserved key
morphological and molecular characteristics of original parental
(P0) tumours, including the expression of proliferation marker
(Ki-67), glucose transport (GLUT1), phospho-EGFR and
phospho-AKT (Fig. 5e). Subsequently, these extensively
characterized P2-HTX were used as surrogates for initial
functional validation of the CANScripts. HTX-derived
CANScripts were concurrently treated with the clinically
approved cytotoxic drug regimen of docetaxel, cisplatin and
5-fluorouracil (TPF), segregated into two groups of responders
and non-responders based on viability, ATP utilization,
proliferation status and loss of tumour area/nuclear
fragmentation (Fig. 6a–c and Supplementary Fig. 8a–c).
Interestingly, we noticed an excellent correlation between the
outcomes in the CANScript platform and the response to
chemotherapy in the HTX studies. For example, cases predicted
as responders using the CANScript tumour ecosystem mapped to
a significant inhibition of tumour growth when the animals were
treated at maximum tolerated dose daily for up to 21 days
(Fig. 6d). The results were further validated at the molecular level
by determining the end point changes in mean tumour area/
nuclear size in sections, Ki-67 and concomitant drug-induced
increase in apoptotic cells by staining with TUNEL method
(Fig. 6e,f). Similarly, cases predicted as non-responders using the
CANScript tumour ecosystem did not show any effect in HTX
system, as defined by the lack of any distinctions in Ki-67 and
active Caspase-3 expression between the treated and untreated
groups (Supplementary Fig. 8a–e).
The ex vivo to in vivo correlation in response to a general
cytotoxic drug combination that we observed in HNSCC samples
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encouraged us to further validate the predictive ability of
CANScript for targeted therapeutics. For this purpose we used
HTXs generated from HNSCCs harbouring wild-type or mutant
KRAS. Consistent with the results observed earlier with
cytotoxics, a positive response in the CANScript explants with
cetuximab (Fig. 6g–i) was mirrored by tumour inhibition in vivo
(Fig. 6j–l).The functional outcome was correlated with a decrease
in Ki-67 positivity, increased TUNEL and a reduction in
phospho-EGFR levels in both the CANScript explants and
in vivo (Fig. 6h,i,k,l and Supplementary Fig. 9a,b). We next
tested the effect of cetuximab in HTX and CANScript explants
generated from CRCs. As shown in Supplementary Fig. 10a–g, an
inhibitory outcome in the CANScript explants correlated with a
significant tumour growth inhibition in vivo, while in the absence
of an inhibitory effect in the tumour ecosystem (TE), minimal
tumour growth inhibition was evident in vivo (Supplementary
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Spearman’s correlation coefficient method.
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Fig. 10h–n). In the cetuximab-treated groups, responders showed
a decrease in Ki-67 and phospho-ERK levels and increase in
cleaved caspase-3 expression (Supplementary Fig. 10b,c,e–g). This
was not evident in the non-responders (Supplementary
Fig. 10i,j,l–n). Collectively, we observed a linear correlation
(R2¼ 0.903, n¼ 26, by
Spearman’s correlation coefficient) between CANScript explants
outcomes and in vivo HTX responses (Fig. 6m).
CANScript as a tool to predict treatment outcome in patients.
The concordance in outcome between HTX in vivo and corre-
sponding CANScript studies suggested the possibility of using the
latter for predicting the treatment outcome in patients. The
CANScript explants were generated from biopsies of CRC and
HNSCC tumours from 109 patients and were incubated with the
same drug combination as that administered to the patient, that
is, docetaxel, cisplatin and 5-fluoro uracil (5-Fu) for the 70
HNSCC patients and cetuximabþ FOLFIRI for the 39 CRC
patients. The functional read-outs from these CANScripts,
quantified in terms of viability, histopathology, proliferation and
apoptosis, together with the observed clinical response in the
matched patients, classified as progressive disease/non-response
(NR), partial response (PR) or complete response (CR) based on
PERCIST guidelines (Fig. 7a), were then used as the training set
for a novel machine learning algorithm. In this algorithm, as the
first step, we classified patients as simply responders or non-
responders, with a focus on ensuring high sensitivity (true posi-
tive rate). This was formulated by maximizing the partial area
under the receiver operating characteristic (ROC) curve (partial
area under the curve (AUC)) up to an acceptable false positive
range (Fig. 7b). To this end, PR and CR were grouped together
into a responder (R) category and a linear prediction model was
learned using SVMpAUC, a recently proposed structural support
vector machine algorithm for optimizing partial AUC. The
learned model was designed to maximize partial AUC while
achieving at least 75% specificity (that is, at most 25% false
positive rate) on the training set, and assigned coefficients of
0.2977, 0.5562, 0.0073 and 0.1388 to the viability, histology,
proliferation and apoptosis read-outs, respectively, together with
a threshold of 19.1 (that is, cases assigned a weighted score419.1
by the learned model were predicted to be responders).The model
achieved 96.77% sensitivity on the training set (Fig. 7c). We then
tested the learned algorithm on a new test group of 55 patients,
consisting of 42 HNSCC and 13 CRC patients treated with the
same drugs as above, where the model achieved 91.67% specificity
and 100% sensitivity (Fig. 7d). In particular, no potential
responders (PR or CR patients) in the test set were predicted as
NR (Fig. 7d).
In the next step, the learned model was refined to classify the
predicted responders into partial and complete responders (PR
and CR), by selecting a threshold that maximized PR versus CR
prediction accuracy on the training set. Following this, scores
between 19.1 and 55.14 were classified as PR, and those 455.14
as CR. As can be seen in Fig. 7e,f, the coefficients assigned to the
four read-outs by the SVMpAUC-learned model, together with
the above thresholds, resulted in predictions that were signifi-
cantly better than what could be achieved by predicting using any
one of the functional read-outs alone. Confusion matrices
summarizing predictions in each category on both the training
and test sets are shown in Fig. 7g,h; break-ups among HNSCC
and CRC cases are shown in Fig. 7i–l. The resulting predictions
had 87.27% accuracy on the test set (Fig. 7h). In particular,
among the 55 test cases, there were only seven prediction errors:
four PRs were predicted as CR; one CR was predicted as PR; one
NR was predicted as PR; and one NR was predicted as CR
(Fig. 7h). This is the benefit of using the SVMpAUC machine
learning algorithm, which explicitly encourages high sensitivity in
the learned model (indeed, a standard support vector ordinal
regression algorithm which directly classified the patients into
one of the three categories yielded a lower accuracy of 81.82% on
the test set, making a total of 10 prediction errors on the 55 cases,
which included 1 PR case predicted as NR). Again, it is worth
emphasizing that these errors using the SVMpAUC machine
learning algorithm were all ‘benign’, in that no potential
responder (PR or CR) was predicted as a NR. While such
‘benign’ errors do mean unwarranted drug use that can result in
potential side effects, it also means that no patient who would
respond to chemotherapy is denied a drug based on a false
prediction. Indeed, current clinical practice also assumes this
principle, where the error rate is significantly higher as seen in
our study. For example, as shown in Fig. 7m, biomarker analysis
selected all 13 CRC patients in the test set, all of whom were
positive for wild-type KRAS, to receive cetuximab. However, as
can be seen, only 3 of these 13 wild-type KRAS patients actually
responded to the drug (1 exhibited CR and 2 exhibited PR), while
the remaining 10 presented with progressive disease. Interest-
ingly, the CANScript platform predicted two CRs, two PRs and
nine NRs, with only one actual NR case being wrongly predicted
as CR. As shown in Fig. 7n, based on standard practice, all 42
HNSCC patients in the test set received TPF. However, 14 of
these patients did not respond to the drug combination. The
CANScript platform could identify 13 of these as NRs. Again,
importantly, all patients predicted by the platform as NRs were
indeed NRs. It should be noted that 13 and 42 are small sample
sizes, and that larger-scale studies are needed in the future to
establish similar results on larger sample sizes; however based on
the observed improvements over the standard/biomarker-based
approach, we anticipate that the CANScript platform can emerge
as a powerful strategy for predicting chemotherapy outcomes.
Discussion
While biomarker driven personalized cancer therapy has emerged
as a powerful concept, the mere presence of a biomarker in a
cancer cell may not translate into clinical efficacy1,6,7,39. This
arises from heterogeneity, where multiple genetic, epigenetic and
phenotypic alterations along with immune and metabolic changes
represent a complex state of the neoplastic transformation40.
Indeed, in the current study, of the 52 patients who received
cetuximab based on wild-type KRAS status, only 1 exhibited CR
and 12 exhibited PR, and the remaining 39 presented with
progressive disease. While the use of more than one biomarkers,
for example, the use of wild-type KRAS and BRAF to select
patients eligible for cetuximab41 is the emerging trend, the ability
to predict chemotherapy outcomes accurately at an early time
point still remains a holy grail in the management of cancer. Here
we have demonstrated the development of a novel technology
platform that integrates a comprehensive explant culture with a
machine learning algorithm to better predict chemotherapy
outcomes. As we have demonstrated in this study, the
CANScript platform is versatile in its ability to predict the
outcomes of both cytotoxic chemotherapy regimens and targeted
therapeutics.
A key attribute of the CANScript platform is its ability to
capture the intratumoral heterogeneity to a greater degree than
achieved by biomarker-based selection of cancer cells. Cancer
stem cells, stromal cells such as intra and peritumoral immune
cells, and vascular components can further add to the hetero-
geneity and contribute towards tumour survival, progression and
metastasis15,17,34,42, suggesting that an explant culture that
globally conserves these distinct cellular components in their
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Figure 7 | Validation of CANScript platform using clinical data. (a) Positron emission tomography–computed tomography (PET–CT) for representative
cases of CR (left), PR (middle) and NR (right) as determined by PERCIST. Primary treatment-naı¨ve HNSCC patients underwent FDG–PET–CT scan
examination before (predose) and after three cycles of TPF treatment (post dose). Clinical response to the drugs for individual patients was evaluated
based on PERCISTdata. (b) ROC plot showing true positive rate (sensitivity) and false positive rate (one minus specificity); the shaded area represents the
partial area under the ROC curve up to false positive rate 0.25. The SVMpAUC algorithm used to learn a NR/R model to distinguish the non-responders
from responders maximized the partial area under the ROC curve up to false positive rate of 0.25 on the training set. This encourages learning a model with
high sensitivity, minimizing the number of potential responders (PR or CR patients) that are predicted to be NR while keeping specificity at least 75%.
(c) Performance of learned NR/R model on the training set. Confusion matrix displays the number of patients with various actual and predicted responses
to TPF for HNSCC and cetuximabþ FOLFIRI for CRC in the training set (n¼ 109). (d) Performance of learned NR/R model on the test set. Confusion
matrix displays the number of patients with various actual and predicted responses in the test set (n¼ 55). (e) Plots showing values of the functional read-
outs from the CANScripts (that is, viability, histology, proliferation and apoptosis), as well as scores assigned by the SVMpAUC-learned model to patients
in the training set, and (f) in the test set. (g) Performance of final refined NR/PR/CR prediction model on the training set. Confusion matrix displays the
number of patients with various actual and predicted responses to TPF for HNSCC and cetuximabþ FOLFIRI for CRC in the training set. (h) Performance of
final refined NR/PR/CR prediction model on the test set. Confusion matrix displays the number of patients with various actual and predicted responses in
the test set. (i,j,k and l) Performance of final refined NR/PR/CR prediction model on HNSCC cases alone in the training and test sets, and on CRC cases
alone in the training and test sets, respectively.(m) CANScript-based model is a better tool than biomarker- (KRAS) based prediction of response to
cetuximab and FOLFIRI in CRC. (n) CANScript-based model is a better tool than standard patient selection for response to TPF in HNSCC.
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original architecture, as evident in the CANScript platform,
is important for increasing the probability of predicting a
chemotherapy outcome. Indeed, anticancer drugs have been
reported to exert their effects by altering both cancer cells and
tumour microenvironment10,11,34,40.
Interestingly, short-term cultivation of primary explants of
human tumours had been explored previously, for example,
growing the specimens in plasma clots43 or using engineered 3D
explant cultures20,25,44–48. While these explant models did
capture the heterogenous cancer and stromal cell population to
certain degree, and were used to study tumour heterogeneity,
invasiveness and response to treatment15–17,21,25,49, these
attempts did not show full viability at diverse functional levels.
While extracellular matrix support was shown to help preserve
and recreate many important morphologic and phenotypic
properties in these 3D spheroids and organotypic cultures,
these studies did not elucidate the importance of conserving
tumour type- and grade-matched matrix factors in maintaining
functional organization and dynamics. Indeed, our results
indicate that the composition of TMPs is distinct between
tumour types and also between grades. Nor did these studies
recreate the oncogenic signalling networks encompassing the
activation of diverse RTK signalling with extensive heterogeneity
and cross-talks20,27,30,50–52. Importantly, our results with
mismatched matrix or HS controls indicate the criticality of a
matched tumour microenvironment together with AS in
preserving the phenotypic and molecular features of the native
tumour. It is evident from the RPPA profiling of key signalling
pathways and physiologically relevant growth factors detectable
in patient serum that extensive heterogeneity exists between
patients and that a truly personalized milieu with an active
balance of multiple parallel signalling cascades can therefore be
successfully created by AS53–57. It should, however, be noted that
while AS and TMP independently and collectively improved
explant culture quality, not all aspects are necessarily dependent
on dual presence of AS and TMP. For example, growth factor
dependent features are better sustained in presence of AS,
whereas TMP plays a dominant role in tumour heterogeneity and
at the phenotypic level in maintaining survival and proliferation.
The ability to predict outcomes is not only attractive from a
clinical perspective, but also has major implications on preclinical
cancer research, where the focus has been to develop assays that
can bridge the translational gap. While animal models have been
used as the front line in predicting efficacy, the predictive value of
these models is debatable, a consequence of using cell lines
cultured over years that are no longer representative of the
original tumour. Furthermore, transgenic murine models may
recapitulate a specific cancer pathway, but fail to capture the true
heterogeneity that is characteristic of human tumours. For
example, we observed in our study that while EGFR generally
plays a critical role in HNSCC, additional driver mechanisms
such EphB4, AKT, ERK1/2, Tie2, VEGFR2, cAbl, FGFR1, HER3
and IR are activated. Indeed, such stochastic heterogeneity has
been implicated in the induction of adaptive resistance. There is
therefore a resurgence in the use of early-passage patient-derived
xenografts for predicting clinical responses. Consistent with these
recent studies, we observed a good concordance in terms of
histopathology and gene expression between the tumour biopsy
(P0) and the 2ndpassage xenografts (P2-HTX). However, we did
observe unique mutations between the P0 biopsy and the
P2-HTX xenografts. It is possible that these differences between
P0 and P2-HTX arise due to intratumour heterogeneity at the
time of implantation50. In our study, the presence of fewer unique
P2-HTX mutations in HNSCC-1, a clinical responder, versus the
high number of unique P2-HTX mutations in HNSCC-2 and
HNSCC-3 tumours, clinically classified as partial and non-
responders, respectively, could indicate a propensity for the
acquisition of new mutations and/or rearrangements during
tumour propagation, consistent with the genetic instability.
Furthermore, the ‘take rate’ in the current studies was o50%,
consistent with published reports, which together with the long
time required to establish a graft has been a limiting factor for
translation of xenotransplant of primary models for predictive
studies58. The ex vivo to in vivo functional correlation data clearly
show the benefit of using CANScript technology as a surrogate of
animal modelling. In addition, the minimal amount of tissue
required to establish the CANScripts means multiple explants per
tumour biopsy, which allows us to better capture the impact of
intratumoral heterogeneity on outcome.
A powerful feature of the CANScript platform is its use of a
novel machine learning approach that is tailored to make accurate
predictions particularly for potential responders. Specifically, the
algorithm operates in two stages: it first employs the recently
proposed SVMpAUC-based learning algorithm to distinguish
between responders and non-responders in a way that maximizes
sensitivity (fraction of responders predicted as responders).
Indeed, the learned model in our case achieved 100% sensitivity
on the test set while keeping specificity in an acceptably high
range. In the second stage, the algorithm learns an additional
threshold to separate responder predictions into complete
responder and partial responder predictions. This approach was
found to be superior to the performance of a standard, widely
used support vector ordinal regression algorithm that directly
aims to make predictions in the three categories and does not
explicitly incorporate the need for high sensitivity. Interestingly,
studies have correlated complete pathological response to the
long-term progression-free survival59, while recent ongoing
clinical trials like adjuvant dynamic marker adjusted
personalized therapy trial (ADAPT) are using short-term
dynamic response prediction biomarkers like decrease in Ki-67
in clinical settings as surrogates for clinical outcome for tailoring
personalized treatment60, indicating that integrating multiple end
points into a single score as adopted in this model could make
response prediction more comprehensive. Combined together,
the comprehensive tumour ecosystem and the SVMpAUC-based
algorithm makes the CANScript platform a powerful predictive
tool that can be used across different tumour types and treatment
regimens, as is evident from the overall response rates observed in
HNSCC and CRC tumours to targeted and chemotherapy
regimens that was similar to clinical outcome observed in
previous studies6,61. Moreover, while for this study we have
focused on predicting the patient response to a single drug
regimen at a time, in the future, the approach can be extended to
predicting a rank order among different drug regimens based on
their likely outcomes, which could help in prioritizing different
treatments. Furthermore, the CANScript platform can afford
nearly high-throughput testing while capturing the patient
intratumoral heterogeneity at a global level with higher fidelity,
allowing predictions to be made within 7 days for truly
personalizing chemotherapy.
Methods
Collection of tumour samples and patient sera. Tumours samples were collected
by core biopsy at the beginning of treatment and at the time of surgical removal for
deserving patients (for patient detail see Supplementary Methods). For each patient
5–10ml of non-heparinized blood was collected at the time of first biopsy in
BD-Vacutainer tubes and serum was separated at 1,000g for 15min. All sera
samples were aliquoted and stored at ! 80 !C for further use.
Isolation of extracellular matrix proteins. Surgically removed fresh tumour
tissues were dissected into small sections (B1–2mm3) and digested with dispase
(Stem cell Technologies Inc. ), and subsequently the cells were separated using
a sieve62. Decellularization process was verified by phase contrast microscopy,
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and further confirmed by 4,6-diamidino-2-phenylindole staining and DNA
quantification. Tissue slices suspended in dispase solution was incubated for 15min
at 48 !C. The tissues were homogenized in a high salt buffer solution containing
0.05M Tris pH 7.4, 3.4M sodium chloride, 4mM of EDTA, 2mM of
N-ethylmaleimide and protease (Roche.11836153001) and phosphatase inhibitors
(Sigma-aldrich, P0044 and P5726) using tissue homogenizer (Cole Parmer). The
homogenized mixture was centrifuged repeatedly three times at 7,000g for 15min
and the supernatant was discarded to retain the pellet. The pellet was incubated in
2M Urea buffer (0.15M sodium chloride and 0.05M Tris pH 7.4) and stirred for
1 h at 50 !C. The complex extracted proteins were solubilised in Urea buffer63. The
mixture was then finally centrifuged at 14,000g for 20min and resuspended in the
2M Urea buffer, aliquoted and stored at ! 80 !C. In addition, extracted protein
samples were run at denaturing conditions in the presence of standard molecular
weight ladder. When the run was complete, the gel was transferred into a suitable
staining tray and fixed in a solution containing formaldehyde in a shaker for 2 h.
The gel was washed three times with 1" wash solution once in every 5min. The
gel was incubated with sensitizing solution containing sodium-thiosulphate for
2min with gentle shaking and visualized using silver staining.
Identification of TMP components by nano LCMS/MS. The protein mixture was
dissolved at the concentration of 1 mgml! 1 in 50mM ammonium bicarbonate
buffer. The pH of protein samples was adjusted toB8.5. The samples (50 ml) were
reduced with 10mM DTT at 56 !C for 45min, incubated at 95 !C for 5min
and then allowed to cool. Alkylation was carried out by using 55mM final con-
centration of iodoacetamide in the dark. Trypsin (13 ng ml! 1) was added at a ratio
of 1:30 and enzyme/sample mixture was mixed well. Tubes with sample were
placed into thermostat and incubated at 55 !C for 2 h and then 37 !C overnight.
Digested samples were subjected for SpeedVac at 30 !C for 2–3 h. 5% formic acid
was added for adjusting the pH to 3. The samples were either subjected directly to
MS analysis or stored at ! 20 !C.
Sample was vacuum dried and reconstituted in 12 ml of 0.1% formic acid
containing 12.5 fmol ml! 1 bovine serum albumin (BSA) or b-gal. One micro liter
of this was injected on column. Hence, the area of BSA/ b-gal was used for
normalization. A separate Mascot run was performed with carboxymethylation as a
dynamic modification to obtain area of BSA or b-gal protein. Area of the respective
protein is normalized to the control area of respective sample. Reserpine (Sigma-
aldrich) was used as a working standard. Digested peptides were subjected to
analysis by injecting into nano LCMS/MS63. The instrument (STAR Elite, Q-TOF
LCMS, Applied Biosystems) was externally calibrated with standard compounds. In
brief, peptide mixtures were dissolved in 25 ml of sample preparation solution and
injected (10 ml pick up) into nano-LC through an auto-sampler system. Peptides
were eluted using nano-reverse phase column (Michrom C18 5 mm particle, 300 Å
pore size, 75mm ID, 150mm length) which was further connected to the Nano
Spray ESI-Q-TOF system (Qstar Elite, Applied Biosystems). A gradient of water
and Acetonitrile was set up for 60min with a flow rate of 400 nlmin! 1. Eluted
peptides from the column were ionized using ESI source with ion spray voltage
2250V and temperature 120 !C. Ionized peptides were analysed by one full MS
scan and four consecutive product ion scans of the four most intense peaks, using
rolling collision energy. An Information Dependant Acquisition (IDA) experiment
was used to specify the criteria for selecting each parent ion for fragmentation,
which included selection of ions in m/z range:4400 ando1600, of charge state of
þ 2 to þ 5, exclusion of former target ions for 30 s, accumulation time of 1 s for a
full scan and 2 s for MS/MS. The data generated by the Analyst software were
stored in a.wiff format. The machine generated data files were analysed using
ProteinPilot version 4.0 software with a combined NCBI Human Database (release
45, containing 39125 non-redundant protein entries, 18.8Mb), Paragon Algorithm
and Proteome Discoverer1.3 software. All searches were performed with tryptic
specificity allowing two missed cleavages. Trypsin and keratin entries were retained
in the list generated. During the analysis, in the search parameters modification of
cysteine by idoacetamide and biological modifications programmed in algorithm
were allowed. Mass tolerance for precursor ion and fragment ions were set to
100 p.p.m. and 0.2 Da, respectively. In Paragon Algorithm, protein score was
calculated on the basis of percentage confidence level of the peptides identified.
Protein score of minimum 0.47 (fit incorrect rate is 0%) corresponding to a
confidence level 466% were used. To rule out false discoveries, we carried out a
False Discovery Rate (FDR) analysis64 using ProteinPilot 4.0 with Paragon
algorithm for data analysis. As part of the Paragon analysis method, a FDR analysis
of the results was carried out by the Proteomics Performance Evaluation Pipeline
Software (PSPEP). Finally, proteins were selected on the basis of their critical FDR
value, that is, 1%. To avoid identifications based on redundant peptides in our
proteome, we did not include proteins that have no unique peptide identifications.
Protein grouping function was disabled for generation of protein list. Proteins that
share some peptides as well as have unique peptide identifications were grouped
accordingly. Deeper annotations were done by accessing specific published
information.
For peptide and protein identification, peak lists were correlated with the
human protein database65–68. The rationale for spectral counting derived protein
abundance is that proteins in higher abundance result in more proteolytic peptides
detected by tandem MS and subsequently identified by database searching.
Following the matching of peptide peaks, peptide abundances in each of the
analysed gradient fractions were calculated from the area under the peak. All data
processing steps were manually inspected to ensure correct peak detection and
matching; overlapping peaks were discarded. Proteins were considered quantifiable
if they were represented in at least 75% of the clinical samples matching the cancer
type and grade. There are many inherent variables, like ionization efficiency,
sensitivity to digestion and interference at the time of elution might influence in the
determination of the relative abundance for a protein. In general the prediction
falls within a ratio of twofold compared with the actual one. Both sample
distance and protein feature distance were calculated using Pearson’s correlation
and average linkage was used for the clustering of both samples and protein
features.
Preparation, coating and detection of TMP mix. TMP cocktails were prepared,
based on the relative abundance of key components obtained from LCMS/MS
analysis of HNSCC and CRC patient tumour tissues using human proteins as
shown in Supplementary Figs 2 and 3. Sterile culture wells were freshly coated
with TMP cocktails (100 mgml! 1) unless mentioned otherwise. To visualize the
coat, the matrix was incubated with anti-Collagen1 antibody at a dilution of 1:50
(rabbit polyclonal, Abcam. ab34710) for 1 h at room temperature. After four
washes in PBS, slides were incubated with Alexa Fluor 555 (anti-mouse, Cell
Signaling Technology.4409) for additional 45min at room temperature in dark.
Slides were washed with PBS and finally mounted with Vecta-Shield DAPI (Vector
laboratories. H-1200) to confirm the absence of nuclear contamination in premixed
TMP cocktail. Images were visualized under immunofluorescence microscopy
setting using red and blue filters (DM4000, Leica Microsystems) and images were
captured with DFC 425C (Leica) camera.
Surface scanning electron microscopy. Electron microscope compatible cover
slips (Thermanox, Ted Pella Inc.) were coated with freshly prepared TMP cocktails
(100 mgml1) for 4 h, washed twice and were fixed in 10% buffered formalin for
10min (to resist metal coating and high electron beam), washed in PBS and
dehydrated with 70 and 100% ethanol for 5min each. Immediately before imaging,
the slides were coated with gold and the images were captured using a Cambridge
scanning electron microscope with EDAX attachment.
Human tumour explant culture. Tumour tissues were sectioned into B300 mm
slices using McIlwain tissue chopper (TedPella). These tumour sections were
randomized and cultured in 48-well flat bottom plates coated with stage and
grade-matched TMP with RPMI medium supplemented with 2% AS, 8% FBS
(Life Technologies. 10270-106), 1" Insulin-Transferrin-Selenium (ITS, Life
Technologies. 41400-045), 1" GlutaMAX (Life Technologies. 35050-061) and
1" penicillin, streptomycin and amphotericin B (Life Technologies. 15140-122).
Tumour slices (n¼ 3) were treated with either anti-EGF neutralizing antibody
(rabbit monoclonal, clone D8A1, Cell Signaling Technology. 12157) or with TPF
(for HNSCC) or with cetuximabþ FOLFIRI (for CRC) or with dimethylsulphoxide
(DMSO; vehicle control) for 72 h. The final concentration of DMSO was kept
Z0.01%. Media with drugs were changed every 24-h interval. A portion of each
tumour slice was used for cell viability (assessed by WST) and remaining tumours
were fixed in 10% buffered formalin and embedded in paraffin. The paraffin-
embedded tumours were used for histological (hematoxylin and eosin stain) and
IHC analysis including proliferation and cell death.
Human tumour xenografts. Freshly isolated primary human tumours were
washed in normal saline and cut into a small pieces (B5mm3) and implanted
subcutaneously onto the flanks (both sides) in immune compromised 5–6 weeks
old, female severe combined immunodeficiency (C.B-17/IcrHsd-PrkdcscidLystbg,
Harlan) mice. Tumour bearing mice (at the time of commencement of treatment
maximum tumour size was restricted to 100–150mm3) were treated with vehicle
(0.9% normal saline;) or concurrent regimen of TPF (cisplatin 2.5mg kg! 1 body
weight, docetaxel 20mg kg! 1 and 5Fu 50mg kg! 1) or single agent cetuximab
(4mg kg! 1) for 3–4 weeks. Tumour volume was calculated using the following
formula, Tumour volume (mm3)¼ (p/6) LWH; where L¼ length (mm),
W¼width (mm) and H¼ height (mm). All mice studies and experimental
protocols were approved by the institutional animal ethics committee.
Gene expression, exome and mutational analysis. See Supplementary Methods
for details. The data are publically available at Gene Expression Omnibus through
GEO series accession number GSE63544 and GSE63545; Biosample accession
numbers, SAMN03271711, SAMN03271712 and SAMN03271713.
Machine learning algorithm. We learned a model for predicting patient responses
as NR/PR/CR in two stages. At the first stage, PR and CR labels were grouped
together into a single responder (R) category, and the recently proposed
SVMpAUC algorithm69 was trained on the training set of 109 patients to learn a
model to assign the scores and predict NR/R for new test cases. Specifically, given a
training set containing n examples (xi,yi), i¼ 1,...,n (here n¼ 109), where xi is a
feature vector containing the four functional read-outs for the i-th patient and yi is
1 if the i-th patient is a responder and ! 1 otherwise, the SVMpAUC algorithm
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learns a weight vector w maximizing (a concave lower bound on) the partial area
under the ROC curve (partial AUC) up to a specified false positive rate b (here
b¼ 0.25), defined as follows70
pAUC ðwÞ ¼
X
i:yi¼1
X
j:yj¼$ 1
1ðw % xi4w % xjÞ % 1ðj 2 SbÞ
Where Sb contains indices j of the top b fraction of non-responders in the
training set, ranked according to scores w.xj. This produced a weight vector w
assigning coefficients of 0.2977, 0.5562, 0.0073 and 0.1388 to the viability,
histology, proliferation and apoptosis read-outs, respectively. Together with a
threshold of 19.1 corresponding to (approximately) b¼ 0.25 false positive rate on
the training set, this yielded an initial NR/R prediction model. In the second stage,
the above model was further refined to classify the predicted responders as PR and
CR; this was done by selecting a threshold (55.14) that maximized PR/CR
classification accuracy on the training set.
Statistical analysis. One way analysis of variance and Student’s t-test, linear
regression and Spearman coefficient of correlation was analysed using GraphPad
Prism version 5 for Windows, GraphPad Software.
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